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1  Introduction  
 
1.1 RNA interference 
The finding that double-stranded RNA (dsRNA) triggers the degradation of homologous 
mRNA is one of the most important recent discoveries. Since the first reports about this 
phenomenon in the late nineties, RNA interference (RNAi) has been broadly recognized by 
many disciplines ranging from functional genomics over biological chemistry to 
pharmacology. Today, the application of dsRNA to specifically silence genes at a 
posttranscriptional level (Posttranscriptional Gene Silencing, PTGS) has become a standard 
technique in the study of gene function, and it is on its best way to become a new weapon to 
combat disease triggered by RNA viruses, parasites or even mutations of the genome, like 
cancer or inherited diseases (Arenz and Schepers 2003; Schepers and Kolter 2001). 
 
1.1.1 The study of gene function 
Only half a century ago, Watson and Crick postulated the helical structure of DNA and its 
significance as the carrier of the hereditary information in all forms of life. Since then, large 
efforts were undertaken to understand the translation of genetic information into gene 
function and the sophisticated coordination of the mechanisms that govern life at a molecular 
level. The expression of genes in each individual cell needs to be highly regulated to activate 
the appropriate subset of genes for specific cellular functions or as responses to 
environmental changes.  
At the turn of the millennium, the publication of the first draft version of the complete 
sequence of the human genome was a scientific milestone (Lander et al. 2001; Venter et al. 
2001). The task resulting from this achievement is much greater: correlating approximately 
30,000 open reading frames with the function of about 100,000 human proteins resulting 
from posttranslational modifications and alternative splicing of the RNA transcripts. This task 
is tackled by functional genomics or functionomics. Its solution is the prerequisite for an 
understanding of complex physiological functions and the key to the development of drugs 
against diseases.  
Traditionally, functional genomics had to trace back inherited diseases from the protein 
defect to the responsible gene in a time consuming process. The generation of knock-out 
animals permitted the specific study of gene defects and their related phenotypes. However, 
the generation of knock-out animals is time consuming and laborious, defects in essential 
genes lead to lethality at early embryonic stages preventing phenotypic studies and not all 
results obtained in model organisms can be transferred to related species, which is 
especially true for humans and mice (Kolter and Sandhoff 1999).  
The combination of large chemical libraries, high throughput screening and elaborate 
screening assays together with findings of classical genetics brought forth the field of 
“chemical genetics”, holding high promises for drug development and functional genomics 
(Frank-Kamenetsky 2001; Stark et al. 1998). 
By means of rationally designed synthetic inhibitors loss of function phenotypes can be 
generated in a short time. Although the lead structures can be optimized to binding 
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efficiencies in the nanomolar range and below (Frank-Kamenetsky 2001), they may also bind 
to unexpected sites on different molecules where they exhibit off-target effects. A recent 
example is the anti-inflammatory drug celecoxib, that was designed to selectively target 
cyclooxygenase (COX) 2 while sparing inhibition of COX-1, but exhibited an unexpected 
nanomolar binding affinity for members of the totally unrelated carbonic anhydrase family 
(Weber et al. 2004). Combinatorial chemistry and the use of chemical evolution allowed the 
development of aptamers as an important tool for gene function studies. These synthetic 
RNAs adopt a specific secondary structure by which they bind to either DNA, RNA, or 
proteins and thus down-regulate protein function (Famulok 1999; Sullenger et al. 1990). 
The free availability of genomic sequencing data opened the door to a rational design of 
synthetic inhibitors to any target gene and generating the corresponding loss-of-function 
phenotype in a straightforward fashion. The first step into this direction was taken in the early 
1990s by antisense technology, in which complementary antisense-oligonucleotides bind to 
the target mRNA-sequence and thereby prevent its translation to the corresponding gene 
product (Brantl 2002). At first, single stranded RNA (ssRNA) was used, which is unstable 
toward degradation by ribonucleases. Many efforts have been made to improve the stability 
of the RNA ranging from protection groups on the ssRNA, thiol-modifications to stabilize the 
ribophosphate backbone, or peptide nucleic acids (PNAs) in which the nucleobases are 
bound to a peptide backbone. Antisense DNAs are not only more stable than RNA, but also 
form hybrid strands with mRNA that are degraded by RNase H. All these approaches require 
a saturation of all targeted mRNA strands with corresponding antisense agents to obtain the 
desired knock-down phenotype. This implies the use of more than stoichiometric amounts of 
antisense agent to inactivate present as well as newly transcribed mRNA until all remaining 
protein has been degraded. However, antisense techniques are a common method in the 
study of gene function and some specific modifications have made their way to clinical 
studies as potential drugs to suppress tumor function.  
 
 
 
 
Figure 1-1 Dissecting the expression of gene products at different stages. Knock-out organisms and 
naturally occurring mutations alter the information stored in the DNA, protein inhibitors and aptamers 
bind to gene products and inhibit protein functions, antisense agents and RNAi act on the level of 
transcripts by preventing ribosomal binding or triggering its degradation. Naturally occurring or 
synthetic small molecules can be selected to target any of the three stages by high throughput 
screening. 
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1.1.2 The discovery of RNAi 
New possibilities were opened up with the discovery of RNA interference that combines the 
advantages of rational design with a much higher efficiency in down-regulating the targeted 
gene-product. Therefore, it was soon adopted as the tool of choice in reverse genomics to 
study gene-protein relations in almost all eukaryotic organisms. 
First hints at this phenomenon had come from antisense experiments in C. elegans, in which 
the sense control exhibited an unusually strong effect (Guo and Kemphues 1995). Assuming 
a contamination with asRNA in the sense control, Fire and Mello demonstrated that the 
simultaneous injection of two complementary RNA strands, and likewise the use of dsRNA, 
could specifically silence the corresponding gene product with an at least 10fold higher 
efficiency than conventional antisense reagents (Fire et al. 1998). Following this key 
discovery, it was shown that RNAi takes place at the posttranscriptional level where a dsRNA 
triggered molecular machinery causes the degradation of homologous mRNA (Montgomery 
and Fire 1998; Montgomery et al. 1998) identifying RNAi as a form of posttranscriptional 
gene silencing (PTGS).  
In C. elegans, RNAi could not only be induced by injecting the dsRNA into the gut (Fire et al. 
1998; Grishok et al. 2000), but also by soaking the worms in dsRNA solution (Tabara et al. 
1998), introduction of transgenes that code for double stranded RNA (Tabara et al. 1999b; 
Tavernarakis et al. 2000) or feeding bacteria that recombinantly express double-stranded 
RNA constructs to the worms (Timmons and Fire 1998). Moreover, a systemic spread of the 
silencing effect was observed and it was even inherited to the progeny (Fire et al. 1998; Sijen 
et al. 2001b). Cultured cells transfected with dsRNA could keep up the silencing phenotype 
for up to 9 cell divisions (Tabara et al. 1998). However, the most important features of RNAi 
are its high specificity and efficiency: Substoichiometric amounts of dsRNA are sufficient to 
significantly reduce the amount of homologous mRNA within a few hours in a highly 
sequence specific manner (Fire et al. 1998). Other mRNAs, even those with point mutations, 
remain unaffected (Bosher and Labouesse 2000; Fire et al. 1998; Hunter 1999). 
 
1.1.3 RNAi is a highly conserved eukaryotic mechanism 
Posttranscriptional gene silencing (PTGS) had been previously reported in plants. In 
Arabidopsis thaliana the attempt to express an endogenous gene from a recombinant vector 
had led to a complete downregulation of the respective gene and the phenomenon had been 
termed cosuppression (Napoli et al. 1990). A related mechanism was found in the fungus 
Neurospora crassa were it became known as quelling (Cogoni and Macino 1997). In plants, 
the infection with RNA viruses expressing dsRNA was discovered to lead to immunity that 
limits the spread of the virus and prevents a second infection with the same virus, a 
phenomenon termed virus-induced gene silencing (Baulcombe 1999). Today, these related 
phenomena are often summarized as RNA silencing.  
With a growing interest in RNAi, dsRNA triggered gene silencing was also found to be 
functional in Drosophila melanogaster (Kennerdell and Carthew 2000; Misquitta and 
Paterson 2000), plants (Hamilton and Baulcombe 1999) and Trypanosoma brucei (Ngo et al. 
1998). It appeared that dsRNA-induced gene silencing is a highly conserved phenomenon. It 
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is assumed to be an ancient defense mechanism against RNA viruses (Ruiz et al. 1998; 
Voinnet 2001) and transposable elements (Ketting et al. 1999; Tabara et al. 1999a). Both 
produce dsRNA in the course of their replication. It may also be involved in the elimination of 
defective mRNAs by degradation (Plasterk 2002) and in the regulation of protein levels in 
response to environmental stimuli (McManus et al. 2002). In the course of evolution, 
organisms have developed alternative strategies to fulfil the same tasks, so that the main 
function of the dsRNA triggered silencing machinery varies from species to species. 
The most prominent, and for RNAi scientists most troublesome, alternative mechanism was 
the induction of an interferon response upon the introduction of dsRNA into mammalian cells. 
Increased levels of β-interferon lead to an activation of RNase L, that non-specifically 
degrades all mRNAs, and of RNA-dependent protein kinase R (PKR), which in turn 
phosphorylates and thereby inactivates the transcription factor elF2α. This results in a 
shutdown of the global protein biosynthesis and thereby in apoptosis (Clemens 1997; 
Clemens and Elia 1997). Therefore, it was doubted that RNAi could be used to study 
mammalian organisms and the question arose whether the molecular machinery for RNAi 
was actually present in mammals.  
 
 
 
Figure 1-2 dsRNA triggers an interferon response in mammals. The different events triggered by 
interferon-β finally lead to apoptosis (Sledz et al. 2003). 
 
Studies in mice oocytes and murine embryonic cancer cell lines, in which the innate defense 
mechanisms are not yet functional, proved that, indeed, RNAi works in mammalian cells 
(Billy et al. 2001; Wianny and Zernicka-Goetz 2000).  
The milestone experiment was published by the Tuschl group (Elbashir et al. 2001a). They 
showed that RNAi could be induced in adult mammalian cells if the trigger dsRNA is short 
enough to omit the interferon response. dsRNAs of 21-25 nt exhibited the highest efficiency, 
whereas shorter dsRNAs were no longer recognized. 
This opened the door to a broader application of RNAi. Not only could RNAi be utilized to link 
the genomic data from humans, mice, and other mammals to protein function, it also 
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constituted a new technique to combat diseases caused by viruses, parasites or genomic 
mutations as in inherited diseases and cancer. 
 
1.1.4 The molecular basics of RNAi 
The existence of an RNAi machinery in almost all eukaryotic organisms allowed the mutual 
exchange of results to elucidate its mechanism and thereby greatly enhanced the rate with 
which the insights into the molecular requirements grew.  
The most intensively studied organisms in the quest for the mechanism of RNAi are C. 
elegans (Plasterk 1999; Smardon et al. 2000), Arabidopsis (Mourrain et al. 2000), N. crassa 
(Cogoni and Macino 1997, 1999b), Drosophila (Kennerdell and Carthew 2000), and 
mammals (Elbashir et al. 2001a). The fact that RNAi takes place in the cytosol greatly 
facilitated the experimental setup as cell extracts from flies or worms mimic the conditions of 
the cytosol (Hutvagner and Zamore 2002b; Kawasaki and Taira 2003; Zeng and Cullen 
2002). This introduction focuses on the findings and developments in animals. Results 
obtained in plants are only cited if they contributed to the understanding of the molecular 
processes in animals. 
The mechanism of RNAi can be divided into two steps. In the initiator step, dsRNA is cleaved 
into 21-25 nt long fragments. In the effector step, these so-called short interfering RNAs 
(siRNAs) are incorporated into a ribonucleotide protein complex (RNP) and serve as a 
molecular template to recognize homologous mRNA that is cleaved.  
Discrete 21-25 nt small dsRNAs with a sequence complementary to the target sequence 
were first observed in transgene or virus-induced PTGS and co-suppression in plants 
(Hamilton and Baulcombe 1999) and it was assumed that these small dsRNAs constituted 
the active component in the examined silencing phenomena. The degradation of long dsRNA 
into 21-23-nt short dsRNAs was also found in Drosophila extracts (Zamore et al. 2000) and 
intact Drosophila embryos (Yang et al. 2000), Schneider 2 (S2) cells (Hammond et al. 2000) 
and C. elegans (Parrish et al. 2000). The Hannon group demonstrated that the short dsRNA 
species is associated with the nuclease activity that leads to the cleavage of the target 
mRNA (Hammond et al. 2000; Hutvagner et al. 2000). These findings suggested that the 
sequence specificity of RNAi was conveyed by the 21-23 nt dsRNA fragments cleaved from 
the trigger dsRNA, that became known as siRNAs (Zamore et al. 2000).  
Closer examination of these short dsRNAs showed that functional siRNAs bear characteristic 
3´-overhangs of 2 nucleotides on both strands (Hamilton and Baulcombe 1999) with 
nonphosphorylated hydroxyl groups (Elbashir et al. 2001c) that are essential for their 
recognition by the RNAi machinery.  
At the same time, these features correspond to the characteristic cleavage pattern of 
nucleases of the RNase III family that specifically cleave dsRNA (Robertson et al. 1968). 
Indeed, proteins with homology to RNase III family members could be identified by homology 
screens of genomic data from Drosophila, C. elegans, and humans (Bass 2000; Bernstein et 
al. 2001; Billy et al. 2001; Ketting et al. 2001). In Drosophila two such homologs were found, 
that both comprise two RNase III domains (Bernstein et al. 2001). Tests upon their role in 
RNAi showed that cells deficient of either one of the two RNases exhibited neither RNAi 
activity nor did the cell extracts produce siRNAs from dsRNA. This confirmed that dsRNA is 
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indeed processed by an enzyme of the RNase III family. As it cleaves dsRNA into equally 
sized fragments it was named Dicer (Bernstein et al. 2001; Ketting et al. 2001). First studies, 
suggested that Dicer is loosely associated with ribosomes at the interface endoplasmic 
reticulum-cytosol (Billy et al. 2001; Provost et al. 2002). 
Corresponding to the widespread occurrence of RNAi in nature, homologs of Drosophila 
Dicer have been found in all eukaryotic organisms ranging from C. elegans (Grishok et al. 
2001; Hutvagner et al. 2001) and Arabidopsis (Jacobsen et al. 1999) to mammals (Zhang et 
al. 2002) and Schizosaccharomyces pombe (Volpe et al. 2002), with baker yeast 
Saccharomyces cerevisiae constituting the only known exception. In plants like Arabidopsis, 
up to 4 Dicer like enzymes (DCL) have been found (Schauer et al. 2002), while in vertebrates 
like mice or humans only one single homolog could be identified (Bernstein et al. 2003; 
Nicholson and Nicholson 2002). In general, Dicer-deficiency leads to developmental 
phenotypes (Carrington and Ambros 2003; Schauer et al. 2002) or even to lethality as in 
mice or zebrafish (Bernstein et al. 2003; Wienholds et al. 2003). In Arabidopsis, the action of 
different DCL enzymes leads to siRNAs of either 21 or 25 nt of which the shorter species is 
responsible for dsRNA cleavage while the longer species ascertains the systemic spread 
(Hamilton et al. 2002). Similarly, in wheat germ extracts, 21mers are cleaved from 
exogenous dsRNA while 24-25mers are derived from transgene derived dsRNA by a distinct 
Dicer ortholog (Tang et al. 2003). Likewise, the two Dicer homologs in Drosophila, Dicer-1 
and Dicer-2 are specialized on the processing of endogenous dsRNA and the degradation of 
exogenous dsRNA triggers, respectively (Lee et al. 2004c). In organisms with only one Dicer, 
associated proteins may convey task specificity. 
As depicted in Figure 1-3, the RNase III family is constituted by three groups of 
endoribonucleases that specifically cleave dsRNA. Class 1 occurs in bacteria and fungi and 
contains only one RNase III domain adjacent to a dsRNA-binding domain (dsRBD). As 
shown for the archaebacterium Aquifex aeolicus this species acts as a homodimer and 
produces 9-10 nt fragments (Blaszczyk et al. 2001). 
 
 
 
 
Figure 1-3 Subgroups of the RNase III family sharing the RNase III domain as a common motif. This 
motif is duplicated in classes II and III that are characterized by proline and arginine-serine (RS)-rich 
domains or ATPase/helicase, PAZ-domain and DUF283, respectively (Carmell and Hannon 2004).  
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Class 2 encompasses metazoan RNases III like the nuclear RNase Drosha in Drosophila 
(Wu et al. 2000). These enzymes comprise two RNase III domains, an N-terminal dsRBD 
and a C-terminal proline-rich and arginine-serine-rich domain (Filippov et al. 2000; Fortin et 
al. 2002; Lee et al. 2003b). Drosophila Dicer I comprising 2249 amino acids is a typical 
representative of an RNase III class 3 enzyme. It contains two RNase III domains arranged 
as an antiparallel dimer (Mian 1997; Rotondo and Frendewey 1996), a dsRNA binding 
domain (dsRBD) (Aravind and Koonin 2001), an amino-terminal DExH/DEAH RNA 
helicase/ATPase domain and a Piwi/Argonaute/Zwille (PAZ) domain (Cerutti et al. 2000).  
PAZ domains have been found in several proteins involved in RNA silencing where they play 
an important role in the recognition of the characteristic dsRNA termini generated by Dicer 
(Lingel et al. 2003; Song et al. 2003b; Yan et al. 2003).  
The existence of an ATPase/helicase domain may explain the finding from S2 cell extracts 
and recombinant enzymes from C. elegans and Drosophila that Dicer activity is greatly 
stimulated upon the addition of ATP (Bernstein et al. 2001; Ketting et al. 2001; Nykänen et al. 
2001). However, common RNase III enzymes do not require ATP for their catalytic activity so 
that it was assumed that ATP is needed for structural rearrangements of the RNA or for 
translocation of the enzyme along the dsRNA template (Bernstein et al. 2001; Hutvagner et 
al. 2001; Ketting et al. 2001; Myers et al. 2003; Provost et al. 2002; Zhang et al. 2002). It is 
also thought that ATP is required to release readily cut siRNAs from the active site and 
prepare Dicer for the following round of cleavage, a process that is moreover regulated by 
Mg2+ ions (Zhang et al. 2002).  
Human Dicer does not require ATP as it cleaves dsRNA into 22mers from its terminus but 
exhibits a lower activity that its Drosophila homolog (Zhang et al. 2002). Possibly the energy 
requirements of Dicer differ according to species. 
The generation of recombinant Dicer homologs from Drosophila (Paddison et al. 2002a) and 
humans (Provost et al. 2002; Zhang et al. 2002) as well as recombinant bacterial RNase III 
from A. aeolicus and E. coli (Blaszczyk et al. 2001; Zhang and Hua 2004) helped to 
understand the mechanism of the RNAi initiator step. Remarkably, these enzymes showed 
dsRNA cleavage activity in vitro but failed to undergo multiple cycles of cleavage apparently 
due to a lack of associated proteins that take over the nascent siRNAs to the effector 
complex (Zhang et al. 2004a) 
According to the size of the cleavage fragments, it was assumed that Dicer aggregates to an 
anti-parallel dimer, in which only 2 of 4 actives sites are involved in dsRNA cleavage leading 
to ~22mers whereas the activity of all four centers would lead to the production of 11mers 
(Blaszczyk et al. 2001).  
Mutagenesis studies replacing the putative catalytically active residues in human Dicer and 
E. coli RNase III demonstrated that all RNase domains comprise only one active center, 
which can only cleave one RNA strand. Upon the formation of homodimers or intramolecular 
dimerization of the two RNase III domains, the two active sites are brought into close 
proximity and can thus produce the characteristic staggered cut in the RNA double strand. 
Sedimentation analysis showed that recombinant Dicer occurs only in its monomeric form, 
that cleaves dsRNA at the interface of its dimerized RNase III domains (Zhang et al. 2004a).  
The PAZ domain that is highly conserved in all Dicer homologs plays an important role in 
dsRNA recognition. In general, the binding affinity of the PAZ domain for nucleic acids is low, 
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but it is able to recognize the 3´-terminal 2nt overhangs of siRNAs and the base-paired 
terminus of siRNAs as confirmed by the X-ray structure (Lingel et al. 2003; Song et al. 
2003b; Yan et al. 2003). The distance between the PAZ bound terminus of the dsRNA and 
the cleavage site on the adjacent RNase III domain b (see Figure 1-4) determines the size of 
the double stranded cleavage fragments to 20-22 nt. (Castro-Obregon et al. 2004). 
 
 
 
 
 
Figure 1-4 Schematic representation of dsRNA cleavage by Dicer. The two RNase III domains RIIIa 
and RIIIb form an intramolecular dimer that brings the active sites in position to produce the 
characteristic 3´- 2nt overhangs. The dsRNA terminus is recognized by the PAZ domain, that interacts 
with RIIIb to determine the length of the cleavage fragments (Zhang et al. 2004a). 
 
1.1.5 The many roles of small endogenous RNAs  
The mechanistic studies on RNA interference aroused the interest in endogenous small 
RNAs that had been long neglected for being too short to be translated into a protein. Soon 
after siRNAs had been identified as the active species, small RNAs of 21-22 nt in length 
were discovered as Dicer cleavage products from endogenous substrates. It soon became 
clear that these now called micro RNAs (miRNAs) played an important role regulating the 
expression of gene products. Until today, about a hundred miRNAs have been found in 
Drosophila and C. elegans (Aravin et al. 2003; Lai et al. 2003; Lau et al. 2001; Lee and 
Ambros 2001; Lim et al. 2003; Llave et al. 2002; Mourelatos et al. 2002; Park et al. 2002; 
Reinhart et al. 2002; Smalheiser et al. 2001), and up to 250 in vertebrates (Lagos-Quintana 
et al. 2001; Lagos-Quintana et al. 2003; Lagos-Quintana et al. 2002).  
The first miRNAs, lin-4 and let-7, were found in C. elegans, where mutation of these loci led 
to a developmental phenotype (Grishok et al. 2001; Ketting et al. 2001; Knight and Bass 
2001; Reinhart et al. 2000). The ~70 nt non-protein coding RNAs transcribed from these loci 
adopt a secondary structure with double-stranded regions with one or two mismatches and 
serve as substrates for a Dicer-homolog (Hutvagner et al. 2001). Many more of these short-
temporal RNA precursors (stRNAs) have been found, which need to be cleaved by Dicer and 
play an essential role in germline development (Grishok et al. 2001; Hutvagner et al. 2001; 
Ketting et al. 2001; Knight and Bass 2001; Reinhart and Bartel 2002). 
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Figure 1-5 Schematic representation of miRNA and siRNA action. MiRNAs originate from long pri-
miRNA precursors that are cleaved to pre-miRNAs by Drosha and exported to the cytosol for further 
processing by Dicer to yield miRNAs. siRNAs are generated by Dicer from exogenous dsRNA. Both 
species are incorporated into RISC. Perfectly homologous mRNAs are cleaved, while for partially 
homologous mRNAs the translation is inhibited by RISC binding. 
 
Many long stem loop precursors (pri-miRNAs) are encoded by highly conserved genes. They 
are cleaved into hairpin shaped pre-miRNAs by Drosha, another enzyme of the RNase III 
family, to yield pre-miRNAs (Lee et al. 2003b; Wu et al. 2000). These hairpin-shaped 
molecules with characteristic 2-nt 3´-overhangs are transferred to the cytosol by exportin-5 
(Lund et al. 2003), where they are cleaved by Dicer into their final shape that resembles an 
siRNA with several mismatches. These miRNAs frequently target regions in the 3´-
untranslated regions (3´-UTR) of mRNA, to which they bind with imperfect homology. As a 
consequence, the mRNA is not cleaved but translation of the open reading frame (ORF) is 
suppressed (Olsen and Ambros 1999; Seggerson et al. 2002; Slack et al. 2000). 
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Today, it is known that siRNAs and miRNAs use common components of the same 
molecular machinery. In animals, it is the homology to the target sequence that determines 
the mode of action: If synthetic siRNAs bear a sufficiently low degree of complementarity, 
target translation will be inhibited without mRNA degradation (Ambros et al. 2003). Also, 
miRNAs will lead to mRNA degradation, if a target with perfect complementarity is provided 
(Doench et al. 2003; Hutvagner and Zamore 2002a; Zeng and Cullen 2003). The imprecise 
pairing between animal miRNAs and their targets implies a large number of putative binding 
sites for every miRNA and therefore a huge regulatory potential (Ambros 2004). 
By means of databases and homology search algorithms it is now attempted to identify 
putative target regions of the known miRNAs. However, the targets found for the same 
miRNA differ depending on the applied algorithm (Kiriakidou et al. 2004; Lewis et al. 2003; 
Rajewsky and Socci 2004; Stark et al. 2003). This indicates that the mechanisms of miRNA 
function are still poorly understood and the search engines to identify putative binding sites 
need more refining. 
As for gene silencing triggered by exogenous dsRNA, several functions could be assigned to 
endogenous short RNAs. Apparently, they are not only responsible for developmental control 
of gene expression, but also for long-term modifications of gene expression patterns. 
In Schizosaccharomyces pombe (Reinhart and Bartel 2002; Volpe et al. 2003; Volpe et al. 
2002) and Tetrahymena (Mochizuki et al. 2002; Taverna et al. 2002) a role for small dsRNAs 
in chromatin remodelling, chromosome dynamics (Hall et al. 2003), and heterochromatin 
silencing (Martienssen 2003) was established. In plants, dsRNA is also involved in DNA 
methylation that leads to transcriptional gene silencing (TGS) if promoter sequences are 
methylated (Jones et al. 2001; Mette et al. 2001; Pal-Bhadra et al. 2002; Wassenegger et al. 
1994). And also in C. elegans, mutations in mut-7 and rde-2, that play a role in RNAi, lead to 
a reorganization of chromatin and a release of transgene repression (Dudley et al. 2002; 
Hannon 2002; Tabara et al. 1999b). Recently, a connection between RNA silencing and 
mRNA turnover was found in plants (Belostotsky 2004; Gazzani et al. 2004). 
 
1.1.6 RISC is responsible for mRNA cleavage and transcriptional repression 
In the effector step, both siRNAs and miRNAs are incorporated into a ~360 kDa ribonuclear 
protein complex (RNP) to either direct sequence specific cleavage of mRNA or translational 
repression. The RNP with the nuclease activity required for RNAi was first observed in 
Drosophila embryo lysates and became known as RNA induced silencing complex (RISC) 
(Hammond et al. 2000).  
As siRNA containing Dicer was found to associate with proteins, it was thought that the 
siRNA was handed over to a dsRNA binding protein that transfers the active species to the 
effector complex (Nykänen et al. 2001). The first of these siRNA binding components was a 
36 kDa protein in Drosophila that associates with Dicer-2, that processes exogenous dsRNA, 
but not with Dicer-1. With reference to its tandem dsRBD and Dicer-2 binding domains it was 
named R2D2 (Liu et al. 2003b). C. elegans Rde-4 was soon recognized as an R2D2 
homolog (Grishok and Mello 2002; Tabara et al. 2002). Both proteins are required to stabilize 
the siRNAs and provide their transfer to RISC (Liu et al. 2003b). R2D2 is capable of binding 
both siRNAs cleaved in vivo and transfected synthetic siRNAs. 
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Figure 1-6 R2D2 forms a complex with Dicer2 and siRNAs and helps in the verification of the siRNA 
identity. 
 
In an ATP dependent step, Dicer-2 and R2D2 and some unidentified proteins assemble to 
form the RISC loading complex (RLC) (Tomari et al. 2004). In RLC, Dicer helps to transfer 
the siRNA to RISC, a role distinct from its dsRNA cleavage task (Schwarz et al. 2004). Dicer 
is required for the RISC incorporation of both native and synthetic siRNAs (Pham et al. 
2004). The siRNA is unwound in an ATP-dependent process (Nykänen et al. 2001) inside the 
RLC, which was confirmed by the finding of RLC associated with single- stranded siRNA 
(Tomari et al. 2004). Duplex unwinding determines the fate of the siRNA strands (Bernstein 
et al. 2001; Nicholson and Nicholson 2002). The so-called passenger strand is expelled from 
the complex and destroyed (Schwarz et al. 2003), while the guide strand serves as a 
template for the recognition of homologous mRNA by conventional Watson-Crick base-
pairing (Martinez et al. 2002a; Tijsterman et al. 2002). 
Statistical analysis of naturally occurring siRNAs, miRNAs and efficient synthetic siRNAs 
revealed a decreased thermodynamic stability at the 5´-ends and to a lesser extent between 
base pairs 9-14 of the strand that is incorporated into RISC as a guide strand (Khvorova et 
al. 2003; Schwarz et al. 2003). This indicated that the RLC helicase is biased towards 
unwinding the less stable 5´-terminus, so that the thermodynamic stability of the siRNA or 
miRNA precursor gives rise to strand selectivity by RISC. Thus, it became clear that artificial 
siRNAs are most efficient if the antisense strand is designed to be unequivocally 
incorporated as the guide strand, while randomly chosen target sequences bear the risk that 
the sense strand is incorporated into the effector complex. Indeed, the silencing efficiency of 
artificial siRNAs could be increased by about two orders of magnitude by designing stability 
patterns in which the 5´-end of the antisense strand is flexible due to mismatches and the 
sense-5´-terminus is tightly bound via C-G interactions (Schwarz et al. 2003). Naturally 
occurring miRNA precursors have evolved to match this stability pattern. If siRNAs are 
cleaved from artificial long dsRNAs or long hairpin shaped RNA transcripts from artificial 
expression vectors, a large fraction of these statistically generated siRNAs will meet the 
requirements to have the antisense strand incorporated into RISC. 
The stability of an siRNA 5´-end is sensed by R2D2. It also detects the presence of a 5´-
phosphate group to verify the identity of the siRNA as an authentic Dicer cleavage product 
(Tomari et al. 2004) confirming early assumptions on 5´-phosphorylation serving as a 
licensing function in RNAi (Nykänen et al. 2001). It is assumed that R2D2 orients the Dicer-
2/R2D2 heterodimer on the siRNA inside the RLC. The orientation of the siRNAs then 
determines the guide strand for target cleavage (Liu et al. 2003b). The 5´-terminus of the 
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strand that enters RISC is located near Dicer-2, while the 5´-terminus of the passenger 
strand is bound in the proximity of R2D2 (Tomari et al. 2004).  
Ago-2, a core component of RISC (Hammond et al. 2001), is essential for siRNA unwinding 
(Okamura et al. 2004). By crosslinking studies it was found that the 5´-terminus of the guide 
strand is bound by Ago-2 (Tomari et al. 2004). Therefore, unwinding only takes place if RISC 
can be assembled to incorporate the guide strand. The ~130 kDa protein Ago-2 is a member 
of the Argonaute (Ago) family. This class of proteins was first linked with RNAi by screening 
of Argonaute mutants in plants, C. elegans and N. crassa (Cerutti et al. 2000). The number 
of homologs found in RNA silencing organisms ranges from one in S. pombe (Verdel et al. 
2004) to over 8 in humans (Sasaki et al. 2003) to twenty in C. elegans (Carmell et al. 2002; 
Grishok et al. 2001). Like Dicer, Ago proteins contain a highly conserved PAZ domain that is 
involved in siRNA recognition and binding (Carmell et al. 2002). The PIWI domain comprised 
by some Argonaute proteins mediates the interactions of Dicer and RISC and facilitates the 
transfer of the guide strand (Doi et al. 2003; Pham et al. 2004; Tahbaz et al. 2004). 
It was proposed that the active effector complex is assembled around the Dicer-2/R2D2 
initiator complex to form a large holo-RISC (Pham et al. 2004). In the same study, an instable 
intermediate R2 was detected. Since all three complexes contain Dicer, R2 may be formed 
by interaction of RLC (R1) with a pre-associated protein complex or a single large factor 
(Pham et al. 2004). As Dicer-2 is specialized on exogenous dsRNAs (Lee et al. 2004c), 
miRNAs may be incorporated into RISC in a similar mechanism involving Dicer-1 (Pham et 
al. 2004).  
Apart from Ago-2 and Dicer, the fully assembled RISC also contains a DEAD-box helicase 
and Tudor-staphylococcal nuclease (Caudy et al. 2003). More recently, dFXR1, the 
Drosophila homolog to FMR, an RNA binding protein responsible for fragile X mental 
retardation, that associates with translating ribosomes, was identified as a component of 
RISC along with VIG (vasa intronic gene) (Caudy et al. 2003; Caudy et al. 2002; Ishizuka et 
al. 2002). For long, the ATP-dependent helicase was thought to unwind the siRNA from its 
5´-end and thereby convert RISC into its active form RISC* (Hammond et al. 2000). 
However, the action of a RISC nuclease is incongruent with the finding that the siRNA is 
already unwound inside RLC, unless unwinding takes place in the process of guide strand 
transfer to Ago-2 and leaves behind RLC with the single-stranded passenger strand.  
For a long time it was thought that RISC associated Tudor-staphylococcal nuclease (TSN) 
was responsible for the endonuclease or “Slicer” activity of RISC (Callebaut and Mornon 
1997; Caudy et al. 2003; Ponting 1997). TSN comprises a Tudor domain and five repeats of 
a nuclease domain known from staphylococcus bacteria. However, the cleavage pattern of 
this nuclease did not match mRNA fragments generated by RISC that generates a 5´-
phosphate and a 3´-hydroxyl-terminus (Caudy et al. 2003). Purification of RISC activity from 
HeLa cells indicated that mRNA cleavage was correlated with either an Argonaute family 
member or a non-identified component of the active fraction (Martinez et al. 2002a). Studies 
with affinity-tagged recombinant Ago homologs and knockout of different Ago family 
members revealed that the Ago-2 is responsible for mRNA cleavage (Meister et al. 2004). 
Purification of RISC associated to biotin-labeled siRNAs under more stringent conditions and 
proteolysis of the residual siRNA-protein complex confirmed these findings (Rand et al. 
2004). Considering the sequence conservation of the Argonaute family, the question for the 
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domain responsible for these unique cleavage properties arose. Recently, several groups 
could elucidate this question by bioinformatics revealing a homology between the PIWI-
domain of the Ago proteins from P. furiosus and RNase H (Song et al. 2004) and between 
Drosophila Ago-2 protein with endonuclease V (Rand et al. 2004). Moreover, mutagenesis 
on the predicted active sites abolished RISC activity in murine cells (Liu et al. 2004). 
 
 
 
 
Figure 1-7 Asymmetry of strand incorporation into RISC. The thermodynamic stability of the 5´-ends 
determines which strand is preferentially incorporated. If the antisense-strand (black) is exclusively 
incorporated, the siRNA is highly efficient in silencing its target. Preferential incorporation of the sense 
strand (blue) leads to off-target effects. 
 
The antisense-strand incorporated into RISC hybridizes with the target mRNA to an A-form 
helix (Chiu and Rana 2003). In this process, the 5´-nucleotides of the siRNA contribute more 
to target binding than the 3´-nucleotides. However, the 3´-region of the guide strand must 
pair with the target for effective target cleavage (Haley and Zamore 2004). The mRNA is 
cleaved between the 9th and 10th base pair from the 5´-end of the guide strand in an ATP-
independent step (Haley and Zamore 2004; Tomari et al. 2004). The formation of at least 
one turn of a contiguous A-form RNA-RNA helix surrounding the scissile phosphate may 
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serve as a means of quality control to decide whether the target-mRNA matches the siRNA 
guide strand (Chiu and Rana 2003; Haley and Zamore 2004) 
The decreased stability between base pairs 9-14 found in the statistical analysis of siRNA 
and miRNA stability (Khvorova et al. 2003; Schwarz et al. 2003) might facilitate target 
cleavage. 
 
 
 
Figure 1-8 Mechanism of dsRNA triggered mRNA degradation. In the initiator step (left column), the 
dsRNA is cleaved into siRNAs by Dicer. R2D2 helps in strand recognition and selection. The 
Dicer/R2D2 complex loaded with the guide strand recruits numerous other proteins to form RISC. In 
the effector step (right column), RISC recognizes homologous mRNA and Ago-2 cleaves the target in 
the middle of the homology region. An ATP-dependent helicase helps to unwind the siRNA-mRNA 
hybrid. The cleavage fragments are released for non-specific degradation and RISC can undergo 
multiple rounds of catalysis. 
 
It may also help in the release of the mRNA fragments for their degradation by non-specific 
RNases (Hutvagner and Zamore 2002a). This rate-determining step requires ATP and is 
essential to restore the RISC activity for further cycles of cleavage (Haley and Zamore 2004). 
Possibly, the function of the DEAD box helicase lies in the mRNA dissociation step, as the 
described instability between base pairs 9-14 would facilitate the dissociation-association 
reaction of DEAD helicase (Nykänen et al. 2001). Further, the action of ATP-dependent 
DEAD helicase would explain the energy requirements of the last step and the activity of 
siRNAs within a broad range of GC content (Reynolds et al. 2004). 
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Due to its large size of 80S (Pham et al. 2004; Zhang et al. 2004a), holo-RISC was 
suggested to be bound to ribosomes. This assumption is based on reports that RISC 
components from Drosophila were also found to precipitate together with ribosomes (Caudy 
et al. 2003; Caudy et al. 2002; Hammond et al. 2001), and Ago-2 and dFMR1 were detected 
in complex with 5S rRNA and ribosomal proteins L5 and L11 (Ishizuka et al. 2002). siRNAs 
conjugated to cell-penetrating peptides (CPPs) were found to localize in the perinuclear 
region for interactions with RISC (Chiu et al. 2004b). 
Ribosomal association of RISC would explain why mRNAs undergoing translation are more 
susceptible to RNAi than untranslated mRNAs. This picture could also explain the action of 
RISC in translational repression (Pham et al. 2004) 
 
1.1.7 The role of RNA dependent RNA polymerases (RdRps) 
For a long time it was debated whether a catalytic mechanism was sufficient to provide the 
high efficiencies observed in C. elegans (Fire et al.) or whether an additional amplification 
mechanism was involved.  
Such amplification could be attributed to RNA dependent RNA polymerases that are thought 
to transcribe aberrant RNA transcripts or long dsRNAs into the corresponding antisense RNA 
that hybridizes with its template. The resulting dsRNA can then be cleaved by Dicer to form 
siRNAs that lead to the degradation of the mRNA. The first RdRp found in context with RNA 
silencing was the Arabidopsis gene locus sgs2/sde2 that is essential for transgene 
suppression (Dalmay et al. 2000; Mourrain et al. 2000). It was followed by EGO-1, RRF-1 
and RRF-2 in C. elegans (Sijen et al. 2001a; Simmer et al. 2002; Smardon et al. 2000) and 
QDE-1 in Neurospora (Cogoni and Macino 1999a, 2000). Findings in C. elegans (Sijen et al. 
2001a) and Drosophila (Lipardi et al. 2001) suggest that siRNAs function as primers in the 
RNA synthesis from mRNA templates by RdRps. In this process, called random degradative 
PCR (Lipardi et al. 2001), the regions upstream of the primary dsRNA sequence are also 
amplified yielding a set of secondary siRNAs that do not show homology to the primary 
dsRNA sequence. In wheat germ extracts, ssRNA originating from transgenes is amplified by 
an RdRP even if no corresponding siRNAs are present (Tang et al. 2003). 
Despite the existence of an RdRp in flies, no secondary siRNAs were found in Drosophila 
(Roignant et al. 2003; Zamore et al. 2000). Mammals are completely deficient of RdRps 
(Stein et al. 2003) so that the high efficiency of RNAi can only be accounted for by the 
catalytic nature of RISC. In fact, it was shown that the siRNA guiding strand remains intact so 
that the active RISC can undergo up to 50 cycles of dsRNA cleavage (Haley and Zamore 
2004). 
 
1.1.8 RNAi in mammalian cells 
Since the discovery of RNAi, many attempts have been made to transfer this technique to 
mammalian cells not only to understand gene function but also to develop therapies against 
human diseases. Understanding the molecular basics of RNAi has played a key role in its 
development into a powerful tool for functional genomics and therapeutic approaches. 
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The first successful attempt to trigger RNAi in mammalian cells with synthetic siRNAs 
(Elbashir, 2001a) was followed by careful studies of siRNA features that are required for their 
recognition by RISC and their efficiency in gene silencing.  
Short RNAs of less than 21 or more than 25 bp have been shown to be significantly less 
efficient than the 21-23 bp species, while more than 30 bp trigger an interferon response. 3´-
overhangs as generated by Dicer play a crucial role in the recognition of the siRNAs, as does 
the phosphorylation of the 5´-hydroxy groups. Uridine overhangs enhance the efficiency of 
siRNAs, and deoxythymidine on both 3´ -ends additionally enhances the stability (Elbashir et 
al. 2001c). 2´-Deoxynucleotides in the 3´-2nt overhangs are generally tolerated, whereas O-
methylated deoxynucleotides abolish the RNAi efficiency completely. 
In chemically modified siRNAs, minor modifications at the 5´-terminus of the sense-strand 
are generally tolerated, such as the addition of fluorescent probes. However, small changes 
of the antisense-strand lead to a dramatic loss of efficiency (Chiu and Rana 2002). As the 
target mRNA is cleaved at the 10th nucleotide counting from the 5`-terminus of the guide 
strand, mispairing is more crucial for the first 10 nucleotides from the 5´-end of the antisense 
strand than for the 3´-terminal sequence (Amarzguioui et al. 2003; Chiu and Rana 2002; 
Elbashir et al. 2001c). As has been discussed above, the efficiency of siRNA strongly 
depends on the flexibility of the antisense-5´-terminus and can be greatly enhanced by 
destabilizing the 5´-terminus of the antisense strand with sequence mismatches and 
choosing stable base pairings for the sense-5´-terminus (Schwarz et al. 2003). 
Besides, mRNA and siRNAs can adopt a secondary structure that inhibits the binding 
recognition of the target mRNA, which reduces the silencing efficiency of the chosen siRNA 
sequence. Regions of high secondary structure can be detected experimentally or 
computationally revealing suitable target sequences that are free from secondary structure or 
protein binding sites.  
Of the different means to generate siRNAs in vitro, solid phase synthesis is the most 
versatile one, as it allows chemical modifications of the individual building blocks and leads 
to uniform siRNAs of high purity. Larger amounts of siRNAs of a defined sequence are 
generated by the in vitro transcription of DNA templates with T7 RNA polymerase (Donze 
and Picard 2002; Milligan et al. 1987; Sohail et al. 2003; Yu et al. 2002). Both 
complementary strands can be transcribed individually and then hybridized. Likewise, short 
inverted repeats that fold back to a hairpin structure are recognized by Dicer and fulfil the 
same function as siRNAs.  
To generate a pool of siRNAs covering different regions of a target gene, dsRNA comprising 
several hundred base pairs of the gene sequence are digested by active Drosophila embryo 
lysates (Holen et al. 2002; Nykänen et al. 2001; Zhang et al. 2002). These 
endoribonuclease-prepared short interfering RNAs (esiRNAs) have been successfully tested 
in mouse embryos (Calegari et al. 2002). Recombinant human Dicer (r-Dicer) was found to 
be well suitable for the in vitro generation of siRNAs (Myers et al. 2003) and is now 
commercially available (Gene Therapy Systems, Invitrogen). Also, artificial ribozymes were 
generated that mimic the Dicer activity and exceed the efficiency of the recombinant proteins 
(Sohail et al. 2003). In this context, allosterically controllable ribozymes, so-called 
maxizymes, have been devised to recognize and specifically cleave mRNAs in a RISC-like 
fashion (Oshima et al. 2003). 
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To further scale up the production of siRNAs in a cost-efficient manner, recombinant tobacco 
plants (Nicotiana tabacum) were generated that express long hairpin-shaped RNA that is 
processed to siRNAs by the PTGS machinery in the living plant. It could be shown that 
siRNAs purified from plants could induce RNAi in mammalian cells with an efficiency similar 
to that of synthetic siRNAs targeting the same endogenous or viral genes (Zhou 2004). 
Without an amplification mechanism, the siRNA concentration in mammalian cells decreases 
in the process of cell division. After 8-10 cycles mRNA levels return to their normal values so 
that siRNA-triggered RNAi in mammalian cells is only transient. Only proteins with a 
sufficiently short half-life time can be targeted so that the remaining protein can be fully 
degraded before the mRNA levels recover. Otherwise, the cells have to be treated 
repeatedly to keep the level of mRNA low. 
Transient methods help to study the function of developmentally important genes in grown-
up organisms where a stable knockout would induce an embryonically lethal phenotype.  
 
1.1.9 Stable RNAi in mammalian cells 
To increase the persistence and efficiency of RNAi in mammals, dsRNA may be generated 
inside the cells. This is achieved by the transfection of plasmids employing siRNA or short 
hairpin RNA (shRNA) expression cassettes under the control of an RNA polymerase III 
promoter. In early experiments, these vectors expressed separate 21nt short RNAs 
corresponding to the target sequence and its complementary sequence that could hybridize 
to form siRNAs (Lee et al. 2002; Miyagishi and Taira 2002). It turned out to be much more 
efficient to express both sequences in one transcript. These so-called inverted repeats fold 
back to form short hairpin RNAs (shRNAs) that resemble pre-miRNAs and undergo 
processing by Dicer (Brummelkamp et al. 2002b; Paddison et al. 2002a; Paul et al. 2002; Sui 
et al. 2002; Yu et al. 2002). The shRNA approach is commonly used due to its higher 
efficiency.  
The amount of siRNA/shRNA generated under the RNA polymerase III promoter allows the 
generation of persistent phenotypes and the down-regulation of gene-products with long half-
life times. However, the generation of the inverted-repeat and the selection of cells exhibiting 
the RNAi phenotype is a time-consuming process. Therefore, an efficient silencing sequence 
needs to be carefully selected as described for the transient approach. Despite many 
attempts to predict the RNAi efficiency of a given sequence, the efficiency is often probed by 
transfecting synthetic siRNAs covering a set of convenient sequences and measuring the 
knock-down rate (Lee et al. 2002). Using a set of siRNAs corresponding to different regions 
of the target sequences leads to cooperative silencing effects (Ji et al. 2003; Zhang et al. 
2002). 
The first stable expression of shRNA in vivo was performed with a pSUPER vector 
containing a human polymerase-III H1-RNA promoter (Brummelkamp 2001). To date, RNA 
polymerase III promoters such as human H1 and murine U6 are commonly used to control 
the expression of shRNAs (Brummelkamp et al. 2002b; Kwak et al. 2003; Lee et al. 2002; 
Miyagishi and Taira 2002; Paddison et al. 2002b; Paul et al. 2002; Sui et al. 2002) as it was 
known from antisense and ribozyme experiments that these systems are highly stable and 
efficient (Ilves et al. 1996; Jennings and Molloy 1987; Sullenger et al. 1990). Transcripts 
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driven by an RNA polymerase III (pol III) promoter terminate with 1-6 uridine residues that 
are readily recognized as a 3´-overhang by the RNAi machinery. Transcription via an RNA 
pol II promoter leads to transcripts with an m7G 5´-cap and a 3´-poly-A tail, that are more 
efficiently exported to the cytosol. More recent approaches make use of tRNAMet (Boden et 
al. 2003b) and tRNAVal derived promoters that lead to an up to 60% higher rate of expression 
and enhance the export rates (Kawasaki and Taira 2003). 
 
 
 
Figure 1-9 Expression of short hairpin RNAs. The choice of the promoter determines the features of 
the RNA transcript. 
 
Minimal siRNA expression units comprising a U6 promoter can be easily obtained by PCR. If 
transfected into mammalian cells, this short stretch of DNA is transcribed into functional 
siRNA. This technique is of special interest for the validation of different siRNA sequences 
and for the screening of siRNA gene libraries (Michienzi et al. 2003). 
siRNAs generated from long hairpin RNAs (lhRNAs) in vivo are likely to be more efficient 
than shRNAs as they cover different regions of the target mRNA. Cleavage of long dsRNA 
by Dicer leads to the binding of the siRNAs to R2D2 facilitating their recruitment by RISC 
(Zamore 2001). Somatic transgenic cell lines expressing lhRNA of up to 800 bp exhibit a high 
degree of RNA silencing and a persistent knock-out phenotype that allows extensive studies 
of metabolic changes (Diallo et al. 2003a; Paddison 2002; Yi et al. 2003). As opposed to 
transfected long dsRNAs, no interferon response was detected in cells endogenously 
expressing lhRNAs. Possibly, transfection and selection is only survived by cells producing 
small amounts of dsRNA or by cells deficient in some component of the interferon pathway. 
By means of electroporation, an shRNA expressing vector was successfully transferred into 
murine somatic cells (Brummelkamp et al. 2002b) and even into embryonic stem cells 
establishing  cell-lines with a stable phenotype (Kunath et al. 2003). However, the phenotype 
is only transient if the cells are not subjected to an antibiotic selection procedure. 
First reports of transgenic mice and rats expressing siRNAs displaying stable phenotypes 
have already been published (Hasuwa et al. 2002) and it was reported that dsRNA 
expressing transgenic vectors are passed on to progeny (Carmell et al. 2003). 
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Figure 1-10 DNA-vector for the expression of long hairpin RNA. The up to 800 bp cDNA sequence is 
cloned twice in sense and inverse orientation. Transcripts from this inverted repeat fold back onto 
themselves to form a long hairpin-shaped RNA (Schepers 2004). 
 
By this method, genes that are essential in early stages of development can be silenced in 
fully-grown animals, if the shRNA expression cassette is preceded by an inducible promoter. 
Thus, shRNA production can be triggered by an external clue such as change in temperature 
or the application of a specific drug (Blochlinger et al. 1991; Gonzalez-Reyes and Morata 
1990). The expression of shRNAs could be also controlled by the Cre/loxP recombination 
system in which the expression vector is switched on by the action of Cre-recombinase that 
is added to the medium and enters the cells due to a cell-penetrating fusion tag (Kasim et al. 
2004). 
All these approaches allow triggering the gene silencing at different stages of development. 
The down-regulation of target genes can be restricted to one tissue, if tissue specific 
promoters are used to control the expression of the hairpin RNA (Brand and Perrimon 1993; 
Giordano et al. 2002; Lee et al. 2003a; Parkhurst et al. 1990).  
 
1.1.10 Viral vectors to trigger RNAi 
Applications of RNAi in mammalian cells are limited as some cell lines and especially primary 
cells are difficult to transfect and cannot be grown in culture for longer periods. Therefore, 
retroviral vectors have been applied to deliver plasmids into cells (Brummelkamp et al. 
2002a; Hemann et al. 2003; Paddison 2002).  
The Moloney murine leukemia virus (MoMuLV) vector was modified by incorporation of a U6 
expression cassette into the long terminal repeat (LTR), which resulted in a duplication of the 
U6 cassette during reverse transcription of the viral genomic RNA. The viral expression of 
the shRNA induced the silencing of the targeted p53 tumor suppressor in murine 
hematopoietic stem cells (Paddison et al. 2002a). The same was achieved with an H1 
expression cassette against p53 that was virally transfected into human fibroblasts (Barton 
and Medzhitov 2002). 
A self-inactivating murine stem cell virus (MSCV) vector was successfully used to express 
shRNAs targeting nuclear Dbf2-related (NDR) kinase (Devroe and Silver 2002) and to 
generate siRNAs directed against a mutated form of Ras that down-regulated the Ras 
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oncogene without affecting the wild-type form in human bladder cancer cells (Brummelkamp 
et al. 2002a).  
Retroviral vectors bear an oncogenic potential and require active cell division for gene 
transduction. To overcome these limitations, adeno-associated viral vectors (AAVs) have 
been employed to efficiently deliver siRNAs and down-regulate genes in dividing and non-
dividing cells (Tomar et al. 2003). Lentiviruses are even more efficient in delivering siRNAs 
into cells. They can infect both dividing and post-mitotic cells (Abbas-Terki et al. 2002; 
Banerjea et al. 2003; Bonci et al. 2003; Scherr et al. 2002; Tiscornia et al. 2003; Tomar et al. 
2003). Lentiviruses have been successfully applied in cultured primary dendritic cells, where 
they led to the expression of shRNAs targeting transgenic green-fluorescent protein (GFP) 
(Stewart et al. 2003) and the pro-apoptotic BimI (Rubinson et al. 2003). The same approach 
was functional in primary T-cells (Rubinson et al. 2003). Despite their enormous potential to 
transfer vectors for siRNA and shRNA expression into cells, retroviruses randomly insert new 
sequences into the host genome which may disrupt genes leading to the formation of tumors 
or leukemias (Hacein-Bey-Abina et al. 2003a; Hacein-Bey-Abina et al.). The same is true for 
adeno-associated viral vectors (AAVs) (Tomar et al. 2003) indicating that the use of viral 
vectors in vivo generally constitutes a considerable risk. Therefore, the application of viral 
vectors may remain limited to analytical applications.  
 
1.1.11 Cure for diseases 
With its establishment in mammalian cells, RNAi became interesting for therapeutic 
approaches. Due to its high specificity and efficiency it bears a high potential to silence RNA 
viruses, interfere with the metabolism of parasites, inhibit the growth of tumor cells, or cure 
the effects of inherited genetic defects. The approaches vary from the mere attempts to 
understand the underlying mechanism to the fight against infectious diseases and cancer. 
Most of the studies clearly show that RNAi will hold its promise to become an efficient tool in 
the treatment of viral and other infectious diseases in human. However, before RNAi can 
make its way to therapeutic applications, an appropriate siRNA delivery system is required to 
guide the active species to the target organs, a problem that is far from being solved. In spite 
of the great excitement created by those studies, it has to be kept in mind that most of the 
experiments were performed in cell culture or model animals using laboratory strains of 
viruses that are well characterized. 
As the human immunodeficiency virus (HIV) constitutes a major threat to people all over the 
world, many groups have started to develop RNAi-based strategies to fight the virus and 
almost all of the viral genome has been targeted by RNAi approaches. 
The first promising attempt to inhibit HIV-infection aimed at the HIV-1 cellular receptor CD4 
and HIV-1 nef (Novina et al. 2002). In the following, siRNAs and shRNAs have been 
successfully applied to inhibit HIV1 replication in human cell lines and primary lymphocytes 
by targeting Rev and Tat (Coburn and Cullen 2002; Dave and Pomerantz 2003; Lee et al. 
2003a), Gag (Capodici et al. 2002; Novina et al. 2002), Env (Park et al. 2003), gp41, nef 
(Dave and Pomerantz 2003), and LTR (long terminal repeat) (Yamamoto et al. 2002). 
Lentiviral vectors have successfully inhibited HIV-1 infection in mice and primary 
macrophages (Banerjea et al. 2003; Lee et al. 2003a) and in human T-cells (Qin et al. 2003). 
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However, the high mutation rate of HIV limits these approaches: HIV-1 has already been 
observed to escape from RNAi by point mutations in the targeted sequence (Boden et al. 
2003a). DNA-vectors expressing a variety of siRNAs may be used to overcome viral 
resistance, and sequences of highly conserved regions of the viral genome have to be 
chosen as targets (Anderson et al. 2003; Boden et al. 2004a; Boden et al. 2003b; Boden et 
al. 2004b; Dunn et al. 2004; Jacque et al. 2002; Lee et al. 2002; Martinez et al. 2002b; 
Michienzi et al. 2003; Novina et al. 2002; Yamamoto et al. 2002). As an alternative, T-cell 
receptors of the host cells essential for viral entry such as CCR5 (Arteaga et al. 2003; Lee et 
al. 2003a; Qin et al. 2003), CXCR4 (Martinez et al. 2002c), and CD4 (Novina et al. 2002) can 
be down-regulated to prevent the infection of new cells. In this context, human lysyl-tRNA 
synthetase was down-regulated to prevent the incorporation of the tRNA-Lys iso-acceptors 
into the HIV 1 particle, which lead to a decrease in infectivity (Guo et al. 2003). 
More striking results were obtained on hepatitis B virus (HBV). RNAi could inhibit the 
production of HBV replicative intermediates in cell culture and in immunocompetent and 
immunodeficient mice transfected with an HBV plasmid (McCaffrey et al. 2003). Upon siRNA 
delivery to mice by hydrodynamic injection, substantially reduced (up to 90%) levels of HBV 
RNAs and replicated HBV genomes were found in mouse liver. In these studies, most of the 
targets are genes that are relatively conserved between different viral strains and exhibit a 
low mutation activity as it is found for the genes essential for replication. The transfection of 
siRNAs also inhibited the replication of hepatitis B virus in hepatic cell lines (Hamasaki et al. 
2003; Shlomai and Shaul 2003; Ying et al. 2003). Likewise, host genes that are required for 
viral entry or that play an essential role in the viral life cycle are also potential targets 
(Lieberman et al. 2003). The downregulation of Fas-protein expression in hepatocytes by 
transfected vectors that express siRNAs has turned out to prevent fulminant hepatitis in mice 
(Song et al. 2003a). 
Like hepatitis B, hepatitis C is rapidly spreading and has been in the focus of RNAi-based 
therapeutical approaches (Shlomai and Shaul 2004). Transfected and vector derived siRNAs 
inhibited the protein expression of the hepatitis C virus (HCV) in hepatocytes without 
affecting endogenous genes (Kapadia et al. 2003; Kronke et al. 2004; Sen et al. 2003). In 
mice, transgenic HCV proteins were degraded by the hydrodynamic injection of siRNAs and 
plasmids expressing shRNAs (McCaffrey et al. 2002).  
The effective silencing of proteins from the respiratory syncytical virus by synthetic siRNAs at 
low nanomolar concentrations in A549 cells was the first report about the use of RNAi to 
combat human viruses (Bitko and Barik 2001). In the meantime a broad range of viruses has 
been targeted comprising γ-herpes virus (Jia and Sun 2003), human papilloma virus (Butz et 
al. 2003; Hall and Alexander 2003; Milner 2003), rotavirus (Dector et al. 2002), influenza (Ge 
et al. 2003), herpes simplex virus (Godfrey et al. 2003), Epstein-Barr virus (Li et al. 2004) 
and human T-cell leukemia virus-1 (Stewart et al. 2003). Attempts to cure the SARS (severe 
acute respiratory syndrome) with siRNA techniques are on their way (He et al. 2003; Qin et 
al. 2003; Wu et al. 2003; Zhang et al. 2004c).  
Soon after the first report that replication of poliovirus in HeLa cells could be reduced by 
silencing a polio-specific capsid protein (Gitlin et al. 2002), it was found that poliovirus can 
also escape from RNAi selection by mutation of the target sequence, indicating that viral 
escape through sequence mutation is a common obstacle in RNAi based viral therapies.  
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Figure 1-11 Cell viability in the presence of siRNA, determined by trypan blue staining at various times 
after infection The graph indicates the number of surviving infected cells after infection with poliovirus 
and treatment with different siRNAs one corresponding to a capsid sequence (siC), another to a viral 
polymerase sequence (siP), and an unrelated siRNA corresponding to a firefly luciferase coding 
sequence (siL). The graph demonstrates that the downregulation of the viral particles is not complete 
that is probably due to several problems such as transfection efficiency, efficacy of the siRNA, and 
viral behavior (source Gitlin et al. 2003). 
 
To overcome this obstacle siRNA double expression (SiDEx) vectors are being developed to 
simultaneously target several viral genes and prevent viral escape (Boden et al. 2003a). 
Moreover, adenovirus VA1 possesses a non-coding RNA that can inhibit shRNAs and 
miRNA biogenesis. Remarkably, RNAi triggered by exogenous siRNAs was not affected. 
However, nuclear export of shRNAs and miRNAs is impaired. Thus, viruses can actively 
block the RNAi mechanism rather than simply escaping specific target sequences (Lu and 
Cullen 2004). 
At the same time, RNAi studies help to understand the functions of viral genes revealing new 
drug targets, as has been shown for the arenavirus (Perez and White 2003).  
The study of gene function in parasites such as the nematode Brugia malayi (Aboobaker and 
Blaxter 2003), the sporocyst Schistosoma mansoni (Skelly et al. 2003), and the protozoa 
Leishmania (Robinson and Beverley 2003) by RNAi will help to develop new antiparasitic 
drugs based on RNAi or on lead structures derived from insights obtained by RNAi. Studies 
on host organisms that transfer parasites to humans as anopheles mosquitos (Brown et al. 
2003; Jayachandran and Fallon 2003) may aid in the development of drugs to specifically 
and efficiently reduce the host population and thereby stall the spread of diseases among 
humans. Several in vitro studies have already demonstrated the potential use of RNAi in 
cancer treatment. Cancer cells usually differ from normal cells by their uncontrolled growth 
and the ability to escape programmed cell death (apoptosis). For nutrition supply, they 
assemble a network of blood vessels around tumors, and to evade chemotherapy, they may 
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change surface composition. Targets for a possible RNAi treatment are therefore genes that 
are either involved in cell division and proliferation such as growth factors, tumor suppressor 
genes, transcription factors, and apoptosis inhibitors (Adams et al. 2001; Aza-Blanc et al. 
2003; Brummelkamp et al. 2003; Chatterjee 2003; Chen et al. 2002b; Cioca et al. 2003; 
Duxbury et al. 2003; Dzitoyeva et al. 2003; Grzmil et al. 2003; Jiang and Milner 2003; Lin et 
al. 2001; Milner 2003; Subramanian and Chinnadurai 2003; Tanaka et al. 2003; Wall and Shi 
2003; Wang et al. 2004; Wilda et al. 2002; Zangemeister-Wittke 2003) or proto-oncogenes 
that take part in many regulatory events and signaling cascades such as Ras and Bcl-2 
(Tanaka et al. 2003), as well as viral oncogenes, such as from human papilloma virus (HPV). 
Another characteristic feature of cancer cells is their uncontrolled growth. Therefore, genes 
that are involved in cell division and proliferation such as growth factors, tumor suppressor 
genes, transcription factors, and apoptosis inhibitors have been targeted by RNAi (Aza-Blanc 
et al. 2003; Brummelkamp et al. 2003; Chatterjee 2003; Chen et al. 2002b; Cioca et al. 2003; 
Duxbury et al. 2003; Dzitoyeva et al. 2003; Grzmil et al. 2003; Jiang and Milner 2003; Lin et 
al. 2001; Milner 2003; Subramanian and Chinnadurai 2003; Tanaka et al. 2003; Wall and Shi 
2003; Wang et al. 2004; Wilda et al. 2002; Zangemeister-Wittke 2003). Similarly, mutated 
forms of proto-oncogenes like Ras (Tanaka et al. 2003), c-myc (Rutz and Scheffold 2004), 
and PKA (Farrow et al. 2003), that play a role in signaling cascades, or genes participating in 
cell-cycle regulation like p53 (Hemann et al. 2003) are common targets in the search for 
cancer therapeutics.  
In many tumors anti-apoptotic proto-oncogenes are overexpressed or mutated to a 
constitutively active form, so that apoptosis is impaired. These cells become resistant to 
chemotherapy and apoptosis triggered by the death receptor pathway (Zangemeister-Wittke 
2003). Downregulation of other proto-oncogenes and apoptosis inhibitors, such as cdk-2, 
mdm-2, pkc-α, tgf-β1, h-Ras, and vegf, effectively suppressed the proliferation of cancer cells 
to different extents leading to the conclusion that chemically synthesized and vector-driven 
siRNAs can inhibit the growth and proliferation of cancer cells (Yin et al. 2003a; Yin et al. 
2003b). Ras is a powerful regulator of several interconnected receptor-signalling pathways. 
In its mutated form it is constitutively active and acts as an oncogene. Oncogenic k-Ras (h-
Ras) is responsible for the early onset of tumors and the maintenance of tumor viability. It is 
thought to contribute to malignant transformation in many cell types, which makes elements 
of this signalling-pathway attractive targets for inhibition by RNAi (Cunningham and 
Weinberg 1985). Previous attempts to silence the k-Ras oncogene with phosphorothioate 
oligonucleotides succeeded in stabilizing the disease. Silencing of crucial effectors in the Ras 
signaling like the Raf-c kinase by oligonucleotides show low to moderate effects in vitro and 
in an in vivo tumor-xenograft model, while treatment with siRNAs can specifically silence 
expression of oncogenic k-Ras in tumor cells leaving the non mutated wild type k-Ras 
untouched (Brummelkamp et al. 2002a; Duursma and Agami 2003). Although the silencing of 
the mutated mRNA was only 95%, the protein level was completely reduced. This led to a 
complete loss of tumorigenicity (Brummelkamp et al. 2002a). 
The RNAi mediated inhibition of these oncogenes has helped to recover the normal 
apoptosis pathways (Konnikova et al. 2003; Lima et al. 2004; Yin et al. 2003a). A common 
example for this class of genes is the B-cell lymphoma protein 2 (Bcl-2), which is discussed 
to convey resistance to chemotherapy and to prevent apoptosis in its constitutively active 
 31
form (Cioca et al. 2003; Futami et al. 2002; Jiang and Milner 2003; Lima et al. 2004; 
Subramanian and Chinnadurai 2003). 
Cancer cells often develop transporters for the export of chemotherapeutics, which leads to 
multidrug-resistance. Tumors also produce factors that trigger angiogenesis (blood vessel 
formation) to provide their own supply with nutrients for further growth. Both classes of 
proteins are potential RNAi targets (Ameri et al. 2004; Bachelder et al. 2003; Deroanne et al. 
2003; Jarad et al. 2002; Liu et al. 2003a; Nagashima et al. 2002; Niu et al. 2004; Riss et al. 
2003; Schafer et al. 2003; Sun et al. 2003; Tien et al. 2004; Zhang et al. 2003; Zippo et al. 
2004). RNAi experiments on cancerogenous targets have been carried out in a number of 
different cells many of which are difficult to target by other therapeutic means like murine 
hematopoietic stem cells (HSC) (Hemann et al. 2003), pancreatic cell-lines (Brummelkamp et 
al. 2002a), lung adenocarcinoma cells (July et al. 2004) and even epithelial lung cultures 
(Sunaga et al. 2004). In a comparative study, single siRNAs and combinations of siRNAs 
were transfected into HeLa cells, lung adenocarcinoma cells, hepatoma cells, ovarian 
carcinoma cells, and melanoma cells. A major drawback for the application of RNAi in 
therapy remains the issue of site- and tissue-specific delivery. Although proto-oncogenes can 
be specifically targeted without affecting the wild type gene, many of the other target proteins 
play their essential role in non-proliferating cells and healthy organs so that their systemic 
knockout would lead to severe side effects. For the down-regulation of such targets, 
techniques for direct delivery to the tumor are required.  
 
RNAi approaches are also applied to study the mechanisms of cardiovascular diseases, that 
cause the highest mortality in the western world beside cancer and infectious diseases 
(Lorenz et al. 2003; Schafer et al. 2003; Wolff and Herweijer 2003). The first step towards 
prophylactic therapies seems to be the systemic application of siRNAs targeting apo-
lipoprotein B, a protein not amenable to inhibition by conventional small-molecule 
therapeutics (Soutschek et al. 2004) in order to decrease the risk of coronary artery disease. 
With the increase of life expectancy in western countries, the number of patients suffering 
from Alzheimer’s disease is steadily increasing. First approaches were already ongoing to 
elucidate possible candidate genes responsible for Alzheimer's disease (Asai et al. 2003; 
Francis et al. 2002; Kao et al. 2004; Marlow et al. 2003; Mattson 2003; Miller et al. 2003; 
Takasugi et al. 2003). Also, mechanisms of Parkinson’s disease have been investigated with 
RNAi (Kiehl et al. 2000; Love 2004; Yang et al. 2003), and dominant disease alleles such as 
mutations in the Cu, Zn superoxide dismutase (SOD1) gene resulting in myotrophic lateral 
sclerosis (Ding et al. 2003; Maxwell et al. 2004; Xia et al. 2003) have been used as targets. 
dsRNA mediated gene silencing finally helped to decrease the spread of prion proteins in 
bovine spongiform encephalopathy (BSE) (Tilly et al. 2003). 
However, neurons in culture are sensitive to invasive procedures and transfection 
efficiencies by conventional methods are poor. In vivo, the blood brain barrier prevents the 
uptake of drugs from the vascular system with exception of small (less than 500 Da), lipid-
soluble molecules preventing the intravenous application of oligonucleotides to the brain 
(Trulzsch et al. 2004). Even though it is possible to treat primary neurons and neuronal cell 
lines with siRNAs (Krichevsky and Kosik; Omi et al. 2004; Trulzsch et al.) in vivo studies in 
mice are just at the beginning and still have their drawbacks. Adenoviral vectors successfully 
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passed the blood brain barrier and were expressed in the brain after intravenous application 
(Moon et al. 2003) and direct injection of siRNA expressing adenoviral vectors into the brain 
lead to a decent RNAi phenotype (Xia et al. 2002). 
The large number of results gathered in hardly four years of RNAi research in mammals 
seems to promise a bright future for RNAi as a therapeutic tool. However, the rapid progress 
also revealed a number of drawbacks of RNAi, and many obstacles need to be overcome 
until RNAi can be applied in clinical studies ranging from siRNA stability in vivo to the 
delivery issue and questions of tissue selectivity. 
 
1.1.12 Non-specific effects of siRNAs 
When the first steps into the direction of RNAi therapy were taken, it was assumed that 
siRNAs or dsRNAs would specifically degrade homologous mRNA without affecting the 
expression of other genes. The specificity issue was put into doubt by the finding that point 
mutations are tolerated by the silencing machinery (Boutla et al. 2001; Holen et al. 2002) 
especially if the mismatches are located in the 3´-terminal half of the antisense strand (Chiu 
and Rana 2003). siRNAs with up to 5 mismatches at the 5´-end and nine mismatches at the 
3´-end can still trigger target cleavage by Dicer albeit at a markedly lower rate (Haley and 
Zamore 2004). Like miRNAs, siRNAs with 3-5 mismatches targeting the 3´-UTR region of a 
gene impair the translation of the mRNA without triggering its degradation (Ambros et al. 
2003; Jackson et al. 2003; Saxena et al. 2003). In this process, 5´-complementarity is 
essential as it provides most of the binding strength (Doench and Sharp 2004), while 
mismatches and wobble base pairs are accepted at the 3´-end. This allows a large number 
of non-specific sequences to suppress translation of the same gene, and vice versa a single 
siRNA can impair the translation of several genes. 
Today, it is well-known that a single siRNA can affect whole cellular expression patterns, and 
that siRNAs targeting different regions of the same mRNA may have entirely different effects 
on expression patterns (Jackson et al. 2003). These off-target effects are attributed to 
mismatched binding of siRNAs leading to translational repression and thus to altered 
expression patterns (Ambros et al. 2003; Jackson et al. 2003). Sense strands with instable 
5´-ends will be preferentially incorporated into RISC, but even if the antisense strand is 
preferred a small fraction of sense strands may be incorporated as guide strands. Therefore, 
when choosing RNAi target sequences, homology screens have to be carried out for the 
sense-sequence, too, to avoid off-target effects (Jackson et al. 2003). 
In this context, the role of the interferon response has to be reconsidered. Although neither 
interferon response nor non-specific effects were found for siRNAs at doses around 100 nM 
(Elbashir et al. 2001a), recent experiments have shown the up-regulation of interferon-
stimulated genes, such as the Jak-Stat pathway, in the nucleus upon the transfection with 
siRNAs or the transcription of shRNAs (Bridge et al. 2003; Sledz et al. 2003). This effect was 
markedly stronger for the transcription of shRNAs, which yields higher intracellular 
concentrations of siRNAs (Bridge et al. 2003). However, it has been long known that the 
transfection of almost all plasmids triggers the interferon response (Akusjarvi et al. 1987). 
Studies in living mice, on the other hand, failed to detect an interferon response triggered by 
Toll-like receptor 3 (TLR3) that recognizes dsRNA, or TLR9 that detects CpG motifs, and no 
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IL-12 or IFN-α responses could be detected (Heidel et al. 2004). It turned out that the 
interferon response was triggered by enzymatically-generated siRNAs, that contain 3´-
triphosphates on both strands. Removal of the triphosphates by incubation of the transcripts 
with phosphatase abolished the interferon response (Kim et al. 2004). 
Non-specific effects can be reduced by using sets of siRNAs that cover several regions of 
the target mRNA, and by avoiding near-homologous off-targets by conducting a BLAST 
search or a Smith-Waterman search with putative siRNA sequences. It was shown that 
effective targets exist in mice, Drosophila and C. elegans that are unlikely to accidentally 
silence other transcripts (Snove and Holen 2004). New design rules for siRNAs have been 
devised in order to increase the efficiency of siRNAs and reduce off-target effects (Khvorova 
et al. 2003; Reynolds et al. 2004; Schwarz et al. 2003; Yamada and Morishita 2004).  
The original design rules for siRNAs were based on experimental findings from the Tuschl 
group (Elbashir et al. 2001a) and therefore became known as the “Tuschl rules”. They 
predict good efficiency for 19 bp sequences with 2 nt overhangs that target an mRNA 
sequence of the form of the form AA(N19)TT (with N as any nucleotide) or less favorable 
NA(N19)TT, where the sense strand corresponds to positions 3-23 and the antisense-strand 
to the complement of positions 1-21. Target sequences with a purine at position 3 and a 
pyrimidine at position 21 yield improved results. 
For long it was thought, that the position of the target sequence on the mRNA was decisive 
for RNAi efficiency (Elbashir et al. 2001c). Recent experiments have shown that neither 
secondary structures in the target sequence nor the localization of this sequence along the 
mRNA strand are decisive. Only the target sequence itself, with different base pairings at 
specific sites determines the siRNA activity (Yoshinari et al. 2004). 
The more recent rules also employ algorithms that account for the thermodynamic properties 
of siRNAs. The 5´-terminus of the antisense strand needs to be destabilized by A-U 
basepairs or single mismatches at positions 2-4, while the 5´- end of the sense strand needs 
to be stabilized by G-C pairings to obtain siRNAs with an exclusive RISC-incorporation of the 
antisense-strand (Schwarz et al. 2003). The difference in thermodynamic stabilities of sense 
and antisense strand directly correlates with the siRNA efficiency. 
Furthermore, an accumulation of less stable A and T bases in the region around position 10 
from the 5´-terminus of the guide strand helps in the unwinding of the siRNA-mRNA duplex 
for target cleavage. This is taken into account by a new algorithm that demands a sense 
strand with a T at position 10, no G at position 13, and no C or G at position 19, as well as an 
A at positions 3 and 19 with respect to the 5´-terminus. Moreover, the G/C content should be 
30-52% and no internal repeats or palindromes should occur to avoid secondary structures 
(Reynolds et al. 2004). 
As the rate of cleavage is low for mismatched siRNAs, off-target effects may be minimized by 
keeping the amount of loaded RISC as low as possible. This means that siRNA design has 
to balance the competing demands of efficacy and specificity (Haley and Zamore 2004). 
 
1.1.13 Modifications of siRNAs for in vivo applications 
Albeit more stable than single-stranded antisense RNA, siRNAs are subject to degradation 
by exonucleases which reduces their in vivo half-life time. Different means to stabilize 
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oligonucleotides for in vivo applications have been examined in context with antisense 
mediated gene silencing, but not all of them are functional in RNAi. In general, modifications 
on the sense strand are tolerated, while manipulating the antisense strand abolishes RNAi 
activity (Chiu and Rana 2002) apparently due to interference with its incorporation into RISC. 
As in antisense techniques, phosphorothioates increase the stability of siRNAs but at the 
same time enhance cytotoxicity. 
 
In the process of nuclease-mediated cleavage, 
2´,3´-cyclophosphates are formed on the 5´-
terminal fragment. So 2´-modifications that 
prevent cyclophosphate formations may help 
to stabilize siRNAs in vivo. Indeed, methylation 
of the 2´-hydroxyl groups leads to persistence 
of RNAi, and apart from allylation most 
modifications are tolerated (Amarzguioui et al. 
2003). This also indicates that 2´-OHs are not 
essential for the recognition by Dicer or the 
incorporation into RISC (Chiu and Rana 2003). 
Early studies have already shown that 
substitution of the ribonucleotides in the 3´-
overhangs by 2´-deoxyribonucleotides 
(especially by dUdU) leads to a stabilization of 
the siRNA (Elbashir et al. 2001c). Such 
modifications prolong the half-life of siRNAs in 
serum up to 2h (Heidel et al. 2004). However, 
2´-deoxyribonucleotides and 2´-methylated 
nucleotides at other positions have been found 
to render siRNAs inactive. 
In recent studies, 2´-fluoro-modifications not 
only increased the half-life span of siRNAs in plasma extracts but also prolonged the duration 
of the gene silencing (Chiu et al. 2004b). 
The fact that the guide strand hybridizes with the target mRNA to an A-form helix (Chiu and 
Rana 2003) explains that siRNAs cannot be replaced by dsDNA (Elbashir et al. 2001c; 
Parrish et al. 2000) as a DNA-RNA hybrid would rather adopt an intermediate between A- 
and B-form helix (Cummins et al. 1995) that impairs RISC mediated target cleavage. At the 
same time, a combination of 2´-fluoro- and 2´-deoxy modifications on the same strand 
permits the formation of A-type helices upon mRNA binding and is therefore tolerated by the 
RNAi machinery (see 1.1.6). 
In the meantime, companies have developed chemical modifications on siRNAs that not only 
lead to a stabilization towards nucleases but also decrease the interferon response. These 
siRNAs are now sold as StealthTM siRNAs (Sledz et al. 2003). 
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Figure 1-12 Conformations of DNA. Major and minor grooves in both helices are of different size. As 
opposed to dsDNA that preferentially adopts a B-form helix, dsRNA is found in an A-helical 
conformation. Hybrids of DNA and RNA adopt an intermediate conformation, that is not recognized by 
RISC (Schepers 2004). 
 
Another recent strategy is the use of locked ribonucleotides (LNA), in which the 2´- and 5´-
positions are bridged by a methylene group to fix the nucleotides conformation and protect 
the 2´-position from nuclease attacks (Braasch et al. 2003). Also, stereoregular 
boranophosphate siRNAs are not only stabilized against nuclease degradation but also 
significantly more effective and more potent than phosphorothioate siRNAs and native 
siRNAs (Hall et al. 2004).  
Recent findings indicate that degradation by nucleases and dilution by cell division are not 
the only factors that limit siRNA efficiency in mammals. Adenosine deaminase acting on RNA 
(ADAR) is responsible for the editing of mRNA sequences, which regulates their nuclear 
export. It recognizes short double stranded regions of the target RNA, where it converts an 
adenosine into an inosine. ADAR-1 is localized to the cytosol, where it exhibits a markedly 
high binding affinity for siRNAs. RNAi efficiency is markedly increased in ADAR deficient 
cells (Yang 2004). Means to circumvent ADAR binding without affecting siRNA recognition 
by Dicer and RISC still need to be devised. 
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1.1.14 The delivery issue 
The application of synthetic siRNAs in vivo is severely restricted by insufficient transfection 
efficiency and the limited persistence of the transient RNAi phenotype. As already described, 
vectors expressing short hairpin RNAs help to establish cell lines with a stable RNAi 
phenotype. However, like siRNAs, DNA expression vectors require classical methods such 
as liposome-mediated transfection (Caplen et al. 2001; Elbashir et al. 2001a; Gitlin and 
Andino 2003; Martins et al. 2002; Novina et al. 2002; Park et al. 2003), microinjection (Usui 
et al. 2003), and electroporation (Cioca et al. 2003; Siegmund et al. 2002) to reach the 
interior of the cells. Many cell lines are easy to transfect, and various cationic liposomal 
formulations were developed to increase transfection efficiency to up to 90% depending on 
the cell type. Without cell division, shRNA (DNA) constructs cannot enter the nucleus as 
required for DNA transcription, and most non-dividing cells are not susceptible to transfection 
as are primary cells and stem cells. Electroporation is an alternative for application of siRNAs 
and shRNA expression vectors in non-dividing cells or cells resistant to chemical transfection 
reagents (Dunne et al. 2003; Heidenreich et al. 2003; Scherr et al. 2003; Walters and Jelinek 
2002). It has also been applied to living organisms such as chicken embryos (Pekarik et al. 
2003) and mouse embryos (Calegari et al. 2002) where liposomal transfection is no longer 
feasible. 
Many of the methods that are successfully used in vitro cannot be used in entire vertebrate 
animals. High toxicity of most cationic transfection reagents prohibits whole body application 
of siRNAs by liposomal or chemical approaches. The delivery of siRNAs or shRNA 
expression vectors by recombinant adenoviruses (Hemann et al. 2003; Rubinson et al. 2003; 
Tiscornia et al. 2003) reaches almost every cell or tissue, including stem cells and neurons, 
but goes along with an intolerable risk of leukemia and other cancers if applied systemically 
in fully-grown organisms (Hacein-Bey-Abina et al. 2003a). 
Physical techniques like electroporation and the hydrodynamic injection method were 
successfully applied in mice. Naked siRNAs applied to mice via tail-vein injection accumulate 
in liver, kidney, spleen, lung, and pancreas where they knocked-down a reporter gene (Lewis 
et al. 2002; McCaffrey et al. 2002) as well as endogenous genes (Chang et al. 2001; Lewis 
et al. 2002; McCaffrey et al. 2003; Zhang et al. 1999). Also, naked siRNAs have been 
successfully applied to neurons by intrathecal bolus injection in mice to target TRP V1 and 
relieve chronic neuropathic pain (Dorn 2004), to the eyes of mice to inhibit 
neovascularization in the eye by downregulation vascular endothelial growth factor (VEGF) 
(Reich et al. 2003), and intranasally to target heme oxygenase-1 in lung epithelium (Zhang et 
al. 2004b). 
Remarkably, naked siRNAs are taken up into tissues without any transfection reagents. Even 
fluorescently labeled siRNAs have been taken up into neurons by a yet unexplained 
mechanism (Grunweller et al. 2003). However, large concentrations and therefore high-
pressure injections are required to achieve these effects. Clinical studies employing this 
technique are hardly thinkable if one considers that an siRNA solution corresponding to 10% 
of the patients body weight would have to be injected (Andino 2003). Moreover, changes in 
critical blood chemistry and liver enzyme levels were observed for high pressure tail vein 
injection in mice (Askjaer et al. 2002). 
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Yet, the first siRNA approaches have made their way into clinical trials. Acuity 
Pharmaceuticals and Sirna Therapeutics are both testing siRNAs stabilized by 
phosphorothioate bonds upon their potential to downregulate VEGF and VEGF receptor as a 
treatment of age-related macular degeneration. In this case, siRNAs are applied locally to the 
eye, and the lowest effective dose remains to be estimated in order to keep side effects as 
low as possible (Couzin 2004). 
siRNAs injected into the bloodstream accumulate in liver and kidney where they are filtered 
for elimination. The tissue specificity can be altered by attaching small molecules to siRNAs. 
The modification of siRNAs with cholesterol led to an increased uptake of these siRNAs in 
the liver and jejunum, heart, kidney, lungs and more importantly fat tissue, where they acted 
to down-regulate apo-lipoprotein B (Soutschek et al. 2004). Apparently, specific ligands can 
mediate siRNA uptake by receptor-mediated endocytosis. As an additional advantage, the 
cholesterol-modification on siRNAs improves its in vivo pharmacokinetics: elimination half-life 
was increased from 6 min to 95 min, plasma clearance was decreased from 17.6 ml/min to 
0.5 ml/min, and a broad biodistribution was found after 24 hours. 
Nanoparticles may constitute an appropriate vehicle for the in vivo delivery of siRNAs. To this 
means ligand-targeted, sterically stabilized nanoparticles have been constructed from 
PEGylated polyethyleneimine modified with a specific peptide ligand to deliver siRNAs to 
tumors in the vascular endothelium. Intravenous application in mice resulted in an 
accumulation of the siRNAs in the tumor tissue where VEGF receptor-2 was down-regulated 
and angiogenesis inhibited. Thus, nanoparticles provide a promising tool for the delivery of 
siRNAs in vivo (Schiffelers et al. 2004). 
 
Very recently, cell-penetrating peptides (CPPs) have been employed to deliver siRNAs. Due 
to their great versatility with respect to cargo and cell type (Derossi et al. 1998; Derossi et al. 
1994; Prochiantz 1996; Schwarze and Dowdy 2000; Schwarze et al. 1999), these short, 
highly positively charged peptides have been recognized as a valuable tool for the 
introduction of siRNAs. The short MPG, a chimeric protein composed of gp41 (the HIV-1 
fusion peptide domain) and the nuclear localization sequence (NLS) of SV40 large T-antigen, 
forms stable non-covalent complexes with nucleic acids. Mutations in its NLS prevent nuclear 
entry and distribute the siRNAs throughout the cytosol (Simeoni et al. 2003). Non-covalent 
complexes of siRNAs with Antennapedia peptide, also known as Penetratin (Derossi et al. 
1996), and with an NLS derived β-sheet forming peptide (Deshayes et al. 2004) could be 
used as an alternative to liposomal complexes. However, comparatively large amounts of the 
CPP are required to transfect sufficient amounts of siRNA. 
A consequent development following these techniques is the covalent coupling of such 
protein transduction domains (PTDs) derived from HIV-Tat or Drosphila Antennapedia 
protein (AntP) to deliver siRNAs to primary cells and non-dividing cells without the toxicity 
associated with transfection (Chiu et al. 2004a; Davidson et al. 2004; Muratovska and Eccles 
2004; Schmitz et al. submitted). Interestingly, in cultured neurons, protein knock-down 
preceded the degradation of targeted mRNA suggesting that perfectly matched siRNAs lead 
to an early translational repression (Davidson et al. 2004).  
Compounds that mediate rapid cellular uptake of siRNAs help to restrict the down-regulation 
of genes to the site of application. As CPPs strongly interact with the plasma membrane in a 
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receptor-independent fashion, conjugates of these peptides with siRNAs or pepsiRNAs 
would be an important step towards the locally restricted application of siRNAs in vivo 
 
1.2 Cell-penetrating peptides and their small molecule analogs 
1.2.1 The delivery issue 
Like RNAi, many modern biological techniques make use of bio-macromolecules to 
manipulate cellular functions in order to study gene function or interfere with pathological 
processes. Common examples are antisense mediated silencing, vector based vaccination, 
gene therapy, and therapeutic antibodies. As these effector molecules act with high efficacy, 
they also hold a great promise as potential cures for all kinds of diseases.  
However, the design of new drugs has ever been limited by the question of bioavailability, 
target recognition, and clearance from the body. Depending on the mode of application, 
these molecules have to cross the epithelium of the intestine or the duodenum, the nasal 
mucosa or the lung epithelium to enter the bloodstream and the endothelium of the blood 
vessel to reach their destination. Unless the compound is directly injected at its site of action, 
more than one cellular membrane has to be overcome. The delivery issue is a major 
challenge, especially if it comes to in vivo applications of bio-macromolecules.  
 
1.2.2 Cellular uptake mechanisms 
As a first step to tackle this issue, one has to understand the mechanisms by which nutrients 
or messenger molecules enter the cell, and the pathways exploited by pathogens to 
penetrate the protective barrier of the cell. 
Membranes form a hydrophobic barrier between the cytosol and the extracellular space or 
between the compartments of the cells and the cytosol. They consist of various lipids like 
unsaturated and saturated phospholipids, sphingolipids, and cholesterol forming a bilayer, 
which incorporates 20% to 60% of proteins depending on the cell type (Voet and Voet 1998). 
To maintain the homeostasis of the cell, these membranes have to be highly selective as to 
which substances they permit to pass. Specialized pores and channel proteins allow the 
regulated uptake of water-soluble molecules and ions from the extracellular space, while 
hydrophobic molecules can cross the membrane by simple diffusion.  
 
1.2.3 Passive transport by diffusion 
Diffusion processes are directed by concentration gradients and potential differences that are 
summarized as the electrochemical gradient. The molecules can diffuse directly through the 
membrane or move through the channels formed by transmembrane proteins if they meet 
the selectivity criteria. In facilitated diffusion, the molecule binds to a carrier molecule on the 
outer leaflet of the membrane that enhances the solubility in the hydrophobic core of the 
membrane (Schmidt 1999). 
The majority of drugs enters the cells by direct diffusion through the plasma membrane, so 
that the features of biological membranes need to be taken into consideration in the design 
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of small molecule drugs. The characteristics of molecules that are taken up by direct passive 
diffusion are described by a set of rules that have become known as “the rule of five” or 
“Lipinski-rules” (Lipinski and F. 1997). For efficient uptake, molecules should not be larger 
than 500 Da. The number of charged functional groups and of hydrogen-bond donors or 
acceptors should be adjusted to provide some solubility in the hydrophobic core of the lipid 
bilayer. At the same time, a certain degree of hydrophilicity is required to keep the molecule 
dissolved in the extracellular space and the cytosol. The proper balance of hydrophilicity and 
hydrophobicity is reflected by the oil-water or octanol/water partition coefficient of the 
molecule, which can be determined experimentally. In general, its value can be directly 
correlated with the membrane permeability of a molecule. To fit the criteria for uptake by 
diffusion, pharmaceutically active substances are often modified or substituted with non-polar 
groups. Novel drugs like antisense-oligonucleotides, DNA-vectors for genetic vaccination or 
ribozymes are too large and too hydrophilic as to permit uptake by passive diffusion. 
 
1.2.4 Active transport by transmembrane transporters 
For the uptake of nutrients, ions and signalling molecules against concentration gradients or 
electric potentials the cells have developed different forms of active transport ranging from 
ATP-dependent pumps to endocytosis. One has to distinguish primary active transport by so-
called pumps, secondary active transport by carriers, and tertiary active transport that is 
driven by a gradient built up by secondary active transport processes (Hierholzer 1997). 
Membrane transporters are specialized proteins or protein complexes that form hydrophilic 
membrane spanning passages by which only molecules of corresponding size, shape, and 
charge distribution can pass into the cytosol following the concentration gradient. To prevent 
ion exchange with the extracellular space and the subsequent loss of concentration 
gradients, some of these channels are gated, like the erythrocyte glucose transporter (Voet 
and Voet 1998). A common example for primary active transport is the ubiquitous 3Na+-2K+-
ATPase pump. The hydrolysis of ATP drives the export Na+-ions and the simultaneous 
import of K+-ions. Two K+ enter the cells with every three Na+ that are pumped out of the cell. 
If a net charge is transported, the pumps are referred to as electrogenous. The Na+-gradient 
built up by this process is exploited by typical representatives of secondary transporters such 
as the glucose/Na+ carrier that simultaneously imports Na+ and glucose acting as a 
symporter. Likewise, amino acids or Cl- ions may be taken up. Antiporters, like the renal 
Na+/H+ carrier, utilize the influx of Na+ to export protons or cationic molecules. Proton 
gradients established by these antiporters may drive tertiary transporters such as the 
intestinal dipeptide transporter acting as a symporter for protons and dipeptides (see Figure 
1-13) (Hierholzer 1997). 
Highly polar substrates like sugars and peptides are taken up by active transport. More than 
200 different solute carrier transporters recognize different types of molecules that are 
permitted to cross the epithelium and enter into the bloodstream. Antibiotics mimicking the 
features of natural substrates can exploit these membrane transporters to enter the cells.  
Other drug molecules can be chemically modified to be recognized by transporters. A 
prominent example is Valacyclovir, an anti-viral guanosine derivative coupled to L-lysine, 
which is recognized by a dipeptide transporter of the intestinal epithelium (Jacobson 1993). 
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Figure 1-13 Active transport by the intestinal dipeptide transporter. The primary ATPase-pump imports 
K+ and removes Na+ from of the epithelial cell resulting in an Na+-gradient that drives the secondary 
Na+/H+ antiporter. Dipeptides are imported into the epithelial cells along with H+ following the proton 
gradient (Schmidt 1999). 
 
The same idea is exploited commercially by XenoPort (Santa Clara, CA, USA) who modify 
drugs with so-called XenoPorter molecules that enhance their uptake by solute carrier 
transporters in the gastrointenstinal tract (Henry 2003). If the drug candidate possesses no 
recognizable features, it is conjugated to a known transporter substrate. If it bears some but 
not all of the required features it is only slightly modified to fit the targeted transporter. 
Xenoporter molecules are of great value if the uptake of the non-modified drug is limited by 
the transporter capacity as it was shown for the epilepsy drug gabapentin. Chemical 
modifications of the drug molecule to target different transporters greatly improved the 
absorption efficiency. Thus, lower doses of the drug are needed to reach the 
pharmaceutically required concentration, which leads to a reduction of costs and, more 
importantly, side effects. 
 
1.2.5 Active transport by endocytosis 
The most important mode of entry is endocytosis, which permits the internalization of larger 
hydrophilic substrates in a highly regulated and substrate specific process. The substrate 
adsorbs to small patches of the plasma membrane that invaginate in an energy-dependent 
process and pinch off to form intracellular vesicles in which the cargo is surrounded by a lipid 
bilayer.  
Three modes of endocytosis are distinguished depending on the size of the internalized 
cargo and the mode of binding. In pinocytosis small volumes of fluid are taken up, while large 
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particles are incorporated by phagocytosis. Highly selective uptake is achieved by receptor-
mediated endocytosis in which a substrate specifically binds to a receptor following 
endocytotic uptake of the receptor-ligand complex as it was originally demonstrated for the 
endocytosis of LDL (Brown and Goldstein 1986). Endocytic vesicles fuse with lysosomes in 
which the cargo molecules are often degraded or chemically modified before they are 
released into the cytosol (Fischer et al. 2002). Drugs that are taken up by endocytosis 
require features that permit a so-called “endosomal escape” of the functional molecule. The 
mechanism of this route is not defined so far, even though there a many speculations. 
 
 
 
Figure 1-14 Receptor-mediated endocytosis. Binding of a ligand to the receptor molecule leads to 
energy-dependent invagination of the plasma membrane. The cargo is enclosed by a lipid bilayer that 
finally pinches off to form an endocytotic vesicle. 
 
Receptor-mediated endocytosis is frequently exploited for targeted delivery. As shall be 
discussed in more detail later, the surface of transport vehicles to deliver drugs is loaded with 
ligand molecules that specifically bind to the receptors found on the targeted cell type. Thus, 
not only the efficiency but also the specificity of uptake is enhanced. This idea has been 
developed even further in synthetic receptor targeting. Here the plasma membranes of living 
cells are loaded with synthetic compounds that function as non-natural receptors, as it was 
shown for conjugates of protein-binding motifs with 3β-cholesterylamines 
(Boonyarattanakalin et al. 2004). The macromolecular ligand comprising a recognition motif 
and the drug molecule binds to the receptor and triggers the formation of lipid rafts and the 
uptake of the receptor-ligand complex via endocytosis. These non-natural receptors capable 
of dissociating from the ligand are recycled to the cell surface. By this method the delivery of 
drugs can be enhanced by a factor of 300 compared to the free drug, and it is assumed that 
cell types with higher rates of endocytosis are more susceptible to delivery by this method 
than others. 
 
1.2.6 Common methods of delivery 
Many classes of bio-macromolecules are used in the study of cell function and in therapeutic 
approaches ranging from peptide inhibitors and antibodies to antisense nucleotides, siRNAs 
and ribozymes. However, the most important cargo is DNA. DNA plasmids may encode 
reporter proteins such as GFP or luciferase, or RNA transcripts that become active as 
ribozymes or trigger RNAi. In gene therapy, the DNA vectors encode recombinant proteins 
that substitute for defective or deficient endogenous proteins. Also, fragments from 
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pathogenic proteins may be recombinantly expressed to prime the immune system for 
viruses, bacteria or even cancer cells. 
To introduce these bio-macromolecules into cells, a number of invasive methods have been 
developed under cell culture conditions. The plasma membrane can be disrupted by 
electroporation, particle bombardment, ultrasound or microinjection, or permeabilized by 
detergents, organic solvents, or hypotonic buffers. In most approaches the degree of 
membrane disruption cannot be controlled, so that very often the cell viability is low. Only two 
approaches, electroporation and particle bombardment, bear a high potential for clinical 
applications. 
In electroporation experiments membranes are subjected to a high voltage electric field 
resulting in the temporary formation of pores that are large enough to allow almost all types 
of molecules to pass (Potter 1988). Although electroporation techniques have been refined to 
be able to treat almost all cell types and even tissues in fully-grown organisms, only few of 
them are suitable for clinical applications. 
DNA vectors and other forms of nucleic acids can be delivered by ballistic particle-mediated 
delivery systems, also known as gene guns. The substrate molecules are attached to 
colloidal gold particles and accelerated by an inert gas to penetrate the target tissue, where a 
small fraction of the particles actually enters the nucleus and the DNA dissociates from its 
carrier. Although gene gun delivery is limited (Johnston and Tang 1993), it bears the 
advantages of high biocompatibility and ease of application, so that it may become the 
delivery method of choice for DNA-based vaccination (Chen et al. 2002a). 
A widespread method to enable the cellular uptake of insoluble or highly charged compounds 
is liposome-based delivery, that was developed for the transfection of DNA vectors and has 
now become the major tool to introduce all kinds of nucleic acids and also proteins, peptides, 
and nanoparticles into cultured cells. Liposomes consist of cargo molecules enveloped by a 
lipid bilayer that is able to fuse with the plasma membrane and release its content directly 
into the cytosol. Depending on their composition, liposomes may as well be incorporated by 
endocytosis (Ulrich 2002). Liposomes mainly consist of amphipathic lipids, which may be 
cationic, anionic, or neutral. Sterols may be added to the lipid mixture to modify the 
liposome’s behavior, and more new properties could be obtained by the incorporation of 
lipophilic or amphiphilic proteins, glycopeptides, and carbohydrates into the lipid bilayer.  
In liposome-based drug delivery, the drug does not get into contact with the cell surface 
molecules, so that unspecific interactions are omitted and the intrinsic toxicity of the drug is 
reduced. Intensive research has led to liposomes with optimized pharmacological features 
such as long-term stability and serum compatibility, broad biodistribution, and slow plasma 
clearance rates. Moreover, selective tissue targeting and intracellular targeting is feasible by 
ligands or antibodies attached to the liposome mediating the recognition of specific cell types 
(Anwer et al. 2004; Kaneda 2000; Turk et al. 2004).  
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Figure 1-15 Self-assembly of target-specific liposomes. Both drug and target recognition motif are 
covalently linked to long hydrophobic chains so that a liposome can form by a self-assembly process 
that directs the drug to the interior and the target recognition motif to the exterior of the liposome 
(Haag 2004). 
 
Different kinds of liposomes have already made their way to therapeutic applications (Cattel 
et al. 2003). In clinical studies antisense oligonucleotides against oncogens encapsulated in 
liposomes were applied as weekly intravenous infusions. This led to hypersensitivity 
reactions and dose-dependent thrombocytopenia, but resulted in the targeted growth 
inhibition of the tumor (Rudin et al. 2004). 
Despite the large efforts to develop more efficient vectors for in vivo use, the behavior of a 
drug carrier system under in vivo conditions is still hard to predict (Tachibana et al. 2002). 
Liposomal transfection of nucleic acids, that has become the method of choice in cell culture, 
is not applicable in vivo as the required cationic lipids are toxic to fully-grown organisms. 
As already discussed in context with RNAi, viral vectors have been successfully employed 
for the delivery of nucleic acids. They are also seen as a straightforward approach in gene 
therapy, where they are supposed to carry functional copies of a deficient gene into the 
tissue of interest. This technology makes use of viral cell-entry strategies to grant an efficient 
delivery of the nucleic acid drug into the cells. Even though the viral genome is depleted of 
sequences coding for pathogenic components, the risk of pathogenic mutations cannot be 
ruled out. Viral vectors can also randomly insert new sequences into the host genome 
leading to the disruption of genes and the formation of tumors or leukemias (Hacein-Bey-
Abina et al. 2003a; Hacein-Bey-Abina et al. 2003b). Therefore, the use of viral vectors may 
remain limited to analytical application. 
Dendrimers are successfully used for the in vivo application of several classes of molecules 
(Fischer 1999; Gittins and Twyman 2003; Haag 2001; Kono et al. 2002; Liu et al. 1999; 
Morgan 2002; Patri 2002). These highly branched, globular macromolecules are synthesized 
in a well-defined manner, that allows selective modifications in size, structure and physical 
properties, such as solubility (Twyman et al. 1999). Dendrimers with hydrophobic core and 
hydrophilic shell have been designed to encapsulate hydrophobic drugs in their interior and 
slowly release them to the surrounding tissue (Liu et al. 1999; Shultz 1999; Uhrich et al. 
1999).  
 44
 
 
Scheme 1-2 Branched polymers like polyglycerol acetate (left) and polyethylenimine (right) are 
commonly used as transfection agents. Due to the highly branched core structure (white), the 
functional groups on the outer shell (light blue) adopt a spherical distribution. In this representation, 
the hydroxyl- and amino-functions of the outer shell are protected. After deprotection another 
generation of monomers could be attached to yield larger structures, or the spheres could be modified 
with other functional groups. 
 
 
 
Figure 1-16 Transfection with polycationic dendrimers. The negatively charged cargo molecules form 
stable complexes with the transfection agent. Interacting with the plasma membrane, these transport 
vehicles are taken up by endocytosis. From the endosomes, the DNA-complexes are transferred to 
the lysosomes, from where they reach the cytosol and the nucleus by a so far unknown mechanism. 
One hypothesis is the intralysosomal accumulation resulting in the fragmentation of individual 
lysosomes, while the majority of lysosomes remains intact.  
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To circumvent toxic side effects of some of the widely used dendrimers, biodegradable and 
biocompatible dendrimers have been developed. Surface modification with polyethylene 
glycol (PEG) is a common method to obtain dendrimers with increased biocompatibility 
(Kobayashi et al. 2001). The pharmacological properties of dendrimers have been further 
improved by attaching various kinds of ligands, such as sugars, folate residues, receptor 
ligands and antibodies to the dendrimer surface. By these modifications the specificity of 
cellular targeting can be greatly enhanced. Rationally designed, dendrimer-based carriers 
help to accurately deliver drugs to their target site and increase the efficacy of drugs. 
A related approach is the delivery of large molecules encapsulated in micro- and 
nanoparticles that are taken up by endocytosis upon interaction with the plasma membrane 
(Cui and Mumper 2003; Douglas et al. 1987; Kreuter et al. 2003; Simeonova et al. 2003). 
Nanoparticles consist of amphiphilic molecules that are degraded after uptake accounting for 
their low toxicity. They are easily prepared and help to stabilize sensitive drugs in vivo 
(Lockman et al. 2002). To enhance the exit from endosomes, endosomolytic agents like 
dioleoyl phosphatidyl ethanolamine, lipid A and cholera toxin have been incorporated into the 
nanoparticles (Cui et al. 2003; Cui and Mumper 2003).  
Like dendrimers, nanoparticles can be designed to fit their purpose by variation of the 
polymer side chains and procedures of preparation. Coating with cell-specific ligands 
enhances the endocytotic uptake of nanoparticles by target-tissues (Bellocq et al. 2003; 
Cegnar et al. 2004; Cui and Mumper 2002; Farokhzad et al. 2004) and it was shown that 
internalization can be directed by coupling of specific antibodies to the nanoparticle (Muro et 
al. 2003). Until today nanoparticles have been very successfully used to deliver conventional 
drugs in the treatment of various diseases (Chawla and Amiji 2003; Mei et al. 2003; Zimmer 
et al. 1994). Recent applications with encapsulated proteins (Cegnar et al. 2004; Li et al.; 
Muro et al. 2003; Panyam 2003), gangliosides (Polato et al. 1994), nucleic acids (Chen et al. 
2003; Kumar et al. 2003; Schiffelers et al. 2004), and RNA aptamers (Farokhzad et al. 2004) 
show that nanoparticles can indeed surpass the classical limitations of drug delivery. A broad 
field for nanoparticle application lies in genetic immunization. In this alternative vaccination 
process, a small quantity of the pathogenic protein is expressed from a recombinant vector to 
trigger an immune response leading to the formation of the appropriate antibodies and B-
cells that recognize the pathogen (Kumar et al. 2003).  
The interaction of cholesterol with the plasma membrane is exploited in a new class of 
transport molecules. These so-called umbrella transporters consist of a central spermidine 
moiety that is enclosed by two steroid molecules attached to its terminal amines. Cargo 
molecules like AMP or ATP can be attached to the thiol-functionalized central amine of the 
spermidine via a disulfide bond, that can be cleaved by millimolar concentrations of 
glutathione as it is found in the cytosol (Schafer and Buettner 2001). After successful tests of 
the prototype, this principle may be extended to the development of drugs, e.g. antisense 
oligonucleotides that can be delivered into cells (Janout et al. 2001). Plain lipids with one 
arginine headgroup and a cholesterol tail possess a significant capability for the delivery of 
DNA as discovered in library-screens for new transfection agents (Yingyongnarongkul et al. 
2004). 
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Scheme 1-3 Umbrella transporter. The central spermidine moiety is flanked by two cholesterol 
molecules that are capable of inserting into the membrane. The cargo is coupled via a disulfide bond. 
 
1.2.7 Membrane penetration by peptides and proteins 
 
Principles to overcome membranes have evolved in viruses, microorganisms and parasites. 
Infective organisms such as viruses and bacteria possess proteins endowed with properties 
to penetrate living cells (Pugsley 1996). Pore-forming toxins such as tetanus toxin (Boquet 
and Duflot 1982), anthrax toxin (Ballard et al. 1996), cytolysins (Rossjohn et al. 1997), and 
diphtheria toxin (Stenmark et al. 1991) facilitate the cellular entry for pathogens or help them 
to employ substrates from the host’s cytosol for their own metabolism. The wasp venom 
peptide toxin mastoparan induces cell death by severely perforating the plasma membrane 
(Matsuzaki et al. 1996). 
The principle of pore formation is also applied by higher organisms like insects and 
vertebrates. The insertion of a large number of pore forming peptides such as melittin, 
protegrins, or defensins into the plasma membrane leads to a leakage of the cytosol, which 
results in a breakdown of the gradients that fuel the metabolic processes. Finally, this leads 
to the decline of the affected cell or whole tissues (Ojcius and Young 1991). These toxic 
peptides are capable of forming amphiphilic structures that are responsible for their 
membrane activity (Fujii 1992). Some of these compounds are used to facilitate the exit from 
endosomes after endocytosis, such as cholera toxin in nanoparticles (Cui and Mumper 2002) 
and amphipilic peptides for the cellular delivery of oligonucleotides. 
 
1.2.8 The discovery of protein transduction 
 
In virus studies in the late 80ies, it was found that HIV-1 trans-activator of transcription (Tat), 
a protein of 101 amino acids essential for HIV-1 replication, is rapidly taken up from the 
culture medium by cultured cells (Frankel and Pabo 1988; Green and Loewenstein 1988). It 
turned out that only a small proportion of the protein was responsible for the internalization of 
the whole protein. The relevant peptide comprises residues 49-57, eight of which are basic 
amino acids (Fawell et al. 1994; Pepinsky et al. 1994; Vives et al. 1997a; Vives et al. 1994). 
In the first examinations of the potential of the basic HIV-1 Tat domain (Tat peptide) to 
mediate the transport of other proteins into cells, large proteins like β-galactosidase, 
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horseradish peroxidase, RNase A and domain III of Pseudomonas exotoxin A were 
successfully incorporated when coupled to full-length HIV-1 Tat and Tat49-57 peptide 
(Anderson et al. 1993). A fusion protein of Tat peptide with β-galactosidase was injected into 
mice to monitor the bioavailability of a Tat-coupled protein. The functional protein could be 
detected in various tissues like heart, liver, and spleen but also lung and skeletal muscle 
(Fawell et al. 1994; Schwarze et al. 1999). Later studies showed that Tat peptide exhibits 
toxic effects at concentrations above 5 µM in the extracellular medium (Hallbrink et al. 2001; 
Vives et al. 1997b). Considering the good delivery properties, Tat peptide was soon 
discussed as a delivery vector for clinical applications.  
Similar properties were found for short basic domains in the Drosophila Antennapedia 
homeobox protein (Derossi et al. 1994) and in the Herpes Simplex protein VP22 (Elliott and 
Ohare 1997). Thus, a rapid development was triggered in which more peptides with the 
capability to enter cells were discovered and broad variety of cargo molecules was delivered 
into cultured cells. 
Initial assays suggested that these peptides could directly penetrate the plasma membrane 
by a novel mechanism that became known as protein transduction. Therefore, the new class 
of peptides was referred to as protein transduction domains (PTDs). After the development of 
synthetic delivery peptides the term cell-penetrating peptides (CPP) was coined to refer to 
naturally occurring PTDs and their functional homologs from organic synthesis. (Jeang et al. 
1999; Lindgren et al. 2000b; Nagahara et al. 1998). As they help to deliver otherwise 
impermeable molecules into cells, they were also called Trojan peptides. 
By the time of the discovery of the CPPs, fluorescence activated cell sorting (FACS) and 
fluorescence microscopy were the solely applied methods to estimate the amount of 
internalized fluorescently labeled CPPs, so that the absolute amount of compound and its 
distribution inside the cell was not quantitatively assessed. It was found that the fluorescent 
compounds were taken up by almost all of the treated cells within minutes, which was 
evaluated and reported as a “high uptake efficiency”. Shuffling of the amino-acid sequence 
and the use of D-amino acids did not inhibit the internalization, so that a receptor-dependent 
mechanism was ruled out (Derossi et al. 1996). Since low temperatures and inhibitors of 
endocytosis, vesicular trafficking, and energy metabolism did not interfere with the observed 
rapid uptake, a non-endocytotic mechanism for protein transduction was proposed (Derossi 
et al. 1996; Polyakov et al. 2000). Reports from fluorescence microscopy indicated that 
fluorescently labeled CPPs reached the cytosol and accumulated in the nucleus (Vives et al. 
1997a). Therefore, it was proposed that protein transduction acted by direct passage of the 
plasma-membrane, and the mechanistic explanations for this phenomenon ranged from 
penetration by passive diffusion through the membrane to pore formation and the generation 
of inverted micelles (Green et al. 2003; Schwarze et al. 1999).  
 
1.2.8.1 Artifacts in early uptake studies 
 
In 2003, two independent reports pointed out, that most of the previously obtained results in 
mechanistic studies had to be attributed to artifacts (Richard et al. 2003; Thoren et al. 2003). 
As the basic residues of the CPPs are positively charged under physiological conditions, 
CPPs interact strongly with negatively charged phospholipids and proteoglycans on the 
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surface of the plasma membrane. Thus, they cannot be removed by washing and are 
counted as internalized compounds in FACS experiments. Treated cells need to be 
incubated with trypsin prior to measurements to remove these artifactual CPPs from the 
exterior of the cell (Richard et al. 2003). Alternatively, the internalized CPPs can be 
distinguished from adhering ones by fluorescence quenching experiments, in which the 
fluorescently labeled peptide is quenched by externally added, non-permeant agents if it 
resides outside the cell (Drin et al. 2001; Hallbrink et al. 2001). In a novel method, 
extracellular peptides are chemically modified by a non-permeant reagent to be 
distinguishable from internalized peptides after cell lysis and HPLC analysis (Hallbrink et al. 
2004). 
 
a)            b)     
 
Figure 1-17 Artifacts in mechanistic studies on CPP uptake. a) Cells with CPPs attached to their 
surface are counted as cells with internalized CPPs. b) Fixation procedures allow an intracellular 
reorganization of CPPs. 
 
Furthermore, the uptake of CPPs into the cytosol and their accumulation in the nucleus was 
put into doubt. Upon fixation, cellular membranes are ruptured and CPPs attached to the cell 
surface or residing in the cytosol are redistributed. Reaching the nucleus they interact with 
the negatively charged nucleic acids thus mimicking a nuclear accumulation (Leifert et al. 
2002; Lundberg et al. 2003; Lundberg et al. 2002). To examine the real intracellular 
distribution, imaging has to be carried out in living cells (Drin 2003; Richard et al. 2003; 
Umezawa et al. 2002). 
 
Studies using corrected procedures (i.e. imaging of living cells) to avoid artifacts revealed 
that fluorescently labeled CPPs were taken up on a much slower time scale. Inside the cells 
they were found localized in vesicular structures that suggested an endocytosis-like 
mechanism. However, a leaking of these compounds to the cytosol was also detectable after 
long incubation times. Fluorescently labeled CPPs were linked to a quencher via a disulfide 
bond, so that the fluorescence was quenched. Upon addition to cultured cells, fluorescence 
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was detected which was attributed to an entry of the compound into the cytosol, where the 
disulfide bond was cleaved and the fluorescent probe released from the quencher (Hallbrink 
et al. 2001). Furthermore, novel studies pointed out a nuclear localization of CPPs (Chiu et 
al. 2004a). 
Moreover, up to 90% of fluorescent probe was found to be associated with degradation 
products of the peptides, which occur after cellular uptake. This was seen as a proof of 
lysosomal degradation by one group (Saalik et al. 2004), while others could show that the 
addition of chloroquine to inhibit lysosomal function did not interfere with the degradation 
(Hallbrink et al. 2004). These differing results have to be attributed to differing methods of 
preparation ranging from the study of single cells (Soughayer et al. 2004) to the preparation 
of lysates (Hallbrink et al. 2004), but also to the nature of the peptides themselves (Saalik et 
al. 2004). More publications dealing with the intracellular distribution of CPPs have been 
announced for the beginning of 2005. 
Over the last months, novel attempts to quantify the intracellular concentration of CPPs and 
to determine their intracellular distribution have been reported (Chiu et al. 2004a; Hallbrink et 
al. 2004; Soughayer et al. 2004). Yet, the existing results are highly controversial: The 
reported overall intracellular concentrations of the CPPs range from an equilibrium with the 
extracellular medium to the 35fold of the external CPP concentration, which can be attributed 
to the peptide to cell ratio, the cell density, the cell-type, the used peptide and the attached 
cargo (Hallbrink et al.; Hallbrink et al. 2004; Lindsay). However and especially notable, none 
of the studies discriminates between the CPP content of cytosol or nucleus and the vesicular 
structures. As long as the decisive parameters have not been identified and standard 
protocols have been developed, the data from CPP uptake studies will be difficult to compare 
and evaluate. At present, the results obtained from mechanistic investigations do not fit into 
one consistent picture.  
However, the literature confers to the uptake of CPPs as highly efficient. This means, that the 
peptide vector is taken up by all cells as opposed to some transfection methods in which only 
a small fraction of the treated cells incorporates the applied effector molecule. Internalized 
compounds are found in endosomes, lysosomes as well as in the cytosol and nucleus. The 
uptake efficiency as determined by FACS and fluorescence quenching experiments reflects 
the overall amount of labeled compound found in endosomes, lysosomes and the cytosol.  
The first experiments to quantify the amount of internalized compound and to determine its 
distribution are expected in the upcoming months. It may turn out that the fraction of cargo-
coupled-CPPs reaching in the cytosol or leaving the endosomal compartment is small. 
However, in numerous experiments it was sufficient to exhibit the desired biological function 
as shall be discussed in the following chapter. None of the current studies explains how the 
“endosomal escape” or endosomal exit might occur. Like the polycationic dendrimers, most 
of the CPPs are protonated within the acidic compartments and might aggregate with 
membranous structures leading to an accumulation in these compartments. Is a high 
concentration of these polycations responsible for the rupture of the lysosome/endosome or 
are there transporters or secretion processes responsible for the cytosolic release? These 
questions have to still be answered. For now, most of the studies refer to “endosomal 
escape” to describe the phenomenon. 
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1.2.9 Cell-penetrating peptides 
Since the first reports about Tat peptide, a large number of naturally occurring CPPs have 
been discovered. They all contain a large proportion of basic amino acids that are positively 
charged under physiological conditions. Many of them can adopt an amphipathic α-helical 
structure. Isolated CPP sequences are able to introduce a variety of covalently bound cargo 
molecules with up to 100% efficiency into almost all cell types (Lindsay 2002; Schwarze and 
Dowdy 2000). To act as delivery vectors, CPPs can be attached to cargo-proteins as fusion 
tags in recombinant expression. They can be conjugated to proteins or non-protein cargo via 
amide bonds, thioethers or, reversibly, by disulfide bonds (Gil-Parrado et al. 2003). Until now, 
over a hundred of these peptides have been identified or generated synthetically based on 
structural similarities found in CPPs and on mechanistic assumptions.  
It has to be remarked, that no common nomenclature has been established yet. The term 
CPP is used by many authors, but these membrane permeating peptides are also referred to 
as peptide delivery vectors, carriers, membrane permeating motifs (MPMs), cell permeable 
motifs, amphipathic model peptides for delivery, or delivery peptides, which makes it difficult 
to follow the proceedings in this field. 
The first non-viral PTD was found in Drosophila Antennapedia homeobox protein (AntP), a 
60 amino acid long carboxy-terminal DNA-binding domain that comprises three α-helices and 
one β-turn. A sequence of 16 amino acids from the third helix is responsible for the cellular 
internalization of the whole protein. Due to its ability to deliver active proteins of up to 100 
amino acids, such as β-galactosidase, Antennapedia peptide (AntP) has been frequently 
used as a delivery vector, and a derivative of its sequence has been patented under the 
name Penetratin™ (Derossi et al. 1998; Derossi et al. 1994). None of the Penetratin™ 
variants tested so far was hemolytic or toxic (Christiaens et al. 2004), although toxic effects 
on cells were observed for systemic applications of Penetratin™ at concentrations exceeding 
36 µM (Derossi et al. 1998). When injected into rat brain in vivo, 10 µg (~250 pmol) of 
fluorescently labeled Penetratin™ per animal led to neurotoxic cell death, whereas doses 
around 1 µg were well tolerated (Bolton et al. 2000) 
AntP/ Penetratin™ requires an essential tryptophan residue for efficient uptake, suggesting 
that this peptide may be taken up via a different mechanism than the other CPPs (Dom et al. 
2003).  
A remarkable feature was found for the CPP of Herpes Simplex Virus (HSV) structural 
protein VP22 (Elliott and Ohare 1997). If recombinantly expressed as a fusion protein in 
cultured cells, this fusion protein exits its cell of origin and is taken up by the surrounding 
cells (Stroh et al. 2003). This principle is exploited in a gene therapy approach in which cells 
from a patient are transfected with expression vectors for VP22 fusion protein in vivo. When 
reintroduced to the donor organism, these recombinant cells produce VP22 fusion proteins of 
an essential protein that is taken up by the surrounding tissue where it substitutes a deficient 
endogenous protein (Kretz et al. 2003). However, fusion proteins with VP22 can have a 
decreased solubility, which has to be considered when establishing new VP22-mediated 
delivery systems (Rutjes 2003). 
Galparan is a synthetic peptide that combines the first 13 amino acids of the N-terminus of 
galanin with the 14 amino acid peptide toxin mastoparan (Pooga et al. 1998a). Galanin is a 
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galanin receptor ligand, whereas the wasp venom mastoparan acts by creating short living 
pores, which leads to lysis of the cells (Matsuzaki et al. 1996). To facilitate coupling to cargo 
molecules amino acid 13 of galparan was replaced by lysine to yield a derivative that has 
become known as transportan (Pooga et al. 1998a). In first studies, transportan was shown 
to deliver covalently coupled GFP into different cell types without loosing the GFP 
fluorescence, indicating that the protein remains intact during the transport process (Pooga 
et al. 2001). Moreover, transportan has a considerably higher estimated half-life time than 
Penetratin™ (Lindgren et al. 2000a). 
Many other proteins with transduction properties have been found, but are not yet used for 
cargo delivery. PTDs like the Drosophila Antennapedia peptide have been discovered in 
several homeoproteins and other proteins with gene regulating functions. Fushi-tarazu (254-
313) and Engrailed (454-513), derived from homeodomains of the two equally named 
Drosophila homeoproteins, are able deliver GFP into cultured cells as efficiently as Tat and 
Penetratin™ (Han et al. 2000). The third helix of the homeodomain of rat insulin-1 gene 
enhancer protein comprises a peptide sequence pIsl that compares well to Penetratin™. 
Conveniently, it comprises one cysteine residue, which may be used couple cargo molecules 
(Kilk et al. 2001). 
The pancreatic and duodenal homeobox factor-1 (PDX-1) is central to the regulation of 
pancreatic development and insulin gene transcription (Noguchi et al. 2003). Due to an AntP-
like sequence, the PDX-1 homeodomain enters isolated pancreatic islets where it leads to 
stimulation of insulin gene expression. Therefore, it may be used to enhance insulin gene 
transcription and to facilitate differentiation of progenitor cells without gene transfer 
technology.  
Homeobox (HOX) proteins are generally known to passively translocate through cell 
membranes. In stem-cell therapy, cultures of hematopoietic stem-cells could be expanded by 
co-culture with recombinant stromal cells secreting HOXB4 that entered into the surrounding 
cells (Amsellem et al. 2003). 
The murine vascular endothelial cadherin (VEC) contains an 18 amino acid sequence that 
can enter into different endothelial cell lines. VEC peptide (pVEC) is able to transport both a 
hexameric peptide nucleic acid and a non-covalently attached 67-kDa protein, streptavidin-
FITC (Elmquist et al. 2001). Its transduction efficiency is lower than that of Tat peptide or 
transportan (Saalik et al. 2004). Another PTD was found in Kaposi fibroblast growth factor 
(FGF), albeit its import efficiency lies 3-4 times below that of penetratin (Lin et al. 1995; Peitz 
et al. 2002). SynB peptide vectors derived from protegrin have been shown to increase the 
transport of drugs across the blood brain barrier. They enter cultured mammalian cells by the 
same mechanism as penetratin (Drin 2003). 
The capability to enter cells was even found in Cre recombinase. Its uptake can be greatly 
enhanced by the fusion with CPPs (Lin et al. 2004; Peitz et al. 2002). 
A different class of CPPs was derived from human calcitonin (hCT). As opposed to most 
CPPs, it mainly consists of non-polar residues. In addition to cellular uptake, calcitonin 
derived CPPs are able to deliver cargo through epithelial barriers, albeit with a limited 
efficiency. Thus, hCT-derived CPPs may be used for localized epithelial delivery (Trehin et 
al. 2004). The ability to enter the interior of cells in a receptor-independent fashion appears 
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to be an intrinsic feature of many proteins involved in the regulation of development or the 
translocation to the nucleus. 
 
 
CPP origin sequence reference 
Tat (48-62) HIV-1 transactivator of 
transcription (48-62) 
GRKKRRQRRRPPQ Vives 1997 
Tat (49-59) HIV-1 transactivator of 
transcription (49-59) 
YGRKKRRQRRR Nagahara 
1998 
Antp, 
penetratin 
Antennapedia 
homeodomain (43-58) 
RQIKIWFQNRRMKWKK Derossi 
1994 
VP22 Herpes simplex virus NAATATRGRSAASRPTQRPRAPARSAS
RPRRPVQ 
Elliott 1997 
galparan, 
transportan 
galanin + mastoparan GWTLNSAGYLLGKINLKALAALAKKIL Pooga 1998 
MPG gp41fusion sequence – 
SV40 NLS 
GALFLGFLGAAGSTMGAWSQPKSKRKV Morris 1997 
  Caiman crocodylus Ig(v) 
light chain – SV40 NLS 
MGLGLHLLVLAAALQGAWSQPKKKRKV Chaloin 
1998 
SynB1 protegrin  RGGRLSYSRRRFSTSTGR Rousselle 
2000 
Fushi-tarazu Fushi-tarazu (254-313) SKRTRQTYTRYQTLELEKEFHFNRYITR
RRRIDIANALSLSERQIKIWFQNRRMKSK
KDR 
Han 2000 
Engrailed Engrailed (454-513) EKRPRTAFSSEQLARLKREFNENRYLTE
RRRQQLSSELGLNEAQIKIWFQNKRAKI
KKST 
Han 2000 
pVEC murine vascular endothelial 
cadherin (615-632) 
TLLIILRRRIRKQAHAHS Elmquist 
2001 
pIsI PIsl (183-243) RVRTVLNEKQLHTLRTCYAANPRPDAL
MKEQLVEMTGLSPRVIRVWFQNKRCKD
KKRSIMM 
Kilk 2001 
KALA model amphipathic peptide WEAKLAKALAKALAKHLAKALAKALKAC
EA 
Wyman 
1997 
KLAL model amphipathic peptide KLALKLALKALKAALKLA Oehlke 
1998 
 
Table 1-1 Prominent CPPs, their origin and their sequence 
 
Potential for intracellular delivery was also found in nuclear localization sequences (NLS) and 
in the N-terminal signal sequences directing secreted proteins, membrane proteins, and 
organelle-specific proteins to their destination, mainly the nucleus and the ER. These signal 
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sequences resemble PTDs since they contain domains of positively charged amino acids 
and hydrophilic regions that give the overall sequence an amphiphilic character. 
Possibly, the NLS not only acts as a signal sequence, but also participates in the process of 
translocation. Since localizations sequences for the same compartment do not necessarily 
share sequence homology, it is thought that characteristic patterns of charged and nonpolar 
residues may lead to characteristic amphipathic structures that are recognized by a less 
specific mechanism. NLS derived from several proteins, such as SV40 large T antigen, 
human T-cell leukemia virus type 1 (HTLV), or transcription factor NF-κB, have been 
successfully used to transport large cargos, mainly DNA, into the interior of cells (Lin et al. 
2004; Ragin and Chmielewski 2004; Ritter et al. 2003; Simeoni et al. 2003). Pep-1, a 21 
amino acid CPP is likewise built up from a protein interacting domain and an NLS separated 
by a linker. It serves to deliver peptides and proteins (Morris et al. 2001). 
The major application for NLS, however, is the intracellular direction of transfected DNA into 
the nucleus. NLS sequences are recognized by importins, protein transporters of the nuclear 
envelope (Aronsohn and Hughes 1998; Branden et al. 2001; Braun et al. 2002; Bremner et 
al. 2004; Ding et al. 2000; Schirmbeck et al. 2001; van der Aa et al. 2004; Zanta et al. 1999). 
Many parameters to grant efficient nuclear localization, from the choice of the NLS to DNA 
morphology and condensation of the DNA on the NLS peptide, still need to be refined 
(Bremner et al. 2004) as not all NLS-derived peptides show nuclear localization activity (van 
der Aa et al. 2004). 
Viruses may also benefit from proteins comprising cell-penetrating domains that may 
facilitate anchoring on the host cell membrane. HIV-1 Vpr, a multifunctional 14 kDa protein, 
contains a CPP-like sequence at its carboxy terminus. Synthetic full-length Vpr and the Vpr-
β-galactosidase fusion protein, but not the basic domain alone efficiently enter into cells 
(Sherman et al. 2002). The fusion peptide domain of HIV-1 gp41 in combination with the NLS 
of SV40 large T antigen was developed into a 27 amino acid gene delivery system MPG1, 
that forms stable complexes with DNA (Morris et al. 1997). At nontoxic concentrations, 
peptides derived from dermaseptin S4, an antimicrobial peptide that destabilizes the 
membrane of bacteria, are found to enter HeLa cells and deliver different peptides. The 
attachment of commonly used NLS-derived peptides lead to an accumulation in the nuclei 
(Hariton-Gazal et al. 2002). 
 
1.2.10 Modifications to optimize CPPs 
No sequence homology has been found for CPPs, and their capability to deliver non-
permeant cargo-molecules into cells seems to be linked solely to their composition of mainly 
basic amino acids and to their amphipathic character. Therefore, it was suggested, that the 
delivery properties are merely evolutionary side effects that had not undergone evolutionary 
refinement. Thus, it was assumed that the transduction potential could be still enhanced by in 
vitro evolution or by modifications based on mechanistic insights. 
 
                                                
1 The abbreviation is not explained by the authors. 
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The amphipathic KLAL (KLALKLALKALKAAKLA-NH2) was one of the first synthetic peptides 
derived from characteristic features of NLSs. Its uptake rate and cargo delivery efficiency 
was indeed higher than that of Tat and transportan (Hallbrink et al. 2001). 
Likewise, the exchange of some amino acid residues in Tat49-59 enhanced its delivery 
efficiency up to 33fold rendering this peptide sequence to one of the best PTDs (Ho et al. 
2001). Likewise, an oligopeptide of the sequence d(AAKK)4, that mimics the alternating basic 
and non-polar residues found in NLSs (Kaihatsu et al. 2004; Lin et al. 2004), and (KFF)3K, 
shown to permeate bacterial membranes (Geller et al. 2003; Petersen et al. 2004), have 
been used for the delivery of PNAs and antisense oligonucleotides.  
 
 
 
Figure 1-18 Helical wheel plot of an improved Tat-derivative (YARAAARQARA) with the 33x uptake 
efficiency of Tat. All arginine residues of the amphipathic helix point into the same direction (Ho et al. 
2001). 
In a combinatorial approach, a M13 phage library of 12-mer peptides was built up and 
putative CPPs were selected on the basis of their varying cationic charge content (Mi et al. 
2000). These randomized peptides were able to deliver ß-galactosidase to a variety of cell 
lines and primary cells including islet β-cells, synovial cells, polarized airway epithelial cells, 
dendritic cells, myoblasts, and tumor cells. Two of these peptides reached an efficiency 
comparable to that of Tat.  
The high uptake rate of naturally occurring PTDs could be attributed to their high content of 
basic amino acids. Therefore, homo-oligomers of the basic amino acids lysine, ornithine, and 
arginine, were synthesized. Application to cultured cells showed that all compounds could be 
internalized (Emi et al. 1997; Jeang et al. 1999; Lindgren et al. 2000b; Mitchell et al. 2000; 
Ryser 1967; Vives et al. 1994). Even oligohistidine works as a pH-sensitive CPP that is 
almost as efficient as Tat (Robbins et al. 2002). 
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Scheme 1-4 Octaarginine 2 (Wender et al. 2001)  
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The highest uptake rates were observed for oligomers of arginine, the most basic of the 
tested amino acids (Rothbard et al. 2000), that surpassed the uptake rate of poly-L-lysine by 
a factor of 10 (Buschle et al. 1997). A factor of 20 was reported for the comparison of 
nonamers of L-arginine compared to lysine, histidine, ornithine and citrulline (Mitchell et al. 
2000), and a factor of >100 for D-arginine nonamers (Wender et al. 2001). Apparently, the 
uptake rates correlated with the density of positive charges, as arginine (pKa = 12.0) is more 
basic than lysine (pKa = 10.0), and histidine (pKa = 6.0) (Voet and Voet 1998). Molecular 
modeling of oligoarginines indicated that, due to the molecule’s helical conformation, only a 
subset of the side chain guanidinium groups interacts with the negatively charged 
headgroups of the phospholipids of the plasma membrane (Rothbard et al. 2002). 
Correspondingly, decamers in which the three arginines facing away from the plasma 
membrane were replaced by non-polar residues exhibited the same uptake behavior as the 
decaarginine.  
 
 
Figure 1-19 Cellular uptake of arginine-rich oligopeptides in Jurkat cells after 15 min of incubation with 
12.5 mM at room temperature as estimated by FACS: The numbers indicate the number of arginine 
residues comprised by the peptide, R denotes the L-amino acids and r the D-enantiomers (Wender et 
al. 2001). 
 
CPPs have been further developed to DNA condensing agents that exhibit a 50-60 times 
higher efficiency than conventional transfection agents. Due to electrostatic interactions, 
oligomers of lysine with N- and C-terminal cysteine residues aggregate with the negatively 
charged DNA strand, and the peptides can spontaneously oxidize to form interpeptide 
disulfide bonds. The cross-linked peptide DNA condensates can reach the cytosol of the 
cells, where the disulfide bonds are cleaved and the DNA cargo is released (McKenzie et al. 
2000). Likewise, arginine-rich peptides with cysteine residues have been used for peptide-
mediated DNA condensation. Interrupting the arginine sequences with glycines and histidine 
allowed reversible plasmid condensation, so that a plasmid could be more easily released 
inside the cell (Siprashvili et al. 2003). 
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Since their discovery, protein precipitation, toxicity issues and costs have retarded the entry 
of cationic peptides into clinical studies. Therefore, efforts were made to improve the stability, 
facilitate the synthesis, and reduce the costs. As a cost efficient alternative to solid phase 
synthesis, oligoarginine could be prepared in a scalable solution-phase synthesis in 13 steps 
with 28% overall yield (Wender et al. 2001). 
 
HS
HS
HS
HS
HS
HS
HS
HS
SH
SH
SH
SH
S
S
S
S
S S
SS
S
S
S
S
condensed
DNA
Cross-linked
DNA
condensate
 
 
Figure 1-20 Condensation of DNA by cysteine-modified oligolysine (McKenzie et al. 2000). After 
aggregation of the positively charged peptides with the negatively charged DNA, the free thiol-groups 
spontaneously oxidize to form disulfide bonds. 
 
1.2.11 Synthetic molecules to mimic CPPs 
Peptides are sensitive to proteases, so that their plasma half-life time in vivo is rather short. 
To obtain stable transport vectors, peptide mimetics were synthesized that combine the 
functional groups of CPPs with a stabilized backbone.  
In this context, three classes of peptide mimetics can be distinguished: Peptide analogs 
consist of oligomeric chains of isosters of naturally occurring amino acids and derivatives 
with modified non-natural side chains. In backbone mimetics, the functional side chains are 
attached to a different type of monomer that can be oligomerized in analogy to amino acids 
by amide bond formation as in the oligomerization of ω-amino acids. They may as well be 
oligomerized via ester or urethane bonds. In scaffold mimetics amino acid functionalities are 
attached to non-linear structures mostly dendrimers and cyclic or polycyclic structures. 
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Figure 1-21 Examples of peptide mimetics: Peptide analog with alternative side chains (3), scaffold 
mimetic (4) backbone mimetic (here a peptoid 5). 
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Peptide mimetics aim to imitate the spatial arrangement of functionalized side chains in order 
to fulfil the functions of their natural examples. For the function of CPPs, a high density of 
positively charged side chains, that can form an amphipathic secondary structure, appears to 
be crucial.  
A prominent example for backbone mimetics are β-peptides, oligomers of β-amino acids, that 
have been studied extensively in recent years (Umezawa et al. 2002). They are not 
degraded by proteases (Schreiber et al. 2002) and adopt well-defined protein-like secondary 
structures (DeGrado 1999; Gademann 1999; Gellman 1998; Poenaru et al. 1999) which 
makes them attractive as mimetics of CPPs (Raguse et al. 2003; Raguse et al. 2002). 
Despite their different backbone, β-homoarginine (Rueping et al. 2002), β-homolysine 
(Garcia-Echeverria and Ruetz 2003), and β-Tat (Potocky et al. 2003) exhibit a remarkable 
membrane penetration activity. β-peptides adopt a 314-helical conformation with a helical 
pitch of exactly 3.0, so that all side chains are positioned in an angle of ~120° to one another 
and there are three discrete positions in a helical wheel plot, where the side chains reside. 
This facilitates the task of designing peptides in which side chains of similar properties are 
aligned at the same face as to form amphipathic helices (Rueping et al. 2004). Thus the 
effects of conformational constraints on translocation activity can be systematically tested. 
 
 
 
Figure 1-22 Schematic representation of the 314-helix and helical wheel plots β-peptides. The 
backbone of the β-peptide forces the residues into an eclipsed conformation leading to three 
predictable sites at which functional groups can reside (Rueping et al. 2004). 
 
Another closely related class of backbone mimetics are poly-N-substituted glycines, known 
as peptoids, that have had an impact on combinatorial gene therapy, drug delivery, and 
biopolymer folding (Figliozzi et al. 1996; Wender et al. 2000; Zuckermann et al. 1994). 
In the peptoid backbone, side chains are attached to the amine, so that the monomers can 
be easily prepared from functionalized diamines and bromoacetic acid. As opposed to α-
peptides, these diverse non-natural, biomimetic oligomers are resistant towards proteases, 
which enhances their life-time in in vivo applications. Due to a lack of hydrogen-bond donors, 
the achiral peptoid backbone cannot form peptide helical structures. Yet, N-substituted 
glycines of only five residues with chiral, aromatic side chains form stable, polyproline-like 
helices, due to the steric influence of the bulky side chains (Sanborn et al. 2002). 
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Scheme 1-5 Fluorescein-coupled peptoid transporter, 6 (n=5,7,9), (Wender et al. 2000) 
 
Like the highly efficient guanidine-rich α-peptides, guanidine-functionalized peptoids are 
taken up by mammalian cells in a concentration dependent manner (Wender et al. 2000). 
The highest uptake rate was observed for the hexamer. In tests of oligomers with side chains 
of varying lengths, it was found that cellular uptake efficiency could be enhanced to even 
exceed Tat peptide and oligoarginine if the guanidine functionalities were attached to the 
peptoid backbone on C6-side chains (Wender et al. 2000). None of the peptoids exhibits 
toxic effects in the lower micromolar concentration range in which the oligomers were applied 
to the cells, rising their potential for in vivo studies (Wender et al. 2000). 
Apparently, the spacing between the individual residues is important for cellular uptake. In 
this context, guanidine-rich peptides and peptoids with 1,4-spaced side chains are more 
efficiently taken up than Tat peptide. Libraries of mixed arginine-rich oligomers were 
examined and a new series of molecular transporters was identified that is made up from 
alternating units of arginine and aminocaproic acid (aca) (Rothbard et al. 2002).  
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Scheme 1-6 Optimized oligoarginine-aminocaproic acid transporter 7 (Rothbard et al. 2002) 
 
Replacing the amide backbone with carbamate results in increased spacing, higher flexibility 
and thus enhanced uptake (Wender et al. 2002). In agreement with studies on peptoids and 
CPPs, the rate of uptake increased with guanidine content (8 > 7) and concentration (Derossi 
et al. 1994; Dom et al. 2003; Vives et al. 1997a; Vives and Lebleu; Wender et al. 2000). The 
best internalization of fluorescein-coupled oligocarbamates into Jurkat cells as analyzed by 
FACS was found for the hepta- and nonamers. The latter belong to the best guanidine-based 
transporters studied to date entering cells 230 times faster than Tat peptide. 
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Finally, attempts have been made to use polyamines to increase the uptake of various 
substances. Polyamines are positively charged under physiological conditions, so that they 
interact with the plasma membrane and may use the same mechanism as CPPs to reach the 
interior of the cells. They might as well exploit the polyamine transporter (PAT) for 
internalization of covalently attached cargos. However, the capability of PAT to transport 
large cargos is limited by the size of a hydrophobic pocket adjacent to the polyamine binding 
site (Gardner et al. 2004).  
In the further parts of this work, β-peptides, peptoids, oligocarbamates and other peptide 
mimetics that function like CPPs to deliver cargo molecules shall be referred to as synthetic 
transporters, while membrane-spanning proteins for the selective transport metabolites are 
denoted as cellular transporters. 
 
1.2.12 The versatility of CPPs 
CPPs and synthetic transporters have been shown to effectively deliver almost all kinds of 
cargoes ranging from peptides and proteins to nucleic acids and from insoluble small 
molecules to nanoparticles, liposomes and entire viruses. For some classes of substances 
peptide-mediated delivery may be the only form to reach the interior of the cells. 
 
1.2.12.1 Peptides and proteins 
 
PTDs were discovered as domains of larger proteins that could be internalized by cells due 
to the presence of the PTD (Derossi et al. 1998; Frankel et al. 1988; Green and Loewenstein 
1988). Therefore, it was reasonable that the first studies of PTDs and later CPPs dealt with 
protein cargoes to replace the protein of origin. Today, fusions of CPPs with model peptides 
are introduced into cells as an important means to study the molecular mechanisms of signal 
transduction and other intracellular processes. Such fusion peptides can be easily prepared 
by solid phase synthesis or recombinant expression. Conjugation can also be performed via 
amide bonds or, reversibly, by disulfide bonds (Gil-Parrado et al. 2003). For non-peptidic 
cargos, chemical coupling constitutes the only way of conjugate formation (Fischer et al. 
2001). 
Coupled to CPPs, the cargo-peptides retain their original behavior with respect to potency 
and biological function. This method permits to study the function of individual domains 
derived from larger proteins. Thus, several signal sequences could be discovered, putative 
phosphorylation sites have been assessed and regions relevant to protein-protein 
interactions identified. From this, many new target sites for potential therapeutic intervention 
have been derived. (Chen et al. 2001; Gil-Parrado et al. 2003; Ruzza et al. 2001; Schaschke 
et al. 2002; Stolzenberger et al. 2001; Yakymovych et al. 2002). Like RNA aptamers, peptide 
aptamers can be refined to bind to specific targets by in vitro evolution. Coupled to CPPs 
these peptides could inhibit the epidermal growth factor receptor (Buerger and Groner 2003). 
The uptake efficiency has to be determined for each peptide-cargo construct individually, as 
pronounced differences in import efficiency were observed even for peptide cargos of very 
similar size (Fischer et al. 2002), and different CPPs could have varying effects on the 
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transport of the same cargo ranging from an increase of uptake efficiency to a decreased 
solubility (Lin et al. 2004). 
The delivery of biologically active full-length proteins is a more challenging task. According to 
one of the proposed mechanisms, the process of internalization takes place under 
denaturing conditions and not all proteins are properly refolded upon reaching the cytosol 
(Schwarze et al. 2000). However, GFP coupled to transportan did not loose its fluorescence 
in the transport process (Pooga et al. 2001), and the activity of Tat-coupled β-galactosidase 
could be still detected in several tissues after in vivo application (Fawell et al. 1994; 
Schwarze et al. 1999). So depending on CPP and cell type, the cargo protein remains 
functional, which is of special interest for the treatment of pre-clinical disease models (Wadia 
and Dowdy 2002). Several clinically important proteins including antibodies have been 
delivered into cells with Tat49–57, transportan, and NLS-derived peptides as fusion tags (Gius 
et al. 1999; Nagahara et al. 1998; Pepinsky et al. 1994; Pooga et al. 2001; Vocero-Akbani et 
al. 1999). The fusion protein of His6-tagged Cre recombinase with an NLS is readily taken up. 
Its uptake, however, can be significantly improved by fusion with Tat peptide reaching over 
95% of recombination efficiency in cultured fibroblasts, primary splenocytes and murine 
embryonic stem cells (Kasim et al. 2004; Peitz et al. 2002). 
Another challenge is the delivery of artificial transcription factors to the nucleus. Exploiting 
naturally occurring gene-regulators that act on genomic DNA, the Tet-repressor was coupled 
to the full-length Antennapedia homeodomain from Drosophila. The conjugate entered the 
cells where it acted to repress a tetracycline regulated reporter unit that was either transiently 
transfected or inserted into the genome of HeLa cells (Mortlock et al. 2003).  
It has to be kept in mind that the fusion with a CPP may also hinder the biological activity of 
its cargo, as it has occurred for kinase inhibitor peptides attached to Tat (Kelemen et al. 
2002) and an anti-tetanus Fab-fragment that was only active if the Tat peptide was conjugated 
by a cleavable disulfide bond (Stein et al. 1999). 
 
1.2.12.2 Small molecules  
 
For some drugs, topical application is desirable to avoid severe side effects that occur upon 
systemic application. To overcome the limitation posed by the low skin permeability of these 
drugs, they can be covalently coupled to CPPs. As an example, cyclosporin A attached to a 
heptamer of arginine was transported into cells of murine and human skin where it inhibited 
cutaneous inflammation (Rothbard et al. 2000). Similarly, arginine-based molecular 
transporters were conjugated to the anti-tumor agent taxol. Depending on the chosen linker 
structure, highly water-soluble substances were obtained that could release the drug in a pH-
dependent manner (Kirschberg et al. 2003).  
 
1.2.12.3 Inorganic particles 
 
As proteins as large as 120 kDa (β-galactosidase) can be delivered by CPPs (Schwarze et 
al. 1999), further studies aimed to assess the size of particles that can be possibly 
internalized by CPPs. Biotin-coupled transportan was complexed with streptavidin-modified 
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gold particles. The largest conjugates taken up by commonly used cell-lines corresponded to 
proteins with a mass of more than 1 MDa (Pooga et al. 2001). 
Superparamagnetic iron oxide nanoparticles (SPION) are used as contrast agents for 
magnetic resonance imaging (MRI) and as reagents for cell labeling. 9-10 Tat peptides per 
nanoparticle are required to improve the uptake efficiency of an MRI contrast agent by up to 
two orders of magnitude (Nitin et al. 2004; Zhao et al. 2002). Likewise, radioactive 
complexes for applications in molecular imaging and radiotherapy could be delivered by Tat 
peptide. For this purpose, oxotechnetium(V) and oxorhenium(V) were complexed by peptide 
based donors attached to Tat peptide. [99Tc]-Tat peptide showed elevated accumulation and 
rapid uptake kinetics in Jurkat cells. Whole body distribution and rapid clearance were found 
in preliminary imaging studies in mice (Polyakov et al. 2000). 
By conjugation with Tat, silica nanoparticles of 70 nm coupled with FITC (fluorescein 
isothiocyanate) could be introduced into cultured lung adenocarcinoma cells and into rat 
brain tissue in vivo for future applications in bioimaging applications (Santra et al. 2004) 
To direct contrast agents specifically to tumor cells, activatable CPPs (ACPPs) have been 
designed, in which the capacity to enter cells is blocked by a linker consisting of negatively 
charged amino acids that interact with the basic residues of the CPP moiety leading to 
charge neutralization. Both domains are linked via a protease recognition site that is specific 
to matrix metalloprotease 2 and 9 that are secreted by tumor cells. Thus, approaching tumor 
cells, the CPP is cleaved from its inhibitor and its potential to associate with the plasma 
membrane is enhanced by one order of magnitude as opposed to the ACCP (Jiang et al. 
2004). 
 
1.2.12.4 Nucleic acids and PNAs 
 
A special need for new delivery agents lies in nucleic acid-based approaches like gene 
therapy, antisense-mediated gene silencing and RNAi. Although many transfection methods 
have been developed and refined for most cell types, yields in primary and non-dividing cells 
are often low and the majority of cells is killed during the procedure. Moreover, the cationic 
lipids often used for transfection are toxic to fully-grown organisms. Therefore, many efforts 
have been undertaken to use CPPs for the delivery of nucleic acids. 
As nucleic acids, especially RNA, are sensitive towards degradation by nucleases, chemical 
modifications have been introduced to increase their in vivo stability. The use of 
phosphorothioates is very common, even though the thiol-containing backbone exhibits toxic 
effects. Those can be minimized, if only small doses are applied. To obtain the desired 
effects with small doses of oligonucleotides the otherwise poor uptake efficiency of these 
molecules needs to be enhanced. 
Peptoids could be used for the delivery of antisense oligonucleotides with a 
phosphorothioate backbone into cells, where they interfered with the transcription of 
homologous RNA. Due to their chemical structure, both, cell-penetrating molecule and 
antisense agent, were stabilized against nucleases and proteases (Innis 2001). Peptide 
nucleic acids (PNAs) are commonly used as antisense agents that are not recognized by 
proteases and nucleases. Coupling to transportan led to the internalization of a PNA 
designed against the transactivation response (TAR) element of HIV-1 to inhibit Tat-
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mediated transactivation in HIV-1 infected H9 cells (Kaushik et al. 2002). Transportan 
(Pooga et al. 1998a), Penetratin™ (Braun et al. 2002; Villa et al. 2000), NLS, and an artificial 
peptide of the sequence D(AAKK)4 (Kaihatsu et al. 2004) have also been used in antisense-
PNA delivery, and (KFF)3K was utilized for the internalization of artificial ribonucleases based 
on PNAs (Petersen et al. 2004). 
PNAs attached to an NLS can be coupled to Penetratin™ via a disulfide bond. Thus, the 
cargo is taken up and the Penetratin™ moiety is cleaved in the cytosol so that it does not 
interfere with the nuclear import of the cargo (Braun et al. 2002). A similar strategy was 
employed to deliver an NFκB decoy that prevents the DNA binding of the transcription factor 
by binding it in the cytosol. A double-stranded consensus sequence mimicking the κB-site 
was synthesized with an overhanging single-strand corresponding to a PNA-sequence that 
would be linked to transportan (TP) or its shorter analog (TP10) via a disulfide bond. This 
complex was able to enter cultured rat insulinoma cells, where it successfully blocked an 
inflammatory response by inhibiting interleukin-6 expression (Fisher et al. 2004). 
Comparison of peptide-mediated uptake with the lipid-mediated delivery of PNA/DNA hybrids 
led to the result that lipid transfection requires less PNA while peptide-mediated delivery was 
simpler and less toxic to primary endothelial cells (Kaihatsu et al. 2004). 
In early experiments, single stranded oligonucleotides of up to 50 nt had been delivered by 
penetratin (Prochiantz 1996), which was not only of high interest for antisense-mediated 
silencing but also for attempts to regulate transcription. Triplex forming oligonucleotides 
(TFOs) are designed to bind to genomic DNA in order to modulate gene expression. 
Attached to penetratin, their efficiency in vivo was enhanced by a factor of 20, which implies 
that peptide-mediated delivery even reaches the chromosomal DNA located inside the 
nucleus (Rogers et al. 2004).  
Genetic vaccination is another field where CPPs are on their way to become a valuable tool. 
In this new approach, the immune system is primed to new epitopes by applying the 
corresponding recombinant peptides or expression vectors coding for the respective 
epitopes. These epitopes are recognized by T-cells and induce the formation of specific T-
cells from native lymphocytes. To improve intracellular delivery, an NLS was coupled to a 
minimalized expression vector of linearized DNA encoding a hepatitis B epitope. Thus, the 
formation of cytotoxic T-cells was triggered upon intramuscular injection into mice 
(Schirmbeck et al. 2001). 
To deliver even larger nucleic acids, the cargo is encapsulated inside of recombinant viruses. 
The uptake of the virus could be greatly enhanced by modifying the surface of recombinant 
replication-deficient viruses with Penetratin™ (Gratton et al. 2003). Alternatively, λ-phages, 
can be used for gene delivery in mammals. As these viruses normally infect bacteria, they 
are less pathogenic in mammals. λ-phages displaying the SV40 NLS on their surface have a 
higher affinity for the nucleus, if delivered to the cytosol, and enhance the expression of the 
cargo DNA (Akuta et al. 2002). The drawbacks of viral therapies have been already 
discussed.  
For the virus-free transfer of large nucleic acids, Tat and Penetratin™ were coupled to 
liposomes, which greatly enhanced the internalization efficiency if on average only five 
peptides per liposome were attached. For efficient delivery into a variety of cells, the 
liposome-attached peptides must be able to freely interact with the cell surface (Torchilin and 
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Levchenko 2003; Tseng et al. 2002). Fluorescent markers entrapped inside liposomes and 
incorporated into the liposomal membrane indicated that the Tat peptide-liposomes remain 
intact within first few hours before they migrate toward cell nuclei and completely disintegrate 
in the course of 9 h. Tat peptide-liposomes containing up to 10 mol % of a cationic lipid 
(DOTAP) are non-toxic toward cells and transfected a variety of cells (Torchilin 2002).  
Unilamellar liposomes of ~100nm required at least 100 covalently linked Penetratin™ or Tat 
peptides for efficient cellular uptake (Marty et al. 2004).  
In similar approaches, cell-penetrating peptoids were coupled to lipids (liptoids) and sterol 
(cholesteroids) yielding a novel class of molecules for the transfection of cells with 
oligonucleotides. They exhibit low toxicity and are compatible with serum (Huang et al. 1998; 
Lobo et al. 2003). 
The combination of an SV40 large T-antigen derived NLS peptide (NLSV40) with preformed 
polyethyleneimine or dendrimer-DNA complexes also resulted in a strong increase of 
transfection efficiency (Ritter et al. 2003). 
Penetratin™ was also used to enhance the efficiency of Lipofectamine, a commonly used 
transfection agent. If a fusion peptide of penetratin and L-4F, an amphipathic lipid binding 
peptide, was pre-incubated with the transfection reagent, the transfection efficiency in 
coronary epithelial cell culture was increased by 64% without affecting the viability of the 
cells (Ou et al. 2003). 
Nucleic acid delivery can be also achieved without the use of lipid transfection agents if the 
DNA is complexed with an excess of penetratin, VP22, Tat or NLS derived peptides (Dom et 
al. 2003; Kretz et al. 2003). Due to electrostatic interactions, the DNA is condensed by the 
peptides resembling the DNA condensation on the histone proteins. The use of NLS-derived 
sequences to complex antisense oligonucleotides leads to a nuclear localization of the cargo, 
as it was shown for fusion peptides from protamine DNA-binding domain with the SV40 NLS 
(Benimetskaya et al. 2002). However, it is assumed that these particles, also termed 
vectosomes, are taken up by a mechanism comparable to conventional transfection 
(Ignatovich et al. 2003; Zavaglia et al. 2003). Vectosomes based on VP22 have been used to 
deliver a variety of nucleic acids, including ribozymes, plasmid DNA and antisense RNA. 
VP22 vectosomes must be activated to release their cargo. Thus, they can be administered 
systemically but will act only locally upon radiation with the appropriate wavelength and 
intensity. As an example, antisense oligonucleotides directed against the c-Raf1 oncogene 
have been incorporated into vectosomes and successfully inhibited tumor growth in mice 
upon light activation (Brewis 2003; Zavaglia et al. 2003). Alternatively, different cleavage 
sites can be incorporated into the protein to use endogenous proteases for release. Very 
recently, the coupling of siRNAs to Tat peptide and penetratin has been reported by several 
groups (Chiu et al. 2004a; Davidson et al. 2004; Muratovska and Eccles 2004; Schmitz et al. 
submitted).  
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Table 1-2 Conjugates of various cargos with different transporter molecules. 
 
Even oligocarbamates could be used to internalize siRNAs (Chiu et al. 2004a). The so-called 
V-siRNAs or pepsiRNAs were internalized by a variety of cells, even primary neurons and 
Cargo Transporters Reference 
Cyclosporin A  Heptaarginine (Rothbard et al. 2000) 
Methotrexate  Polylysine  (Ryser et al. 1988) 
Doxyrubicin  SynB1 (Rousselle et al. 2001)  
Taxol Oligoarginine (Kirschberg et al. 2003) 
Benzyl-Penicillin  SynB1 (Rousselle et al. 2002) 
GFP (238 aa) Fushi-tarazu, Engrailed (Han et al. 2000)  
Cathepsin B inhibitors (5 aa)  Penetratin (Schaschke et al. 2002) 
Horseradish peroxidase  poly-L-lysine (6.7 kDa) (Shen and Ryser 1978) 
β-galactosidase Tat peptide (Fawell et al. 1994; Schwarze 
et al. 1999) 
Biotin Oligocarbamate transporters (Wender et al. 2002) 
GFP Transportan (Pooga et al. 2001) 
Cre-recombinase Tat peptide, NLS (Kasim et al. 2004; Peitz et al. 
2002) 
Fab-fragment Tat peptide (Stein et al. 1999) 
Tet-repressor Antennapedia full-length (Mortlock et al. 2003) 
silica nanoparticles + FITC Tat peptide (Santra et al. 2004) 
Superparamagnetic iron oxide 
nanoparticles 
Tat peptide (Nitin et al.; Zhao et al. 2002) 
Radioactive isotopes, Tat peptide (Polyakov et al. 2000) 
Fluorescein Oligoarginine (Vives et al. 1997b) 
Fluorescein Peptoids (Wender et al. 2000) 
Fluorescein β-peptides (Umezawa et al. 2002) 
Fluorescein Oligocarbamates (Dom et al. 2003) 
NF-κ-B decoy Transportan  (Fischer et al. 2001) 
DNA  Penetratin (non-covalent) (Dom et al. 2003) 
DNA Penetratin, VP22, Tat or NLS (Kretz et al. 2003) 
DNA MPG (Morris et al. 1997) 
Linearized DNA vector NLS (Schirmbeck et al. 2001) 
Antisense-PNA Transportan (Kaushik et al. 2002; Pooga et 
al. 1998c) 
Antisense-PNA D(AAKK)4 (Kaihatsu et al. 2004) 
Triplex-forming oligonucleotides Penetratin (Rogers et al. 2004) 
Antisense RNA  Penetratin (Astriab-Fisher et al. 2002) 
Antisense oligonucleotides Tat peptide, penetratin, VP22 
(non-covalent) 
(Brewis 2003; Zavaglia et al. 
2003) 
Antisence nucleotides Peptoids (Zuckermann et al. 1994) 
siRNAs Penetratin (Davidson et al. 2004; 
Muratovska and Eccles 2004; 
Schmitz et al. submitted) 
siRNAs Tat peptide, oligocarbamates (Chiu et al. 2004a) 
λ phages SV40-NLS (Akuta et al. 2002) 
Recombinant viruses Penetratin (Gratton et al. 2003) 
Adenovirus  Polylysine (Mulders et al. 1998) 
Dendrimer-DNA complexes NLS-SV40 (Ritter et al. 2003) 
200-nm  liposomes  (Torchilin et al. 2001) 
Stabilized liposomes Tat peptide, penetratin (Tseng et al. 2002) 
100 nm liposomes  Tat peptide (Marty et al. 2004) 
Lipofectamin/DNA Penetratin (Ou et al. 2003) 
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fibroblasts, were they triggered the degradation and translational inhibition of the targeted 
mRNAs. 
 
1.2.13 The mechanism of peptide-based delivery 
Despite the wide use of CPPs and synthetic transporters to deliver bioactive molecules into 
all kinds of cells, the mechanism of their internalization is still poorly understood, and the 
results obtained in numerous studies lead to controversial hypotheses. 
All proposed mechanisms need to explain the localization of labeled CPPs in vesicular 
structures and their exit from these compartments to the cytosol. They also have to account 
for the fact that no receptors are required and that no leakiness of the cells has been 
observed implying that the plasma membrane is neither ruptured nor perforated in the 
process as measured by 2-[3H]-deoxyglucose-6-phosphate leakiness (Hallbrink et al. 2001; 
Terrone et al. 2003). 
It is commonly assumed that CPPs and synthetic transporters enter the cells in a two-step 
mechanism that is now referred to as peptide-mediated delivery or uptake. First, the 
positively charged transporter interacts with negatively charged residues on the plasma 
membrane where it adopts an active conformation. This induces a membrane reorganization 
process in which the affected region of the membrane is internalized by endocytosis 
(Console et al. 2003; Drin 2003; Vives 2003). Most CPPs accumulate in the 
endosomal/lysosomal compartment, but at least a small portion of the CPPs leaves the 
endosome to reach the cytosol by an as yet unknown mechanism. The mode of uptake may 
depend on cell-type, cargo, and the CPP or synthetic transporter itself, and it is even 
possible that several mechanisms are involved simultaneously (Letoha et al. 2003).  
 
1.2.13.1 Non-endocytotic concepts 
 
Other models are based on non-endocytotic pathways. One early hypothesis was the 
formation of inverse micelles. The CPP attached to the membrane was thought to disturb the 
membrane structure due to surface charge neutralization and thus induce the formation of a 
hydrophilic cavity that encloses the peptide and its cargo (Berlose et al. 1996; Derossi et al. 
1998). However the dimension of cargo molecules like ß-galactosidase (120 kDa) (Schwarze 
et al. 1999) and nanoparticles of 45 nm in diameter (Lewin et al. 2000), that have been 
delivered by CPPs, forbids the formation of corresponding micelles within the hydrophobic 
core of the plasma membrane that measures less than 5 nm.  
Pore formation was proposed, when the hydrophobic helix domain of KLAL was detected on 
the inner monolayer of phospholipid vesicles at high peptide concentrations (Dathe et al. 
1996). In an electroporation-like mechanism the asymmetrical distribution of the peptide was 
proposed to cause a transmembrane electrical field that leads to lateral and curvature stress 
resulting in the disruption of the membrane (Binder and Lindblom 2003). However, entrapped 
carboxyfluorescein does not leak from phospholipid vesicles upon action of Penetratin™ 
(Persson et al. 2003) and cellular membranes remain intact during Tat internalization 
(Potocky et al. 2003; Ziegler et al. 2003). However, spontaneous pore formation has not 
been abandoned from discussion until today.  
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1.2.13.2 CPP-membrane interactions  
 
The interaction of the positively charged CPPs with the negatively charged surface of the 
plasma membrane is essential to peptide-mediated uptake. This was confirmed by alanine 
exchange studies with penetratin and Tat peptide (Christiaens et al. 2004; Dom et al. 2003; 
Thoren et al. 2003) and by the fact, that oligomers of basic amino acids are functional as 
CPPs (Jeang et al. 1999; Lindgren et al. 2000a; McKenzie et al. 2000; Mitchell et al. 2000; 
Vives et al. 1994).  
Peptide interactions with lipid model membranes have been subject to intense studies. Small 
unilamellar vesicles (SUVs) can be made up from phospholipids with hydrophobic tails of 
differing chain length and differently charged polar head groups. Measurements of circular 
dichroism (CD) detect changes in the secondary structure of the peptide upon its interaction 
with the membrane. The behavior of Penetratin is monitored by the fluorescence of its two 
tryptophan residues that is indicative of the hydrophobicity of its environment and therefore of 
its insertion into the membrane. Similarly, the insertion of aromatic residues changes their 
contribution to CD spectra (Persson et al. 2004). Shifts of individual signals of 1H-NMR 
spectra can be also taken as a measure of peptide-membrane interaction  
 
 
 
 
Scheme 1-7 Peptide membrane interactions a) Interaction of guanidinium headgroups with 
phospholipids. The formation of two hydrogen bonds and the electrostatic interaction result in a tight 
binding. b) Upon membrane interaction decaarginine adopts a conformation in which 7 arginine 
residues face the membrane, while three are oriented in the opposite direction (Rothbard et al. 2002).  
 
In most cases, the peptide adopts an amphipathic structure that can interact with the model 
membrane via hydrophobic interactions, that have been calculated to be independent from 
the surface charge density (Persson et al. 2003). As determined by isothermal titration 
calorimetry, the nonclassical hydrophobic effect and a lipid-induced change of the secondary 
structure make up for an exothermic partial molar enthalpy of -20 to -30 kJ mol-1 that drives 
membrane binding of penetratin (Binder and Lindblom 2003). For neutral vesicles or those 
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with a low surface charge these hydrophobic interactions are decisive. If the model vesicles 
bear a highly negative surface charge, electrostatic interactions prevail (Magzoub et al. 
2002). This is confirmed by the finding that most CPPs interact much stronger with negatively 
charged vesicles than with neutral ones (Bellet-Amalric et al. 2000; Christiaens et al. 2002; 
Dathe et al. 1996; Drin et al. 2001; Magzoub et al. 2001). The amount of internalized peptide 
correlates with the quantity of peptide initially associated with the cell surface (Drin et al. 
2001). 
Although the presence of tryptophan residue 48 is essential for the uptake of Penetratin™, it 
appears to be not involved in the initial interaction of the peptide with the membrane 
(Christiaens et al. 2004). For the cationic peptide derived from NF-κB, the replacement of 
individual basic residues by alanine had a weaker effect on uptake efficiency than 
substitution of a glutamine and a leucine residue (Ragin and Chmielewski 2004). Both 
findings indicate that there are more factors determining the driving force for membrane 
translocation. 
 
1.2.13.3 Structural requirements for CPPs 
 
Studies of the relationship between CPP conformation and its membrane translocation ability 
have led to contradicting results. 
Tat peptide and Penetratin™ can both form an amphipathic helix in which all positively 
charged residues point into one direction and the non-polar residues to the opposite direction 
(Drin et al. 2001; Rothbard et al. 2002). Therefore, it was proposed that helical amphipathy is 
a prerequisite for membrane interaction. Indeed, the interaction with phospholipid vesicles 
grows stronger if the helical amphipathy is increased (Drin et al. 2001). The magnitude of 
hydrophobic moment and helical wheel plots for fusion peptides with Penetratin™ and Tat 
peptide are a direct measure for their ability to deliver the attached cargo-peptide (Li et al. 
2002). Correspondingly, the most efficient arginine-rich oligopeptides are able to form this 
kind of amphipathic helixes (Ho et al. 2001). Studies on amphiphilic peptides designed to 
prefer an α-helical or a β-sheet conformation showed that conformational properties can 
influence the interactions with phospholipids (Deshayes et al. 2004).  
 
 
 
Figure 1-23 Helical wheel plots of Penetratin™ (left) and Tat peptide (right). Positively charged 
residues (red) are located toward one face of the helix. 
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However, no correlation between helical conformation and membrane translocation could be 
found for Penetratin™ and its homologs (Drin et al. 2001). Moreover, the introduction of the 
“helix-breaker” proline into the Penetratin™ sequence does not alter its cellular uptake 
(Derossi et al. 1996). Amphipilic proline-rich peptides from the antimicrobial peptide 
bactenecin7 have recently been discovered as a novel class of CPPs (Fernandez-Carneado 
et al. 2004; Sadler et al. 2002). Possibly, a non-helical conformation can mediate uptake as 
long as the majority of positive residues can interact with the membrane.  
Apparently, the membrane composition itself determines the secondary structure of the 
CPPs, many of which show no ordered conformation in free solution. The α-helical state is 
adopted at low concentrations of peptide and at low surface charges (Christiaens et al. 2002; 
Magzoub et al. 2002; Magzoub et al. 2001) and has little effect on the membrane as the 
peptides lie parallel to surface. β-sheet-like structures are induced by vesicles with high 
negative surface charges or high peptide concentrations and lead to membrane perturbation 
(Magzoub et al. 2002). The artificial MPG generally adopts a β-sheet upon interaction with 
phospholipids, while Pep-1 is found in a helical conformation (Deshayes et al. 2004). The α-
helical conformation of Penetratin™ and its homologs is increased when associating with 
model membranes. The peptide resides at the water-lipid interface with the tryptophan 
residue partially buried in the membrane. The membrane insertion is increased if individual 
arginines and lysines are replaced by alanine (Christiaens et al. 2004). Using PEGylated 
lipids, it was shown that vesicle aggregation induces an α-helix to β-sheet conformational 
transition in Penetratin™ and homologous peptides (Persson et al. 2004). It has been 
proposed that the lipid-induced secondary structure determines the hydrophobicity of the 
CPPs and thereby the insertion mode that precedes internalization (Binder and Lindblom 
2003). 
 
1.2.13.4 Other components involved in CPP-membrane interaction 
 
In none of these studies the peptide was found inside the vesicle indicating that uptake by 
spontaneous membrane penetration is less likely and that some other features of living cells 
are required for internalization (Drin et al. 2001; Kramer and Bentley 2003; Ziegler et al. 
2003). As already mentioned, receptor interactions had been ruled out by the first reports 
about protein transduction. Non-lipid negatively charged structures such as extracellular 
glycosaminoglycans appeared to be a suitable target for CPP binding (Console et al. 2003). 
Indeed, the internalization of Tat and Penetratin™ was significantly reduced in mutant cells 
defective for glycosaminoglycan synthesis. Free heparan sulfate proteoglycans (HSGs) 
diminished the uptake of penetratin, while heparin and dextran sulfate inhibited Tat-mediated 
uptake indicating that the specific interaction with distinct glycosaminoglycan species is 
preferred over the interaction with the lipids of the plasma membrane (Console et al. 2003). 
Heparin also inhibited the uptake of Tat and Penetratin™ modified liposomes, and these 
cargos could not be taken up by glycosaminoglycan-deficient CHO cells, confirming the role 
of glycosaminoglycans for CPP uptake (Marty et al. 2004). 
These results were contradicted by studies in which Tat peptide entered readily into HeLa 
and KB 3-1 cells, but not into renal epithelial and colonic carcinoma cells, although all cell 
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lines express HSGs (Violini et al. 2002), and in which the uptake of Tat peptide did not 
involve HSGs (Silhol et al. 2002). 
 
1.2.13.5 Energy requirements and Endocytosis 
 
After correcting the procedures to avoid artifacts it was found that CPPs are taken up over a 
time-course of several hours (Richard et al. 2003; Umezawa et al. 2002) rather than minutes 
as had been previously reported (Vives et al. 1997a). Up to 10 hours were required to fully 
internalize a Tat-GFP fusion protein (Fittipaldi et al. 2003). However, due to the high 
membrane interaction of the cationic peptides, pulsed incubation times of only 5 min are 
sufficient to attach a significant amount of peptide-coupled cargo to the membrane to be 
taken up in the course of the following hours (Soughayer et al. 2004). 
 
Fluorescently labeled CPPs reside in vesicular structures (Drin 2003; Fischer et al. 2004; 
Kaihatsu et al. 2004; Richard et al. 2003; Thoren et al. 2003; Trehin et al. 2004; Umezawa et 
al. 2002; Vives and Lebleu 2003). Tat and nonaarginine conjugates with fluorescein were not 
only found distributed in dots, but also colocalized with endocytotic markers (Diaz-Griffero et 
al. 2002). And also fusion proteins of VP22, Tat, oligoarginine, and oligolysine are confined 
to the endosomes (Lundberg et al. 2003; Richard et al. 2003).  
The uptake of CPPs is markedly reduced at 4°C pointing at an energy-dependent 
mechanism. Correspondingly, the accumulation of CPPs in endosomes could be inhibited by 
the addition of sodium azide and 2-deoxyglucose that interfere with oxidative phosphorylation 
leading to ATP depletion (Console et al. 2003; Drin 2003; Lin et al. 2004; Saalik et al. 2004; 
Thoren et al. 2003; Vives et al. 2003). All these findings propose an endocytosis-based 
mechanism.  
This is confirmed by a series of studies using inhibitors of endocytosis to inhibit the uptake of 
SynB (Drin 2003), Penetratin™ (Drin 2003; Fischer et al. 2004), Tat peptide and Arg9 
(Fischer et al. 2004). Likewise, inhibition of endocytosis by hyperosmolar medium containing 
0.4 M sucrose decreased the uptake of penetratin, Tat peptide, transportan and pVEC 
(Saalik et al. 2004). Treatment of the cells with β-cyclodextrin leads to a cholesterol depletion 
that goes along with a disappearance of rafts and caveolae and the inhibition of their re-
formation (Thyberg 2002). Under cholesterol depletion none of the tested CPPs was taken 
up, which indicates an involvement of rafts or caveolae in peptide-mediated uptake (Saalik et 
al. 2004). Recently, it was found that fusion peptides of Tat with Cre recombinase are taken 
up by macropinocytosis of lipid rafts (Wadia et al. 2004).  
The fact that only a fraction of the CPP-related fluorescence co-localized with the transferrin 
receptor, confirmed the original reports about a receptor-independent process (Potocky et al. 
2003). Strong evidence exists that lipid rafts and caveolae are involved in the uptake of Tat 
(Fittipaldi et al. 2003). 
Interestingly, Penetratin™ and Tat are not taken up by isolated mitochondria even when 
conjugated to lipophilic triphenylphosphonium (TPP) cations, that are known to trigger the 
uptake of attached molecules into the mitochondria driven by the membrane potential. In cell 
culture, Tat and Tat-TPP accumulate in endosomes but do not enter into mitochondria. 
Obviously, neither CPP can overcome the mitochondrial phospholipid bilayer. As 
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mitochondria do not possess a vesicular transport system, this result strongly supports the 
view of an endocytosis-mediated uptake of CPPs (Ross and Murphy 2004). 
One could imagine, that CPPs simply stick to the surface of the plasma membrane from 
where they are internalized along with their cargo in the process of membrane recycling. 
Considering that half of the fibroblast cell surface is recycled within a few minutes (Thilo et al. 
1995) the CPP-coupled cargo molecules are likely to be rapidly internalized once they 
associate with the plasma membrane.  
In microorganisms like Staphylococcus aureus, Candida albicans and Mycobacterium 
smegmatis, pVEC and TP10, a transportan derivative, act very much like antimicrobial 
peptides. Within minutes, the peptides accumulate on the microbial surface and enter into 
the cells leading to a lethal permeabilization of the membrane. At low micromolar doses, 
microbes are seriously damaged, while HeLa cells remain unharmed, so that mammalian cell 
cultures can be cleared from microbial infections (Nekhotiaeva et al. 2004). Endocytosis may 
actually help to protect mammalian cells from membrane damage caused by CPPs. 
Alterations of membrane thickness and structure upon interaction with CPPs have been 
shown for phospholipid vesicles (Binder and Lindblom 2003; Deshayes et al. 2004; Salamon 
et al. 2003), and transportan alters the resistance of an epithelial barrier model (Lindgren et 
al. 2004). Such changes in membrane constitution may trigger a series of events that result 
in the removal of the destabilized patch of membrane by endocytosis. Yet, as opposed to 
microinjection or pinocytic loading, neither membrane repair pathways, nor stress induced or 
proteolytic pathways were triggered by Tat-fusion peptides (Soughayer et al. 2004). 
 
 
1.2.13.6 The way to the cytosol 
 
The endocytotic model accounts well for the overall integrity of the plasma membrane 
observed throughout the internalization process. However, CPPs have been found leaking to 
the cytosol and entering the nucleus in the course of few hours (Fischer et al. 2004; Thoren 
et al. 2003; Zaro and Shen 2003). CPP-delivered substrates for cytosolic kinases were even 
shown to be accessible after 30 min with the majority being available after 1h (Soughayer et 
al. 2004). Many more biological responses obtained from otherwise non-permeant molecules 
(see 1.2.12) can only be explained by a cytosolic localization of the cargo molecules. The 
leaking of fluorescently labeled CPPs to the cytosol is not observed if ammonium chloride, an 
inhibitor of endosomal acidification, is added to the culture medium (Potocky et al. 2003; 
Thoren et al. 2003) suggesting that a pH-shift is required for “endosomal escape” or release.  
 
In recent studies, it was found that intact fluorescein-labeled Penetratin™ and Arg9 escaped 
into the cytosol, while Tat peptide had obviously been degraded by endosomal proteases so 
that its fragments were found in the supernatant of the cultured cells (Fischer et al. 2004). 
Here, the incubation of the cells with bafilomycin A1 and chloroquine, inhibitors of endosomal 
acidification, led to an increase of the Tat related fluorescence in the endosomes, confirming 
that acidification is required for release from the endosomes. Although a direct pH-dependent 
membrane penetration has been observed for botulinum C2 toxin (Barth et al. 2000), 
acidification of the cell culture medium could not trigger a direct cytosolic localization of either 
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peptide (Fischer et al. 2004). None of the tested peptides colocalized with lysosomal 
trackers, indicating that endosomal escape takes place at an early stage of maturation. Co-
incubation of the cells with CPPs and fluorescently labeled dextran led to the same 
distribution as found for dextran alone, so that the endosomes must stay intact while the 
CPPs exit to the cytosol (Fischer et al. 2004). 
 
 
 
 
Figure 1-24 Suggestions for the mechanism of peptide mediated delivery. The peptide interacts with 
negatively charged phospholipids or glycosaminoglycans on the cell surface. Thereby the membrane 
composition is disturbed and the peptide is taken up by endocytosis. Acidification is required for 
endosomal escape that releases the peptide into the cytosol. Alternatively, interaction with the plasma 
membrane could lead to spontaneous pore formation followed by internalization of the peptide. 
 
Brefeldin A, an inhibitor of retrograde trafficking, could interfere with the uptake and cytosolic 
activity of Tat-GFP conjugates (Fittipaldi et al. 2003). For fluorescein-labeled Tat, the exit to 
the cytosol was also inhibited by Brefeldin A. Apparently, the CPPs are taken up into a 
compartment distinct from endosomes, that is functionally coupled to the cytosol (Fischer et 
al. 2004). Correspondingly, NDGA, that induces the rapid retrograde movement of Golgi 
stack and TGN membranes, led to an increase of cytosolic fluorescence, when cells were 
pre-incubated with peptides and then chased with the lipoxygenase inhibitor NDGA. If Golgi 
stack and TGN are disrupted by the addition of NDGA prior to CPP incubation, much less 
cellular fluorescence was observed. Co-incubation with Bodipy-ceramide, a cell permeant 
Golgi tracer, led to only a partial colocalization with the labeled Penetratin™ and Tat peptide, 
which may be due to a rapid passage through the Golgi (Fischer et al. 2004). It was 
concluded that cationic CPPs act similar to some plant and bacterial toxins such as ricin and 
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Shiga toxin that after endocytosis pass the Golgi and the ER to enter the cytosol (Sandvig 
and van Deurs 2000). Interestingly, all of these toxins contain an arginine-rich motif. 
Moreover, gentamycin and other cationic aminoglycosides reach the cytosol by retrograde 
transport (Sandoval and Molitoris 2004), that may constitute a general pathway for cationic 
low molecular weight compounds (Fischer et al. 2004). 
 
1.2.13.7 Recent indications for direct transduction 
 
In most experiments, CPP uptake was never fully inhibited at low temperatures or when 
endocytosis was inhibited, giving room for speculations about non-endocytotic side-
mechanisms of CPP uptake (Drin et al. 2001; Letoha et al. 2003; Soughayer et al. 2004; 
Thoren et al. 2003; Zaro and Shen 2003) that have not been settled, yet. Many recent 
reports still hold to the idea of pore formation, as in the process of MPG-mediated delivery of 
oligonucleotides (Deshayes et al. 2004; Letoha et al. 2003). These ideas are supported by 
the finding that Penetratin™ and its homologs, in which individual arginine and lysine 
residues are replaced with alanine, lead to the leakage of calcitonin-filled vesicles 
(Christiaens et al. 2004). Of the well-studied CPPs, Penetratin™ is most likely to act by a 
different mechanism, as its cellular uptake strongly depends on the presence of tryptophan 
residue 48 (Christiaens et al. 2004; Dom et al. 2003). On the contrary, the Norden group 
reported that substitution of the tryptophan residues did not alter the uptake characteristics. 
However, they found that a heptaarginine peptide with a tryptophan residue at its C-terminus 
is internalized via an energy-independent non-endocytotic pathway (Thoren et al. 2003). 
Penetratin™ (Binder and Lindblom 2003; Thoren et al. 2003), but also hexamers of arginine 
and lysine, were found to enter into artificial systems (Terrone et al. 2003). In the presence of 
a transmembrane potential, they were detected on the inner leaflet of large unilamellar 
vesicles (LUVs) bearing negative charge inside. The uptake efficiency strongly depends on 
the lipid composition. Remarkably, leakiness assay detected only minor disturbations of 
overall barrier function of the lipid bilayer upon peptide uptake (Terrone et al. 2003). These 
findings were confirmed by a study in which penetratin and its homologs readily entered giant 
unilamellar vesicles (GUVs, >1µm), but not LUVs (100nm), and accumulated at the inner 
leaflet of the vesicles (Persson et al. 2004). 
According to Binder and Lindblom, a transmembrane potential can be generated in vesicles 
with a high concentration (>50%) of negatively charged phospholipids. At a critical peptide-
to-lipid ratio of ~1/20 the membrane becomes permeable and the peptide can enter in a kind 
of electroporation mechanism that involves inversely curved transient membrane structures. 
However, this is only possible if the negative charges on the membrane are high enough to 
recruit a sufficient amount of peptide accounting for the required field strength (Binder and 
Lindblom 2003). Domains of sufficiently high negative charge density may occur in the 
plasma membrande (Murray et al. 1999), and more negatively charged lipids are recruited to 
the vicinity of membrane associated cationic peptides (Binder and Lindblom 2003; May and 
Ben-Shaul 2000). The central question remains whether the peptides can directly penetrate 
the plasma membrane or whether direct penetration plays a role in the exit from the 
endosomes, where a comparable potential is built up upon acidification and accumulation of 
positively charged peptides. 
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1.2.13.8 The specificity of peptide-mediated delivery 
 
According to the latest results, CPPs act nonspecifically by attaching to negatively charged 
residues on the cell surface. The stronger the interaction with the plasma membrane, the 
more efficient is the cellular uptake. It was shown as early as 1993 (Anderson et al. 1993) 
that Tat-coupled Fab-fragments targeting a cell surface antigen enter the cells more readily 
with more peptide moieties attached at the cost of a reduced specificity. This non-specificity 
of CPP-membrane interactions sets a limit to attempts to target specific cell types or tissues. 
To restrict peptide mediated delivery to a certain tissue, the peptide-coupled compound 
needs to be applied locally, as for example cutaneously to treat skin disease, orally or 
intranasally to reach the respective mucosa, or by injection into the tissue of interest.  
A way towards more specificity lies in activatable CPPs (ACPPs), in which the capacity to 
interact with the cell surface is blocked by a linker consisting of negatively charged amino 
acids that neutralize the basic residues of the CPP. If both domains are linked via a protease 
recognition site that is specific to a protease secreted by a specific cell type, the CPP is 
cleaved from its inhibitor once it approaches the targeted cells. This concept was first applied 
to direct contrast agents specifically to tumor cells secreting matrix metalloprotease 2 and 9. 
Cleavage of the inhibiting domain enhanced the CPP’s potential to associate with the plasma 
membrane by one order of magnitude as opposed to the ACCP (Jiang et al. 2004). 
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2 Aims of this work 
 
As it has been shown in the introduction, RNA interference bears an enormous potential for 
medical application that will only become fully exploitable if methods are found to  
transport dsRNAs or siRNAs into human tissues with the highest efficiencies and with as few 
side effects as possible. 
 
The aim of this work is the establishment of a new concept to introduce siRNAs into 
mammalian cells for the transient generation of RNAi phenotypes as an alternative to 
transfection, electroporation and direct injection.  
To enhance their cellular uptake, siRNAs are to be covalently linked to cell-penetrating 
peptides modified with a C-terminal cysteine. The coupling shall be performed via disulfide 
bridges that are susceptible to the reducing environment of the cytosol, so that the siRNAs 
are released once they enter this compartment. 
These so-called peptide-coupled siRNAs (pepsiRNAs) are to be tested upon their uptake in 
mammalian cell culture in comparison to chemical transfection of siRNAs as the standard 
procedure of transient RNAi today. 
This requires efficient strategies to generate the pepsiRNA building blocks in large quantities. 
Cell-penetrating peptides have to be synthesized and modified with a cysteine moiety that 
needs further activation to permit the formation of peptide-RNA heterodimers. Likewise, 
siRNAs with a thiol-modification are required. Due to the sensitivity of RNAi toward 
antisense-strand modifications and alteration of 3´-overhangs, this functionality has to be 
specifically attached to the 5´-end of the sense strand.  
Moreover, new cell-penetrating molecules are to be synthesized and tested upon their 
capability to transport reporter molecules into mammalian cells, and linked to siRNAs as a 
first step toward the larger class of cepsiRNAs, cell permeating siRNAs. 
 
3 The concept of pepsiRNAs  
 
The first and still broadly used transient RNAi-method introduced by Tuschl and coworkers 
(Elbashir et al. 2001a) is based on the transfection of siRNAs by liposomal transfection. With 
the technologies at hand, transient RNAi experiments can be performed in a straightforward 
fashion: With the help of computer programs and databases, it is possible to design a set of 
highly efficient siRNA-sequences. Of the currently available methods to generate siRNAs of 
a specific sequence, in vitro transcription by T7 RNA polymerase and solid phase synthesis 
are the most important ones. These siRNAs are then transfected into cultured cells with 
liposomal transfection reagents and cell-type specific protocols readily available. 
If pepsiRNAs are to be developed as an alternative system to expand the possibilities of 
transient RNAi for applications in tissue culture and fully-grown organisms, a system 
consisting of individual building blocks would be most convenient for the potential user. 
To achieve this, different ways have been developed to provide siRNAs of any given 
sequence with a functionality that can form disulfide bonds with a set of thiol-modified cell-
penetrating peptides or synthetic cell permeable molecules. Thus, the membrane 
permeability of the siRNAs would be greatly enhanced. As opposed to transfection reagents, 
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cell-penetrating peptides have as yet exhibited a low cytotoxicity up to concentrations of 10-
30 µM which is about three orders of magnitude above the concentration range needed for 
RNAi experiments. Thus, the use of pepsiRNA in vivo appears feasible.  
 
 
•synthetic peptides •synthetic siRNAs 
•recombinantly expressed peptides •in vitro transcribed siRNAs  
•cell permeable small molecules (•siRNAs processed by Dicer) 
 
Figure 3-1 Schematic representation of pepsiRNAs consisting of three essential building blocks: The 
CPP (light blue) can be coupled to the siRNA (red) via a variety of linkers that require specific 
functionalities upon the peptide (blue) and siRNA (orange) moieties.  
 
Both peptide and siRNA can be synthesized on solid phase yielding compounds with high 
purity in the order of milligrams or micromoles at comparatively high costs (Table 3-1). As 
this approach permits specific modification of the oligomers at specific sites by the use of 
modified monomers or the attachment of functional residues prior to cleavage from the solid 
phase, it is of great use for proof-of-principle experiments in which the cellular localization of 
the compounds shall be determined or the effects of sequence variations on uptake and 
knock-out efficiency are to be examined. 
 
Substance Quantity Price Provider 
PenetratinTM 500 µg € 370.60 Qbiogene 
siRNAs 5 nmol (purified) 
10 nmol (unpurified) 
€ 330.00 
€ 220.00 
Proligo 
RiboMAXTM 10 reactions € 224.62  Promega 
DNA-Oligos 2x 38nt + 1x 17 nt ~ € 50.00 Sigma-ARK 
 
Table 3-1 Comparing prices of commercial compounds obtained from solid phase synthesis 
 
If larger quantities are required, molecular biological methods become more interesting. 
siRNAs can be generated by in vitro transcription from DNA-oligonucleotides that can be 
obtained from customized solid phase synthesis offered at comparatively low prizes 
considering that one set of template-DNAs is sufficient for several hundred in vitro 
transcription reactions. If the transcription of sense and antisense strand is carried out 
separately, one strand can be selectively functionalized by the addition of functionalized 
nucleotides to the reaction mixture or subsequent enzymatic ligation of modified nucleotides 
to the RNA strands. An alternative route is the generation of long stretches of dsRNA from 
the cDNA covering 800-1000bp of the target gene that are subsequently cleaved into native 
siRNAs by recombinant Dicer or appropriate RNase III mutants. These siRNAs are then 
modified for coupling by enzymatic ligation of modified nucleotides. 
P
P
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Apart from solid phase synthesis, cell-penetrating peptides can be obtained in large 
quantities from expression in E. coli. For this purpose, recombinant plasmids are generated 
by cloning an artificial gene that encodes the CPP. This approach also permits the 
functionalization of the peptide by adding a cysteine codon for a later disulfide-bond 
formation to the 3`-end of the synthetic nucleic acid sequence. The expression as fusion 
proteins greatly facilitates the purification of the peptides. Moreover, cell permeable small 
molecules can replace the CPPs. If their structures are sufficiently simple their synthesis on 
solid phase may be straightforward and less costly than the synthesis of peptides and 
maintain the opportunity to incorporate reporter groups and other useful modifications. 
 
Over the last decades, a set of coupling groups has been used to attach biomolecules to 
reporter molecules and drugs or to immobilize them on solid phase. Functional groups for 
coupling are easily introduced into the respective molecules under physiological conditions. 
These functional groups can form covalent or non-covalent bonds. Some of these bonds are 
stable in vivo, others are cleaved under reducing conditions or at low pH (see Figure 3-2). 
For in vivo applications, disulfide bonds appear to be particularly useful. CPPs accelerate the 
uptake of attached cargo molecules, but also increase the rate of cellular escape until an 
equilibrium is reached (Lindgren et al. 2004). The escape of the cargo molecules can be 
prevented, if the conjugates break apart upon reaching the cytosol. Thus, the tissue 
distribution of pepsiRNAs would be restricted allowing for locally focused applications. 
Moreover, if the conjugates are cleaved, the siRNA is released and the CPP can no longer 
interfere with the RNAi machinery.  
In this work, the disulfide coupling strategy is followed exclusively. However, thiol-modified 
compounds can also form stable thioether linkages that are more interesting for systemic 
applications. 
 
CPPs obtained by recombinant expression (AntP from Drosophila Antennapedia protein and 
TAT from HIV-TAT protein) and from solid phase synthesis (Penetratin™) as well as 
synthetic peptide mimetic were used. siRNAs were either custom-made or generated by a 
modified in vitro transcription that permits a selective functionalization of the siRNA: 
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Figure 3-2 Common strategies for the formation of bioconjugates. Linkers after coupling and the 
complementary functionalities on the peptide (R1) and the reporter or cargo-molecule (R2) required for 
linker formation are shown. Depending on the available functional groups, R1 and R2 may be 
exchanged. 
 
1. The first part describes the development of a strategy for the thiol-modification of in vitro 
transcribed siRNAs and their subsequent coupling to activated PenetratinTM from solid phase 
synthesis.  
 
2. The hence obtained pepsiRNAs are tested in cell culture and compared with traditional 
transfection strategies. This is described in part 2. 
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3. The third part deals with the expression and purification of the CPPs Antp-Cys and Tat-
Cys as GST-fusion proteins from E. coli. Also, the generation of a GST- or His6-labeled TEV-
protease and its utilization for the cleavage of GST-CPP-fusion proteins is described. 
 
4. The final part reports the development of novel small molecules with cell permeating 
properties, that were coupled to fluorescein and porphyrin to assess their capability to enter 
cultured cells and to deliver large, otherwise non-permeant cargo-molecules. 
 
3.1 Design and synthesis of thiol-modified siRNAs 
For an efficient in vivo RNAi it is absolutely essential to choose the most efficient siRNA. For 
its design, many factors have to be considered. Thus, 2nt 3´-overhangs are important for 
recognition (Zamore et al. 2000). 5´-phosphorylation of the antisense strand increases the 
efficiency, but can be provided by kinases in the cytosol if the 5´-termini are non-
phosphorylated (Chiu and Rana 2002; Nykänen et al. 2001), whereas 5´-triphosphates are 
discussed as a trigger for interferon response and non-specific effects (Kim et al. 2004). 5´-
modifications on the sense strand are well tolerated, while modification of the 5´-terminus of 
the antisense strand lead to a dramatic loss of efficiency (Czauderna et al. 2003). However, 
3´-modifications on both strands are generally tolerated (Chiu and Rana 2002; Czauderna et 
al. 2003). The introduction of larger residues like fluorescent probes to the central region of 
both strands is less tolerated, especially modifications of the antisense strand abolish its 
activity (Elbashir et al. 2001c). Finally, 3´-deoxy overhangs have been found to stabilize 
synthetic siRNAs in vivo (Elbashir et al. 2001c). The tolerated modifications are summarized 
in Figure 3-3. 
 
 
 
Figure 3-3 Effects of various modifications on the efficiency of siRNAs. 
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These issues determine the site of siRNA functionalization for coupling experiments. It was 
decided to attach the thiol-group to the 5´-terminus of the sense-strand to maintain the 3´-
hydroxyl groups and to leave the antisense-stand unchanged. 
Additional functionalities can be easily introduced by solid phase synthesis. The modified 
sense strand and the antisense strand are synthesized separately and hybridized after 
cleavage from the solid phase. Here, a C6-SH-function was introduced to the 5´-end of the 
sense strand of a commercially synthesized siRNA (Dharmacon, Promega). As already 
discussed, solid phase synthesis yields pure substances in good yields but still at 
comparatively high prices (Dharmacon, 749,- US-$ for 80 nmol). However, synthetic siRNAs 
were used in preliminary experiments to test the functionality of pepsiRNAs. 
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Scheme 3-1 Guanosine with a ω-thiol-C6-modification at its 5’-position 8. It can be coupled to the 5´-
end of oligonucleotides under standard solid phase conditions.  
 
To establish the pepsiRNA technique in a variety of cell lines, larger amounts of siRNAs are 
required, so that enzymatic generation of siRNA by in vitro transcription becomes an 
interesting issue. With the increasing use of siRNA transfection for reverse genomic 
experiments in mammals and the growing demand for larger quantities of siRNAs, in vitro 
transcription methods have been refined for the generation of siRNAs and are readily 
available. As first reported by Milligan (Milligan et al. 1987), T7 RNA polymerase recognizes 
a double stranded DNA T7 recognition sequence and synthesizes RNA in 5´→3´-direction 
from a single stranded DNA-template attached to the 3´-end of the recognition sequence 
(see Figure 3-4). 
 
Adenosine and guanosine have been found to enhance the initiation rate of the T7 in vitro 
transcription, in which guanosine is superior to adenosine. The optimal sequence for a 
transcription start is GGG followed by GG or GC. GGG should be followed by 17–22 gene-
specific nucleotides. Avoiding A and T in the first three base pairs would greatly enhance the 
yield but decreases the silencing efficacy (Reynolds et al. 2004). 
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Figure 3-4 Schematic representation of the function of T7 RNA polymerase. Starting at the 3’-end of 
the double-stranded T7-recognition sequence, the antisense strand is transcribed in 3’-5’-direction with 
respect to the template strand yielding a single stranded RNA transcript. Two cytosine residues at the 
3´-end of the DNA-template are required for the optimal function of the T7-RNA-polymerase (Milligan 
et al. 1987). All DNA-templates end with a 5´-terminal AA that is transcribend into a 3´-terminal UU, 
which in turn yields the most efficient 2 nt 3´-overhang upon hybridization of the single strands to form 
siRNAs (Elbashir et al. 2001a). 
 
The oligonucleotides consist of the target sequence plus a minimal or elongated T7 RNA 
polymerase promoter sequence. Moreover, the elongated version of the T7 promoter may 
increase yield by allowing more efficient polymerase binding and initiation (see Figure 3-5), 
but is more expensive.  
 
 
 
Figure 3-5 T7 recognition sequences. Additional bases at the minimal T7 promoter (A) may increase 
the yield as they allow more efficient T7 polymerase binding and initiation (B). 
 
siRNA sequences can be designed according to the latest design rules aided by freely 
available computer software offered by siRNA providers (Dharmacon, Qiagen, Invitrogen) 
(Schepers 2004). The selected target mRNA sequence needs a guanosine at its 5´-terminus 
and three cytidines at its 3´-terminus. 
DNA-templates with the T7 recognition sequence (Milligan et al. 1987) are easily obtained 
from commercial synthesis. After degradation of the DNA templates, the RNA transcripts for 
sense and antisense-strand are purified and hybridized to yield siRNAs with the appropriate 
3´-2nt overhangs. 
 
In the fast growing field of RNA research comprising RNA aptamer and ribozyme techniques, 
RNA libraries, and in vitro evolution, the search for convenient methods to functionalize 
enzymatically generated RNAs has been going on for several years, and two major 
approaches have been established: 
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a) modification of the 3´-terminus by attaching synthetically modified nucleotides or 
oligonucleotides with T4-RNA-ligase (Hausch 1997; Igloi 1996; Romaniuk and 
Uhlenbeck 1983) 
b) modification of the 5´-terminus by selective incorporation of GMP derivatives as 
initiator nucleotides during transcription reaction with T7 RNA polymerase (Pitulle 
1992; Seelig 1997, 1999).  
 
 
 
Figure 3-6 Design of primers for enzymatic generation of siRNA by in vitro transcription. The minimal 
T7 promoter sequence is attached to the 5´-termini of both strands of the target sequence 5´-
G(N)17CTT-3´. A deoxyoligonucleotide complemetary to the T7-promoter sequence is needed to form 
the double-stranded recognition sequence. Note that both templates require a 3´-terminal CC to allow 
the incorporation of the initiator nucleotide, a GMP derivative, and a 5´-GAA to yield transcripts with a 
UU at their 3´-terminus that increases the efficiency of the hybridized siRNAs. Only the N17 sequence 
is complementary in sense and antisense-strand template (Schepers 2004). 
 
The latter bears the advantage that the modified RNA can be generated in one step. Once 
the modified guanosine monophosphate (GMP) is available, it is added to the reaction 
mixture and no further changes of the procedure are necessary to achieve 5´-modified RNA. 
Moreover, nucleoside monophosphates can only act to start the reaction but not to elongate 
the RNA transcript like triphosphates. So the modification carried out by a GMP derivative 
will be restricted to the 5´-terminus. This method has been successfully established by the 
groups of Jäschke (Seelig 1997, 1999) and Zhang (Zhang et al. 2001a).  
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The use of 5´-thioguanosine monophosphorothioate (Zhang et al. 2001b) is of special 
interest to the pepsiRNA approach. Once incorporated at the 5´-teminus of the RNA the 
phosphate ester can be cleaved by alkaline phosphatase and a sulfhydryl group is liberated 
at the 5´-terminus. Thus, the interference of the modification with the RNAi enzymes can be 
minimized. Moreover, as opposed to a long flexible linker, a minimal linker should diminish 
the probability of an intramolecular aggregation of the positively charged peptide with the 
negatively charged siRNA. 
 
3.1.1 Synthesis of GSMP 
5´-Deoxy-5´-thioguanosine monophosphorothioate (GSMP, in reference to GMP) was 
synthesized according to Zhang (Zhang et al. 2001b) with some modification as shown in 
Scheme 3-2.  
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To selectively modify the 5´-hydroxyl group, the 2´- and 3´-hydroxyl groups were protected by 
an acetal. Reaction of guanosine with acetone in the presence of catalytic amounts of 
perchloric acid led to 2´,3´-O,O-isopropylidene guanosine (10) in 94% yield in a straight-
forward reaction.  
Scheme 3-2 Transformation of guanosine 9 into GSMP 15 via
a 4-step or 5-step route. Reaction conditions a) acetone, cat.
HClO4, 4h RT b) MTPI, THF, 30 min –65°C, 4h RT c)
(MeO)2HCNMe2, DMF, 4h 50°C d) 50% HCOOH, 3d  e)
Na3PO3S, water, 3d, RT. 
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To substitute the 5´-hydroxyl group with iodine, 10 was reacted with methyltriphenoxy-
phosphonium iodide (MTPI, 16) in a Moffat reaction. The 5´-hydroxyl group substitutes one of 
the phenoxy-substituents at the phosphonium center. Then the nucleophilic iodide anion 
attacks the 5´-carbon, and the methyl phosphate acts as a leaving group, which is favored by 
the oxophilic nature of the phosphorous center (see Scheme 3-3). 
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Scheme 3-3 Mechanism of the Moffat reaction to transform alcohols into iodides (Brückner 2000). 
 
The reaction had to be carried out at –65°C to avoid the cyclization of the iodoguanosine 
derivative (Verheyden and Moffat 1970). The crude product was a sticky paste that 
obstructed chromatography columns even when mounted on silica gel/sodium sulphate. The 
light-sensitivity of the product and its poor solubility in most organic solvents complicated the 
purification procedure. Pure 5´-deoxy-5´-iodo-2´,3´-O,O-isopropylideneguanosine 11 was 
obtained in 39% yield as a white powder. 
 
A side product was observed in all NMR spectra of 11. The 1H-NMR shifts in d6-DMSO 
correspond to 2´,3´-O,O-isopropylidene-N3,5´-C-cycloguanosine 20 that is formed by the 
nucleophilic attack of the purin-N3 on the ribose-C5´ and substitution of the iodide ion as first 
described by Verheyden and Moffat (Verheyden and Moffat 1970). The 1H-NMR of 20 is 
characterized by the two 5´-H signals at 3.98 ppm and 4.74 ppm, respectively, that split into 
doublets of doublets with a large geminal coupling constant of 14.0 Hz (see Figure 3-7 and 
Figure 3-9). 
1H-NMR Spectra of pure 11 in d6-DMSO could be only obtained if the dried compound was 
dissolved in the deuterated solvent immediately prior to measurement.  
A strong tendency towards cyclization was even found in the dried iodide 11. After 4 weeks 
of storage at –20°C under argon, only ~ 31% of the purified compound could be recovered in 
a new round of column chromatography on silicagel, while the larger proportion had reacted 
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to the less soluble cyclized compound as verified by TLC. The cyclized side-product was also 
found as a contamination in the following reaction step, so that efforts had to be undertaken 
to stabilize the iodide and to increase the yield of pure 11. 
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Scheme 3-4 Cyclization of 11 to yielding 2´,3´-O,O-isopropylidene-3,5´C-cycloguanosine 20 according 
to Verheyden and Moffat (Verheyden and Moffat 1970). The purine base can rotate freely along the 
C1´-N9-axis. In the syn-form with the purine base residing above the ribose ring, the N3-nitrogen is in 
close proximity to the C5´-carbon. In an intramolecular nucleophilic substitution, the nucleophilic purin-
N3 attacks the electrophilic ribose-C5´ releasing the iodide that in turn abstracts the H1-proton.  
 
As the cyclization requires a freely accessible purin-N3 center (see Figure 3-6), it was 
assumed that the reaction rate could be decreased by incorporating a bulky group at the 
purin-N3 or in its proximity. Thus, the free energy of the syn-form of the nucleoside, in which 
the purin-N3 is in close proximity the 5´-C, would be increased. Moreover, a bulky group 
would sterically hinder the nucleophilic attack of N3 on C-5´  
 
The free amino group was protected to reduce the rate of cyclization and thereby stabilize 
the iodination product. After testing different protection groups, the formation of a Schiff base 
with dimethylformamide-dimethylacetal appeared to be most convenient (Zhang et al. 
2001b). 10 was reacted with the acetal in DMF and the pure 2-N,N-dimethylaminomethylene-
2´,3´-O,O-isopropylideneguanosine 12 was obtained by precipitation in 80% yield. 
Preliminary experiments showed that both protecting groups, the acetal and the imine, can 
be removed by stirring in 50% formic acid for 3 days at room temperature.  
 
Iodination of 12 was performed under the same conditions as the iodination of 10. The 
increased solubility of 2-N,N-dimethylaminomethylene-2´,3´-O,O-isopropylidene-5´-deoxy-5´-
iodoguanosine 13 in methanol facilitated its purification by column chromatography on 
silicagel leading to a yield of up to 99%. For 13, cyclization in d6-DMSO to the protected 
cycloguanosine 21 was also observed, but at a much slower rate. After the dried compound 
had been stored for 4 weeks at 4°C, no contamination of the cyclization product could be 
identified in a sample of compound 13. 
 
To compare the rates of cyclization, two long-term 1H NMR experiments were performed, in 
which spectra of the same sample were recorded in intervals of 30 min over 24h for the 
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iodide 11 (see Figure 3-7 and Figure 3-9) and the protected iodide 13 (see Figure 3-8 and 
Figure 3-11). For iodide 11, integration of the individual signals with reference to the solvent 
signal and plotting of the average from 5 significant signal integrals against time revealed first 
order kinetic with k = 0.181±0.008 h-1 corresponding to a half life of 3h 50min (±10 min) 
(Equation 1-1 and Figure 3-10). These values were confirmed by the plot of the average 
integrals of the product signals that could be fitted with the same rate constant according to 
Equation 1-2. 
 
 
 (1)   ciodide = c0 e-kt 
(2)      ccyc = 1- c0 e-kt 
 
Equation 1 The transformation of 11 follows a first order kinetic with c0 as the initial concentration of 
11, ciodide the concentration of 11 at time t, ccyc the concentration of A3 at t, and the rate constant k = 
0.181±0.008 h-1.  
 
The long-term 1H NMR experiment for 13 showed that the protected iodide was also subject 
to cyclization, but at a much slower rate (see Figure 3-8 and Figure 3-11). Integration of the 
relevant signals and plotting of the average integrals against time yielded another first order 
kinetic which could be fitted to k = 0.0145±0.0008 h-1 corresponding to a half life of 47h 
48min (± 2h 40min) (Figure 3-12).  
 
Thus, it could be shown, that the introduction of the protection group prior to iodination 
increased the stability of the iodide in solution by a factor of 12. 
The ease of preparation and the higher overall yield (79% in two steps versus 39% in one 
step) justified the introduction of the additional protection step. 
 
The protection groups in 11 and 13 were removed with 50% formic acid for 3 days. All side 
products (acetone, DMF, formic acid) could be removed under reduced pressure and the 1H-
NMR shows a sufficiently pure substance, so that no further purification is required. 5´-
Deoxy-5´-iodoguanosine A7 is obtained in quantitative yield from 11 and 13. About 5% of the 
cyclized product are observed after deprotection of 11. Remarkably, 5´-deoxy-5´-
iodoguanosine yields no defined degradation product after 48h in d6-DMSO. Apparently, the 
conformation forced upon the ribose ring by the five-membered acetal ring plays a crucial 
role in the cyclization reaction. 
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Figure 3-7 Cyclization of 11 yielding 20. Stacked plot of 1H NMR spectra taken in 4 h intervals at RT 
(top). Overlay of the 1H NMR spectra of 2´,3´-isopropylidene 5´-deoxy-5´-iodoguanosine (11, red) and 
its cyclization product (20 black) (bottom). Note the two 5´-H signals at 3.98 and 4.74 ppm, that split 
into doublets of doublets with a large geminal coupling constant of 14.0 Hz. 
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Figure 3-8 Cyclization of iodide 13 yielding 21. Stacked plot of 1H NMR spectra taken after 0, 1, 2, 3, 
6, and 9 days at RT (top). Overlay of the 1H NMR spectra of 2-N,N-dimethylaminomethylene-2´,3´- 
isopropylidene-5´-deoxy-5´-iodoguanosine (11, red) and its cyclization product (21 black) (bottom). 
Note the two 5´-H signals at 3.83 and 5.30 ppm, that split into doublets of doublets with a large 
geminal coupling constant of 15.0 Hz. 
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Figure 3-9 Cyclization of iodide 11 yielding 20. Stacked plot of 1H NMR spectra taken in 4 h intervals 
at RT. The region representing the ribose protons is enlarged. 
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Figure 3-10 Cyclization of 11. Averages of significant integrals for 11 (red solid squares) and the 
cyclized product 20 (blue open circles) plotted against time. The continuous lines correspond to the 
fitted first order kinetics with k = 0.181 h-1. 
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Figure 3-11 Cyclization of iodide 13 yielding 21. Stacked plot of 1H NMR spectra taken after 0, 1, 2, 3, 
6, and 9 days at RT. The region representing the ribose protons is enlarged. 
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Figure 3-12 Introduction of an N,N-dimethylaminomethylene protection group increases the half life 
time of 11 by a factor of 12. Averages of significant integrals for 13 (blue diamonds) and unprotected 
11 (red squares) plotted against time. Both sets of data are fitted with a 1st order kinetic with 
k=0.0145h-1 and k=0.181h-1, respectively. 
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Figure 3-13 Deprotected 5´-deoxy-5´-iodoguanosine is stable towards cyclization. After 4 days in d6-
DMSO at room temperature only small amounts of degradation products are found in the region of the 
ribose protons.  
 
14 was reacted with a 2-3fold molar excess of sodium thiophosphate in degassed water 
under argon to yield 5´-deoxy-5´-thioguanosine monophosphorothioate 15 (GSMP). Yields 
can be improved if the thiophosphate is dissolved in degassed water and the precipitate is 
removed prior to the addition to the degassed suspension of 14. After three days, a clear 
solution has formed and 1H-NMR indicated a complete transformation of 14. 31P-NMR 
spectroscopy indicated quantitative formation of the 5´-thio-monophosphorothioate 15 
(GSMP, δ = 19 ppm) rather than the 5´-oxo-monophosphorothioate (GMPS, δ = 43 ppm). 
 
compound C5´-X δ(13C-NMR) in ppm 
10 C-O 62.0 
12 C-O 61.9 
20 C-N 55.3 
21 C-N 54.1 
11 C-I 7.7 
13 C-I 6.9 
14 C-I 8.5 
GSMP C-S 34.5 
Ref C-S 26.4 
 
Table 3-2 13C NMR shifts of the 5´C-carbon depending on the neighbor-atom X (Ref = reference 
substance, 5´-deoxy-5´-thioguanosine (Mariott 1990)). 
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Moreover, the 13C NMR shift could be taken as an evidence for a carbon-sulfur bond as 
illustrated by  
Table 3-2. As it constitutes the only methylene-carbon in the molecule, the C5´ can be easily 
identified as the only negative signal in the DEPT-135 NMR-spectrum. 
 
3.1.2 Purification of GSMP 
The purification of GSMP from sodium thiophosphate turned out to be difficult due to the 
similar solubility of the two substances and the sensitivity of GSMP to temperatures above 
30°C. 
The water was removed from the reaction mixture under reduced pressure without avoiding 
temperatures above 25°C. To remove a proportion of the excessive thiophosphate, the 
residue was resuspended in water and the thiophosphate was precipitated with methanol. 
Different purification strategies were assessed.  
 
1) The crude product was subjected to anionic exchange chromatography on 2-
(diethylamino)ethyl (DEAE) Sephadex A-25 sepharose. It was eluted with a gradient of 
triethylamine bicarbonate buffer (TEAB, 0.01 (pH 6.9) to 1.00 M, (pH 7.5)). The HPLC run 
was monitored by UV absorption at 260 nm. A typical chromatography profile is shown in 
Figure 3-14. Fractions 32-39 were pooled and lyophilized. To remove triethylamine, the 
product fraction was repeatedly lyophilized from water and GSMP was obtained as a brown 
oil in poor yields (2-5%). 
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Figure 3-14 Purification of GSMP by FPLC using a DEAE Sephadex A-25 anionic exchange column. 
Thiophosphate salts are eluted before the beginning of the gradient (fractions 1-2) while GSMP 15 is 
eluted at ~0.31 M TEAB (fractions 31-39), so that the compounds are well separated. The peaks 
ranging from fractions 21-23 and 27-31 are small if fresh product is purified and become larger, if the 
crude product is stored for prolonged times before purification.  
mAU     - UV-detection (260 nm) - percentage of 1M TEAB  - conductivity  - fractions 
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2) As the formation of GSMP can be monitored by thin layer chromatography on silicagel 
plates with a mixture of isopropanol, water and 25% ammonia (6:1:3 (v/v/v)), the same 
solvent was used for column chromatography on silicagel. GSMP was obtained as a pale 
yellow solid in 35% overall yield. 1H-NMR indicated a contamination with about 13% of a 
hydrolysis product.  
 
3) The crude product was subjected to reverse phase chromatography on an analytical RP-
18 column and GSMP 15 was eluted with water. Due to the similar solubility of GSMP and 
sodium thiophosphate the two fractions overlap if the capacity of the column is exceeded. 
The HPLC run was monitored photometrically at 260 nm. Figure 3-15 shows a typical 
chromatogram.  
 
 
 
Figure 3-15 Purification of GSMP by FPLC with an analytic RP-18 column (∅ 2mm; h = 25 mm, resin 
3µM). The elution with water is monitored at 260 nm (red), 280 nm (blue) and by its conductivity (light 
blue) and fractions of 200 µl are collected. GSMP 15, absorbing at 260 and 280 nm, is eluted at 2.7-
2.9 ml immediately after the thiophosphate (2.0-2.8 ml) that can be identified by the increase in 
conductivity. Both peaks overlap, so that the purification capacity is reduced if larger amounts of crude 
product are applied to the column. The peak at 6.5-7.6 ml has the retention time and pattern of 
guanosine. 
 
Fractions A11, that contain a mixture of thiophosphate and GSMP 15, and A12 containing 
the pure product were collected separately. Mixtures of GSMP 15 and thiophosphate where 
lyophilized and purified again. Product fractions from subsequent runs were pooled and the 
concentration was determined photometrically at 260 nm against GTP standards. The 
aqueous GSMP solution could be readily used for in vitro transcription without further 
purification. It was split into aliquots sufficient for an in vitro transcription reaction in a total 
volume of 100µl and stored at –80°C. 16% of pure GSMP could be obtained in this 
procedure. 
 
4) Flash chromatography on RP-18 (LiChroprep 40-63 µm, Merck) was found to be the most 
efficient purification method. The product was eluted with water by gravity flow, and the 
fractions were monitored by TLC. Pure GSMP 15 was obtained as a white solid in 68% yield. 
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Thiophosphate contaminations lead to a yellow stain as the compound decomposes. Product 
fractions were pooled, lyophilized and stored under argon at –20°C. 
 
An overall yield of 53% was obtained for the synthesis of GSMP 15 in 5 steps as opposed to 
the reported 35% in 4 steps (Zhang et al. 2001b). 
 
3.1.3 in vitro transcription of siRNAs from T7-DNA-oligonucleotides  
Short DNA-oligonucleotides coding for 19 nt of the sense or antisense strand of the siRNA 
were designed as templates for the in vitro transcription experiments. The sequences were 
chosen from the ORF of the target gene that was obtained from the NCBI database 
according to the rules for the design of highly efficient siRNAs and of efficient templates for in 
vitro transcription (Schepers 2004):  
 
a) 5´-GG or 5´-GGG for enhanced initiation rates and 5´-incorporation of GSMP 
b) exclusion of homologies to other mRNAs (controlled by a BLAST search) 
c) low secondary structure to facilitate access to the mRNA-target-sequence 
d) sequences >200 nt downstream of the start-codon to avoid interference with 
promoters 
e) modification of the 3’-terminus by AA  
 
Target sequences for siRNAs targeting GFP, Lamin A/C, and glucosyl ceramide synthase 
(see Table 3-3) were selected from database sequences of the corresponding genes, and 
sense and antisense-templates were designed, so that hybridization of the transcripts would 
yield duplexes with the characteristic 2nt 3´-overhangs. The 17 nt T7 recognition sequence 
was added at the 5´-terminus of the template sequence. Recognition required hybridization 
of the T7 sequence with a 17 nt complementary strand. Figure 3-16 illustrates a ready-to-use 
T7-DNA-template.  
in vitro transcription reactions were carried out with the T7 RiboMAX-Kit (Promega) 
according to the manufacturers instructions. To allow the modification of the sense strand 
without affecting the antisense strand, the two templates were transcribed in separate 
reactions. An eightfold excess of GSMP over rNTPs was added to the reaction mixture of the 
sense strand. This leads to an incorporation of GSMP into ~80% of all strands (Zhang et al. 
2001a). 
 
 
 
Figure 3-16 Double stranded DNA recognition sequence for T7 polymerase (Milligan et al. 1987). 
Note that all DNA templates require a C or CC at the 5´-end of the double-stranded T7-recognition 
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sequence to enable the incorporation of guanosine-derived initiator nucleotides. GAA at the 5´-
terminus leads to 21 nt transcripts with CUU ends that have been shown to render siRNAs more 
efficient (Elbashir et al.). 
 
Oligo template sequence 
273 T7 5´-TAATACGACTCACTATAG-3´ 
331 Lamin as1 5´-AAGGGCGCAGGCCAGCTCCACTATAGTGAGTCGTATTA-3´ 
332 Lamin s1 5´-AAGTGGAGCTGGCCTGCGCCCTATAGTGAGTCGTATTA-3´ 
333 Lamin as2 5´-AAGCAGGAGCTCAATGATCGCTATAGTGAGTCGTATTA-3´ 
334 Lamin s2 5´-AAGCGATCATTGAGCTCCTGCTATAGTGAGTCGTATTA-3´ 
335 Lamin as3 5´-AAGGTCAGCCGCGAGGTGTCCTATAGTGAGTCGTATTA-3´ 
336 Lamin s3 5´-AAGGACACCTCGCGGCTGACCTATAGTGAGTCGTATTA-3´ 
337 Lamin as4 5´-AAGCCCGCCTGCAGCTGGAGCTATAGTGAGTCGTATTA-3´ 
338 Lamin s4 5´-AAGCTCCAGCTGCAGGCGGGCTATAGTGAGTCGTATTA-3´ 
339 Lamin as5 5´-AAGGTGACCTGATAGCTGCTCTATAGTGAGTCGTATTA-3´ 
340 Lamin s5 5´-AAGAGCAGCTATCAGGTCACCTATAGTGAGTCGTATTA-3´ 
430 GCS s1 5´-AAGGAGGACAGGGTGGGCGCCTATAGTGAGTCGTATTA-3´ 
431 GCS as1 5´-AAGGCGCCCACCCTGTCCTCCTATAGTGAGTCGTATTA-3´ 
432 GCS s2 5´-AAGGCAGCCCGTGAACCAAGCTATAGTGAGTCGTATTA-3´ 
433 GCS as2 5´-AAGCTTGGTTCACGGGCTGCCTATAGTGAGTCGTATTA-3´ 
434 GCS s3 5´-AAGGATTTCCTCTGCTGTACCTATAGTGAGTCGTATTA-3´ 
435 GCS as3 5´-AAGGTACAGCAGAGGAAATCCTATGTGAGTCGTATTA-3´ 
 
siRNA sequence 
GFP     5´-GCUGACCCUGAAGUUCAUCdTdT-3´ 
3´-dTdTCGACUGGGACUUCAAGUAG-5´ 
HexA     5´-UGAUGACCAGUGUUUACUCdTdT-3´ 
3´-dTdTACUACUGGUCACAAAUGAG-5´ 
 
Table 3-3 DNA-primers used for the generation of siRNAs against various targets.  
 
Lyophilized GSMP 15 aliquots were dissolved in water or 10 mM Tris-HCl pH 7.5 prior to use 
and the insoluble residue was removed by centrifugation. The concentration was determined 
at 260 nm with reference to a commercial rGTP (Promega). According to the protocol for in 
vitro transcription in 100 µl (RiboMAX), a defined volume of rNTPs (30 µl, 25 mM) is added 
and the reaction micture has to be filled up to 100 µl with water. In the modified experiment, 
this volume is filled up by a solution of rNTPs and GSMP with a molar ratio of 1:8 for GTP to 
GSMP. Usually, 50-300 nmoles of rNTPs would be used in a 100 µl reaction mixture. An 
equal amount of rNTPs was used in the antisense reaction mixture and the remaining 
volume filled up with water. 
 
 
 95
 
 
Scheme 3-5 Generation of 5´-thiol-modified siRNAs by in vitro transcription. GSMP is added in excess 
to the reaction mixture of the sense strand to be incorporated at the 5´-terminus. Phosphatase is 
added to both transcripts to liberate the 5´-thiol-group or remove triphosphate groups that may trigger 
an interferon response. 
 
Transcription was carried out at 37°C overnight (18-24 h). The DNA-templates were digested 
with DNase. Eventually, calf intestine phosphatase (CIP) was added to both reaction 
mixtures to liberate the 5´-thiol group and to remove 5´-triphosphates that might lead to non-
specific effects in cell culture experiments. 
The RNA transcripts were precipitated and dissolved in 100 mM DTT-solution to avoid the 
formation of homodimers. Concentrations were determined photometrically and equimolar 
amounts of RNA were mixed together and hybridized to siRNAs. In vitro transcriptions with 
250-750 pmoles of template yielded 65-130 µg RNA in a total volume of 100 µl. 
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3.1.4 Coupling of 5´-thiol modified siRNAs to PenetratinTM  
 
Cell-penetrating peptides are used in several fields of research and a modified form of the 
protein transduction domain of Antennapedia has been patented and is commercially 
available as PenetratinTM (Q-biogene). The product is synthesized on solid phase and can be 
modified according to the customer´s needs. In this work, a PenetratinTM derivative with a C-
terminal thiol-modification and an N-terminal biotin-tag was used. The latter was needed to 
localize the Penetratin™ moiety in the interior of treated cells as a proof of successful 
uptake. 
To favor the formation of peptide-siRNA heterodimers over the formation of homodimers, the 
peptide moiety needs to be activated. Thiopyridine is a convenient activating group as it 
yields mesomery-stabilized thiopyridone upon disulfide exchange reaction for which the back 
reaction is unfavorable. The mechanism of the disulfide exchange reaction is shown in 
Scheme 3-6. The reaction can be monitored by the characteristic absorption of thiopyridone 
(λmax = 345 nm). 
 
 
 
Scheme 3-6 Disulfide exchange reaction with activation by thiopyridine. Nucleophilic attack of the free 
thiol-group on the disulfide bond leads to the formation of heterodimers R1-S-S-R2 and a thiopyridone 
ion that is stabilized by mesomery. 
 
siRNAs were incubated with DTT to reduce putative homodimers. Prior to coupling, DTT was 
removed by gel filtration on MicroSpin G-25 columns (AP-Biotech). Upon the first elution only 
30-40% of the siRNA is obtained. The full amount of siRNA can only be recovered after 3 
further elutions with 10 mM Tris-HCl pH 7.5. However, DTT co-eluted with these fractions 
rendering them useless for coupling experiments. 
 
The concentration of the siRNA-eluate was determined photometrically at 260 nm. 
Considering that only 80% of the siRNAs are thiol-modified (Zhang et al. 2001b), 0.8 
equivalents (eq) of aqueous PenetratinTM solution were diluted to the same volume and 
added dropwise to the reaction mixture supplying an inert atmosphere with argon. An 
appropriate amount of 10x PBS was added to both components to avoid the dissociation of 
the siRNA and the aggregation of free peptides with siRNAs. At high concentrations a yellow 
ring of thiopyridone (λabs = 345 nm) could be observed at the interface of the two 
components. One hour of incubation at 37°C is sufficient to drive the coupling reaction to 
completion (Antopolsky et al. 1999). In some cases, a white precipitate formed due to 
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aggregation. It could be partially dissolved by adding 3M sodium chloride solution up to a 
total concentration of 400 mM as suggested by Vives and Lebleu for the coupling of DNA-
oligonucleotides to Tat peptide (Vives and Lebleu 1997) 
 
3.1.5 Gel electrophoresis with pepsiRNAs 
 
The success of the coupling reactions was tested by reducing and non-reducing 15% SDS-
PAGE. Samples of peptide-coupled siRNA (pepsiRNAs) and free peptide were prepared with 
the corresponding amounts of reducing and non-reducing 5x Laemmli buffer. 50µg of 
PenetratinTM and pepsiRNAs with a peptide content of 17.6µg were separated in a 20% SDS-
PAGE and stained with Coomassie blue. The results are shown in Figure 3-17. 
The band of the non-reduced pepsiRNA lane was shifted to a higher mass of about 8 kDa 
and could be clearly distinguished from the free peptide bands at ~4kDa and the reduced 
pepsiRNA. This also shows that the thiol-linker is indeed cleaved under reducing conditions.  
It has to be noted, that the gel shift observed for the conjugate does not correspond to the  
mass of ~10 kDa expected for the denatured conjugate (peptide+ssRNA), which may be due 
to the coupling of the siRNA and its separation properties. The control with PenetratinTM 
under non-reducing conditions shows that no peptide-homodimers were formed that may be 
mistaken for the conjugate.  
 
 
 
Figure 3-17 Control of the coupling of PenetratinTM with siRNA by 20% SDS-PAGE (Coomassie 
Stain). Samples of penetratin (lanes 1 and 2) and pepsiRNA (lanes 3 and 4) were prepared under 
reducing (lanes 2 and 4) and non-reducing conditions (lanes 1 and 3). Under non-reducing conditions, 
pepsiRNAs show a higher mass due to the coupled siRNA moiety. The siRNAs is cleaved under 
reducing conditions, so that only the peptide band can be seen. No peptide-homodimers can bee seen 
under non-reducing conditions for the peptide control.  
 
As the silver stain is more sensitive than Coomassie stain (0.1-1.0 ng versus 0.1 µg 
(Sambrook 1989)) control gels could be routinely run as coupling controls without loosing to 
much of the compounds. 20% SDS-PAGE was repeated with smaller amounts of peptide (2-
20 µg) and pepsiRNA (1-6 µg peptide content). However, the silver stain failed for both 
standard SDS-polyacrylamide and SDS-urea-acrylamide gels. 
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3.1.6 MALDI-TOF mass spectrometry of pepsiRNAs 
Matrix assisted laser desorption ionization (MALDI) provides sufficiently mild conditions to 
transfer entire pepsiRNAs into the gas phase. Commercially obtained thiol-labeled siRNAs 
were reacted with biotin-labeled activated PenetratinTM in an equimolar ratio for one hour. 
After gel filtration, the reaction mixture was prepared for MALDI-MS. 
Trihydroxyacetophenone (THAP) has favorable properties as a matrix for the measurement 
of oligonucleotides (Jensen et al. 1996). First measurements were carried out in the negative 
mode with an DNA-oligonucleotide of known size as a reference.  
 
 
 
Figure 3-18 MALDI analysis of pepsiRNAs a) The MALDI spectrum of the unmodified substance 
(negative mode, matrix: THAP, NH4Ac added) shows five peaks corresponding to ssRNA (~7kDa), 
ssRNA coupled to PenetratinTM (~9.8 kDa), siRNA (~14kDa) and siRNA coupled to PenetratinTM [M]--
~16.8 kD, [M]2-~8.4 kDa).  
b) Denaturation of the sample by heating to 80°C and immediate cooling to 0°C before preparation 
leads to a significant reduction of the peaks representing dsRNA. 
c) Peaks corresponding to disulfide-coupled compounds are diminished if the compound is treated 
with DTT to reduce disulfide bonds prior to sample preparation. (calculated masses: sense-RNA 6.804 
kDa, asRNA 6.757kDa, ssRNA-PenetratinTM-biotin 9.379, siRNA 13.561 kD, siRNA-PenetratinTM-biotin 
16.137kD). 
 
a) 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
c) 
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Both pepsiRNA and standard oligonucleotide were detected as broadened peaks. Due to the 
high acidity of the backbone phosphates, these residues are deprotonated at neutral pH. The 
siRNAs bear 42 negatively charged residues and are thereby found as mixtures of sodium 
and potassium salts, so that broadened peaks are found. As described by Jensen (Jensen et 
al. 1996), the pepsiRNA and reference samples were treated with ammonium acetate to 
exchange sodium and potassium ions for ammonium ions that dissociate to volatile NH3 and 
H+ in the gas phase leaving behind protonated phosphate residues. The thus obtained peaks 
were much more focused, but could still not be assigned to one distinct mass. In three 
measurements of aliquots of the same sample, the value for the dsRNA peak varied between 
14180 and 14649 Da corresponding to a maximum deviation of 1.8% from the average of the 
three measured values. This was much higher than the deviations of 0.08% reported for 
short model conjugates of peptides with oligodeoxynucleotides of an overall mass of 1942 to 
4381 Da as determined by MALDI-MS (Jensen et al. 1996). One reason for this was the low 
signal to noise ratio obtained for the pepsiRNAs, which led to ambiguous results in the 
determination of the peak maximum. Additionally, the incomplete removal of associated Na+-
ions resulted in a mass distribution of the oligoribonucleotides, and finally, the siRNAs might 
have been subject to nuclease degradation during sample preparation leading to fragments 
of different size. Evidence for this comes from 12% TBE-PAGE (7 M urea) by which 
fragments could be detected in a sample of radioactively labeled, denatured siRNAs (see 
Figure 3-19). This could be also due to strand termination during solid phase synthesis. 
 
 
 
Figure 3-19 12% TBE-PAGE (7 M urea) with three different aliquots of a commercially obtained 
siRNAs to target HexA. siRNAs were labeled at their 5´-ends with [32P]-γ-ATP by T-4 kinase, dissolved 
in loading buffer and denatured prior to loading to the gel. Radioactivity was detected with a 
phosphoimager screen (Bas III, Fuji). The siRNAs do not exhibit a uniform size distribution. Shorter 
nucleotides may result from degradation by nucleases during sample preparation or from strand 
termination during solid phase synthesis. 
 
In the mass sprectrum obtained for the pepsiRNA sample, all expected species are present: 
pepsiRNAs at ~16.8 kDa and ~8.5 kDa (for the doubly charged species), free siRNAs at 
~14kDa, Penetratin coupled to the siRNA sense strand at ~9,8 kDa and 21nt single stranded 
RNAs that form the largest peak at ~7 kDa. The chemical identity of these peaks was 
confirmed by two experiments as shown in Figure 3-18.  
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Denaturation of the sample by heating to 80°C and rapid cooling on ice greatly reduced the 
amount of double stranded RNA (14 kDa) and pepsiRNAs (16.8 kDa). Reduction of the 
sample with DTT prior to measurements led to the elimination of the peaks representing the 
disulfide-bridged compounds (double stranded (16.8 kDa) and single stranded RNA-
penetratin conjugates (9.8 kDa). 
 
The peak corresponding to single stranded RNAs is large compared to dsRNA peptide 
coupled RNAs. It has been reported, that conjugates of peptides and nucleotides pose 
special problems, since the two polymeric components have conflicting requirements for 
ionization (Jensen, 1996). This may be more pronounced for the larger conjugates as 21 bp 
siRNA coupled to the 16 residues of PenetratinTM, than for the reported conjugates of an 11-
amino-acid peptide with thymidine decamers and hexamers. It is also likely that a proportion 
of the dsRNAs dissociated during the ionization process or that the double strands partially 
separate in the desalted solution after gel filtration. The signal at 7.2 or 7.0 kDa originated 
from dissociated dsRNAs as well as from antisense-strands dissociated from the pepsiRNA. 
However, the existence of a dsRNA signal indicated, that not all of the siRNAs in the reaction 
mixture had reacted with the peptide. 
 
Thus, the result from the MALDI-TOF-MS analysis has to be evaluated as proof of the 
existence of peptide-coupled siRNAs. It cannot be taken as a quantitative measure of the 
coupling efficiency, but indicates qualitatively that not all of the siRNAs were coupled to the 
peptide, which could not be deteced by SDS-PAGE. Therefore, for the following cell culture 
studies one must consider that the concentration estimated for the experiments might be 
much lower than depicted, even though the pepsiRNAs were subjected to gel-filtration. The 
final concentration was determined by photometrical measurements at 260 nm. 
 
3.2  Test of pepsiRNAs for their potential to trigger RNAi in vivo 
After the successful generation of pepsiRNAs, this new tool was to be tested in cell culture. 
To provide a comparison to conventional methods, model systems were chosen, for which 
siRNA-induced RNAi experiments had been reported. To probe the versatility of the 
pepsiRNAs, different cell lines were to be tested with an emphasis on cells that were known 
to be difficult to address by liposomal transfection, like primary cells and non-dividing cells 
and especially neurons. 
 
3.2.1 Targeting recombinant genes with pepsiRNAs 
For proof-of-principle the pepsiRNAs were tested in cells of transgenic mice ubiquitously 
expressing the green-fluorescent protein (GFP) (Schmitz 2002). This system is especially 
convenient as a successful GFP knockout can be readily observed as a loss of fluorescence 
without further detection methods. With a turnover of about 24 h, GFP levels should be 
visibly reduced 2-3 days after its biosynthesis is knocked out. 
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In cooperation with the Wernig group (Institute of physiology II, Bonn), it was possible to test 
anti-GFP pepsiRNAs in dividing myocytes and non-dividing myotubes of GFP-expressing 
mice.  
Cultured myocytes were treated with 10, 25, 50, 100, 200, and 400 nM of pepsiRNA built up 
from solid phase-synthesized peptides and siRNAs. The cells were washed several times 
and the treatment was carried out in serum free medium (SFM) to avoid undesired 
interactions of the CPP with free DNA from the serum. As negative controls, the cells were 
treated with uncoupled Penetratin™ to assess non-specific or toxic effects of the CPP, and 
with pepsiRNAs directed against HexA (Sandhoff et al. 1977) (data not shown). Additionally, 
the cells were treated with SFM alone. 
Due to the strong interactions of CPPs with the plasma membrane, it is likely that pepsiRNAs 
adhere to cells adjacent to the site of application rather than distributing evenly over the 
culture dish. Therefore, pepsiRNAs are added dropwise to the adherent cells covered with 
half the total volume of SFM to ensure an even distribution of the compound. 
After 30-60 min of incubation at 37°C, the serum free medium was exchanged for culture 
medium supplemented with 10% serum (fetal calf serum (FCS)) and the cells were incubated 
for 24-72 h before the GFP-knock-down yield was assessed by fluorescence microscopy. A 
significant loss of fluorescence was already observed in myocytes at concentrations of 10-25 
nM. Fluorescence levels found in control cells treated with free PenetratinTM, anti-HexA-
siRNAs and SFM alone resembled those of the non-treated controls. Figure 3-20 showed 
that pepsiRNAs are well capable of triggering RNAi in myocytes in the 25 nM range and that 
the downregulation of GFP levels cannot be attributed to non-specific effects of pepsiRNA, 
CPPs or the depletion of serum (see Figure 3-20). To monitor the effect of biotinylated 
pepsiRNAs on over-expressed mRNA such as GFP, treated primary myogenic cell cultures 
from a transgenic GFP mouse were analyzed using immunofluorescence staining. Using a 
concentration of 25 nM pepsiRNA(GFP) completely decreases the GFP expression, while 
the biotinylated Penetratin can be detected in the nuclei of the cells (see Figure 3-20).  
,n of the pepsiRNAs that was estimated photometrically. The concentration for the 
experiments might be much lower than depicted, even though the pepsiRNAs were 
subjected to gel filtration due to incomplete coupling and degradation of the compounds.  
 
3.2.2 pepsiRNAs to knock out Lamin A/C in HeLa cells 
In the first report of RNAi to knock out endogeneous genes in mammalian cells, Lamin A/C 
was downregulated in HeLa cells (Elbashir et al. 2001a). Therefore, the next experiments 
were carried out with anti-Lamin A/C pepsiRNAs of equal sequence in HeLa cells.  
The downregulation of the protein was monitored by immunofluorescence microscopy. The 
cells were plated on 6well plates and incubated 24h prior to treatment. To synchronize the 
cell cycles of HeLa cells and obtain comparable levels of lamin A/C in all cells, the cells were 
incubated at 4°C for 1h to force the cells into cell cycle arrest and allowed to recover for 30 
min at 37°C. As described in 3.2.1, the cells were washed with serum free medium and the 
pepsiRNAs were also diluted in serum free medium for treatment. PepsiRNAs were applied 
in concentrations of 10, 25, 50, 100, 200, and 400 nM. As a control, 200 nM of non-specific 
pepsiRNA and 200 nM of uncoupled peptide were applied to control cells. After 30 min of 
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incubation at 37°C, the application medium was removed and the cells were incubated in 
culture medium supplemented with 10% FCS. 
After 6 days, the cells were plated on FCS-coated cover slips in 24well dished and allowed to 
attach over night. The cells were fixed with 4% paraformaldehyde (PFA) and incubated with 
anti-Lamin A/C IgG (mouse, kindly provided by M. Osborn, Göttingen) as primary antibody 
and anti-mouse IgG coupled to Cy3 as secondary antibody. The cells were attached to 
microscopy slides suspending in a drop of anti-bleach. Fluorescence microscopy revealed 
equal levels of Lamin A/C in untreated and Penetratin™ treated control cells. Protein levels 
were significantly reduced in cells treated with 100 nM anti-Lamin A/C pepsiRNAs. Co-
staining of the same cells with anti-hexosaminidase A antibody showed no reduction in the 
levels of the non-targeted protein (see Figure 3-20). 
 
 
 
 
Figure 3-20 Gene silencing with pepsiRNAs. Upper row: Downregulation of GFP by treatment with 
anti-GFP pepsiRNAs. Flurorescence microscopy shows the basic fluorescence level of untreated 
myocytes, cells treated with 10 nM, and with 25 nM anti-GFP pepsiRNA. The slide on the right shows 
treated cells after staining the CPP-biotin-tag with streptavidin-coupled dye. Lower row: 
Downregulation of Lamin A/C levels in HeLa cells after the treatment with anti-Lamin A/C pepsiRNAs. 
Immunofluorescence detection of Lamin A/C (red) in untreated HeLa cells, cells treated with 100 nM 
uncoupled peptide, and cells treated with 100 nM anti-Lamin A/C pepsiRNAs. Staining with anti-
hexosaminidase A IgG (green) shows that overall protein expression is not impaired (Zeiss Axiovert 
35, filter set 15: λexcit. = 546nm, λem >590nm, filter set 17: λexcit. = 485nm, λem = 515-565nm).  
 
3.2.3 PepsiRNAs to knock out proteins of the sphingolipid metabolism in fibroblasts  
 
In further experiments, proteins of the sphingolipid metabolism were targeted with 
hexosaminidase A (anti-HexA) (Sandhoff et al. 1977) and glucosylceramide synthase (anti-
GCS) pepsiRNAs. These proteins play a significant role in the metabolism of the skin and the 
brain (Schuette et al. 2001), where large effector molecules are generally difficult to apply. 
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Therefore, it was of great interest whether pepsiRNAs could be taken up by the 
corresponding cell types and silence their target-genes. mRNA levels were to be estimated 
by RT-PCR and protein levels by Western blotting. The corresponding pepsiRNAs were 
tested in primary fibroblasts and melanocytes as a model for primary cells that are more 
difficult to transfect. As opposed to HeLa cells, the cell cycle is arrested for fibroblasts once 
the bottom of the culture dish is covered with a confluent monolayer of cells. Thus, the cells 
did not have to be diluted in the course of the experiment and the RNAi phenotypes were 
expected to last longer as no siRNAs were lost due to dilution by cell division. 
The cells were treated as described in 3.2.2 for HeLa cells. pepsiRNAs were applied in 
concentrations of 5, 10, 25, 50, 100, 200, and 400 nM, and 200 nM of uncoupled peptide 
were applied to control cells. After 30 min of incubation, the cells were incubated in culture 
medium for varying times. 
After 2 days the cells were harvested and the total RNA was isolated. To assess the residual 
amounts of Lamin A/C mRNA an RT-PCR with Lamin A/C specific primers was carried out. 
Lamin A/C levels were normalized against the levels of sphingolipid activator precursor 
protein (SAP) as a negative control. At high concentrations of 100-400 nM no residual mRNA 
of HexA and GCS, respectively, could be detected. At 50 nM mRNA levels were decreased 
to ~2 % compared to the untreated control, at 25nM ~2% were detected for HexA but 8% for 
GCS. At 10 mM 70% of the GCS mRNA in myoblasts and 80% of the HexA mRNA in 
fibroblasts was degraded. At 5nM of pepsiRNA still 25% of HexA mRNA and 75% of GCS 
mRNA could be found. No down-regulation was observed for non-specific pepsiRNA and 
Penetratin controls. The results are summarized in Figure 3-21.  
 
 
 
Figure 3-21 Treatment of primary fibroblasts with HexA-pepsiRNAs (a) and melanocytes with GCS- 
pepsiRNAs (b). The totalRNA levels were corrected with respect to a SAP control (sphingolipid 
activator protein (Schuette et al. 2001), residual mRNA levels are normalized to the untreated control. 
Concentrations of 50-400 nM lead to an almost complete degradation of target-mRNA. Residual levels 
are observed at 5-25 nM, where a stronger effect is observed for HexA in primary fibroblasts. (c) 
Degradation of GCS leads to a loss of black pigment in melanocytes. The degradation of GCS protein 
is confirmed by the Western blot. 
 
Further, the protein levels were assessed after 7 days by preparing the harvested cells for 
12% SDS-PAGE, blotting the protein samples to a PVDF membrane and immunostaining for 
HexA, GCS and Lamin A/C (control) as primary antibodies and anti-mouse and rabbit IgG 
coupled to horse raddish peroxidase (HRP) as the secondary antibody, which was detected 
by the chemiluminescence induced by the HRP in reaction with the LumiGlo reagent. 
The results matched those found for the mRNA levels. 
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Remarkably, the melanocytes had lost their pigmentation 7 days after treatment with anti-
GCS pepsiRNA (see Figure 3-21 c). In wildtype melanocytes, tryrosinase is transported 
within specialized vesicles to the melanosomes, where it converts tyrosine to L-DOPA in the 
first rate-limiting step of melanine systhesis and pigmentation. It was suggested that 
tyrosinase is transported within vesicles enriched in glucosylceramide (GlcCer), which is 
generated by the addition of a glucosyl residue to ceramide catalyzed by GCS. Wildtype 
melanoma cells stain almost black due to pigmentation, while in GCS knock-out mice, 
tyrosinase is mislocated, so that the cells do not show any pigmentation (Sprong et al. 2001). 
The same was found for melanoma cells expressing lhRNA targeted against GCS (Diallo et 
al. 2003b). Thus, the findings from the pepsiRNAs experiment are in good agreement with 
these results. The degradation of GSC could be shown by Western blotting as depicted in 
Figure 3-21c. 
 
3.2.4 Test of pepsiRNAs in various mammalian cell lines 
To assess the versatility of this new technique, pepsiRNAs directed against HexA were 
applied to various mammalian cell lines. The same treatment protocol as in 3.2.2 was 
applied. The cells were treated with 100 nM of anti-HexA pepsiRNA for 30 min and after 2 
days of incubation the knockdown efficiency was assessed by RT-PCR. The normalized 
results are shown in Figure 3-22. In HeLa cells, human primary fibroblasts, human epithelial 
kidney cells and even primary murine neurons the target-mRNA was completely degraded.  
A knock-down up to ~98% was found for melanocytes, while mRNA levels of 7% and 20% 
were found in myotubes and myocytes, respectively. The residual activity might be explained 
by the setup of the experiment. Due to serum reduction the myocytes begin to differentiate 
very quickly to myotubes that are much more difficult to address. However, it can be 
concluded that treatment with pepsiRNAs in the upper nanomolar range leads to a significant 
reduction of target mRNA in a variety of cell lines and primary cells. To ensure a complete 
knockout, the appropriate amounts of pepsiRNA need to be estimated for every given cell 
line. 
 
 
Figure 3-22 Versatility of pepsiRNAs. 100nM of pepsiRNAs directed against Lamin A/C were tested in 
various human cell lines and primary cells and the RNAi efficiency was estimated by RT-PCR with 
isolated total RNA. 
 105
 
3.3 Recombinant expression of CPPs in E. coli 
As an alternative to solid phase synthesis, recombinant expression allows the generation of 
large amounts of the desired CPP once an appropriate expression and purification system 
has been established. 
In this work, the protein transduction domains of the antennapedia protein (Antp) from D. 
melanogaster and the HIV-I transactivator of transcription (Tat) were chosen as CPPs, since 
they have been successfully used to transport various cargo molecules. The sequences of 
interest comprise only 15 amino acids for Antp and 11 for Tat, respectively. Thus, the coding 
DNA sequences could be generated as synthetic genes by hybridizing overlapping DNA-
oligonucleotides comprising the appropriate sequences. To allow coupling of the expressed 
peptide with the modified siRNAs, a cysteine codon was added to the 3´-terminus of either 
gene sequence prior to the stop-codon. 
 
CPP Sequence 
Tat Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-SH 
Antp Arg-Gln-Iso-Lys-Iso-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-SH 
 
Table 3-4 Amino acid sequences of Tat and AntP modified with a C-terminal cysteine residue. 
 
Due to their highly positive overall charge, cell-penetrating peptides are likely to aggregate 
with negatively charged macromolecules like mRNAs or the bacterial genome. Therefore, the 
CPPs are to be expressed with a large fusion tag to compensate the overall charge and 
prevent diffusion to the extracellular space. In addition to this the purification of the target 
protein from the bacterial lysate can be greatly enhanced if the fusion protein functions as an 
affinity tag. Here, glutathione-S-transferase (GST) was chosen as a fusion partner to allow 
purification by affinity chromatography on glutathione-sepharose. The pGEX-expression  
system (AP Biotech) provides a cloning vector with a multiple cloning site adjacent to a GST 
fusion cassette. To subsequently release the CPPs from the N-terminal GST-tag, an 
additional sequence was introduced at the 5´-terminus of the synthetic CPP-genes coding for 
the recognition site of tobacco etch virus (TEV) protease. Figure 3-23 shows the fusion 
protein and the corresponding full-length synthetic gene.  
 
 
 
Figure 3-23 Schematic representation of the GST-CPP-Cys fusion protein and the corresponding 
synthetic gene and GST-expression cassette.  
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3.3.1 Generation of a recombinant expression vector for modified CPPs 
The full ORF-sequences of Antennapedia and HIV-1 Tat were obtained from NCBI database 
genebank Locuslink and the stretches encoding the CPPs selected according to Derossi 
(Derossi et al. 1994). The full-length synthetic genes comprising the codons for TEV 
recognition site, the CPP and the cysteine residue as well as the stop-codon were designed 
to bear cohesive 5´-ends corresponding to the restriction sites of the BamHI  and EcoRI in 
the multiple cloning site (MCS) of the pGEX-vector. This double stranded sequence was 
synthesized as five (four) different overlapping oligonucleotides as shown below. 
 
BamHI TEV PTD Cys Stopp
EcoRITEV PTD PTD Cys Stopp
GATCCGAAAACCTGTATTTTCAGGGCC GCCAGATAAAGATTTG GTTCCAGAATCGGCG CATGAAGTGGAAGTGTTAAG
GCTTTTGGACATAAAAGTCCCGG CGGTCTATTTCTAAAC CAAGGACTTAGCCGC GTACTTCACCTTCACAATTCTTAA
Antp-Cys
GATCCGAAAACCTGTATTTTCAGGGCTATG GCAGGAAGAAGC GAAGACAGCGACGAAGATGTTAAG
GCTTTTGGACATAAAAGTCCCGATAC CGTCCTTCTTCG CTTCTGTCGCTGCTTCTACAATTCTTAA
Tat-Cys
O245 O246 O247
O249O248
O234 O235
O232 O233
 
 
Figure 3-24 Sequences of synthetic genes and their distribution into overlapping oligonucleotides for 
hybridization.  
 
Equal amounts of corresponding oligonucleotides are hybridized to yield the full double-
stranded peptide-coding sequence. The best results were obtained with denaturation 
temperatures of 80°C and the use of an appropriate amount of 10x annealing buffer II. The 
double-stranded constructs were ligated into the BamHI and EcoRI site of the pGEX-4T2 
vector (AP Biotech).  
 
The ligated vectors were amplified in E. coli DH5α. Vectors purified from monoclonal 
overnight cultures were tested for successful ligation by restriction analysis and PCR.  
Digestion with BamHI and EcoRI yielded 78 bp for the Antp insert or 66bp for the Tat insert. 
The linearized vector was observed as a 4900 bp band. 
In PCR control-experiments the vector was used as a template for the amplification of the 
insert. A GST-specific forward oligonucleotide (GST uni 5´, see appendix) and one of the 
reverse oligonucleotides corresponding to the CPP were used as primers, so that a 140 or 
128bp PCR product was expected for positive clones.  
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Figure 3-25 Cloning of synthetic genes into the MCS of pGEX-4T2. 
 
Results for Tat and AntP vectors are shown in Figure 3-26. The exact size of the restriction 
fragments and PCR products could not be determined by gel electrophoresis. Thus, the 
positive vectors were sequenced to ensure that the full-length peptide-encoding sequence 
had been inserted and that it contained neither mutations nor single nucleotide insertions that 
would shift the reading frame.  
 
 
 
Figure 3-26 Results from control-PCR with putative Tat and AntP-vectors as templates (1.5% 
agarosegel electrophoresis, ethidium bromide stain). The amplified inserts can be seen aa 120-140 bp 
bands. Re-ligated vectors yield bands of ~5 kbp representing the plain vector. 
 
Sequencing revealed that successful clones with full-length inserts were comparatively rare, 
point mutations were corrected by site directed mutagenesis-PCR with the corresponding 
full-length oligonucletide-primers. Only one primer per reaction mixture was used. Thus, the 
number of corrected copies would increase linearly with the number of PCR-cycles and the 
yield would be significantly lower than in reaction with forward and reverse primers, for which 
the number of copies grows exponentially.  
After PCR reaction mixtures were digested with Dpn I to specifically remove the methylated 
DNA templates. Thus, only the non-methylated products of the mutagenesis reaction were 
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obtained. A small fraction of the PCR-product was analyzed by agarose-gel electrophoresis 
and the larger fraction was transformed into E. coli DH5α and incubated on amplicillin 
selection plates.  
The sequence of antennapedia peptide was easily corrected from an A→T mutation and the 
insertion of a guanosine residue with the standard site directed mutagenesis and a clear 
band for the mutagenesis product could be detected after 1% agarose gel-electrophoresis. 
For Tat peptide the annealing temperature had to be adjusted from 55°C to 58°C in order to 
obtain the desired vector. Although the band for the mutagenesis product could be hardly 
seen on the agarose-gel, transformation and selection from ampicillin-LB-agar yielded 
recombinant colonies. The plasmids from all successful clones were amplified and analyzed 
by sequencing.  
 
3.3.2 Expression of GST-CPPs in E.coli 
Amplified vectors containing the correct CPP insert were transformed into E. coli BL21 cells  
for expression. During the mutagenesis experiments, one Tat vector had been obtained, in 
which one of the arginine codons (R6, CGG) was mutated to glutamine (CGG → CAG, Tat-
R6Q). This vector was included in the expression experiment to compare the uptake 
properties in differently charged CPPs. 
In a preliminary experiment, 20 ml of LB or S.O.C. medium were inocculated with a clone 
from an overnight culture. Expression was induced with 100 µM IPTG (isopropyl-
thiogalactopyranoside) during the exponential growth phase (OD600 = 0.6-0.7). By the 
addition of this structure mimetic of galactose, the suppression by the lac-repressor upstream 
of the recombinant sequence in the expression vector is released and the cells start to 
overexpress the recombinant gene. 
 
Control expression was carried out in recombinant bacteria containing the plain pGEX-4T2 
vector. Protein samples were taken 18h after inoculation and analyzed by 12% SDS-PAGE 
to assess the expression efficiency of the individual clones. A clear shift in size was observed 
between the GST-CPP fusion proteins (28-29 kDa) and the pure GST (26 kDa) expressed in 
control cultures as shown in Figure 3-27. Double protein bands were obtained from clones 
expressing both GST-CPP fusion protein and plain GST. 
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Figure 3-27 15% SDS-PAGE of expression of GST and GST-fusion proteins in E. coli stained with 
Coomassie Stain. Expression bands can be seen at 26 kDa for pure GST and at 28-29 kDa for the 
GST-fusion proteins with AntP and Tat. GST was used as a size marker in all gels. The numbers are 
derived from the number of the plasmid and the number of the clone. 
 
3.3.3 Purification of GST-CPP fusion proteins by affinity chromatography 
 
The pellets from expression cultures with high expression rates were chosen for further 
purification. Plain GST was purified as a control.  
Pellets from 20 ml expression culture were resuspended in pGEX-Lysis buffer supplemented 
with DTT, lysozyme and DNase. After 30 min incubation on ice, the cells were homogenized 
and the insoluble components pelleted by centrifugation. Samples were taken from pellets 
and supernatants to be analyzed by SDS-PAGE. The lysates were incubated with 
glutathione-sepharose-beads that bind the GST-tagged proteins with high affinity. The 
supernatant was removed by filtration and the sepharose beads were washed with several 
volumes of lysis buffer and pre elution buffer to remove non-specifically bound protein. The 
GST-fusion proteins were eluted with reduced glutathione solution (10 mM in 50 mM Tris-HCl 
pH 8.0) and collected in several fractions. The protein content was determined 
photometrically against BSA-standards. As shown in Table 3-5, only very small amounts of 
GST-Tat and GST-Antp could be eluted from the glutathione sepharose, although the large 
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yields of plain GST indicated that the utilized glutathione resin was functional. Remarkably, 
slightly higher amounts of GST-Tat(R6Q) were obtained in comparison to GST-Tat.  
 
protein yield from 20 ml 
expression culture 
yield per liter 
of expression culture 
GST (control) 190  µg 9.5   mg 
GST-AntP  2    µg 0.1   mg 
GST-Tat 11   µg 0.7   mg 
GST-Tat(R6Q) 57   µg 2.9   mg 
 
Table 3-5 Protein yields obtained from affinity purification on glutathione sepharose. Protein amounts 
were estimated photometrically against a BSA standard after incubation of protein samples with 
Bradford reagent. 
 
 
 
Figure 3-28 12% SDS-PAGE of eluates (E1-E3) from purification experiments (Coomassie Stain). 
GST eluate 2 was used as a size marker for the GST-CPP eluates. Double bands in GST-Tat can be 
discerned consisting of GST-CPP and plain GST. 
The values obtained by comparison with BSA standards have to be taken as relative values. 
It is known that the extinction of the BSA-Coomassie complex that forms in the reaction with 
Bradford reagent differs from that of most other proteins, so that a correction factor has to be 
estimated for every individual protein to obtain absolute values (BioRad, User manual). 
However, the obtained values reflect the order of magnitude of the purified proteins.  
As confirmed by 12% SDS-PAGE, only plain GST was dissolved in the supernatant, while 
GST-Tat, GST-Tat (R6Q) and GST-Antp resided in the pellet (data not shown). Apparently, 
the potential of CPPs to strongly interact with membranes leads to an association with lipids 
and membrane fragments in the bacterial pellets (see Figure 3-28). It has to be noted, that 
substitution of a single arginine residue in GST-Tat-R6Q leads to an increased solubility and 
a weaker membrane association.  
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3.3.4 Refining of the purification protocol for GST-fusion proteins for GST-CPPs 
 
To solubilize the GST-CPPs the pellets were resuspended in pGEX-lysis buffer 
supplemented with 5 mM DTT and 1% of Triton X-100 (Lysis + Buffer, see  
Table 3-6). After centrifugation, samples of supernatants and pellets were analyzed by 12% 
SDS-PAGE in comparison to pellets and supernatants from cell lysis in pGEX lysis buffer see 
Table 3-6. An improved solubility could be observed for all GST-CPPs. The amount of 
soluble GST-AntP is markedly smaller than the amount of soluble GST-Tat. 
 
 
 
Figure 3-29 Resuspension of pellets with Lysis + buffer increases the amount of soluble protein in the 
supernatant. Equal volumes of supernatant were used for all samples. The product bands were 
identified in comparison with GST-eluate as a size marker. (15% SDS-PAGE, Coomassie Stain, S = 
supernatant, P = pellet) 
Apparently the amount of soluble protein depends on the composition of the lysis buffer. 
Since the basic CPPs bear less positive charges at high pH, their interaction with membrane 
fragments in the pellet may be reduced by a more basic buffer. Therefore, the pH of the 
pGEX lysis buffer was adjusted from 7.4 to 8.0, which corresponds to the maximum pH at 
which GST efficiently binds to glutathione. According to the pGEX user manual, urea 
concentrations of up to 2M may be used to increase the yield of soluble GST-fusion proteins. 
Thus, four buffers with different concentrations of urea, DTT, and Triton X-100 based on 
pGEX lysis buffer were used for the preparation of fresh 20ml GST-Tat expression cultures: 
 
buffer DTT Triton X-100 urea pH 
pGEX 1 mM 1% - 7.4 
Lysis + 5 mM 2% - 7.4 
A 10 mM 3% - 7.4 
B 5 mM 2% - 8.0 
C 5 mM 2% 1M 7.4 
D 5 mM 2% 2M 7.4 
 
Table 3-6 Supplements to pGEX-lysis buffer yielding buffers A, B, C, and D. 
For evaluation, equal amounts of the four supernatants were analyzed by 12% SDS-PAGE in 
comparison with the supernatants obtained from the pGEX-lysates and the pellets 
resuspended in Lysis + buffer as shown in Figure 3-30. No significant difference was 
observed for the 4 buffers and only a small increase to GST-Tat lysed with plain pGEX lysis 
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buffer could be discerned. Remarkably, resuspending the pellet in Lysis + Buffer yielded an 
additional amount of soluble protein. 
 
 
 
Figure 3-30 Influence of lysis buffer composition on soluble GST-CPP. Equal amounts of the 
corresponding supernatants were applied to the gel and GST eluate was used as a size marker. 
Lysis+ buffer was used to resuspend the pellets obtained from lysis with pGEX lysis buffer. Buffers A-
D were used for lysis. The names of the fusion proteins are abbreviated to the name of the fusion 
peptide (15% SDS-PAGE, Coomassie Stain). 
 
Therefore, the four GST-Tat pellets were resuspended in buffer B and left at room 
temperature (~22°C) for 1 h before centrifugation. The supernatants obtained after 
centrifugation contained a markedly increased amount of protein. Apparently, incubation at 
elevated temperature helps with the solubilization of the GST-CPPs. 
GST-AntP was treated similarly as GST-Tat. Although the amount of recombinant protein in 
the overnight cultures was comparable to that of GST-Tat, the amount of soluble GST-Antp 
protein obtained after lysis with buffers A and C was markedly smaller than that of GST-Tat, 
and resuspension of the pellets in buffer B did not increase the yield, either. With the notion 
that solubilization may be temperature-dependent, the pellets were dissolved again in buffer 
B and incubated for 90 min at room temperature and at 37°C, as well as at 37°C on a thermo 
mixer at 400 rpm. Indeed, a considerable amount of GST-AntP was found in the 
supernatants after centrifugation. Incubation at 37°C yielded higher amounts than incubation 
at ambient temperature, while shaking of the sample at 37°C did not increase the yield of 
soluble GST-Antp. 
 
 
 
Figure 3-31 Incubation of insoluble pellets from GST-AntP expression in buffer B under at elevated 
temperatures. Equal volumes of supernatant were loaded onto the gel. Incubation at RT (23°C) and 
incubation at 37°C under constant rocking lead to lower yields of soluble protein than incubation at 
37°C. GST was used as a size marker (15% SDS-PAGE, Coomassie Stain).  
From these findings, a new purification protocol was established in which the bacterial pellets 
were worked up at room temperature and the homogenates were allowed to incubate at 
37°C before centrifugation. Using the modified protocol, large amounts of soluble protein 
were obtained from new GST-Tat and GST-AntP over night expression cultures. The yield of 
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GST-Tat could be further improved by sonication of the homogenate prior to incubation at 
37°C, while sonication reduced the yield of soluble AntP. 
 
 
 
Figure 3-32 Preparation of homogenates from GST-CPP expression cultures with the modified 
purification protocol. Equal volumes of supernatant were loaded onto the gel. The homogenized 
suspensions were split and one fraction incubated at 37°C for 1h while the other was sonicated in a 
cup horn (3x 10s-blasts, 200W, 20 MHz, 15s intervals). Remarkably, the yield of soluble Tat was 
increased by sonication, while less soluble GST-Antp was obtained from the sonicated homogenate. 
This finding was confirmed by repetitive experiments (15% SDS-PAGE, Coomassie Stain). 
 
The supernatants obtained in the last step were incubated with GST-sepharose beads as 
described in 3.3.3. The eluates were tested upon their protein content with Bradford reagent 
and the protein content of the pooled eluates was estimated by photometric evaluation 
against a BSA standard. For GST-Tat a total amount of 1,2 mg was obtained from 60 ml of 
expression culture corresponding to ~20 mg/l, while the total amount of GST-Antp was 0,6 
mg corresponding to ~10 mg/l. This corresponds to the amount of GST purified from the 
control expression after preparation with the pGEX protocol. 
 
 
3.4 Expression of TEV protease in E. coli 
The GST-tag needs to be cleaved to liberate the cysteine-modified CPPs. Purification of the 
CPPs from tobacco etch virus (TEV) NIa protease and the cleaved fusion tag can be greatly 
facilitated if the protease itself is attached to a fusion-tag. If GST is used as a fusion tag, both 
protease and cleaved tag can be removed by a single step affinity chromatography as 
illustrated in Figure 3-33.  
 
The GST-tag is almost as big as TEV-protease (26 kDa versus 28.6 kDa, respectively). Its 
pH for optimum folding lies at 7.0-7.5, whereas TEV-protease requires a pH of 8.5 for 
refolding. Thus, it is uncertain whether conditions exist under which both moieties fold to their 
functional conformation. Moreover, it cannot be ruled out that affinity binding to glutathione or 
cleavage activity of the protease renders the opposed domain dysfunctional so that the 
purification strategy cannot be carried out to its end.  
 
Therefore, it was not only attempted to generate a GST-TEV fusion protein but also TEV 
protease with the much smaller His6-tag. Six N-terminal histidine residues do not interfere 
with TEV function (Kapust et al. 2001). However, His6-TEV cannot be removed from reaction 
mixtures along with the cleaved GST-tag, but needs to be bound by Ni-NTA in a distinct step. 
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Figure 3-33 Schematic representation of GST-CPP cleavage and purification of the CPP. GST-tagged 
TEV-protease cleaves the fusion protein at the C-terminus of the TEV recognition site. Both GST-tag 
and GST-TEV protease are then removed by affinity binding to glutathione-sepharose. 
 
3.4.1 Expression of GST-TEV-protease in E.coli 
The ORF of TEV-protease was amplified from a cDNA clone and ligated into the BamHI and 
EcoRI restriction sites of the pGEX-4T2 expression vector. The vector for the expression of 
GST-tagged TEV protease (GST-TEV) was amplified in E. coli DH5α and after restriction 
tests transformed into E.coli BL21. Positive colonies were selected on ampicillin-LB-agar 
plates and grown as overnight cultures. As a test-expression, 20 ml LB were inoculated with 
GST-TEV overnight-cultures. The plain pGEX vector expressing GST was used as a control. 
Expression was induced with 100 µM IPTG at an optical density of OD600=0.6-0.7 and protein 
samples were taken after 90 min and over night incubation at 37°C and analyzed by 12% 
SDS-PAGE. The 55 kDa band of overexpressed GST-TEV and the 26 kDa band of the GST-
control could be easily detected (see Figure 3-34).  
 
 
 
 
 
 
 115
 
Figure 3-34 10% SDS-PAGE (Coomassie stain) of GST-TEV test expression. After over night (ON) 
expression the 55 kDa band of GST-TEV can be seen for both clones. Plain GST was expressed as a 
control.  
As the expression in BL21 cells was rather weak, the GST-TEV expression vector was 
transformed into E. coli BL21 DE3 pLysS. The expression experiment was repeated with two 
clones of each strain in 20 ml LB as described above. After expression over night, the cells 
were harvested by centrifugation and purified according to the pGEX-protocol (Amersham 
Bioscience). SDS-PAGE of the pellets and supernatants obtained by centrifugation of the 
homogenized lysates revealed that the protein exclusively resided in the pellet. No difference 
could be determined between the expression levels in E.coli BL21 and BL21 DE3 pLysS.  
 
 
 
Figure 3-35 10% SDS-PAGE of GST-TEV lysates. After cell lysis according to the pGEX-protocol the 
recombinant protein resides in the pellet (P). Expression in BL21 or BL21 DE3 pLysS and at 37°C (a) 
leads to no significant changes in the amount of soluble protein. Only poor yields of recombinant 
protein are obtained by overnight expression at 17°C (b). (ON = overnight culture, P = pellet, S = 
supernatant, the numbers refer to the clone). 
 
As the amount of soluble protein may depend on the expression temperature, the experiment 
was repeated with an incubation temperature of 17°C. However, overnight expression at 
these temperatures yielded very low levels of recombinant protein, so that no detectable 
amounts ob soluble GST-TEV were obtained after cell lysis. 
Apparently, GST-TEV forms inclusion bodies. The two equally sized protein domains might 
interfere with each others folding process leading to the precipitation of the misfolded protein. 
To obtain soluble GST-TEV protease from inclusion bodies, a protocol for the purification of 
His6-TEV protease is applied with some modifications (Lucast et al. 2001).  
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The cell pellets were resuspended in lysis buffer supplemented with lysozyme and DNase. 
After 1h of incubation on ice, the cells were homogenized and the insoluble components 
pelleted by centrifugation. SDS-PAGE from pellets and lysates revealed that the major 
proportion of the overexpressed protein still resided in the pellet (data not shown).  
Therefore, the pellet containing the insoluble protein was purified under denaturing 
conditions as described previously (Lucast et al. 2001). For affinity binding to glutathione-
sepharose, the protein needs to be refolded. Therefore, the denatured protein solution was 
dialyzed against TEV-refolding buffer and pGEX-Lysis buffer, respectively. In both buffers a 
large fraction of the protein precipitated. The precipitate was removed by centrifugation and 
the supernantant was incubated with glutathione sepharose for 2h at room temperature to 
recover any fusion protein with a properly refolded GST-fusion tag. SDS-PAGE of the 
supernatants and eluates indicated that the recombinant protein was dissolved in the 
denaturing supernatant and in the dialysis sample albeit a major proportion of protein was 
lost due to precipitation. However, only very small amounts of the protein could be eluted 
from the resin (see Figure 3-36). GST-TEV bands in the eluates from the BL21 DE3 pLysS 
strain originate from a protein precipitate that occurred during the incubation with glutathione 
sepharose, that could not be fully removed from the resin by repeated washing. 
 
 
 
Figure 3-36 Inclusion body preparation of GST-TEV expressed in BL21 and BL21 DE3 pLysS. The 
recombinant protein from the overnight culture (ON) forms inclusion bodies that are found in the 
insoluble pellet (P). Treatment of the pellet with denaturing buffer redissolves GST-TEV that is found in 
the dialyzed supernatant but does not bind to glutathione sepharose as shown by the eluates (E1-3) 
and the supernatant decanted from the resin (GS). Note the thin GST band that is copurified at ~26 
kDa (12% SDS-PAGE, Coomassie Stain). 
 
As the pH optimum for refolding is 7.0 for GST (Amersham Bioscience) and 8.5 for TEV-
protease, the pH of the refolding buffer was adjusted to values between 7.5 and 8.5. The 
dialyzed protein solutions were incubated for 2h with glutathione-sepharose beads. During 
the incubation the protein precipitated, and no significant amounts of protein could be 
detected in the eluates with Bradford reagent or by 10% SDS-PAGE (see Figure 3-37). 
Photometric quantitation of the eluates against a BSA standard indicated that the protein 
yield was below 1 mg/l for both samples. 
Incubation of the supernatant for 3h on ice did not improve the results (data not shown).  
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Figure 3-37 10% SDS-PAGE of GST-TEV refolding and purification experiments at different pH 
(Coomassie Stain). Dialysis to refolding buffer at pH 7.4 and 8.2 does not yield properly refolded 
protein, so that no GST-TEV can be bound by glutathione-sepharose and no protein can be seen in 
the eluates. (ON = overnight expression culture, S = supernatant from cell lysis, DS = denaturing 
supernatant, GS = supernatant after incubation with glutathione sepharose, P = pellet from cells lysis , 
E = eluates). 
 
The precipitated protein could neither be redissolved in larger volumes of refolding or pGEX 
buffer nor by the addition of DTT to a concentration of 2 mM. Also, sonification with a cup 
horn could not resdissolve the protein. 
 
3.4.2 Expression of His6-TEV-protease from E.coli 
To avoid interactions of the GST-tag with TEV protease and the formation of inclusion 
bodies, TEV protease was expressed with 6 histidine residues attached to its N-terminus 
(His6-tag), which permits affinity purification on Ni-NTA sepharose. The addition of 6 amino 
acids is less likely to interfere with the folding of TEV protease.  
The ORF of TEV-Protease was amplified from a cDNA clone and ligated into the EcoRI and 
SalI restriction sites of the pQE-30 expression vector. The vector for the expression of His6-
tagged TEV protease (His-TEV) was amplified in E. coli DH5α, tested by restriction 
experiments, and transformed into E.coli BL21. First expression experiments were carried 
out in 20ml LB inoculated with GST-TEV and plain GST overnight-cultures. Expression was 
induced with 100 µM IPTG at an optical density of OD600=0.6-0.7, and protein samples were 
taken after 4h incubation at 37°C and analyzed by SDS-PAGE. The 28 kDa band of 
overexpressed His-TEV was clearly visible (see Figure 3-34). 
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Figure 3-38 15% SDS-PAGE of test expression of His-TEV. The 28 kDa band of His-TEV can be 
detected in all samples. Three different E. coli BL21 strains were used (Coomassie Stain, ON = 
overnight expression culture). 
 
The expression was continued overnight (18 h) and the cells were harvested by 
centrifugation at 100,000 x g. The cells were lysed under native conditions with lysozyme in 
lysis buffer supplemented with DNase according to the Qiagen Ni-NTA protocol. After 
homogenization and centrifugation, samples were taken from pellets and supernatants. The 
supernatants were applied to Ni-NTA mini-spin columns according to the provider´s manual. 
After washing with pre elution buffer to remove non-specifically bound protein, elution was 
carried out with imidazole elution buffer. SDS-PAGE of the obtained eluates revealed that 
hardly any protein had been bound by the Ni-NTA columns, and a large amount of protein 
appeared to be residing in the pellet.  
The experiment was repeated under denaturing conditions. Cells were lysed in 6M urea 
buffer. After centrifugation, the supernatants were applied to the Ni-NTA mini-spin columns. 
The columns were washed with pre-elution buffer at pH 6.3 and eluted with elution buffer at 
pH 4.3. However, no binding to the columns was observed in SDS-PAGE samples. It was 
found that most of the recombinant protein was again residing in the pellet. Expression at 
20°C and reduction of the amount of IPTG for induction to 40 µM failed to increase the 
amount of soluble protein. 
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Figure 3-39 15% SDS-PAGE of HisTEV purification under denaturing and native condition using the 
Qiagen NiNTA MiniSpin Kit (Coomassie Stain, ON = overnight expression culture, P = pellet, S = 
supernatant from lysis, E1 = eluate1). 
 
Apparently, even the shorter His-TEV fusion protein is not properly refolded in E. coli and 
accumulates in inclusion bodies. Preparation of the lysates as described in 3.4.1, did not 
increase the amount of soluble protein. The pellets containing the insoluble His-TEV were 
dissolved in denaturing guanidinium chloride buffer. After centrifugation, the supernatant was 
incubated with loose Ni-NTA beads (Amersham Bioscience) for several hours. However, 
after washing with denaturing pre-elution buffer, no protein could be eluted from the Ni-NTA 
beads with elution buffer (see Figure 3-40). 
 
 
Figure 3-40 Purification of HisTEV after inclusion body preparation. No binding of the protein to the 
NiNTA columns or loose NiNTA resin was observed. (15% SDS-PAGE, Coomassie-Stain; ON = 
overnight expression culture, S = supernatant from Lysis, NB = supernatant decanted from NiNTA 
beads, E1-3 = eluates) 
It appeared that the His6-tag is not freely accessible in the denatured form of His-TEV. 
Dialysis in the refolding buffer described by Lucast led to precipitation of the protein, so that 
no His-tagged protein could be recovered from the filtrates with loose Ni-NTA beads (data 
not shown). 
 
As reported by others, exchange of serin at position 219 against valin (S219V) markedly 
increases the solubility of recombinant TEV (Kapust et al. 2001), albeit it is reported that 
eluates of the mutant His-TEV are contaminated by significant amounts of other proteins 
(Lucast et al. 2001). The vector for the expression of soluble mutant form HisTEV (HisTEV 
(S219V)) transformed in E. coli BL21 (DE3) RIL was kindly provided by Anne Ulrich, 
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University of Karlsruhe (TH). Expression experiments were carried out in 20 ml TB medium 
inoculated with overnight cultures of the mutant strain. Expression was induced at an OD600 = 
0,6 after 30 min of cooling the cells on ice by addition of IPTG to a final concentration of 100 
µM. Control experiments showed that a considerable amount of recombinant protein was 
overexpressed during the first 4 h but no significant increase was observed if the expression 
is continued over night. Preparation of the pellets obtained by centrifugation led to good 
yields of soluble protein. The supernatant was incubated with Ni-NTA beads (Amersham 
Bioscience) for 90 min at RT, and the beads were thoroughly washed with native pre-elution 
buffer and eluted with elution buffer containing 250 mM imidazol. As shown by 12% SDS-
PAGE large amounts of HisTEV (S219V) could be eluted from the Ni-NTA resin. 
Quantification of the eluates with Bradford reagent against a BSA standard showed that 230 
µg of protein were obtained from the 20 ml expression culture corresponding to a yield of 
11,5 mg of protein per liter expression culture. 
 
 
 
Figure 3-41 Expression of TEV-protease. Expression bands are found at ~ 28kDa in comparison to a 
prestained protein marker (NEB, not shown). Protein levels increase over time. Clone 3 exhibits the 
strongest expression (15% SDS-PAGE, Coomassie Stain). 
 
3.4.3 Cleavage of GST-CPP fusion proteins with TEV protease 
 
The recombinantly expressed HisTEV (S219V) protease was tested upon its activity to 
cleave GST-CPP fusion proteins in comparison of commercially available TEV protease 
(AcTEV, Invitrogen). According to the manufacturers protocol, 20 µg of GST-Tat eluate were 
incubated with 10 u of AcTEV, the amount required to cleave 85% of 30 µg control substrate 
in 1h at 30°C in 1h according to the manufacturer in TEV-buffer supplemented with DTT in 
an overall volume of 150 µl at 30°C. Correspondingly, 20 µg of GST-Tat eluate were 
incubated with 5 and 10 µg of purified HisTEV (S219V). 
Samples of 20 µl were taken after 1, 2, 4, and 16 h and analyzed by 15% SDS-PAGE. 
Unmodified samples of GST-Tat and HisTEV were used as controls. No peptide bands were 
observed due to the low peptide concentrations (0.1 µg per sample if all peptide was cleaved 
from GST). However, GST-Tat bands of ~28 kDa were clearly visible in close proximity of the 
HisTEV bands. (As HisTEV (S219V) and AcTEV have approximately the same molecular 
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weight, 26 kDa, they are both referred to as HisTEV in the discussion of the SDS-PAGE 
results). In the course of the experiment, the GST-Tat bands become weaker as the fusion 
protein is degraded to GST and Tat peptide.  
 
 
 
Figure 3-42 15% SDS-PAGE of cleavage of GST-Tat with commercially obtained TEV protease 
(AcTEV, invitrogen) and recombinantly expressed HisTEV (S219V) protease (HisTEV) (Coomassie 
Stain). 
 
As AntP and Tat peptide make up for only 6% and respectively 4% of the mass of the fusion 
protein, the cleavage experiments were repeated with 300 µg and 400 µg of GST-AntP and 
GST-Tat, respectively, to provide peptide amounts visible in SDS-PAGE. If all fusion protein 
was cleaved, 18 µg of either peptide were to be obtained. As before, the cleavage 
experiment was carried out with 10 u of AcTEV or 10 µg of HisTEV (S219V) in TEV buffer 
supplemented with DTT 150 µl. According to the manufacturer’s information, 1 u of AcTEV 
cleaves 3 µg of protein in 1h at 30°C, so that incubation over night should lead to a complete 
cleavage of the applied fusionprotein. No peptide could be seen when 20µl samples were 
analyzed by 15% SDS-PAGE (data not shown).  
 
 
 
Figure 3-43 15% SDS-PAGE of over night cleavage reaction with GST-Tat and GST-AntP. The non-
incubated GST-CPPs, GST, HisTEV (S219V) and PenetratinTM (AntP) are used as standards. 
Reaction mixtures: I = 400 µg GST-Tat + 10 u AcTEV, II = 400 µg GST-Tat + 10 µg HisTEV (S219V), 
III = 300 µg GST-AntP + 10u AcTEV, II = 300 µg GST-Tat + 10 µg HisTEV (S219V). Equal amounts of 
the four reaction mixtures were loaded onto the gel. No GST-CPP bands can be discerned in any of 
the samples after incubation at 30°C overnight (Coomassie Stain). 
 
However, analysis of 1 µl with references of untreated GST-CPPs, GST and HisTEV 
revealed that the band corresponding to the GST-CPPs could not be detected for any of the 
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over night reactions. This shows that 1 u of commercially obtained AcTEV and 1 µg of 
recombinantly generated HisTEV (S219V) are able to cleave up to 400 µg of GST-CPP at 
30°C over night. 
The obtained amounts of peptide may be too small to be detected by the Coomassie stain. 
They may be detected photometrically when purified from the reaction mixture by FPLC 
reversed phase chromatography. This would separate the peptides from GST, HisTEV, and, 
more importantly, from DTT, that is required in the reaction buffer, but would prevent the 
formation of disulfide bonds. 
 
3.5 Novel cell-penetrating molecules for the delivery of siRNAs 
It could be shown that cell-penetrating peptides bear a high potential to deliver siRNAs in 
vivo. However, as already described, many protein transduction domains used as CPPs do 
not fulfil any known function in vivo and it is thought, that they have not been optimized by 
evolutionary processes. This opens up the possibility of improving the cell-penetrating 
function of these molecules by varying the amino acid sequence. Synthetic peptides with 
enhanced cell-delivery properties have already been synthesized (Emi et al. 1997; Hallbrink 
et al. 2001; Ho et al. 2001; Mi et al. 2000; Rothbard et al. 2000; Vives et al. 1994) and also 
the synthesis of peptide analogs that mimic CPP function has been described (Potocky et al. 
2003; Raguse et al. 2002; Rueping et al. 2002; Rueping et al. 2004; Wender et al. 2000; 
Wender et al. 2002).  
Peptide mimetics bear several advantages over CPPs. They are not degraded by proteases 
in vivo, so that they stay intact in the gastrointestinal tract or in the bloodstream, which 
improves the range of possible applications in vivo. Their toxicity and pharmacokinetic 
properties may be optimized by alterations of the molecular structure of potent candidates. 
Once the synthesis of effective structures has been established, it may be optimized toward 
ease of preparation and cost efficiency. 
As many reports have pointed out a role for amphipathy and secondary structure in the 
cellular uptake process, synthetic CPP analogs ought to be designed as backbone mimetics 
that provide enhanced stability in vivo and a straightforward synthesis. A high density of 
positively charged side chains appears to be even more important for uptake efficiency. 
Therefore, backbone mimetics need to be functionalized with basic functionalities such as 
amine or guanidinium groups in order to exhibit cell-penetrating behavior.  
β-peptides have been intensively studied (Rueping et al. 2004). With one methylene group 
inserted between the carboxyl group and the former α-carbon, these backbone analogs 
constitute the higher homologs of the α-peptides. They form stable helices that are 
structurally more confined than those formed by α-amino acids. They are also stable toward 
degradation by proteases, and their structures can be more readily predicted. It could be 
shown that β-peptides functionalized with guanidinium groups (in comparison to arginine) are 
able to translocate into the interior of cultured mammalian cells (Wender et al. 2000).  
Likewise, oligo-N-alkylglycines, more commonly known as peptoids, have been subject to 
intensive studies (Figliozzi et al. 1996; Goff and Zuckermann 1992; Wender et al. 2000). As 
opposed to α-peptides, the side chains are attached to the amine, so that the monomers can 
be readily synthesized from functionalized diamines by reaction with 2-bromo-acetic acid. 
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Peptoids with guanidinium-headgroups attached to alkyl chains of varying lengths are taken 
up by mammalian cells (Wender et al. 2000). They have been successfully used to mimic 
peptide-hormones, antibiotics and receptor ligands (Uno et al. 1999). 
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Scheme 3-7 Representatives of peptides (22) and peptoids (23) and β-peptides (24). 
 
In this work, two approaches toward small cell-penetrating molecules were followed up in 
collaboration with Tina Schröder and Yvonne Schmidt (Schmidt; Schroeder 2004) 
 
• the use of unbranched oligoamines of varying length to transport reporter molecules 
into cells and  
• the development of peptoids of varying chain length and side chain composition to 
mimic CPP function. 
 
3.5.1 Preliminary tests of polyamines 
 
It is well known that high densities of positive charges are essential for delivery molecules.  
Aliphatic polyamines appear to be suitable as backbones for polycationic structures, since 
they are positively charged at physiological conditions. As players in several biochemical 
pathways, such as signaling and protein biosynthesis (Igarashi and Kashiwagi 2000), they 
naturally occur in cells at millimolar concentrations, so that they are not expected to exhibit 
toxic side effects at the micromolar range that is reached in uptake experiments.  
In preliminary experiments, the cell-uptake or delivery properties of naturally occurring 
oligoamines and long synthetic polyamines was assessed. Propylamine, ethylenediamine, 
spermine and a mixture of synthetic polyamines (Lupasol) were coupled with rhodamine 100 
isothiocyanate to yield N-terminally labeled compounds (see Figure 3-44a). HeLa cells and 
primary fibroblasts were treated with the crude products at different concentrations (0.5, 1, 3, 
and 6 µM) for different times (5, 10, 15, 30, and 60 min). The cells were washed, fixed with 
methanol/acetone, and immediately examined by fluorescence microscopy. Ethylenediamine 
and propylamine did not enter into the cells. Spermine and polyamine were found to attach to 
the plasma membrane and enter the cytosol after 5-15 min of incubation. Incubation times of 
30 min and one hour lead to an accumulation of the fluorescent compound in the nucleus of 
the cells. This demonstrates the potential of the utilized backbones to enter into mammalian 
cells when attached to a cargo. 
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Figure 3-44 Fluorescence micrographs of preliminary tests of rhodamine-labeled oligoamines for their 
uptake by HeLa cells. After one hour of incubation with the labeled propylamine and ethylenediamine, 
the cells are only weakly stained, while cells treated with labeled spermine and polyamine exhibit a 
much stronger staining. Interestingly, the rhodamine-spermine conjugate accumulates in the nuclei, 
while the nucleus seems to be precluded to propylamine and ethylenediamine conjugates. (All pictures 
were taken with an exposure time of 16 seconds to obtain a sufficiently strong and comparable signal; 
Zeiss Axiovert 35, filter set 15: λexcit. = 546nm, λem >590nm, exposure time 16s). 
 
3.5.2 Spermine-coupled porphyrin for photodynamic therapy 
 
Based on these experiments, spermine appered to be a promising candidate for the 
development of a new transporter. Over the last decade, the tetra-amine spermine has 
gained considerable importance for the delivery of DNA (Boletta et al. 1997; Kichler et al. 
1997; Mack et al. 1994), RNA (Lu et al. 1994) and antisense oligonucleotides (Aoki et al. 
1998; Guy-Caffey et al. 1995; Wong et al. 2002). Due to its four positive charges at neutral 
pH it forms non-covalent complexes with the negatively charged DNA (Symons 1995). 
Conjugates of spermine or spermidine with lipids as in dioctadecylaminoglycyl-spermine 
(DOGS, transfectam) are commonly used as a transfection agent (Boletta et al. 1997; Kichler 
et al. 1997; Mack et al. 1994) and likewise, spermine conjugates with cholesterol enhance 
the cellular uptake of oligonucleotides (Guy-Caffey et al. 1995; Lee et al. 1996; Lee et al. 
2004a). The relative non-toxicity of the polyamines toward mammalian cells is a great 
advantage over other cationic headgroups (Guy-Caffey et al. 1995). 
By covalent attachment of spermine, DNA cleaving agents such as acridine and iron 
chelators have been targeted to the DNA (Bergeron et al. 2003; Delcros et al. 2002). Finally, 
covalently coupled spermine was shown to enhance the activity of an RNA cleaving DNA 
enzyme and its affinity to the target RNA (Kubo et al. 2003).  
For these reasons, novel transporters based on spermine were synthesized and coupled to a 
variety of cargo molecules such as the fluorescent dyes fluorescein and porphyrin. Porphyrin 
is of specific interest for the treatment of tumors. In photodynamic therapy (PDT), porphyrins 
are transferred into their excited triplet state upon irradiation with light. Upon relaxation to the 
ground state, the absorbed energy is transferred to oxygen, which is in turn excited to its 
singlet state. Singlet-oxygen is highly reactive leading to the oxidation of unsaturated lipids, 
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nucleobases, and aromatic amino acids. As porphyrin undergoes many rounds of excitation 
and relaxation, a large number of radical species is generated inducing severe damage in 
the affected cell that is killed in the process. To avoid damage to the entire organism, 
porphyrins need to be locally taken up by the tumor and kept from diffusing to healthy tissue. 
This can be achieved by enhancing the cellular uptake of porphyrins by covalent coupling to 
transport molecules such as spermine.  
To this means, spermine was coupled to the solid phase and functionalized with either 
fluorescein as a probe to assess cellular uptake or with a hydrophobic porphyrin derivative 
with long aliphatic side chains upon its methylene groups. The syntheses as carried out by Y. 
Schmidt (Schmidt 2004) and F. Hahn (Hahn 2005) are briefly outlined in the following: 
Spermine 26 was attached to 4-formyl-3-methoxy-phenoxymethyl-polystyrol (FMOP)-resin 25 
by reductive amination, in which the resin´s aldehyde function and the spermine´s primary 
amines form an imine in the presence of trimethylorthoformiate (TMOF). The Schiff base is in 
turn reduced with tetrabutylammoniumborohydride (TBAB) to yield a secondary amine. 
 
O
OMe
CHO CHOPS =
a) b)
25  
 
Scheme 3-8 a) FMOP resin consists of polystyrene (PS) beads functionalized with an aldehyde group 
that permits coupling of amines by reductive amination. Upon treatment with trifluoroacetic acid (TFA) 
the amine is released. The graphic representation of the resin is facilitated as shown in b).  
 
To distinguish the free primary amine from the secondary amines the functionalization step 
the primary amine is protected with acetyldimedone (Dde-OH). The secondary amines are 
then protected with tert-butoxycarbonyl (Boc)-groups, that are not affected by the subsequent 
deprotection of the primary amine with 2% hydrazine hydrate. N-Fmoc-protected 
aminohexanoic acid was activated with PyBrOP and coupled to the free amino-terminus via a 
peptide bond as in solid phase peptide synthesis. This C6-spacer was meant to diminish 
interactions of spermine with the cargo molecule. 
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Scheme 3-9 Immobilization and protection of spermine. Spermine 26 is coupled to FMOP-resin by 
reductive amination (a). After selective protection of the primary amine with Dde (b), the secondary 
amines are protected with Boc-groups (c) and the orthogonal Dde-group is removed (d). Reaction 
conditions: (a) 1.) 5 eq spermine, DMF/TMOF (4:1) 17 h, RT 2.) 4 eq TBAB, 15 min, RT, 3.) glacial 
acetic acid, RT, 5h (b) 10 eq Dde-OH in DMF, 17h, RT (c) 10 eq di-tert-butyl-dicarboxylate in 1,4-
dioxane, 20h, RT, argon (d) 2% hydrazine hydrate in DMF, 2x5 min, RT. 
 
After removal of the Fmoc-protection group with piperidine, the cargo molecule, 
carboxyfluorescein 34 or carboxy-porphyrin 35 (Balaban et al. 2003), was attached to the 
free amine via an amide bond. Finally the conjugates were deprotected and cleaved of the 
solid phase by reaction with 50% trifluoroacetic acid (TFA) in one step.  
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Scheme 3-10 Synthesis of fluorescein 34 and porphyrin 35 conjugated to spermine. N-Fmoc-
aminohexanoic acid is attached as a linker (e), deprotected (f) and in turn linked to the 
carboxyfluorescein or carboxyporphyrin (g). Deprotection of the secondary amines and cleavage from 
the solid phase occur simultaneously to yield functionalized spermine 33 (h). Reaction conditions: (e) 3 
eq N-Fmoc-aminohexanoic acid, 2 eq PyBrOP, 5 eq DIPEA in CHCl3, 20h, RT (f) 20% piperidine in 
DMF, 3x2 min, RT (g) 3 eq carboxyfluorescein, 3 eq HOBt, 3 eq DIC, CH2Cl2/DMP (1:1, (v/v)), 5d, RT 
(h) 50% TFA in CH2Cl2 2 min, RT. 
 
The uptake behavior of porphyrin-labeled spermine (PorSp) was examined in HeLa cells, 
primary fibroblasts and COS cells. For preliminary uptake experiments the compounds were 
thoroughly dried, characterized by mass spectrometry and used without further purification. 
The preparation of stock solution with PorSp and free carboxy-porphyrin revealed that the 
spermine modification greatly enhances the compound´s solubility. The precursor-porphyrin 
is insoluble in water and only poorly soluble in methanol. Upon sonication in methanol a 
saturated solution of 840 µM could be obtained. The spermine-porphyrin conjugate exhibited 
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a markedly higher solubility in both water and methanol. A 20 mM stock solution in methanol 
could be easily prepared. 
 
Preliminary uptake experiments were performed in HeLa cells, human primary fibroblasts 
and COS7 cells at 0.1, 1, 10, 50 and 100 µM. After 4 hours the cells were thoroughly washed 
as described in the CPP section and evaluated by transmission and fluorescence microscopy 
without any fixation to avoid artifacts due to membrane perforation and diffusion or simple 
adsortion to the membrane. 
At the highest concentration, severe toxic effects were observed for all cell types (Figure 
3-45). In comparison with the untreated controls, about 5-15% of the cells remained attached 
to the culture dish exhibiting signs of necrosis. However, a large portion of these cells was 
fluorescent with the internalized compound.  
 
 
Figure 3-45 Phototoxicity of porphyrins. If cells are illuminated after treatment with high doses of 
spermine-coupled porphyrin, the majority of cells is killed. Fragments of cells treated with 100 µM of 
the compounds show intense red fluorescence from the associated porphyrin. (Zeiss Axiovert 35, filter 
set 15: λexcit. = 546nm, λem >590nm; exposure time: 7s) 
 
To test whether the toxicity at high concentrations could be attributed to photochemical 
reactions induced by the porphyrin moiety, the experiment was repeated in the dark, which 
led to an increase of the cell viability to 70-80%. 
 
As opposed to the unmodified compound that could not be detected inside the cells the 
PorSp exhibited a cellular uptake to a certain extent. A further confocal fluorescent 
microscopic analysis is underway to clearly localize the compound to the cell’s interior. At a 
concentration of 10 µM all cells were stained after 4h. The porphyrin fluorescence was 
restricted to vesicular structures, endosomes or lysosomes that appeared to accumulate in 
the perinuclear region. Remarkably, fluorescent staining could also be observed on the cell 
surface resembling PorSp molecules clustered in highly restricted regions of the cellular 
membrane or attached to surface molecules. 
After incubation over night, fluorescence could also be seen in the cytosol. After long 
incubation times, cellular uptake could even be observed for concentrations as low as 100nM 
in almost all cells which would imply a slow uptake of the material from the loosely attached 
compound on the plama membrane. No reliable signs for uptake could be detected at lower 
concentrations. However, punctuated fluorescent staining could be detected on the surface 
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of fibroblasts incubated with as little as 10 nM. Possibly, the fluorescence intensity of the 
porphyrin is not sufficient to be detected in low concentrations. 
 
 
 
Figure 3-46 Treatment of COS-7, HeLa cells and human fibroblasts with spermine-coupled porphyrin. 
After 30 min incubation with 10µM, the compound is taken up into vesicular structures that accumulate 
in the perinuclear region. After incubation for 30 min with 100µM, more fluorescence is detected in a 
similar pattern. After 4h the intensity of fluorescence inside the cells increases and diffuse 
fluorescence is observed throughout the cells, while the nuclei are precluded (Zeiss Axiovert 35, filter 
set 15: λexcit. = 546nm, λem >590nm; exposure time: 7s).  
 
For the control experiments with unmodified porphyrin the highest concentration tested was 
42 µM implying a methanol concentration of 5% in the medium. After 4 hours weak 
fluorescence could be detected inside all tested cells. Almost no Porphyrin was detected in 
the cells. 
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This demonstrates that a simple spermine modification on an otherwise poorly soluble 
porphyrin greatly enhances its solubility in both water and methanol and increases its cellular 
uptake.  
 
 
 
Figure 3-47 Control experiment. Unmodified porphyrin in a concentration of 42 µM is taken up by 
COS-7 (a), HeLa cells (b), and fibroblasts (c), but with a much lower efficiency than the spermine 
modified compound (Zeiss Axiovert 35, filter set 15: λexcit. = 546nm, λem >590nm; exposure time: 7s). 
 
The observed fluorescence patterns and the long times required for uptake suggest that 
PorSp is taken up by an endocytosis-like mechanism followed by endosomal escape, which 
is indicated by an increased cytosolic staining after long incubation times. Once taken up into 
the cells, the porphyrin exhibits its phototoxic effects. During the treatment with high 
concentrations (50, 100 µM), daylight is sufficient to kill the majority of the cells within 30 min. 
However the concentration of the compounds to kill the cells is still in the µM range. The 
spermine-porphyrin solution used in these preliminary experiments was used from solid 
phase synthesis and was not further purified and contained a mixture of conjugates with and 
without aminohexanoic acid. The dosage experiments have to be refined by using a single 
species of the conjugates since one of the conjugates might be more active than the other. 
 
3.5.3 Solid phase synthesis of peptoid transporters 
In the peptoid approach, a polyamide backbone with amino-functionalized side chains was 
synthesized. Different side chain lengths and peptoids built from varying numbers of 
monomers have been tested in cell culture. The patterns of alternating side chain lengths 
had to be assayed on their effect on uptake efficiency. The syntheses that were carried out in 
collaboration with the Bräse group by T. Schröder (Schroeder 2004), are briefly outlined: 
 
Monomeric building blocks were built up from diamines 36 (n = 1,2,3) of varying lengths (C4, 
C6 and C8, respectively). After protecting one amino group with the tert-butyloxycarboxyl 
(Boc, 41) group or 2-nitrophenylsulfonyl (o-Nosyl, 42), respectively, to permit orthogonal 
deprotection of the side chains, the mono-protected diamines 37 were reacted with 
bromoacetic acid ethylester and the resulting aino acetic acid esters 38 were hydrolyzed with 
sodium hydroxide. The secondary amines were finally protected with 9-
fluorenylmethoxycarbonyl to yield ready-to-use 39 as building blocks for solid phase 
synthesis. 
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Scheme 3-11 Synthesis of monomeric building blocks 40 (n=1,2,3) for peptoid synthesis. Diamines of 
varying lengths 36 (n = 1-3) are protected with Boc (a) or o-Nosyl at one side (b), reacted with 
bromoacetic acid ethylester (c), hydrolyzed (d) and protected with Fmoc 43 (e). Reaction conditions: 
(a) 0.13 eq Boc2O, dioxan, RT, under argon, 22.5 h, (b) 0.13 eq o-nosyl-chloride, dioxane, RT, under 
argon, 22.5 h, (c) 1 eq bromoacetic acid ethylester, THF, RT, 16 h, (d) 4N NaOH, MeOH, MeCN, RT, 
30 min, (e) 1 eq 9-fluorenylmethylsuccinidylcarbonate, H2O/MeCN (1:1), RT, 30 min.  
 
An additional chiral building block 47 was provided by F. Lauterwasser, University of 
Karlsruhe (TH) (Lauterwasser 2004). Instead of a protected amino side chain it contains an 
aromatic ring derived from S-1-phenylethylamine that is reacted with bromo acetic acid ester, 
hydrolyzed and protected with Fmoc to yield a chiral monomer to impose steric restrictions 
upon the conformation of the assembled peptoid. 
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Scheme 3-12 Chiral building block 47 derived from S-1-phenylethylamine 44 in a 3-step synthesis as 
kindly provided by S. Bräse, F. Lauterwasser, Karlsruhe. Reaction conditions: (a) bromoacetic acid 
butylester, KI, K2CO3, DMF, (b) 9-fluorenylmethylsuccinidylcarbonate, THF, 0°C – RT, 12h, (c) 
HCl/H2O, reflux, 2h. 
Peptoid transporters were synthesized on solid phase using Fmoc-chemistry. Solid phase 
synthesis greatly facilitates the synthesis as the growing oligomer attached to a solid support 
can be easily purified from excess reactants by washing the resin with the appropriate 
solvents and filtration. The protection of free amino groups with Fmoc as a temporary 
protection group has been well established as it can be quantitatively removed under mild 
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conditions in a short time. Rink resin (see Scheme 3-13) was chosen as a solid support due 
to its stability at ambient conditions, ease of the first coupling step, and mild cleavage 
conditions.  
O
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Scheme 3-13 a) Rink amide resin 48 consists of polystyrene (PS) beads functionalized with an amide 
group that permits coupling of activated carbon acids by the formation of peptide bonds. The chemical 
environment further facilitates cleavage by trifluoroacetic acid (TFA). The graphic representation of the 
resin is shown in b)  
After removal of the Fmoc group that protects the amino-functionalized resin, an activated, 
Fmoc-protected monomer was coupled to the solid support via a peptide bond. In this 
reaction, bromo-tris(pyrrolidino)phosphonium-hexafluoro-phosphate (PyBrOP) was used to 
generate an activated ester, and N,N-diisopropylethylamine (DIPEA) to enhance the rate of 
ester formation. The Fmoc-group is removed with piperidine to prepare the coupled 
monomer for the attachment of the next building block. Coupling of the monomers to the 
growing peptoid chain proceeds under the same conditions as the attachment of the first 
building block to the solid support. All reaction steps are followed by repetitive washing steps 
ending with a solvent, in which the resin is expanded to expose the reactive sites to the next 
reagents. The cycles of coupling and deprotection were repeated until a peptoid of desired 
length had been obtained. The procedure is outlined in Scheme 3-14. 
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Scheme 3-14 Solid phase synthesis of
peptoids: After deprotection of the resin, the
first monomer is coupled via a peptide bond.
The Fmoc-group protecting the amino terminus
is removed and the following building blocks
attached under the same conditions. Reaction
conditions a) 20% pyridine in DMF, 3x 2min; b)
2 eq monomer, 2 eq PyBrOP, 4 eq DIPEA in
CH2Cl2, RT, 24h. 
A reporter group was required to monitor 
the cellular uptake of the different peptoids 
under the microscope. 5(6)-
Carboxyfluorescein 34 (λabs = 492 nm, λem 
= 517 nm) was coupled to the transport 
molecules prior to cleavage from the solid 
phase. 6-Aminohexanoic acid was used as 
a linker to prevent interactions of the 
reporter molecule with the peptoid moiety. 
As outlined in Scheme 3-15, the Fmoc-
protected linker molecule was attached to 
the amino termini of the peptoids under 
standard coupling conditions 52 and the 
protection group was removed with 
piperidine to yield 53. 5(6)-
Carboxyfluorescein could form a peptide 
bond via its carboxy group under mild 
coupling conditions with no detectable side 
reactions. In this reaction step 1-
hydroxybenzotriazole (HOBt) and 
diisopropylcarbodiimide (DIC) were used to 
activate the carboxyl function. 
 
In the final step, the labeled peptoids 53 
were cleaved from the solid phase and the 
Boc-protection groups were simultaneously 
removed by treatment with trifluoroacetic 
acid (TFA) supplemented with 5% 
triisopropyl silane (TIS). Peptoids 
containing the o-Nosyl-protection group had to be deprotected by treatment with 2-
mercaptoethanol and DBU prior to cleavage from the solid supports. The free peptoids were 
precipitated with diethylether and characterized by mass spectroscopy. 
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Scheme 3-15 Attachment of fluorescein 34 as a reporter molecule. Fmoc-6-aminohexanoic acid was 
coupled to the peptoids 51 under standard conditions and 5(6)-carboxyfluorescein was attached via a 
peptide bond 53. Reaction conditions: a) 20% pyridine in DMF, 3x 2min; b) 2 eq Fmoc-aminohexanoic 
acid, 2 eq PyBrOP, 4 eq DIPEA in CH2Cl2, RT, 24h, c) 3 eq 5(6)-carboxyfluorescein, 3 eq HOBt, 3 eq 
DIC in DMF/CH2Cl2 (1:1), RT, 5h. 
 
Five different peptoid transporters of varying lengths and side chain compositions were 
synthesized as depicted in Scheme 3-16. Peptoid 54 comprised four monomers with C6 side 
chains (40 (n=2)) of which the carboxy-terminal pair was protected with o-Nosyl and the 
amino-terminal pair with Boc. Peptoid 55 was assembled likewise with two additional Boc-
protected C6-building blocks attached to its amino terminus. Peptoids 56 and 57 consisted of 
6, respectively 8 building blocks with alternating Boc-protected C4- (40 (n=1)) and C8-side 
(40 (n=3)) chains starting with a C4-side chain at the N-terminus. 
 
Peptoid 58 was synthesized as a pentamer starting from the N-terminus with an o-Nosyl-
protected C6-monomer 40 (n=2) followed by an alternating sequence of two chiral building 
blocks 47 and two Boc-protected C6-monomers 40 (n=2) (see Scheme 3-16). 
 
3.5.4 Cellular uptake of fluorescein-labeled peptoids 
The fluorescein-labeled peptoids obtained by solid phase synthesis (as provided by T. 
Schröder) were tested in cultured mammalian cells upon their potential to act as molecular 
transporters. The minimal concentrations required for visible uptake and the maximum non-
toxic concentrations were to be estimated. Fluorescence microscopy (Zeiss, Axiovert 200, 
λexcit = 490-520 nm, λem = 517 nm) provided a means to assess the mode of uptake and to 
recognize the intracellular localization of the internalized compounds. 
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The peptoids were tested on human and simian cancer cell lines (HeLa and COS7, 
respectively), as well as on human primary fibroblasts (91/21). At the beginning of the cell 
experiments, the appropriate treatment conditions had to be estimated. Serum free medium 
was tested versus serum containing medium as many transfection reagents had been shown 
to be sensitive to serum due to interaction with proteins or nucleic acids and other 
compounds contained in the serum. On the other hand, the cells might suffer from lack of 
serum for prolonged times. 
 
 
H2N N
O (CH2)6
NH2
O
N
(CH2)6
NH2
O
N
(CH2)6
NH2
N
O (CH2)6
NH2
O
N
H
Fluo
H2N N
O (CH2)6
NH2
O
N
(CH2)6
NH2
O
N
(CH2)6
NH2
N
O (CH2)6
NH2
O
N
(CH2)6
NH2
N
O (CH2)6
NH2
O
N
H
Fluo
H2N N
O (CH2)4
NH2
O
N
(CH2)8
NH2
O
N
(CH2)4
NH2
N
O (CH2)8
NH2
O
N
(CH2)4
NH2
N
O (CH2)8
NH2
O
N
H
Fluo
H2N N
O (CH2)4
NH2
O
N
(CH2)8
NH2
O
N
(CH2)4
NH2
N
O (CH2)8
NH2
O
N
(CH2)4
NH2
N
O (CH2)8
NH2
O
N
(CH2)4
NH2
N
O (CH2)8
NH2
O
N
H
Fluo
NH2
O
N
O
N
(CH2)6
NH2
N
O
O
N
(CH2)6
NH2
H2N N
O (CH2)6
O H
N
Fluo
OHO O
CO2H
5
5
5
5
5
Fluo =
54
55
56
57
34
58
 
 
Scheme 3-16 Fluorescein-labeled peptoids 54-58 after deprotection and cleavage from the solid 
phase. Cleavage from the Rink-resin leads to a C-terminal amide functionality. 
 
With reference to the recent findings that fixation procedures lead to an artifactual uptake 
(Lundberg et al. 2002; Potocky et al. 2003; Richard et al. 2003), cells were prepared for 
microscopy either with the standard paraformaldehyde fixation protocol or without fixation by 
simple washing and attaching the cover slips to the microscopy slides in isotonic solution. 
The cell morphology under both conditions was compared. 
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For preliminary tests, the peptoids were thoroughly dried, assessed by mass spectroscopy 
and applied without further purification. All experiments with the fluorescein-labeled 
compound were carried out in the dark to avoid photo-bleaching of the light-sensitive probe 
molecule.  
 
Tetrapeptoid 54 was dissolved in PBS to yield a 10 mM stock solution, which was further 
diluted with serum-containing (+FCS) or serum free (-FCS) culture medium to final 
concentrations of 5, 10, 50, 100, 500 nM and 1 µM, respectively. Uncoupled 
carboxyfluorescein was used as a control. 
The cells were grown on 24-well plates on cover slips (∅ 13 mm) coated with fetal calf serum 
(FCS) to 10-20% confluency. After removal of the culture medium, the individual 24-wells 
were filled with half of the final volume of medium +FCS or –FCS and a doubly concentrated 
peptoid solution was added dropwise while constantly rocking of the culture dish to ensure a 
homogenous distribution of the compound. After 5, 20, 60 or 120 min of incubation at 37°C, 
the peptoid-containing medium was removed and the cells prepared for fluorescence 
microscopy.  
 
No signal could be detected at concentrations below 1 µM, which could be attributed to the 
weak intensity of fluorescein fluorescence or to the small amounts taken up by the cells. 
Therefore, subsequent experiments were carried out at 20, 50 and 100 µM as described for 
the related peptoid in a similar study (Peretto et al. 2003). These dosages appear to be very 
high especially since it is known that cationic amphiphiles are manly stored in the lysosomes 
eventually leading to the disruption of the latter.  
 
 
 
Scheme 3-17 PFA fixation leads to an artifactual redistribution of peptoids in the interior of the cells. 
While in PFA-treated cells fluorescence is localized to vesicular structures and the nucleus, which 
corresponds to an artifactual distribution, aggregation in proximity to the unstained nucleus, cytosolic 
staining and nuclear uptake with accumulation in the nucleoli are observed for fixed cells (Zeiss 
Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
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It can be assumed that in agreement with other cationic amphiphiles the petoids as well as 
the polyamines or the CPPs tested in the previous sections are protonated when they reach 
the acid lysosom (pH 4.5). There they will interact with any kind of negatively charged lipids 
and and might aggregate while slowly getting released into the cytosol. Since the compounds 
tested in these experiment are still crude after the cleavage from the resin and comprise a 
mixture of labeled and unlabled peptoids the dosages have to be refined with further purified 
peptoids. A new synthesis of peptoids is still ongoing and the experiments will be repeated 
with purified peptoids and analyzed by confocal microscopy to determine the uptake kinetics.  
 
Cells fixed with paraformaldehyde (PFA) actually showed a different intracellular distribution 
than the living cells. The latter show a characteristic pattern of vesicular structures that 
appear to aggregate around the nucleus, which is devoid of fluorescence. Fixed cells, on the 
contrary, exhibit cytosolic and nuclear staining with remarkably less vesicular structures, 
which confirms the reports of artifacts caused by fixation procedures that rupture membranes 
and permit diffusion of charged molecules to oppositely charged cellular components. Living 
cells prepared on ice exhibit a clear morphology for about 2h even at room temperature. 
After longer intervals, the morphological changes have to be attributed to the effects of the 
anti-bleach and starvation of the cells. 
In control experiments with hexameric 55, prolonged incubation in –FCS medium led to 
significant changes in cell morphology and cell death as depicted by  
Figure 3-48. Compared to the +FSC group, absence of serum did not result in an increase of 
uptake for any of the tested concentrations or incubation times. Therefore, subsequent tests 
were carried out in serum-containing medium. 
 
 
 
Figure 3-48 Depletion of serum leads to changes in cell morphology after 2 h of incubation. COS7 
cells incubated for 2h and 4h in –FCS (a) and +FCS (b) treated with 50 µM of tetrapeptoid 54 are 
shown. (Zeiss Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
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The vesicular structures observed in the preliminary experiment indicate an endocytosis-like 
mechanism for the uptake of the peptoids. Therefore, the experiment was repeated with 
incubation times of 4 and 16h, respectively to monitor the fate of the vesicular structures and 
whether the fluorescent peptoids are able to escape to the cytosol. The cell treatment with 
peptoid medium could be facilitated toward direct application of the medium without rocking 
of the culture plate. To avoid the strong background fluorescence observed at high peptoid 
concentrations, additional washing steps with 0.2% BSA solution in PBS+ were included into 
the preparation protocol as described for the CPPs and the spermine-coupled porphyrin. 
Under the given conditions, uncoupled carboxyfluorescein is not taken up by the cells even if 
incubated over night (16h, Figure 3-49). 
 
 
a) Nomarski image   b) fluorescence mode 
Figure 3-49 Uncoupled carboxyfluorescein is not taken up by mammalian cells after 16h of incubation 
at 37°C. The picture was taken in transmission (a) and fluorescence mode (b) to illustrate the outline 
of the cell. (Zeiss Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
In further experiments, it was shown that the other fluorescein-labeled peptoids 56, 57, and 
58  were taken up by all cell types. Comparison of images taken in the fluorescence mode 
with the same pictures taken in the transmission mode revealed that the compounds had 
entered the interior of all cells. 
 
 
Figure 3-50 Treatment of COS-7 and HeLa cells with 100 µM of the tetrameric peptoid 54 coupled to 
fluorescein. Vesicular structures accumulated in the perinuclear region and a diffuse fluorescence in 
the cytosol can be seen after one hour. Two hours after treatment, the fluorescence-labeled 
compound starts to enter the nucleoli of both cell types and is found in the nucleus of COS-7 cells. 
(Zeiss Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
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At the applied concentrations of 20 to 100 µM, intracellular fluorescence was clearly 
discernible. At 20 µM the signal was weaker and at lower concentrations the fluorescein 
labels could be only recognized at longer exposure times. For HeLa and COS7 cells 
internalization at 100 µM was detectable after 1-2h. At these shorter times, punctate 
fluorescence could be seen on the plasma membrane, while the center of the cells exhibited 
diffuse fluorescence. 
Vesicular structures throughout the cell and accumulated in the perinuclear region were 
observed in all experiments. After incubation over night, staining of the nucleoli was visible 
and the fluorescence of the interior of the cells was markedly increased. Thus it was 
assumed that the labeled molecules had escaped from the vesicles into the cytosol. Wheter 
this is due to the active or vesicle mediated transport mechanisms or to rupture of the 
lysosomal compartment remains to be analyzed. This assumption was supported by different 
forms of nuclear staining observed for different compounds in different cell lines. 
Experiments using confocal microscopy are required to decide how much of the compounds 
enters the cytosol or whether the diffuse staining originates from compounds evenly 
distributed on the plasma membrane. The use of lysosomal markers, would help to decide 
whether the components are entrapped in lysosomes or another species of transport vesicle.  
 
Those studies have been performed on other peptoids by Wender and Bradley using 
confocal microscopy (Peretto et al. 2003; Wender et al. 2002). They could show an 
internalization of the peptoids rather than a loose attachment of the peptoids on the cell 
membrane. Those studies would support our experiments and give rise to further 
experiments on this field. 
While the uptake of all tested peptoids shares some common features, pronounced 
differences could be observed among the individual compounds and in different cell types. 
The tetramer 54 showed a perinuclear localization of the vesicular structures and a distinct 
homogenous fluorescence throughout the cells even after one and 2 hours at 100 µM. Weak 
staining of the nuclei was also observed (Figure 3-50). 
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Figure 3-51 Treatment of COS-7, HeLa-cells, and human fibroblasts with the chiral pentameric 
peptoid 58 coupled to fluorescein. At concentrations of 20, 50, and 100 µM, the fluorescence is found 
localized to vesicular structures after incubation over night. Diffuse fluorescence is observed from the 
interior of all cells. In HeLa cells, the vesicular structures tend to aggregate in the perinuclear region 
and some fluorescence can be seen from the nucleus at 100 µM. At this concentration some 
fluorescence is also found in the nuclei of COS-7, while at lower concentrations the fluorescent 
compound is precluded from the nuclei. In fibroblasts, no nuclear uptake is observed. (Zeiss Axiovert 
35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
 
The chiral pentameric peptoid 58 was entrapped in vesicular structures. A tendency to 
accumulate in the perinuclear region was only observed in HeLa cells and much less 
pronounced in COS-7 cells. Staining of the nuclei was only visible after incubation over night 
at 100 µM (Figure 3-51) 
The hexameric peptoid 55 was visible in vesicular structures even after one hour of 
incubation at 50 and 100 µM. Remarkably, after two hours a clear distinction could be made 
between vesicles associated with the plasma membrane and those localized in the 
perinuclear region. Also, a patchy background fluorescence and a staining of the nucleoli 
was observed (Figure 3-52).  
After treatment with the hexameric peptoid with alternating C4- and C8-side chains 56, an 
increased amount of diffuse fluorescence was observed throughout the interior of the cells in 
addition to the vesicular structures of bright fluorescence. 
In COS-7 cells and HeLa-cells, these structures accumulate in the perinuclear region, which 
is less obvious for the fibroblasts even after incubation over night. In all cells, the nuclei are 
stained, with bright fluorescence in the nuclei of COS-7 cells and the weakest staining in the 
nuclei of the fibroblasts.  
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Finally, the octameric compound 57 exhibited the highest amounts of putative cytosolic 
staining, while the vesicular fluorescence was decreased in cells with a high degree of 
diffuse staining. Fluorescence was precluded from the nuclei but resided in the nucleoli. After 
incubation over night, vesicular structures were found to aggregate in the perinuclear region 
(Figure 3-54).  
 
In summary, the putative cytosolic stain was stronger for peptoids with longer chain-lengths 
and went along with uptake into the nucleoli. The chimeric compound appeared to be 
entrapped in vesicular structures with markedly less diffuse fluorescence. With an increase of 
incubation time, vesicular structures redistributed from the proximity of the plasma 
membrane to the proximity of the nucleus. This tendency was markedly less pronounced for 
the hexamer with alternating side chain lengths than for the homohexamer. The results are 
summarized in Table 3-7. Nevertheless, the uptake kinetics have to be further analyzed with 
purified peptoids and the mechanism of uptake refined by biochemical and further cell 
biological experiments as mentioned above. 
 
 
Compound vesicular 
structures 
perinuclear 
localization 
“cytosolic” 
fluorescence 
nuclear 
staining 
nucleolar 
staining 
tetramer 54 H, C H,C H,C - C 
pentamer 58 H,F,C H(+), C(-) F (-) H, F, C (100) - 
hexamers 55 H, C H (+), C (+) H, C (-) - H, C(-) 
hexamers 56 H,F,C F (-) C>H>F C>H>F - 
octamer 57 H,F,C  H,F,C H(+),F(+),C(+) - H,F,C 
 
Table 3-7 Comparison of cellular uptake of different peptoids. (+) and (-) indicate pronounced or weak 
effects. Note that the tetramer and the hexamers 55 were not tested in fibroblasts (C = COS-7; F = 
human fibroblast; H = HeLa). 
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Figure 3-52 Treatment of COS-7 and HeLa cells with 100 µM of the hexameric fluorescein-labeled 
peptoid 55. Fluorescence is found concentrated in vesicular structures and more dilute in the interior of 
the cells. After two hours, the vesicular structures start to accumulate in the perinuclear region and 
staining of the nucleoli is already visible, pointing out that the compound must have reached the 
interior of the cells. Note the assembly of vesicular structures along the plasma membrane of the 
COS-7 cells. (Zeiss Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
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Figure 3-53 Treatment of COS-7, HeLa-cells, and human fibroblasts with the fluorescein-labeled 
hexameric peptoid with alternating of C4- and C8-side chains 56. In all cells fluorescence is 
concentrated in vesicular structures, but a diffuse staining of the interior of the cells is also observed. 
In COS-7 cells the vesicular structures tend to accumulate in the perinuclear region. After 4h at 100 
µM the nuclei are intensely stained. A less pronounced nuclear staining is also observed for the 50 µM 
after incubation over night. In fibroblasts, no accumulation of the vesicular structures in the perinuclear 
region can be seen, but for the 100µM overnight sample. Nuclear staining is observed at 100µM, albeit 
less pronounced than for the COS-7 cells. In HeLa cells, the fluorescent vesicular structures 
accumulate in the perinuclear region and the staining of the nuclei is stronger than in the fibroblasts 
but much weaker than in COS-7 cells. (Zeiss Axiovert 35, filter set 17 λexcit. = 485nm, λem = 515-
565nm; exposure time: 10s). 
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Figure 3-54 Treatment of COS-7 and HeLa-cells with the fluorescein-labeled octameric peptoide 57. 
Fluorescence is localized to vesicular structures and staining of the nucleoli can be observed, while 
the main region of the nucleus is precluded from staining. In COS-7 cells, the vesicular structures are 
less pronounced in favor of more diffuse fluorescence spread over the interior of the cells indicating a 
cytosolic localization of the compound. In fibroblasts, the intracellular fluorescence is much less 
pronounced after 4h but increases after incubation over night. At these long incubation times, brightly 
fluorescent vesicular structures accumulate in the perinuclear region. Diffuse fluorescence throughout 
the cells is also observed in HeLa cells. A concentration of vesicular structures around the nuclei is 
also visible (Zeiss Axiovert 35, filter set 17: λexcit. = 485nm, λem = 515-565nm; exposure time: 10s). 
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4 Discussion 
 
Since the discovery of RNAi as an efficient tool for gene silencing, it has been discussed to 
cure diseases related to genetic defects like cancer or inherited genetic disorders, or to 
combat infections of viruses and parasitic organisms. In recent years, great advances have 
been made into this direction and experiments showed that RNAi was indeed able to reduce 
viral titers of HIV in cell culture (Novina et al. 2002) or to inhibit hepatitis B in mice (McCaffrey 
et al. 2002). However, it turned out that one major obstacle was the delivery of siRNAs in 
vivo. 
Viral vectors were introduced to transfer siRNAs or shRNA expressing plasmids into 
mammalian cells (Brummelkamp et al. 2002a; Hemann et al. 2003; Paddison et al. 2002b). 
The adenoviral approach, that was appreciated for its versatility (Tomar et al. 2003) was 
soon abandoned, since it was shown to lead to random insertion into the host genome with 
the risk of causing leukemias (Hacein-Bey-Abina et al. 2003a). Lentiviral vectors appeared to 
be a more convenient solution. However, it turned out that the delivery of shRNA expressing 
plasmids by lentiviral vectors triggered significant immunogenic responses, so that it is likely 
to exhibit adversary effects on fully-grown organisms (Fish and Kruithof 2004). 
Tail vein injection of naked siRNAs turned out to be efficient for gene silencing in the liver, 
where siRNAs accumulate upon high-pressure injection (Lewis et al. 2002; McCaffrey et al. 
2002). However, this mode of application is not transferable to clinical studies, since it 
requires large volumes to be injected in short times and leads to severe changes in blood 
pressure and liver enzyme levels (Heidel et al. 2004).  
 
Cell-penetrating peptides offer a new possibility to solve the delivery issue. The have been 
shown to efficiently deliver a broad variety of cargos into almost all types of cells, even 
beyond the blood brain barrier (Schwarze et al. 1999). Moreover, the rapid uptake reported 
for CPPs conjugated to cargo molecules (Lindsay 2002; Schwarze et al. 2000), and the 
accumulation of CPPs from the culture medium in the interior of the cells (Hallbrink et al. 
2001; Lindsay 2002) were favorable features for a versatile delivery tool. Finally, they 
appeared to exhibit no toxic effect in the concentration range required for RNAi (Hallbrink et 
al. 2001; Vives et al. 1997b). At the beginning of this work, the delivery of CPP-coupled 
antisense-oligonucleotides (Innis 2001; Prochiantz 1996) and PNAs (Derossi et al. 1998; 
Pooga et al. 1998b) had already been reported. Later, NLS sequences, PenetratinTM, VP22 
and Tat peptide were used to deliver siRNAs into cells by formation of non-covalent 
complexes (Benimetskaya et al. 2002; Dom et al. 2003; Kretz et al. 2003). 
Very recently, comparison of peptide-mediated uptake with the lipid-mediated delivery of 
PNA/DNA hybrids has led to the result that lipid transfection requires less PNA while peptide-
mediated delivery was simpler and less toxic to primary endothelial cells (Kaihatsu et al. 
2004). 
 
The coupling of siRNAs with CPPs to yield pepsiRNAs appeared to provide a promising tool 
for RNAi applications in vivo that allowed the specific silencing of endogenous or parasitic 
genes even in non-dividing cells and primary cells that had been found difficult to transfect 
with siRNAs by conventional methods. It even held a promise for applications in fully-grown 
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mammalian organisms. It was decided to use disulfide bonds for coupling so that the siRNA 
would be released from the delivery peptide once it reached the reducing milieu of the 
cytosol (Fischer et al. 2001; Schafer and Buettner 2001). Thus interactions of components of 
the RNAi machinery with the delivery peptide could be avoided. 
 
In the course of this work, proof of principle experiments with commercially obtained, thiol-
modified siRNAs coupled to PenetratinTM showed that these pepsiRNAs enter primary 
myocytes and silence recombinantly expressed GFP when applied in concentrations of 25-
100 nM. With reference to the first siRNA experiments in mammals (Elbashir et al. 2001a), 
pepsiRNAs targeting lamin A/C were applied to HeLa cells and primary fibroblasts and it was 
found that the endogenous gene was silenced as proven by immunostaining experiments. 
However, it should be noted that the immunostaining is restricted to the quality of the 
antibody and the detection efficiency.  
To assess the versatility of this new technique, pepsiRNAs directed against HexA were 
applied to various mammalian cell lines. The same treatment protocol was applied. The cells 
were treated with 100 nM of anti-HexA pepsiRNA for 30 min and after 2 days of incubation 
the knockdown efficiency was assessed. In HeLa cells, human primary fibroblasts, human 
epithelial kidney cells, and even primary murine neurons the target-mRNA was completely 
degraded.  
A knock-down up to ~98% was found for melanocytes, and greater than 99% for neurons , 
Hela cells , kidney epithelial cells, and fibroblasts, while mRNA levels of 7% and 20% were 
found in myotubes and myocytes, respectively. The residual activity might be explained by 
the setup of the experiment. Due to serum reduction, the myocytes begin to differentiate very 
quickly to myotubes that are much more difficult to address. However, it can be concluded 
that treatment with pepsiRNAs in the upper nanomolar range leads to a significant reduction 
of target mRNA in a variety of cell lines and primary cells. 
Thus, pepsiRNAs are functional as triggers of RNAi in the intermediate nanomolar range for 
endogenous and recombinant target genes. They are evenly distributed, taken up by all cells 
in the culture dish, and efficiently trigger RNAi even in primary cells.  
 
When the first steps were taken into the generation of pepsiRNAs, the combination of RNAi 
and CPPs seemed to offer unlimited possibilities. However, later findings indicated that the 
RNAi efficiency in mammals is lower than in C. elegans, where it was first described. Unlike 
worms, mammals do not possess an RNA dependent RNA polymerase (Stein et al. 2003) so 
that the efficiency of RNA solely depends on the number of catalytic cycles undergone by 
RISC (Haley and Zamore 2004). However, human RISC can perform up to 50 cycles of 
mRNA degradation so that RNAi keeps its advantage of catalytic activity over stoichiometric 
antisense techniques. 
 
Furthermore, siRNAs can be bound by the dsRBD of ADARs, which decreases their 
intracellular concentration (Yang 2004). As the RNAi machinery in mammals mainly serves 
regulatory processes, and the processing of siRNAs may share components with the miRNA 
pathway, side effects are to be expected if all available RISC complexes are saturated with 
exogenous siRNAs (Zeng and Cullen 2003). 
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However, these effects can be circumvented by keeping the concentration of siRNAs as low 
as possible by designing highly efficient siRNAs. If the design of an siRNA leads to a 
preferred incorporation of the antisense-strand into RISC, less siRNAs are lost by 
incorporation of the sense-strand (Schwarz et al. 2003) and putative off-target effects caused 
by RISC loaded with the sense-strand are avoided (Jackson et al. 2003). Today, the design 
of highly efficient siRNAs has been greatly facilitated by novel design rules and 
corresponding computer tools (Khvorova et al. 2003; Reynolds et al. 2004; Schwarz et al. 
2003; Yamada and Morishita 2004). 
Additionally, the stability of siRNAs towards nucleases can be enhanced by modifications of 
the ribose-phosphate backbone such as the incorporation of phosphorothioates (Harborth et 
al. 2003), locked ribonucleotides (Braasch et al. 2003; Grunweller et al. 2003), 
boranophosphates (Hall et al. 2004), 2´-methylated or 2´-fluorinated ribonucleotides or 
deoxyribonucleotides at selected sites (Amarzguioui et al.; Askjaer et al. 2002; Chiu and 
Rana 2003). Thus, a prolonged effect can be achieved with an equal dose of stabilized 
siRNAs. 
 
The broad field of CPP based research suffered a drawback, when it was reported that many 
of the early mechanistic findings were due to artifacts. Due to their high membrane affinity, 
these highly basic peptides adhere to the negatively charged compounds of the plasma 
membrane thereby mimicking high uptake rates in cell counting assays (Richard et al. 2003; 
Thoren et al. 2003). They also reorganize during cell fixation procedures and accumulate in 
the nucleus (Leifert et al. 2002; Lundberg et al. 2002). After correcting the procedures to 
avoid artifacts, it turned out that CPP-coupled reporter molecules were taken up within 2-4 h 
rather than in 10-30 min. No uptake was observed at 4°C and the molecules were localized 
in vesicular structures all pointing out an endocytosis-like mechanism (Drin 2003; Fischer et 
al. 2004; Richard et al. 2003; Thoren et al. 2003; Umezawa et al. 2002; Vives 2003). 
 
However, it was the high uptake rate that had to be revised, while the high membrane 
association of CPPs was confirmed by these reports. Many publications about CPP-coupled 
cargos that exhibited their desired effects in the cytosol, suggested that these bioconjugates 
must have reached the cytosol (Braun et al. 2002; Derossi et al. 1998; Kasim et al. 2004; 
Peitz et al. 2002; Pooga et al. 1998c; Soughayer et al. 2004). In fact, novel mechanistic 
studies confirmed that CPP-coupled reporter molecules were taken up by endocytosis, but 
were able to escape the endocytic vesicles (Thoren et al. 2003; Zaro and Shen 2003). It is 
assumed that they reach the cytosol via retrograde transport across the trans-Golgi network 
similar to cholera-toxin (Fischer et al. 2004). Since no quantitation has been made this is still 
an assumption. 
 
Although the rate of uptake is much slower than previously reported, short incubation times 
are still sufficient to achieve a good cellular uptake even though it is not clear in which 
compartments the CPPs are pesent. As described before most of the studies do not report 
the quantitation of the CPPs that are taken up and the CPPs that remain in the medium after 
thourough washing. Those studies are still ongoing. Although those numbers are still not 
known, it can be assumed that the amount of the CCPs that actually enter the cells is much 
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lower than the applied concentrations reflect so far. CPPs strongly interact with the plasma 
membrane, they attach to cellular surfaces within the first minutes after their applications. 
The binding is strong enough to withstand repeated washing steps and can only be released 
by treatment with proteases (Richard et al. 2003). Thus the CPP-conjugates remain 
associated with the cells when the medium is exchanged after 15-30 min of incubation. They 
can then enter the cells by endocytosis, wherein the prolonged time of uptake can be 
exploited as a depot effect for prolonged availability of the compounds inside the cells. 
 
Thus, peptide mediated delivery, like the pepsiRNA approach, bears the advantage, that 
incubation times and thereby the exposure to serum free medium can be kept short which is 
less stressing for sensitive cell types. 
 
The high membrane affinity of CPPs also conveys some degree of specificity to this 
approach. The cationic peptides quickly associate with negatively charged structures in the 
close proximity. Therefore, when applied to a fully-grown organism, a large proportion of a 
CPP conjugate would be taken up at the site of application while a smaller amount would 
circulate in the bloodstream. Thus, the pepsiRNA approach provides a local restriction of the 
siRNA-mediated gene silencing. At the same time, the strong membrane interactions prevent 
the delivery to specific cell types by targeting specific surface structures.  
Early studies using a CPP-coupled FAB fragment have shown that proteins coupled to few 
CPPs are taken up more specifically but less efficiently and vice versa (Anderson et al. 
1993).  
An elegant approach to circumvent the specificity issue is the development of activatable 
CPPs (ACPPs), in which the capacity to enter cells is blocked by a linker that can be 
specifically cleaved by a protease secreted by the target cells (Jiang et al. 2004). 
On the other hand, the local restriction of CPPs is of great interest for the treatment of skin 
disorders. It has been already shown that hemagglutinin (HA) epitopes coupled to CPPs and 
fluorescently labeled cationic β-peptides penetrated to the deep dermis after one hour after 
topical application (Robbins et al. 2002; Rueping et al. 2004). Thus, pepsiRNAs could be 
used in the treatment of psoriasis or for the study of the water-permeability barrier of the skin 
in vivo. 
 
During the work on the pepsiRNAs approach reported here, the same idea has been 
developed and tested by other groups. The first reports on penetratin (Davidson et al. 2004; 
Muratovska and Eccles 2004) and Tat or oligocarbamate-coupled siRNAs (Chiu et al. 2004a) 
confirm the findings presented in this work: CPP-coupled siRNAs via disulfide bonds are 
taken up by various kinds of mammalian cell lines and primary cells and the coupling to 
CPPs does not interfere with the RNAi efficiency so that significant levels of more than 99% 
of downregulation are already obtained in the lower nanomolar range depending on the cell 
type. pepsiRNAs, also named V-siRNAs for vector-coupled siRNAs, are taken up by primary 
neurons, where they downregulate the targeted genes (Davidson et al. 2004; Schmitz et al.). 
It was also shown that the decrease of mRNA is preceded by a drop of protein levels due to 
translational inhibiton (Davidson et al. 2004). 
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All reports on peptide-coupled siRNAs are based on compounds generated by solid phase 
synthesis (SPS). As thiol-modified nucleotides for SPS are readily available on the market, 
the synthesis of thiol-modified siRNAs is straightforward, once the technique has been 
established in the lab. However, siRNAs and peptides from solid phase synthesis are 
obtained in small amounts at comparedly high costs. Therefore, the work presented here 
aimed at developing a strategy that allows the scale up of pepsiRNA synthesis.  
Large amounts of siRNAs have been obtained from recombinant organisms overexpressing 
hairpin-shaped RNAs. It has been demonstrated that lhRNA recombinantly expressed in 
Nicotiana tabacum was processed into siRNAs by the host organism. These siRNAs could 
be applied to mammalian cells, where they down-regulated endogenous and viral target 
genes with an efficiency comparable to synthetic siRNAs (Zhou 2004). However, such 
siRNAs need to be functionalized by a subsequent step, which appears to be a non-trivial 
task if the modification has to be directed to the sense strand of the native siRNA. 
 
In vitro transcription by T7 RNA polymerase (Milligan et al. 1987) is a convenient approach to 
generate large amounts of RNA, that has gained considerable interest for the generation of 
long dsRNAs and siRNAs. It bears the advantage that single stranded RNAs can be 
generated in separate reactions and hybridized in a subsequent step. To functionalize 
enzymatically generated RNAs, chemically modified nucleotides can be attached to the 3´-
terminus with T4-RNA-ligase (Hausch 1997; Igloi 1996), or GMP derivatives that act as 
initiator nucleotides can be added to the reaction mixture to be selectively incorporated at the 
5´-terminus (Seelig 1997, 1999). For the coupling of peptides to siRNAs via an in vivo 
cleavable disulfide bond, a thiol-modified initiator nucleotide is required. Although guanosine 
monophosphorothioate (GMPS) can be readily incorporated into RNA and used for the 
formation of disulfide bonds (Lorsch and Szostak 1994), the resulting phosphortioate-sulfide 
compound (R-SSPO3-RNA) is not very stable (Goody and Walker 1971; Sengle et al. 2001). 
5´-Deoxy-5´-thioguanosine-monophosphorothioate (GSMP) yields 5´-thiophosphate modified 
RNAs that can be transformed into 5´-SH-RNAs by incubation with phosphatase (Zhang et 
al. 2001a). This approach brings the two oppositely charged coupling partners into close 
proximity, which makes interaction less likely than conjugation via a long chain flexible linker.  
 
Although the synthesis of GSMP has been reported with yields of 35% in 4 steps (Zhang et 
al. 2001a), it was found difficult to reproduce. The major obstacle consisted in the purification 
of 5´-deoxy-5´-iodo-2´,3´-O,O-isopropylideneguanosine. The dried reaction mixture needs to 
be washed prior to column chromatography, which leads to losses due to its stickiness. The 
crude product is poorly soluble in the solvents required for column chromatography and 
tends to obstruct chromatography columns, leading to further losses. Moreover, the iodide is 
subject to an intramolecular cyclization reaction that has been previously described 
(Verheyden and Moffat 1970). Due to the high rate of this side reaction in DMSO, it is difficult 
to determine the purity of the product by NMR-spectroscopy. The instability of the iodide also 
leads to contaminations in the subsequent deprotection step.  
As the cyclization requires a freely accessible purin-N3, the adjacent primary amine was 
protected as an imine in an additional reaction step. Thus, the nucleophilic attack of N3 on 
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the ribose C5´ was sterically hindered, which resulted in an increase of the half-life time of 
the iodide by a factor of 12. 
Due to its increased solubility, the protected iodide was readily purified and quantitative 
yields could be obtained by column chromatography. The overall yield of the additional 
protection reaction and the iodination (79%) was about twice as large as the yield for the 
unprotected iodide (39%) and even exceeded the literature yield (62%) (Zhang et al. 2001b). 
The protected iodide was stable even after months of storage and did not lead to any 
contaminations during the deprotection reaction. 
 
As the solubility of GSMP in water is similar to that of thiophosphate, it is difficult to purify 
from the excess of reactant. After the first precipitation step as described by Zhang (Zhang et 
al. 2001b), chromatography methods have to be applied to obtain GSMP without 
contaminations of thiophosphate. FPLC via an anionic exchange column (DEAE-Sepharose 
A25), column chromatography on silica gel and reversed phase chromatography on RP-18 
material were compared as purification methods. The highest yields were obtained by 
column chromatography on RP-18 material with gravity flow elution with water that yielded 
68% of GSMP. An overall yield of 53% was obtained for the refined synthesis of GSMP in 5 
steps as opposed to the reported 35% in 4 steps (Zhang et al. 2001a). 
 
GSMP 15 was added to the in vitro transcription reaction for the generation of the siRNA 
sense strands. The reaction mixtures for the sense strand and for the antisense strand were 
incubated with phosphatase to liberate the thiol-group from the thiophosphate and to remove 
5´-terminal triphosphates, respectively, that have been reported to induce an interferon 
response in mammalian cells (Kim et al. 2004). After precipitation and hybridization, modified 
siRNAs are obtained in a reasonable yield. 
The thiol-modified siRNAs were coupled to commercially obtained biotinylated penetratinTM. 
The reaction can be easily monitored by a yellow ring of thiopyridone at the interface of the 
peptide and siRNA solution at elevated concentrations. In some experiments, the formation 
of a precipitate due to aggragation of the oppositely charged compounds was observed, 
which could be redissolved by the addition of concentrated NaCl solution. Precipitation could 
be largely avoided if the experiment was carried out in a flow of argon and if the solution was 
not agitated to mix the compounds. The formation of conjugates could be confirmed by 15% 
SDS-PAGE and by MALDI-TOF analysis. Separate experiments under reducing and non-
reducing conditions indicated, that the disulfide bond could be cleaved to release the two 
monomers. This demonstrated that thiol-modified siRNAs could be generated in one step by 
in vitro transcription if the modified initiator nucleotide was readily available. 
Both pepsiRNA and standard oligonucleotide were detected as broadened peaks. Due to the 
high acidity of the backbone phosphates these residues are deprotonated at neutral pH. The 
siRNAs bear 42 negatively charged residues and are thereby found as mixtures of sodium 
and potassium salts, so that broadened peaks are found. As described by Jensen (Jensen et 
al. 1996), the pepsiRNA and reference samples were treated with ammonium acetate to 
exchange sodium and potassium ions for ammonium ions that dissociate to volatile NH3 and 
H+ in the gas phase leaving behind protonated phosphate residues. The thus obtained peaks 
were much more focused but could still not be assigned to one distinct mass. In three 
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measurements of aliquots of the same sample, the value for the dsRNA peak varied between 
14180 and 14649 Da corresponding to a maximum deviation of 1.8% from the average of the 
three measured values. This was much higher than the deviations of 0.08% reported for 
short model conjugates of peptides with oligodeoxynucleotides of an overall mass of 1942 to 
4381 Da as determined by MALDI-MS (Jensen et al. 1996). One reason for this was the low 
signal to noise ratio obtained for the pepsiRNAs, which led to ambiguous results in the 
determination of the peak maximum. Additionally, the incomplete removal of associated Na+-
ions resulted in a mass distribution of the oligoribonucleotides, and the siRNAs might have 
been subject to nuclease degradation during sample preparation leading to fragments of 
different size. Finally, those nucleotides may result from strand termination during solid 
phase synthesis. Due to these results the cell culture studies must be considered with 
caution concerning the final concentration of the pepsiRNAs estimated photometrically. The 
concentration for the experiments might be much lower than depicted, even though the 
pepsiRNAs were subjected to gel filtration, due to incomplete coupling and degradation of 
the compounds.  
 
The recombinant expression of CPPs is a straightforward approach towards a large-scale 
generation of pepsiRNAs. Vectors for the expression of GST-coupled Antennapedia peptide 
and Tat peptide with C-terminal cysteine residues were generated by cloning the 
corresponding synthetic genes into a GST-expression vector. The presence of the insert was 
confirmed by PCR and sequencing. Unlike plain GST, the overexpressed GST-CPP fusion-
proteins could not be purified by the standard protocol, as the recombinant proteins resided 
in the pellet. This was thought to correlate with the degree of CPP-membrane interaction, 
since a GST-Tat mutant (R9Q), in which one of the cationic arginine residues is replaced by 
a neutral glutamine residue, thus reducing the degree of electrostatic interactions, shows a 
higher solubility than Tat. Thus, it was necessary to develop a novel purification protocol that 
allowed the solubilization of GST-CPPs. It was found that increased amounts of DTT and 
Triton X-100, a higher pH and elevated temperatures enhanced the solubility of the 
recombinant protein. The yield of GST-Tat could be further increased by sonication. The 
yields of GST-CPPs obtained with the modified protocol correspond to those found with plain 
GST. 
 
According to the design of the recombinant GST-CPPs, TEV protease was required to cleave 
the CPPs from the GST-tag. Recombinant vectors were generated to express GST-tagged 
TEV protease. The overexpressed fusion-protein resided in the insoluble fraction of the 
lysate. Apparently, the fusion protein did not fold back properly and formed insoluble 
inclusion bodies. After solubilization under denaturing conditions and dialysis against 
different refolding buffers no soluble native protein could be obtained. Attempts to express 
recombinant TEV protease with a His6-tag led to similar results. The solubility of the 
recombinant protein could neither be increased by expression at lower temperatures nor by 
expression in different strains. The protein obtained by inclusion body preparation did not 
bind to the Ni-NTA resin for affinity purifiaction. 
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The formation of inclusion bodies is a well-known problem in the expression of TEV protease 
(Kapust et al. 2001; Lucast et al. 2001). Various mutations have been tested to increase its 
solubility and to suppress its autoproteolysis activity. From a collaboration, a recombinant 
strain of E.coli BL21 DE3 pLysS was obtained that expressed the mutant S219Q in which an 
autocatalytically active residue is replaced by an inactive one (A. Ulrich, TH Karlsruhe). This 
mutant is also known for its improved solubility (Lucast et al. 2001). The recombinant protein 
could be prepared in a straightforward manner following the protocol for native preparation 
by Lucast (Lucast et al. 2001). The amounts of protein obtained after affinity purification on 
Ni-NTA were comparable to the amounts of plain GST obtained by affinity purification on 
glutathione sepharose. The pooled eluates were tested in a cleavage reaction with GST-Tat 
and GST-AntP in comparison to commercially obtained TEV protease. The used amounts of 
commercial and recombinantly generated protease exhibited a comparable cleavage activity 
in an overnight cleavage assay. 
Peptide bands could not be detected by 15% SDS-PAGE, which may be explained by the 
weak staining of the peptide and the generally less focused peptide bands that are more 
difficult to detect, as known from PenetratinTM controls. As only 4% and 6% of the protein 
mass are made up by Tat peptide and AntP, respectively. Only small amounts of peptide are 
to be expected even if the full amount of GST-CPP is cleaved. Although, His6-tagged TEV 
protease and free GST-tags could be removed by the corresponding affinity-resins, it is more 
convenient to purify the reaction mixtures by FPLC on RP-18, since both resins require 
different conditions to bind their substrate, and DTT needs to be removed prior to coupling of 
the CPP to the siRNA via a disulfide bond. Moreover, by UV-detection during elution from an 
RP-18 column at 280 nm the amounts of free peptide and uncleaved GST-CPP could be 
assessed and the purity of the peptide fractions could be monitored.  
 
Peptides are sensitive to degradation by proteases and to oxidation, which affords great care 
when working with CPP-coupled substances. It also lowers the half-life of these compounds 
in vivo and reduces the fraction that reaches its target site. Moreover, peptides may be 
recognized as epitopes and trigger immunogenic responses. Therefore, small molecules with 
membrane permeating properties were developed and tested in cell culture as a future 
replacement of the CPP moiety for the delivery of siRNAs.  
 
Preliminary tests with rhodamine-coupled oligoamines, indicated that spermine was a 
suitable candidate as a backbone for novel cell-permeating molecules, as it bears a 
significant potential to enter cells. 
Over the last decade, conjugates of spermine or spermidine with lipids like 
dioctadecylaminoglycylspermine (DOGS, transfectam) have been established as transfection 
agents (Boletta et al. 1997; Kichler et al. 1997; Mack et al. 1994). Furthermore, spermin 
conjugates with cholesterol have been developed for the delivery of oligonucleotides (Guy-
Caffey et al. 1995; Lee et al. 1996; Lee et al. 2004b). All of these approaches make use of 
the formation of non-covalent complexes of the positively charged amine with the negatively 
charged DNA cargo (Symons 1995). Covalent attachment of spermine has helped to target 
DNA-cleaving effector molecules like acridine and iron chelators to their target site (Bergeron 
et al. 2003; Delcros et al. 2002). Finally, covalent coupling spermine to an RNA cleaving 
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DNA enzyme could enhance the enzyme´s activity and its affinity to the target RNA (Kubo et 
al. 2003). 
In this work, conjugates of spermine with carboxyfluorescein and porphyrin as reporter 
molecules were tested in cultured mammalian cells. Porphyrin is of specific interest for the 
treatment of tumors in photodynamic therapy. Upon irradiation, porphyrins generate highly-
reactive singlet oxygen that leads to fatal damage of the affected cell (Capella and Capella 
2003; Detty et al. 2004). 
Uptake experiments with fluorescein-labeled spermine in mammalian cell lines showed that 
the spermine conjugates were taken up in vesicular structures after 4h of incubation with 100 
µM of the compound as assessed by life microscopy. Further incubation over night, led to a 
distribution of these structures throughout the cell. The time-frame required for uptake and 
the finding of vesicular structures indicate an uptake by endocytosis followed by endosomal 
escape. Unmodified carboxyfluorescein was not taken up by any of the tested cell types, so 
that the observed phenomena must be due to the conjugation with spermine. It has been 
reported that conjugates of spermine with small molecules have a high affinity for the cellular 
polyamine transport system (PTS) (Bergeron et al. 2003; Delcros et al. 2002). However, 
others have found a role for endocytosis (Soulet et al. 2002), which is in agreement with the 
results presented here. 
The same patterns were observed in the experiments with spermine-coupled porphyrin. At a 
concentration of 10 µM, all cells were stained after 4h of incubation. After incubation over 
night, fluorescence could also be seen in the cytosol, and cellular uptake was observed for 
concentrations as low as 100 nM in almost all cells. Punctate fluorescent staining on the 
surface of fibroblasts could be even detected at concentrations of 10 nM. It is assumed that, 
the fluorescence intensity of the porphyrin is not sufficient to be detected after cellular uptake 
in low concentrations. 
At concentrations of 50 and 100 µM of conjugate, severe toxic effects were observed for all 
cell types. In comparison with untreated controls, over 80% of the cells had detached from 
the culture plate, and the remaining cells showed signs of cell death after 30 min of 
incubation. In the transmission mode many of the remaining fragments were fluorescent with 
the associated porphyrin conjugate. This effect was significantly pronounced in cells treated 
in daylight, while the majority of cells retained a healthy phenotype when treated in the dark. 
This confirms the phototoxicity of the porphyrin-derivative. The association of the spermine-
coupled porphyrin with the cell surface helps to restrict this kind of light-induced damage to 
the site of application. In photodynamic therapy, porphyrins are used to destroy tumors by 
application to the affected tissue followed by irradiation at high intensities. In these 
applications, spermine-porphyrin conjugates may reduce systemic side effects by localizing 
the phototoxic compounds to the site of administraion and decrease the efficient dose due to 
an enhanced uptake. 
 
For future applications for the delivery of siRNAs, peptoids were selected as a peptide-
mimetic with increased stability toward proteases in vivo. The synthesis of peptide analogs 
that mimic CPP function has been described by several groups (Potocky et al. 2003; Raguse 
et al. 2002; Rueping et al. 2002; Rueping et al. 2004; Wender et al. 2000; Wender et al. 
2002). For efficient uptake, such backbone mimetics must bear a high number of positively 
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charged side chains that can adopt an amphipathic secondary structure in which polar and 
non-polar fractions of the molecule point into opposite directions.  
β-peptides, the higher homologs of the α-peptides, form stable helices that are structurally 
more confined than those formed by α-peptides. (Rueping et al. 2004). They are stable 
toward degradation by proteases and their structures can be more readily predicted. β-
peptides functionalized with guanidinium groups enter cultured mammalian cells with high 
efficiency (Wender et al. 2000). As opposed to α-peptides, the side chains in oligo-N-
alkylglycines or peptoids are attached to the amine, so that the monomers can be readily 
synthesized from functionalized diamines (Figliozzi et al. 1996; Goff and Zuckermann 1992; 
Wender et al. 2000). Like β-peptides, peptoids with guanidinium-headgroups enter 
mammalian cells, where they have been used to mimic peptide-hormones, antibiotics, and 
receptor ligands (Murphy et al. 1998; Wender et al. 2000). 
In this work, fluorescently labeled peptoids consisting of a polyamide backbone of varying 
length with amino-functionalized side chains of different side chain lengths as kindly provided 
by T. Schröder (Schroeder 2004) have been tested in HeLa- and COS7 cells and in primary 
fibroblasts. 
In preliminary experiments, it was found that the presence of serum in the application 
medium does not interfere with the uptake of the compound. On the contrary, long incubation 
times in serum free medium alter the morphology of the treated cells. The artifactual 
redistribution of the fluorescent conjugates with localization to the nucleus, as previously 
described by others (Leifert et al. 2002; Lundberg et al. 2002), was confirmed by these 
experiments, so that further experiments were evaluated by life cell microscopy in isotonic 
buffer. Concentrations of 10, 50, and 100µM and incubation times of 4h and 16h were found 
as conditions under which uptake of the fluorescein-labeled peptoids could be observed in all 
of the treated cells. 
The putative cytosolic stain was stronger for peptoids with longer chain lengths and went 
along with uptake into the nucleoli. Vesicular structures were less pronounced for the 
octamers, which exhibited the strongest staining of the cellular background. This is in 
agreement with reports about synthetic oligopeptides, where no uptake was observed for 
less than 6 amino acids and the highest efficiency was found for the octamer (Rothbard et al. 
2000). The chimeric compound appeared to be entrapped in vesicular structures with 
markedly less diffuse fluorescence. With an increase of incubation time, vesicular structures 
redistributed from the proximity of the plasma membrane to the proximity of the nucleus. This 
tendency was markedly less pronounced for the hexamer with alternating side chain lengths 
than for the homohexamer. 
As for the spermine conjugates, vesicular structures distributed throughout the cell and 
accumulated in the perinuclear region were observed in all experiments with the fluorescent 
peptoids, while incubation over night also led to a staining of the nucleoli. Moreover, the 
overall fluorescence inside the cells and the cytosolic fluorescenc was markedly increased 
after incubation over night suggesting an escape of the labeled molecules from the vesicles 
into the cytosol.  
Nevertheless, lysosomal markers need to be used to determine whether the components 
were entrapped in lysosomes or another species of transport vesicle. 
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Apparently, all of the synthetic positively charged small molecules were taken up by an 
endocytosis-related mechanism followed by endosomal release. In this, they resemble the 
uptake behavior of CPPs.  
With 10-100 µM, the concentration range required to visualize cellular uptake of the labeled 
peptoids and spermine conjugates lies 2-3 orders of magnitude above the concentrations 
used in CPP-mediated delivery. In the experiments with the cationic amphilic synthetic 
transporters, dosages appear to be very high, especially since it is known that cationic 
amphiphiles are manly stored in the lysosomes eventually leading to the disruption of the 
latter. It can be assumed that in agreement with other cationic amphiphiles, the petoids as 
well as the polyamines or the CPPs tested in the previous sections are protonated when they 
reach the acid lysosom (pH 4.5). There they will interact with any kind of negatively charged 
lipids and might aggregate while slowly getting released into the cytosol. Since the 
compounds tested in these experiment are still crude after the cleavage from the resin and 
comprise a mixture of labeled and unlabled peptoids the dosages have to be refined with 
further purified peptoids. A new synthesis of peptoids is still ongoing and the experiments will 
be repeated with purified peptoids and analyzed by confocal microscopy to determine the 
uptake kinetics. 
However, these findings confirm the reports of homologous peptoid transporters that act in a 
similar concentration range (Yingyongnarongkul et al. 2004). Reasons for this discrepancy 
may lie in a weak reporter signal. Fluorescence microscopy is made difficult by rapid 
photobleaching of fluorescein. Similar studies have been performed on other peptoids by 
Wender and Bradley using confocal microscopy (Shi Kam et al. 2004; Yingyongnarongkul et 
al. 2004). They could show an internalization of the peptoids rather than a loose attachment 
of the peptoids on the cell membrane. Those studies would support our experiments 
Moreover, the tested structures are only lead-structures that are to be developed into 
powerful delivery agents. An elongation of spermine or the functionalization of the peptoids 
with arginine residues could be reasonable modifications for further investigations. 
 
With this work, some first steps have been taken into the vast field of artificial delivery 
molecules. The finding that molecules that are otherwise excluded from the cells can be 
delivered after covalent coupling with spermine or amino-functionalized peptoids points at the 
potential of these compounds for the delivery of drugs and especially siRNAs. The coupling 
of these novel delivery molecules to siRNAs and the testing of these conjugates will be 
subject to future work. 
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5 Materials and methods 
 
5.1 Bacteria culture 
5.1.1 Culture conditions 
Wild type and recombinant E. coli strains are grown in LB medium supplemented with the 
following antibiotics required for selection: 60µg/ml ampicillin, 10µg/ml tetracyclin, 50µg/ml 
kanamycin or 7 µg/ml gentamycin, respectively. Single colonies are incubated over night at 
37°C in 20 ml LB-medium or the corresponding selection medium. These overnight cultures 
are used to start large-scale expression experiments (50 – 1000 ml) or to amplify plasmids. 
E. coli DH5α cells are used for plasmid amplification and E. coli BL21 strains for protein 
expression. 
5.1.2 Storage 
For the generation of glycerol stocks, 1 ml of the overnight culture is pelleted (15 min at 2000 
rpm, RT, Microcentrifuge MiniSpin, Eppendorf). After discarding the supernatant, the cells 
are resuspended in 0.5 ml freezing medium (20% glycerol in LB medium) and stored at -
80°C. Glycerol stocks remain functional for several years. To start an overnight culture, it is 
sufficient to pick some of the bacteria from the frozen glycerol culture surface using a sterile 
pipette tip and drop it into a flask with selection medium for inoculation. 
5.1.3 Generation of competent cells 
500 ml LB-Medium are inoculated with 1ml bacteria suspension and incubated at 37°C to an 
optical density (OD600) of 0.5-0.7. The cell suspension is stored on ice for 30 min and pelleted 
by centrifugation (10 min, 4°C, 3000 rpm, Megafuge 2.0 Heraeus). Pellets are resuspended 
in 300 ml of sterile and cooled 0.1 M CaCl2 solution and stored at 4°C for 1-2 days. The 
bacteria are pelleted as described above and resuspended in 20 ml of cold 0.1M CaCl2 
solution containing 10% glycerol. The cells are kept at 4°C for about 5 days and stored in 
200 µl aliquots at -80°C for several months.  
5.1.4 Transformation and selection 
For the transformation of recombinant DNA into prokaryotic cells, 5 µl of the ligation sample 
or 5-10 ng of a purified plasmid is added to 200µl of competent cells and incubated on ice for 
30 min. The cell pores are closed by heat shock (30-45 s at 42°C), and the suspension is 
cooled on ice for another 2 minutes. One ml of LB-medium is added to the cells, and the 
suspension is incubated on a shaker or overhead roller for 1 h at 37°C. After centrifugation (5 
min at 5000 rpm, RT, Microcentrifuge MiniSpin, Eppendorf), 1 ml of culture medium is 
removed. The pellet is resuspended in the remaining medium. 50-100 µl of the suspension 
are plated on culture dishes with selection agar (LB medium, 1,5 % agar, 60µg/ml ampicillin, 
10µg/ml tetracycline, 50µg/ml kanamycin or 7 µg/ml gentamycin, respectively) and incubated 
for 12-18 h at 37°C.  
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5.2 Cell culture techniques for mammalian cells 
5.2.1 General procedures 
All procedures with mammalian cells are carried out under sterile conditions. 
Human fibroblasts, COS1-, COS7- and HeLa-cells are cultured in 10% DMEM (DMEM 
supplemented with 10% FCS, 1 u/ml streptomycin (and tylosine)). For the cultivation of 
murine myocytes, HAMs Nutrient Medium F-10 (E15-014, PAA-Laboratories GmbH) without 
glutamine supplemented with 10% FCS, 1 u/ml penicillin, and streptomycin is used. Jurkat 
cells are kept in RMPI 1640 with 10% FCS as a suspension culture.  
Mature dendritic cells (DC 721) are kept as suspension culture in RPMI medium 
supplemented with 10% FCS. For immature dendritic cells VLE-RPMI containing 10% FCS is 
used. All cells are incubated at 37°C in a 5% CO2 atmosphere. Adherent monolayers of cells 
are harvested with a trypsin/EDTA solution after removal of culture medium and washing with 
PBS. The process is stopped by the addition of a threefold excess of culture medium. 
 
5.2.2 Storage of mammalian cells in liquid nitrogen  
For long time storage in liquid nitrogen, the cells are kept in DMEM with 50% FCS and 9% 
DMSO to prevent the formation of intracellular ice crystals. 
Cells are harvested as described above. The cell suspension is pelleted at 2000 rpm for 5 
min (Centrifuge 5810 R, Eppendorf), the supernatant is removed, and the cells are 
resuspended in FCS. An equal volume of freezing medium (serum free medium with 20% 
DMSO) is added. 1 to 1.3 ml of cell suspension is transferred into freezing vials and 
deposited in a Nalgene freezing container. After storage at –80°C over night, the freezing 
vials are transferred into liquid nitrogen.  
 
5.2.3 Preparation of FCS-coated cover slips 
Sterile cover slips are placed into 24-wells and covered with 0.5 ml of inactivated FCS. After 
2 min the FCS is removed and the cover slips are permitted to dry for 10-15 min with the lid 
of the culture dish open. 
 
5.2.4 Treatment of adherent cells with pepsiRNAs 
Confluent cells from 75 cm² (25 cm²) dishes were harvested as described above, diluted with 
culture medium to 25 ml (8 ml) and plated in 6-well plates (1 ml per well) or on cover slips 
coated with FCS (0.5 ml per 24well). The dilution of the cells was adjusted to achieve 
approximately 80% confluency at the time of treatment (see Table 5-1). Plated cells are 
permitted to attach to the culture dish for at least 4 h or over night (18 h). 
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 6-well, 4h  6-well, 18h 24-well, 4h 24-well, 18h 
25 cm² 4 ml  
 
8 ml 8 ml 16 ml 
75 cm² 12 ml 
 
25 ml 25 ml 50 ml 
Table 5-1 Volume of culture medium required to dilute confluent cells in order to be plated in 6-well or 
24-well dishes and to achieve 80% confluency within 4 or 18 h. Volumes of cell suspension are 1 ml 
per 6-well and 0.5 ml per 24-well. 
To avoid cross-reactions of the conjugate with free DNA, the cells are washed twice with 
serum free medium. The culture dishes are then filled with half the final volume of serum free 
medium (DMEM, 250 µl for 24well plates, 0,5 ml for 6well plates). The same amount of 
pepsiRNA solution with a twofold concentration of conjugate in serum free medium is added 
in a dropwise fashion under constant rocking of the culture plate. This procedure provides an 
even distribution of the conjugate to all cells. After 15-30 min of incubation at 37°C the 
application medium is removed and replaced with growth medium (DMEM with 10% FCS). 
5.2.5 Transfection of adherent cells with siRNAs  
To compare pepsiRNAs with conventional techniques, control experiments are carried out in 
which adherent cells are transfected with siRNAs using Lipofectamine 2000 (Invitrogen). 
The cells are cultured in 6well-plates over night to reach a confluency of 80-90%.  
Prior to treatment, 10µl of Oligofectamine are incubated for 5 min in 240 µl of OptiMEM for 
each sample. The siRNA stock solutions are diluted in OptiMEM to a total volume of 250 µl, 
added to the Oligofectamin solutions, and incubated for 20 min. In the meantime, the culture 
medium is removed and the cells washed twice with serum free medium. 1.5 ml of serum 
free medium are pipetted into each 6well-dish, and the transfection reagent is added 
dropwise under constant rocking of the culture plate. The cells are incubated at 37°C for 4 
hours before the transfection solution is exchanged for culture medium. 
5.2.6 Treatment of suspension cultures with pepsiRNAs 
5 ml of cell suspension (1x 106 cells/ml) are pelleted (5 min, 1000 rpm, 20°C, Centrifuge 
5810 R, Eppendorf) and the cells washed twice with serum free medium (RPMI 1640) by 
resuspending, centrifugation, and removal of the supernatant. The cells are then 
resuspended in 1 ml of serum free medium and subsequently mixed with 1 ml of 2x 
concentrated pepsiRNA solution in serum free medium. After 20 min of incubation at 37°C, 
the cells are pelleted as described above and resuspended in culture medium (RPMI 1640 
with 10% FCS). 
5.2.7 Treatment of adherent cells with novel cell permeating molecules 
One day prior to treatment, confluent cells are harvested from 25 cm² dishes by 
trypsin/EDTA, diluted 1:50 with culture medium and plated on cover slips coated with FCS 
(0.5 ml per 24well). The fluorescein or porphyrin coupled oligoamines or peptoids to be 
tested are dissolved in methanol to yield a 20 mM stock solution and further diluted with 10% 
DMEM to yield the respective application solution. To avoid differences due to a varying 
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content of methanol, dilutions of the stock solution in methanol are used to prepare test 
solutions of lower concentrations.  
For treatment, the culture medium was removed and replaced by 0.5 ml of application 
solution. After varying incubation times at 37°C, the cells were cooled on ice and washed 
three times with 0.2% BSA in PBS+ and three times with PBS+. Without fixation, the cover 
slips were attached to the microscopy slides with 25µl of Mowiol 4-88 solution (10% in 10% 
glycerol 0.1M Tris), fixed with nail polish, and immediately evaluated by light and 
fluorescence microscopy (Zeiss Axiovert 35, 400x, filter set 15: λexcit. = 546nm, λem >590nm; 
filter set 17: λexcit. = 485nm, λem = 515-565nm). 
5.2.8 Fixation of cells for microscopy 
The cells are harvested one day after treatment, diluted 1:50, plated on FCS coated cover 
slips, and allowed to attach for at least 4 hours.  
After treatment and appropriate times of incubation, the culture medium is removed and the 
cells thoroughly washed with pre-cooled PBS+. 0.5 ml of a 4% paraformaldehyde (PFA) 
solution in PBS+ is added per 24well, and the cells are incubated 30 min on ice. The PFA is 
quenched by incubation with a 50 mM NH4Cl solution in PBS+ at room temperature for 5 min. 
The cells are washed three times with PBS+. 
Alternatively, the pre-washed cells can be fixed with methanol and acetone by incubating 
with each pre-cooled solvent for 5 min on ice, starting with methanol. The cells are then 
washed three times with PBS+ to remove any solvent. 
The cover slips are removed from the culture dish and attached to a microscopy slide with 25 
µl of antibleach solution (25% phenylenediamine in 80% glycerol/PBS) and sealed with nail 
polish. The microscopy slides are stored at –20°C.  
5.2.9 Preparation of cells grown on cover slips for immunofluorescence microscopy 
For immunofluorescence experiments, the fixed and washed cells are washed twice with 
0.2% BSA in PBS+. The BSA solution is exchanged against 1% Triton X-100 in 0.2% BSA 
solution, and after 10 min of incubation the cover slips are transferred into a moist chamber. 
The Triton/BSA solution is replaced by 25µl of primary antibody (AB1) solution in Triton/BSA 
and allowed to incubate at RT for 40-60 min or at 4°C overnight.  
 
Primary antibody Donor organism Concentration kindly provided by 
anti-LaminA/C (human) mouse 1:50, 1:100 M.Osborn, Göttingen 
anti-HexA (human) rabbit 1:50, 1:100 A.Hasilik, Marburg 
anti-GCS (murine) rabbit 1:50 R.Pagano, San Diego, 
USA 
Table 5-2 Antibodies used for immunofluorescence microscopy 
 
The cover slips are washed 3x with PBS+ and 2x with 0.2% BSA solution as described 
above. The cells are incubated with 25-35 µl of secondary antibody (AB2) solution (anti-
mouse-Alexa 688, 1:500; anti-rabbit-Alexa 688, 1:500) in Triton/BSA for 30 min excluding 
light to protect the dye-coupled antibody from photobleaching. The cover slips are thoroughly 
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washed with PBS+ and attached to a glass slide with mounting medium as described in 
5.2.8.  
 
5.3 DNA-Techniques 
5.3.1 Photometric measurement of nucleic acid concentration 
Concentration and purity of DNA, RNA and oligonucleotides are determined photometrically 
at 260 nm und 280 nm (Sambrook 1989) on SmartSpecTM 3000 Spectrophotometer 
(BioRad). Samples are diluted to keep the absorption in the range of 0.010<A<1.000 to avoid 
errors due to a lack of sensitivity or saturation effects, respectively. 
5.3.2 Separation of DNA by agarose gel electrophoresis 
Separation by gel electrophoresis depends on different migration rates of negatively charged 
DNA molecules in an electric field. DNA samples are treated with a corresponding amount of 
5x gel loading buffer and applied to an agarose gel (0,7-3% agarose in TAE) containing 
0,1µg/ml ethidium bromide for DNA staining. Electrophoresis is performed at 10-100 mA at a 
voltage of about 1-5 V per cm of gel length.  
Agarose gels are evaluated on a UV-transilluminator by the fluorescence of intercalated 
ethidium bromide. Fragment sizes are estimated in reference to a DNA-standard (1 kb 
ladder, Invitrogen). 
 
5.3.3 Extraction of DNA from agarose gels 
The DNA fragments of interest are excised from the gel and transferred to a microfuge tube. 
300 µl of QG buffer (QIAquick gel extraction kit) are added per 100 mg of gel and the gel 
dissolved by heating to 50°C for 10 min. DNA-fragments >5kb are supplemented with 100µl 
isopropanol per 100 mg of gel, smaller fragments are directly applied to a MiniElute-column 
and centrifuged (1 min, 14,000 rpm, Microcentrifuge MiniSpin, Eppendorf). After washing 
with another 500µl of QG buffer and 750µl of pre elution buffer (PE) the columns are dried by 
centrifugation (1 min, 14,000 rpm), and the DNA eluted with 30 µl of EB (Elution Buffer). 
5.3.4 Synthetic gene cloning 
Lyophilized oligonucleotides (Sigma) are dissolved in RNase free water to yield a 25 or 100 
nmol/µl solution. Equimolar amounts of complementary ssDNA solutions are pipetted 
together, heated to 80°C for 5 min and allowed to cool to room temperature over several 
hours. Oligonucleotides are designed with overlapping 12-17nt sequences of forward and 
reverse strands so that hybridization yields full-length double-stranded sequences that are 
sufficiently stable to be ligated to a vector and transformed into bacteria. 
 
5.3.5 Enzymatic restriction of plasmids 
Type II restriction endonucleases are utilized to clone DNA-fragments or to analyze 
recombinant vectors. Thus, the DNA is cleaved within the recognition sequence leading to 
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single stranded overhangs on both sides (sticky ends). Reaction conditions are adjusted 
according to the manufacturer´s protocol for every given enzyme or set of enzymes. For 
analysis 1-5 µg DNA are incubated with 0.5-1 u enzyme in a total volume of 20 µl for 1-5 h at 
37°C. For preparative purposes 5-10 µg DNA are cleaved with up to 20 u of enzyme in a total 
volume of 20-60 µl over night.  
 
5.3.6 Ligation of DNA-fragments 
The formation of phosphodiester bonds between matching sticky ends produced by a type II 
endonuclease is catalyzed by T4-ligase. The vector of interest is cleaved with corresponding 
restriction endonucleases, purified by gel electrophoresis and extracted from the gel as 
described in 5.3.2 and 5.3.3. 50-200 ng of the purified vector and a 2-100fold molar excess 
of insert-DNA with sticky ends corresponding to the cleavage sites are added together with 2 
µl of 5x dilution buffer and 10 µl of ligase buffer yielding a typical volume of 18 µl. 2 µl (10u) 
of T4-ligase is added and the reaction mixture incubated at room temperature for 15-45 min. 
5.3.7 Plasmid isolation from recombinant bacteria cells 
The isolation of pure plasmid DNA is performed by alkaline lysis (Birnboim and Doly 1979) 
with subsequent purification by anion exchange chromatography according to the 
manufacturer´s protocol. All reagents are taken from the QIAprep Mini Kit (QIAGEN). 
Bacteria from overnight culture are pelleted by centrifugation (15 min, RT, 4000 rpm, 
Megafuge 2.0 Heraeus) and resuspended in 0.25 ml of resuspension buffer P1. The cells are 
lyzed by adding 0.25 ml alkaline buffer P2, and the reaction is stopped after 3-5 min by the 
addition of 0.35 ml neutralizing buffer N3. Precipitated proteins and chromosomal DNA are 
pelleted by centrifugation (10 min, RT, 14.000 rpm, Microcentrifuge MiniSpin, Eppendorf) and 
the plasmids purified from the supernatant by anion exchange chromatography according to 
the manufacturer´s protocol. 
5.3.8 PCR : in vitro amplification of DNA 
PCR (polymerase chain reaction) is a method for the selective in vitro amplification of DNA. It 
is based on repeated cycles of denaturing of template DNA, annealing of sequence specific 
sense and antisense oligonucleotides, and elongation of the reverse strand by a 
thermostable DNA-polymerase from the thermophile Thermus aquaticus (Taq-polymerase). 
 
Mastermix 1  1.0 µl primer 1 (20 pmol) 
 1.0 µl primer 2 (20 pmol) 
 1  µl dNTP solution (10 mM) 
 22-23 µl water 
 
Mastermix 2  0.2-1.0 µl  template DNA (5-50 ng) 
   5  µl buffer 2 (10x) 
 0.5-1.0 µl Taq polymerase  
 19 µl water 
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The mastermixes are added together on ice and placed on a thermocycler (PTC-200, 
Biozyme Diagnostic) to run the amplification program: 
 
hot start: 94°C 2:00 min   
denaturing: 94°C 0:30 min    
annealing*: 58°C 0:30 min  35 cycles 
elongation:  68°C  2:00 min   
last extension:  68°C 5:00 min   
 
The annealing temperature is chosen according to the Tm of the primer-template complex. 
Elongation may be extended from 0:30 to 3:00 min depending on the length of the target 
sequence (1min per 1000 bp). PCR-products are purified from reagents and side products by 
agarose gel electrophoresis and gel extraction. 
 
5.3.9 Mutagenesis-PCR 
Point mutations or single base insertions in expression vectors can be corrected by 
mutagenesis-PCR. Only one primer is used that comprises ~20nt of the sequence to be 
corrected with the appropriate base exchanged or excised. For the correction of synthetic 
genes the full-length oligonucleotides were used as primers.  
 
reaction mixture: 0.5-1 µl template vector (50-100 ng) 
     1 µl  mutagenesis primer 
     1 µl dNTPs (25 mM) 
     5 µl 10x Pfu buffer 
     1 µl Turbo Pfu polymerase (2.5u/µl) 
   42 µl water  
 
The reaction mixture is prepared on ice and placed on a thermocycler (PTC-200, Biozyme 
Diagnostics) to run the mutagenesis program: 
 
hot start: 95°C   0:30 min   
denaturing: 95°C   0:30 min    
annealing*: 55/58°C   1:00 min  30 cycles 
elongation: 68°C   10:00 min   
last extension: 68°C 10:00 min   
 
Elongation is adjusted to the length of the target sequence (2min per 1000 bp). The 
annealing temperature has to be modified according to the primer sequence. Best results 
were obtained with 55°C for AntP and 58°C for Tat. PCR-products are incubated for 1h with 
Dpn I to degrade methylated DNA templates, and 10-20µl are immediately transformed into 
E. coli DH5α.  
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5.4 RNA techniques 
5.4.1 Isolation of RNA  
Total-RNA is isolated according to the RNeasy protocol (QIAGEN). The culture medium is 
removed and the cells washed twice with PBS. 600µl RTL buffer supplemented with 6µl ß-
mercaptoethanol are added. The cells are removed with a rubber policeman and transferred 
into a microfuge tube. DNA is destroyed by homogenizing the lysates 5-8 times through a 
G20 needle. After mixing with 600 µl of 70% ethanol, the lysates are transferred onto 
RNeasy microspin columns and centrifuged for 15s at 10,000 rpm (Microcentrifuge MiniSpin, 
Eppendorf). The flow-through is discarded and the columns washed with 700 µl of RW1 
buffer by centrifugation. The collection tube is replaced and the columns are treated twice 
with 500 µl RPE buffer and centrifuged. The flow-through is discarded and the columns 
centrifuged at 14,000 rpm for 2 min to remove all residual buffer. The total RNA is eluted with 
50µl RNase free water and collected in Rnase-free microfuge tubes. 
 
5.4.2 Separation of dsRNA 
RNA-molecules are separated via gel electrophoresis under RNase free conditions on 1% -
1.5% agarose in TAE with 40µl/l ethidium bromide of gel for detection (see 5.3.2).  
 
5.4.3 RT-PCR 
To obtain cDNAs from mRNA or to estimate the levels of mRNA in cells, RNA transcripts can 
be converted into copy-DNA (cDNA) by reverse transcriptase. In subsequent PCR steps, the 
cDNA strands are amplified to yield detectable levels. Prior to RT-PCR, RNA templates are 
heated to 75°C for 5 min to denature the RNAs, and cooled on ice to prevent re-annealing.  
RT-PCRs are carried out with the Titan-Kit (Roche) according to the manufacturer´s protocol. 
 
Mastermix1:    1  µl  dNTPs (10 mM) 
                         1  µl  primer1 (25 µM) 
                         1   µl  primer2 (25 µM) 
                         2.5 µl  DTT (100 mM) 
                       0.5  µl  RNasin (40u/µl) 
                       10 µl  template RNA (100 µg/ml) 
  14 µl RNase free water 
 
Mastermix2:   10  µl RT-PCR buffer (5x) 
    5    µl  RNase free water 
     0.8 µl enzyme-mix 
                       
The two mastermixes are combined in a 500µl tube, placed in a thermocycler (PTC-200, 
Biozym Diagnostics), and incubated according to the following program:  
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reverse transcription:  50°C 30:00 min  
denaturation:  94°C    00:30 min 
annealing: 62°C    00:45 min 30 cycles 
elongation:  68°C    01:00 min     
last extension:  68°C    10:00 min  
 
5.4.4 In vitro generation of 5´-thiol-modified siRNAs with T7-polymerase 
The antisense strand is generated according to the RiboMAX-protocol (Promega). To 
generate the 5‘-thiol-modified sense strand an 8fold excess of GSMP over the non-modified 
NTPs is added to the reaction mixture. 1-2µl of RNasin are added to compensate for the non-
RNase-free synthesis procedures. GSMP is synthesized as described in chapters 3.1.1 and 
3.1.2. The purified product is dissolved in 10 mM Tris-HCl, pH 7.5. Following the in vitro 
transcription reaction, DNase is added to both reaction mixtures to degrade the DNA 
templates. Also, 4 µl of CIP are added to remove 5´-triphosphates and to release the thiol- 
function from the 5‘-thiophosphate group of the sense strand. After 15 min of incubation at 
37°C, the 21mers are precipitated and dried according to the manufacturer´s manual. The 
RNA pellet is dissolved in Rnase-free water, and the concentration determined 
photometrically. Equimolar amounts of sense and antisense strand are pipetted together, 
supplemented with the corresponding amount of 10x annealing buffer, heated to 75°C for 5 
min, and allowed to cool to RT over several hours for hybridization.  
 
5.4.5 Reduction of homodimers of 5´-thiol-modified siRNAs 
Under oxidizing conditions, free thiol groups may react to form disulfide bonds that link two 
monomers together. To enable the coupling of siRNA and CPPs, these spontaneously 
formed homodimers have to be reduced. 
Synthetic siRNA aliquots of 20 nmol are dissolved in 120 µl of RNase free 0.1 M DTT 
solution (Titan-Kit, Roche). Enzymatically generated siRNAs are supplemented with ¼ of the 
total volume of 100 mM DTT-solution (Roche). Both reaction mixtures are incubated at 37°C 
for at least one hour. 
To remove the DTT, the reduced siRNAs are purified by gel filtration (MicroSpinTM G-25 
Columns, AP-Biotech) according to the manufacturer’s manual. 
 
5.4.6 Coupling of synthetic siRNA and CPP 
After over night incubation with DTT, synthetic thiol-modified siRNAs are purified by gel 
filtration via MicrospinTM G-25 colums (AP-Biotech). In the last step of the procedure, the 
siRNA aliquot is eluted into an equimolar amount of the activated peptide. The reaction 
mixture is incubated 1 h at 37°C. 
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5.4.7 Coupling of enzymatically synthesized siRNA and CPP 
After gel filtration of the enzymatically synthesized siRNA, the concentration is determined to 
avoid errors due to free nucleotides. An equimolar amount of peptide solution is diluted in EB 
to the same volume and both solutions are pipetted together under argon. Precipitate forming 
at high concentrations due to aggregation of pepsiRNAs can be dissolved by the addition of 
NaCl-solution to a final concentration of up to 400 mM. 
 
5.4.8 Radiolabelling of siRNAs 
T4-kinase attaches the terminal phosphate residue of [32P]-γ-ATP to free 5´-hydroxyl-groups 
of oligonucleotides. The lyophilized enzyme is dissolved in 25 µl of water. After 5 min of 
quelling, 50-100 pmol of siRNA and water are added to yield 24 µl. After the addition of 1 µl 
of [32P]-γ-ATP (10 mCi/µl) the reaction mixture is incubated at 37°C for 30 min and the 
reaction stopped with 5 µl of 250 mM EDTA. Residual ATP is removed by gel filtration 
(MicroSpinTM G-25 Columns, AP-Biotech) according to the manufacturer´s manual. 
 
5.4.9 Analysis of siRNAs on sequencing gels 
siRNAs are radioactively labeled and run on a 25 cm x 55 cm 10% TBE-urea sequencing gel 
of 0.1 mm thickness. The Macromould glass plate is prepared with 3 x 200µl of binding-
silane and the thermoplate is coated with 1 ml of repel silane. Both plates are thoroughly 
cleaned with ethanol to remove an excess of silane.  
The 12% gel is prepared by dissolving 42g of urea in 10 ml of 10x TBE and 25 ml of water by 
gentle heating. After cooling down, 30 ml of 40% acrylamide solution is added and the 
solution filtered to remove undissolved solid. For polymerization and cross-linking, 0.8 ml of 
APS solution and 40 µl of TEMED are added. Prior to running, the gel is heated to 50°C via 
the thermoplate of the gel chamber, and 3000V/28mA are applied for 30 min to equilibrate 
the gel with the TBE buffer. 
The 10µl samples are prepared by adding 10µl of formamide loading buffer, heating to 95°C 
for 5 min. The samples are placed on ice. 3-6 µl of sample are loaded and the gel is run at 
3000 V at 21-27 mA. The gel is fixed by soaking in 10% acetic acid for 30 min, washed with 
water for 5 min, and dried at 70°C for 45-60 min. The detection of the radioactivity is 
performed using a phosphorimager screen (BAS III, Fuji). Radioactivity screens are read out 
on a Bas reader (Fujix Bas 1000, Fuji) and the results evaluated on Tina 2.0 software. 
0.5M NaOH is used to remove the gel and binding-silane from the carrier-glass plate. 
 
 
5.5 Protein techniques 
5.5.1 Preparation of protein samples 
Protein samples from bacterial expression cultures or plated mammalian cells are prepared 
for SDS-PAGE in a reducing SDS-containing buffer according to Laemmli: 1 ml of 
suspension culture is pelleted by centrifugation (5 min, 14,000 rpm, Microcentrifuge MiniSpin, 
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Eppendorf) and the pellet is resuspended in 0.5 ml of 1x Laemmli buffer. Adherent cells are 
directly treated with 1x Laemmli buffer (0.5 ml per 6well), detached from the culture plate with 
a rubber policeman and transferred into a microfuge tube.  
Purified protein, peptide and pepsiRNA solutions are supplemented with appropriate 
amounts of 5x Laemmli buffer. After resuspension, the samples are boiled at 95-100°C for 5 
min. To separate the proteins, 15-20 µl per sample are applied to 10-12.5% SDS-PAGE at 
70-110 V. 
5.5.2 SDS-PAGE 
Proteins are separated in non-reducing and reducing gels (10-20%) according to Laemmli.  
Electrophoresis is performed in 6x8 cm vertical gels of 0.5-0.75 mm thickness in a Hoefer 
Minigel apparatus (Hoefer Mighty Small 250). Gels are run at 70-110 V. 
 
 (per gel) stacking gel, 
5% 
separating 
gel, 10% 
separating gel, 
12.5 % 
separating 
gel, 20% 
acrylamide (31%) 0.5 ml 3.35 ml 4.2 ml 5.0 ml (40%) 
Tris-HCl (pH 6.8, 1M) 0.325 ml - - - 
Tris-HCl (pH 8.8, 1M) - 5.0 ml 5.0 ml 5.0 ml 
Water 2.06 ml 1.5 ml 0.64 ml - 
SDS (20%) 30 µl 0.1 ml 0.1 ml 0.1 ml 
TEMED 3 µl 10 µl 10 µl 10 µl 
APS (10mg/ml) 30 µl 50 µl 50 µl 50 µl 
 
5.5.3 Protein staining with Coomassie Brilliant Blue R250 
For protein detection, SDS-PA gels are boiled in a 0.25 % Coomassie Brilliant Blue R250-
staining solution for 2 min in a microwave or incubated at room temperature over night. 
Excess dye is removed by repeated boiling in water in a microwave or destaining for 4-6h 
using destaining solution. Gels are evaluated on a transilluminator. 
 
5.5.4 Silver staining of protein gels 
The gel is fixed in formaldehyde solution for 1-24h. After washing 3x 20min with 50% 
ethanol, the gel is incubated in sodium thiosulfate solution (200mg/l) for 1min and washed 3x 
20s with bidistilled water. The gel is soaked 20min in silver solution and washed 2x 20s with 
bidistilled water. The gel is incubated in developing solution until the first protein bands can 
be seen, rinsed with water and soaked 10 min in stop solution. The developed gel is stored in 
wash solution for >20min. 
5.5.5 Western blot 
Protein samples are separated via SDS-PAGE and transferred to a PVDF membrane by wet 
blotting (Towbin et al, 1979). Before blotting, the PVDF membrane is soaked in methanol and 
equilibrated in transfer buffer (10 mM CAPS, pH11, 10% MeOH). The membrane is placed 
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on the gel and covered with filter cardboard and sponge pads both soaked in transfer buffer. 
The assembly is enclosed in the blotting apparatus (Mini Protean II, BioRad) filled with 
cooled transfer buffer. Blotting is performed for 30 min at 400mA and >100V. After the 
protein transfer, the PVFD membrane is saturated with 5% milk in TBS-T for 1-2h at RT or 
overnight at 4°C. For the identification of the proteins, the membrane is incubated in a 
solution of the appropriate primary antibody in milk buffer for 1h at RT or overnight at 4°C on 
an overhead rotor.  
 
Primary antibody Donor Concentration kindly provided by 
anti-LaminA/C (human) mouse 1:1000, 1:250 (ON) M.Osborn, Göttingen 
Anti-Lamin A/C (murine) rabbit 1:1000 M.Osborn, Göttingen 
anti-HexA (human) rabbit 1:1000, 1:100 (ON) A.Hasilik, Marburg 
Anti-GCS-1,2 (human) rabbit 1:1000 R.Pagano, San Diego, USA 
  
Table 5-3 Antibodies used for Western blotting (ON = incubation overnight at 4°C) 
 
The membrane is washed 3x 10 min TBS-T and incubated with the appropriate secondary 
antibody (anti-mouse-HRP 1:1000, anti-rabbit-HRP, 1:10000, HRP = horse radish 
peroxidase) in milk buffer for 1 h at RT. After further washing steps in TBS-T, the membrane 
is incubated for 1 min with 1 ml of chemiluminescence substrates A und B (1:1; LumiGlo, 
BioRad). The chemiluminescence of the secondary antibody is detected by a photographic 
film (10s to 1 min depending on chemoluminescence intensity).  
 
5.5.6 Quantitative measurement of protein concentrations 
Proteins are detected by the Bradford reagent that is based on the blue stain of Coomassie 
blue in acidic solution upon reaction with proteins. In a range between 0.1 to 20µg/ml the 
protein concentration can be determined photometrically according to the Lambert-Beer law. 
To this means, a calibration curve is calculated from the absorptions obtained from 10 
standard solutions ranging from 0.0 to 2.0 µg/ml. 
20µl of standard or protein sample at varying dilutions are added to 200µl of Bradford 
reagent diluted 1:4 in PBS. 
Absorption measurements and calculation of sample concentrations are carried out 
photometrically on a Multiskan Ascent readout instrument (Labsystems). 
5.5.7 Protein expression in bacteria 
All used expression vectors contain the promoter of the lac-operon, so that the expression of 
the recombinant gene can be induced by the synthetic lactose analogon IPTG (isopropyl-
thio-galactopyranoside). 20 ml (400 ml) of LB are inoculated with 5 ml (20 ml) of overnight 
culture and grown at 37°C to an optical density of OD600 = 0.6 to 0.7 and stored on ice for 15-
30 min. Protein expression is induced by addition of 40µl (800 µl) 100 mM IPTG solution and 
incubated at 37°C (30, 22 or 17°C for TEV-fusion proteins). Samples are taken prior to 
induction, after 1, 2, and, 4 h and after incubation over night and analyzed by SDS-PAGE. 
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Alternatively, expression can be performed in TB or SOC medium. Lower temperatures 
(down to 17°C), smaller amounts of IPTG, and shorter expression times may prevent the 
formation of inclusion bodies. 
5.5.8 Preparation of native GST-fusion proteins (pGEX protocol) 
After overnight expression at 37°C, recombinant BL21 cells are harvested by centrifugation 
(15 min, 4000 rpm, 4°C, Megafuge 2.0, Heraeus). The supernatant is discarded and the 
pellets resuspended in 1ml/20ml (expression culture) of pGEX lysis buffer on ice, and 60µl of 
a 100 mg/ml solution of lysozyme in pGEX lysis buffer is added. After 20 min incubation on 
ice, 5 µl of DNase (1u/µl, Ribomax Kit, Promega) is added to degrade genomic DNA, and the 
cell suspensions are incubated for another 20 min. The cell suspensions are homogenized 
using a Potter Elvogen Homogenizer (Potter S, B. Braun Melsungen AG) and centrifuged (50 
min, 14,000 rpm, 4°C, Centrifuge 5402, Eppendorf). Protein samples taken from supernatant 
and pellets are prepared in 5x and 1x Laemmli, respectively, for SDS-PAGE. 
 
5.5.9 Preparation of native GST-fusion proteins (modified protocol) 
After overnight expression at 37°C, recombinant BL21 cells are harvested by centrifugation 
(15 min, 4000 rpm, 4°C, Megafuge 2.0, Heraeus). The supernatant is discarded and the 
pellets resuspended in 1ml/20ml (expression culture) of pGEX lysis buffer at room 
temperature, and 20µl of a 100 mg/ml solution of lysozyme in pGEX lysis buffer is added. 
After 20 min incubation at room temperature, 6 µl of DNase (1u/µl, Ribomax Kit, Promega) is 
added to degrade genomic DNA, and the cell suspensions are incubated for another 20 min. 
The cell suspensions are homogenized using a Potter Elvogen Homogenizer (Potter S, B. 
Braun Melsungen AG). GST-Tat homogenates are sonicated (3x 10s-blasts, 200W, 20 MHz, 
15s intervals) and incubated for 30 min at 37°C, while GST-AntP homogenates are incubated 
for 45 min at 37°C. After centrifugation (50 min, 14,000 rpm, 4°C, Centrifuge 5402, 
Eppendorf), protein samples are taken from the supernatant and pellets to be prepared in 5x 
and 1x Laemmli, respectively, for SDS-PAGE. 
 
5.5.10 Preparation of native TEV-protease 
Cells are grown in 20ml LB to OD600 = 0.7 and expression is induced with 80 µl of IPTG (100 
mM). Expression is carried out at 37°C over night. Protein samples are taken and cells are 
harvested by centrifugation (20 min, 4000 rpm, 4°C, Megafuge 2.0, Heraeus). The pellets are 
resuspended in 1 ml of freshly prepared lysis buffer (per 20 ml of expression culture) 
containing DNase and lysozyme. After 30 min of incubation on ice, cells are lysed by three 
freeze and thaw cycles, 11 µl Triton-X 100 are added (yielding a final concentration of 1%) 
and the suspension is vortexed for 1 min. Alternatively, cell suspensions are homogenized 
using a Potter Elvogen Homogenizer (Potter S, B. Braun Melsungen AG) and centrifuged (50 
min, 14,000 rpm, 4°C, Centrifuge 5402, Eppendorf). Protein samples taken from supernatant 
and pellets are prepared in 5x and 1x Laemmli, respectively, for SDS-PAGE (Lucast et al. 
2001). 
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5.5.11 Preparation denaturing of TEV-protease from inclusion bodies 
If the main fraction of the recombinant protein is found in the pellet, inclusion bodies have 
formed from which the denatured protein needs to be purified and subsequently refolded. 
The pelleted inclusion bodies (from 20ml of expression culture as obtained in 5.5.8, 5.5.10 or 
5.5.15) are resuspended in 1 ml of denaturing resuspension buffer (per 20 ml expression 
culture) and heated to 65°C on a thermomixer for 15-20 min (Thermomixer 5436, 
Eppendorf). After centrifugation (20 min, 14,000 rpm, 4°C, Centrifuge 5402, Eppendorf) the 
supernatant is transferred into a dialysis chamber (cut-off = 12-14,000 Da) and dialyzed over 
night against pGEX-Lysis buffer or Ni-NTA lysis buffer, respectively (Lucast et al. 2001). 
 
5.5.12 Purification of GST-fusion proteins on glutathione-sepharose 
The supernatant containing the GST-fusion proteins is incubated with 25 µl (per 20 ml of 
expression culture) of a slurry of GST-sepharose beads equilibrated in pGEX lysis buffer. 
After 4 h of incubation at room temperature (or overnight incubation at 4°C, respectively), the 
supernatant is removed by centrifugation (5 min, 1500 rpm, Microcentrifuge MiniSpin, 
Eppendorf) or filtration and the beads washed with a 10x volume of pGEX pre-elution buffer 
to remove non-specifically bound proteins. GST-fusion proteins are obtained by eluting 3-8x 
with 50 µl of elution buffer.  
The purity of the eluates is verified by SDS-PAGE and the protein concentration determined 
as in 5.5.6. Eluates containing recombinant TEV-Protease are subsequently dialyzed against 
TEV storage buffer. 
 
5.5.13 Preparation of sepharose beads 
GST-Sepharose beads are stored as a suspension in twice the volume of 20% ethanol. Prior 
to use, the resin is sedimented by 3 min centrifugation at 1500 rpm (Microcentrifuge 
MiniSpin, Eppendorf). The supernatant is carefully removed and the beads resuspended in 
the 5-10fold volume of the buffer corresponding to the protein solution to be purified. This 
procedure is repeated twice to ensure a sufficient buffer exchange.  
5.5.14 Regeneration of GST-sepharose beads 
Used GST-Sepharose resin is pooled and after removal of the supernatant buffer 
resuspended in a 10x volume of pGEX high-pH buffer. The buffer is removed by 3 min 
centrifugation at 1500 rpm and removal of the supernatant or by filtration via filter columns if 
larger amounts are to be regenerated. Likewise, 10 volumes of pGEX low-pH buffer are 
applied to the resin and the alternating treatment with both buffers is repeated twice. For 
storage, the last regeneration buffer is replaced by 20% ethanol in water as described under 
5.5.13. 
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5.5.15 Native preparation of His6-TEV from E. coli 
After protein expression over night at 37°C, 1 ml of bacteria suspension is prepared as a 
control for SDS-PAGE. The remaining cells are harvested by 15 min of centrifugation at 
4,000 rpm and 4°C (Megafuge 2.0, Heraeus). The supernatant is discarded and the pellet 
resuspended in 1 ml of native lysis buffer (per 20 ml of expression culture) on ice. 2 mg of 
lysozyme (or 20 µl of a 100 mg/ml solution of lysozyme in lysis buffer) and 6 µl of DNase 
solution (1 µg/ml, RiboMAX-Kit, Proligo) are subsequently added, and after each addition the 
suspension is incubated for 20 min on ice. The cell suspensions are homogenized by a bug 
crusher (Potter S, B. Braun Melsungen AG) and centrifuged 60 min with 14,000 rpm at 4°C 
(Centrifuge 5402, Eppendorf). Protein samples are taken from pellet and supernatant and 
analyzed by SDS-PAGE to determine which fraction contains the recombinant protein. 
 
5.5.16 Denaturing preparation of His6-TEV from E. coli 
After protein expression over night at 37°C, 1 ml of bacteria suspension is prepared as a 
control and prepared for SDS-PAGE. The remaining cells are harvested by 15 min of 
centrifugation at 4,000 rpm and 4°C (Megafuge 2.0, Heraeus). The supernatant is discarded 
and the pellet resuspended in 1 ml of denaturing lysis buffer (per 20 ml of expression culture) 
and incubated for 1h on an overhead roller at room temperature. The lysate is centrifuged 
(50 min, 14,000 rpm, 4°C, Centrifuge 5402, Eppendorf) and protein samples are taken from 
pellet and supernatant. 
Alternatively, the lysates are prepared according to Lucast (Lucast et al. 2001) and after 
centrifugation the pellets are dissolved in denaturing guanidinium chloride buffer as 
described for GST-TEV in 5.5.10 and 5.5.11. 
 
5.5.17 Purification of His6-fusion proteins on Ni-NTA-sepharose 
Analytic expression (20 ml) 
Ni-NTA microspin columns (QIAGEN) are equilibrated with 600 µl of lysis buffer by 
centrifugation (2 min, 2,000 rpm, 4°C, Centrifuge 5402, Eppendorf). 600µl of the protein 
containing supernatant are applied to the Ni-NTA columns up to three times until all 
supernatant has been passed through the columns by centrifugation (2 min, 2,000 rpm, 4°C, 
Centrifuge 5402, Eppendorf). 20 µl protein samples are taken from the flow-through and 
prepared for SDS-PAGE. The columns are washed twice with 600 µl of Ni-NTA wash buffer, 
and the His6-fusion protein is eluted with 2x 50 µl of elution buffer. A dilute sample of the 
eluate is prepared for SDS-PAGE. 
 
Large scale expression (120-1000 ml) 
The supernatant is incubated for 4 h at room temperature or over night at 4°C with 25µl/ml of 
Ni-NTA slurry equilibrated in lysis buffer. The supernatant is removed by centrifugation at 
1500 rpm or filtration, and the beads are washed with a 10x volume of wash buffer to remove 
non-specifically bound proteins. His6-fusion proteins are obtained by eluting 3x with 50 µl of 
elution buffer. 
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The purity of the eluates is verified by SDS-PAGE and the protein concentration determined 
as in 5.5.6. Eluates containing recombinant TEV-Protease are subsequently dialyzed against 
TEV storage buffer. 
 
5.5.18 Dialysis 
Protein solutions are dialyzed against a 20-100fold volume of exchange buffer at 4°C over 
night. Dialysis tubing is chosen according to the size of the respective protein and prepared 
by boiling twice in 1l of sodium hydrogencarbonate/EDTA buffer for 10 min and rinsing 
extensively with distilled water to remove the buffer. Ready-to-use dialysis tubing can be 
stored in 50% EtOH at 4°C. 
Alternatively, dialysis of small volumes can be carried out with Spin-Concentrators (Vivaspin 
500 µl Concentrator, Vivascience) of varying pore sizes (GST-TEV: < 50,000 Da, His-TEV: < 
10,000 Da) by centrifugation (6 min, 12,000 rpm, Centrifuge 5415 C, Eppendorf) and 
repeated buffer exchange.  
 
5.5.19 Cleavage of GST-fusion peptides with TEV 
300-400 µM of GST-peptide substrate in Elution buffer (10 mM glutathione, 50 mM Tris-HCl 
pH 8.0) are supplemented with an appropriare amount of EDTA to yield a 1 mM solution. 
1.5µl 100 mM DTT, an appropriate amount of 20x TEV buffer, and either 5-10 µl of HisTEV 
(S219V) protease or 1 µl of AcTEV protease (invitrogen) are added. The reaction mixture is 
filled up with water to 100 µl and the reaction allowed to proceed at 30°C for 6-24h h. To 
analyze the amount of cleaved peptide, 20 µl samples are taken from the reaction mixture 
and analyzed by 15% SDS-PAGE. To examine the amounts of GST-CPP and GST 1ml 
samples are analyzed by 12% SDS-PAGE. 
 
5.5.20 Handling of PenetratinTM 
Commercially available penetratin (Qbiogene) is delivered in batches of 500 µg in lyophilized 
form. After short centrifugation to clear the substance from the lid, 500µl of bidistilled water 
are added and the peptide is allowed to dissolve slowly. The 0.27 mM peptide solution is 
distributed into 50µl aliquots and stored at –80°C. Repeated freeze-and-thaw cycles are to 
be avoided. Fractions of the aliquots are taken under a stream of argon to avoid the contact 
of oxygen with the sensitive peptide. 
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5.6 Chemical syntheses 
5.6.1 Thin layer chromatography  
To control the completion of a reaction or to monitor column chromatography samples of the 
reaction mixture, chromatography fractions are analyzed by thin layer chromatography (TLC) 
on silicagel-aluminium plates (2.5x6.5 cm or 7x5 cm respectively). Prior to each run, the 
liquid phase was allowed to equilibrate in the TLC chamber to obtain an atmosphere 
saturated with the applied solvents. TLC plates were dried and evaluated either under UV-
light or by staining with molybdophosphoric acid (10% in methanol).  
 
5.6.2 NMR spectroscopy 
All NMR-spectra were recorded on Bruker spectrometers DPX300 and DPX400 at room 
temperature. 1H-spectra were obtained at 300 and 400 MHz, 13C-spectra at 75 and 100 MHz, 
respectively. Chemical shifts are reported in parts per million [ppm] in reference to the 1H- or 
13C chemical shift of tetramethylsilane (TMS). All spectra were processed with WinNMR 6.1 
(Bruker). If no internal standard was used, the signal was calibrated according to the signal 
of DMSO (δ (1H) = 2.49 ppm, δ(13C) = 39.7 ppm) or DHO (δ (1H) = 4.79 ppm). The signals 
were assigned to protons and carbon centers according to the numeration depicted in the 
corresponding schemes. Multiplet structures are named with the following abbreviations: s 
(singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), td (triplet of doublets) m 
(multiplet), br (broadened signal). The 5´-carbon is the only secondary carbon in the 
guanosine system, so that only one negative signal is detected in DEPT-135 spectra, which 
is indicative for the success of each reaction. 
 
5.6.3 Long-term NMR measurements 
Long-term 1H NMR experiments to estimate the rate of transformation from the 5´-iodo-
guanosines to the corresponding 2,5´-cycloguanosines were carried out on a Bruker 
spectrometer DPX500 at 500 MHz. The dried compounds were dissolved in d6-DMSO 
immediately prior to measurement. Spectra were recorded in intervals of 30 min for 24 h. The 
sets of 49 spectra were phase corrected and integrated by the serial processing option of 
WinNMR 6.1 (Bruker). All integrals were calculated with reference to the DMSO signal. 
Further evaluation was carried out under Microsoft Excel 2000. The integrals of significant 
iodide signals, that showed no overlap with other signals over the course of the experiment, 
were normalized to the initial value and averaged. Correspondingly, the integrals of 
significant signals of the cyclized product were normalized to the end value. The averages 
were plotted against time with the recording of the first spectrum as t(0). To estimate the rate 
constant k, the normalized integrals of the iodide (ciodide) were plotted as their negative 
natural logarithm, - ln(ciodide), against time. k was obtained as the slope of the best fit straight 
line. To estimate the deviation σ from k, two more straight lines were drawn with the slopes 
k+σ and k-σ so that ~2/3 of the data points were included between these lines. 
 
 173
5.6.4 Mass spectroscopy 
All FAB (fast atom bombardment) mass spectra were recorded in meta-nitrobenzoic acid 
(mNBA) matrix on a Kratos MS 50 (70 eV) instrument, Thermo Quest Finnigan MAT 95 XL. 
EI (electron impact ionization) spectra were recorded on a Kratos MS50 (I) instrument, 
ThermoQuest Finnigan MAT 95 XL (II). High-resolution (HR) masses were derived from EI 
spectra. 
ESI (electron spray ionization) mass spectra of GSMP were measured on Micromass Q-
TOF-2TM from 100 pmol/µl GSMP solutions in 99.5% methanol in the negative mode. 
MALDI (Matrix assisted laser desorption ionization) spectra were obtained with a 
HiResMALDI FT-ICR (Ionspec, Lake Forrest, CA; 7 T magnet, pulsed laser 337 nm). 
pepsiRNAs were measured from a matrix of trihydroxyacetophenone (THAP) in the negative 
mode against a standard deoxyoligonucleotide of known mass. Samples were treated with 
ammonium acetate prior to treatment to exchange sodium and potassium ions for ammonium 
ions, so that narrower peaks are obtained. 
 
5.6.5 Anion exchange chromatography 
Triethylamine bicarbonate (TEAB) buffers are obtained by dissolving the appropriate amount 
of HPLC grade triethylamine in bidistilled water and bubbling the cooled solutions with 
carbondioxide until a pH of 7.5 is reached. Buffers have to be stored and processed at 4°C to 
avoid the formation of bubbles. The pH of the buffers is measured with indicator paper prior 
to column chromatography. 
The DEAE Sephadex A-25 column (CV = 34 ml; Amersham Bioscience) is prepared by 
washing with at least 10 column volumes (CVs) of low salt buffer (0.01 M, pH 6.9), 7 CVs of 
high salt buffer (1.0 M, pH 7.5) and 10 CVs of low salt buffer. The column was built into the 
FPLC instrument (ÄKTA-FPLC, AP-Biotech), that is set in an air-conditioned closet at 4°C. 
The set-up was equilibrated with low salt buffer over night at 0.3 ml/min. The crude product 
was dissolved in low salt buffer and centrifuged (1min, 14 000 rpm, 4°C, Centrifuge 5402, 
Eppendorf) to remove any precipitate. 0.5 - 2.0 ml are loaded onto the column over a 2ml-
loop and the chromatography is run according to the following program: 
 
Flow rate:     1.0 ml/min 
Flowthrough:    12.5 ml 
Loop injection:    12.5 ml 
Start Fractionation  
Fraction size:    12.5 ml 
Clean with:    12.5 ml 
Gradient length:   20    CV 
Target Concentration:   60    % 1.0 M TEAB 
Wash column with: 100    % 1.0 M TEAB 
    1    CV 
End Program 
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5.6.6 Reversed phase HPLC 
The analytical RP-18 column is built into the HPLC instrument (EttanLC, Amersham 
Bioscience) and prepared by running a gradient from 0% to 100% methanol over 20 min, 
washing with methanol for 20 min, and running a gradient back to 0% methanol over 20 min 
at a flow rate 0.5 ml/min. 
The crude product is dissolved in bidistilled water and centrifuged (1min, 14 000 rpm, 4°C, 
Centrifuge 5402, Eppendorf) to remove any precipitate. After preliminary experiments to 
determine the maximum capacity of the column, up to 0.8 ml are loaded with a 1ml loop. Due 
to the short elution times and the need to exchange collection vessels and store product 
fractions immediately on ice, the run is performed manually. After injection of the sample the 
auto-sampler is started and fractions of 0.2 ml collected. At flow rates of 0.8 ml/min the 
sample and side products are eluted with bidistilled degassed water. The run is monitored by 
a photocell at 280 and 260 nm, and the elution of the thiophosphate is detected by a 
conductivity cell. Several runs are necessary to purify 5-10 ml of crude product solution 
obtained from one reaction on an analytic column. 
 
5.6.7 2´,3´-O,O-Isopropylideneguanosine, (10) 
8.99 g (31.8 mmol) of guanosine 9 are suspended in 
600 ml of acetone. 3 ml of aqueous 70% perchloric acid 
are added and the clear reaction mixture is stirred for 4 
h at room temperature. The reaction is stopped by the 
addition of 3 ml of 25% aqueous ammonia solution 
resulting in the formation of a white precipitate. The 
solvent is removed under reduced pressure without 
previous filtration and the white residue stirred with 40 
ml of water over night. The residue is filtered and 
thoroughly washed with cold water. After drying in 
vacuo, 9.7 g (30,0 mmol; 94%) of a white powdery product are obtained. All steps are carried 
out under protection from light. Tm > 200°C - Rf = 0.70 (in CHCl3/MeOH 4:1 (v/v)); 0.21 (in 
CHCl3/MeOH 9:1 (v/v)). - 1H NMR (400 MHz, d6-DMSO): δ [ppm] = 10.64 (s, 1H, NH), 7.89 
(s, 1H, H-8), 6.47 (s, 2H, NH2), 5.91 (d, J = 2.8 Hz, 1H, H-1´), 5.17 (dd, J = 2.8 Hz, 6.3 Hz, 
1H, H-2´), 5.00 (t, J = 5.3 Hz, 1H, 5‘-OH), 4.95 (dd, J = 3.0 Hz, 6.3 Hz, 1H, H-3´), 4.10 (dt, J = 
3.0 Hz, 5.3 Hz, 1H, H-4´), 3.58 -3.46 (m, 2H, H-5´), 1.50 (s, 3H, CH3), 1.30 (s, 3H, CH3). - 13C 
NMR (101 MHz, d6-DMSO): δ [ppm] = 156.8, 153.9, 150.9 (C-4, C-2, C-6), 136.0 (C-8), 116.9 
(C-5), 113.2 (C-quart), 88.6, 86.8, 83.7, 81.3 (C-1´ to C-4´), 61.7 (C-5´), 27.2 (CH3), 25.4 
(CH3). FAB-MS (MeOH, mNBA): m/z = 324 [M+1]; EI (70 eV) m/z (%) = 323 (12 %) +; 293 (4 
%) [M–CH2O]+; 234 (6 %) [M–NH2, CH3C(CH2)O2]+; 157 (4 %) [M–guanine, CH3]+; 151 (100 
%) [guanine]+ - HR-MS: 323.1225 (± 0.8ppm) calculated: 323.1230. 
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5.6.8 2´,3´-O,O-Isopropylidene-5´-deoxy-5´-iodoguanosine, (11) 
4.85 g (15.0 mmol) of ground 10 are resuspended in 150 
ml of dried THF under argon and cooled to –70°C by a 
mixture of acetone and dry ice. 10.0 g (22.1 mmol; 1.5 eq) 
of methyltriphenoxyphosphonium iodide are added. Due to 
the light sensitivity of the reactant and the product all 
subsequent steps have to be carried out under exclusion 
of light. After 30 min of stirring the reaction mixture is 
allowed to warm to room temperature and stirred for 
another 4 hours. The reaction is stopped by the addition of 
12 ml of methanol and the solvent is removed under 
reduced pressure. The residue is resuspended in a 
mixture of diethyl ether and cyclohexane (1:1 (v/v)), filtered and thoroughly washed with 
diethylether and cyclohexane. The crude product is a bright yellow powder that is 
subsequently purified by column chromatography (silicagel: Merck 0.40-0.65 µm; eluent: 
CHCl3/MeOH 9:1 (v/v)). After removal of the solvent, 11 is obtained as a pale yellow powder 
in 38% yield (0.51 g, 1.18 mmol). To avoid side reactions that lead to a cyclization, moisture 
has to be strictly excluded in the first steps and the product should not be exposed to polar 
solvents. Tm: 134-136°C (degradation) - Rf = 0.80 (in CHCl3/MeOH 4:1 (v/v)); 0.32 (in 
CHCl3/MeOH 9:1 (v/v)). - 1H NMR (300 MHz, d6-DMSO): δ [ppm] = 10.73 (s, 1H, NH), 7.89 
(s, 1H, H-8), 6.56 (br, 2H, NH2), 6.02 (d, J = 2.1 Hz, 1H, H-1´), 5.31 (dd, J = 2.1 Hz, 6.3 Hz, 
1H, H-2´), 5.03 (dd, J = 3.1 Hz, 6.3 Hz, 1H, H-3´), 4.23 (ddd, J = 3.1 Hz, 7.6 Hz, 6.4 Hz, 1H, 
H-4´), 3.42 (dd, J = 7.6 Hz, 10.0 Hz, 1H, H-5´), 3.33 (dd, J = 6.4 Hz, 10.0 Hz, 1H, H-5´), 1.50 
(s, 3H, CH3), 1.31 (s, 3H, CH3). - 13C NMR (101 MHz, d6-DMSO): δ [ppm] = 157.5, 154.6 (C-
4, C-6), 151.3 (C-2), 137.2 (C-8), 114.2 (C-5), 113.2 (C-quart), 87.3, 84.7, 84.3, 81.1 (C-1´ to 
C-4´), 27.7 (CH3), 26.1 (CH3), 7.7 (C-5´). EI (70 eV) m/z (%) = 433 (1%) [M+H]+; 305 (100%) 
[M-HI]+, 290 (13 %) [M–HI–CH3]+;151 (20 %) [guanine]+, 128 (65%) [HI]+, 127 (31%), [I]+. 
 
5.6.9 N,N-Dimethylaminomethylene-2´,3´-O,O-isopropylideneguanosine (12) 
5.75 g (17.8 mmol) 2´,3´-O,O-
isopropylideneguanosine 10 are resuspended in 
60 ml of N,N-dimethylformamide and 8.91 ml of 
N,N-dimethylformamide dimethylacetal are 
added under argon to yield an orange-brown 
solution. The reaction mixture is stirred at 50°C 
for 4h. The solvent is removed under reduce 
pressure and at elevated temperatures (~55°C), 
and the white precipitate removed by filtration. 
The filtrate is dried under reduced pressure, 
redissolved in 25 ml of methanol yielding a 
fluorescent green solution and precipitated with 50 ml of ethylacetate. After storage at 4°C 
over night, the residue was removed by filtration and the joined fresidues are thoroughly 
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washed with ethyl acetate and thoroughly dried under reduced pressure. 12 is obtained as a 
white powdery solid in 80% yield (5.38 g, 14.2 mmol). All steps are carried out under 
protection from light. Tm > 200°C - Rf = 0.47 (CHCl3/MeOH 8:1 (v/v)); 0.08 (CHCl3/MeOH 
19:1 (v/v)). - 1H NMR (400 MHz, d6-DMSO): δ [ppm] = 11.32 (br, 1H, NH), 8.56 (s, 1H, H-
imine), 8.00 (s, 1H, H-8), 6.03 (d, J = 3.0 Hz, 1H, H-1´), 5.26 (dd, J = 3.0 Hz, 6.3 Hz, 1H, H-
2´), 5.03 (dd, J = 5.4 Hz, 5.4 Hz 1H, 5´-OH), 4.95 (dd, J = 2.9 Hz, 6.3 Hz, 1H, H-3‘), 4.13 
(ddd, J = 2.9 Hz, 4.9 Hz, 4.9 Hz, 1H, H-4´), 3.59 - 3.47 (m 2H, H-5´), 3.15 (s, 3H, N-CH3), 
3.03 (s, 3H, N-CH3), 1.53 (s, 3H, CH3), 1.33 (s, 3H, CH3). - 13C NMR (101 MHz, d6-DMSO): δ 
[ppm] = 158.3 (C-imine), 157.6, 157.5 (C-4, C-6), 149.6 (C2), 136.0 (C-8), 119.9 (C-5), 113.2 
(C-quart), 88.6, 86.4, 83.6, 81.2 (C-1´ to C-4´), 61.5 (C-5´), 40.8 (N-CH3), 34.8 (N-CH3), 27.2 
(CH3), 25.3 (CH3). - MS-EI (70 eV) m/z (%) = 378 (89%) +, 363 (6%) [M-CH]+, 348 (6%) [M-
2CH3]+, 333 (2%) [M-NH(CH3)2]+, 206 (100%) [M-DAMG]+, 191 (26%) [DAMG-CH3]+, 176 
(3%) [DAMG-2CH3]+, 150 (6%) [guanine]+ - HR-MS: 378.1654 (±0.0095) calculated: 
378.1652 (DAMG = 2-N´N-dimethylaminomethylene guanine). 
 
5.6.10 N,N-Dimethylaminomethylene-2´,3´-O,O-isopropylidene-5´-deoxy-5´-
iodoguanosine (13): 
2.20 g (5.81 mmol) of ground 12 are resuspended in 
110 ml of dried THF under argon and cooled to –70°C 
by a mixture of acetone and dry ice. 3.94 g (8.71 
mmol; 1.5 eq) of methyl-triphenoxyphosphonium 
iodide are added. Due to the light sensitivity of the 
reactant and the product all subsequent steps have to 
be carried out under exclusion of light. After 30 min of 
stirring the reaction mixture is allowed to warm to 
room temperature and stirred for another 4 hours. The 
reaction is stopped by the addition of 5 ml of methanol 
and the solvent is removed under reduced pressure. The dark red residue is dissolved in 2.5 
ml methanol/chloroform (1:4 (v/v)) and 7 ml of chloroform are added. The solution of the 
crude product is subjected to column chromatography on silicagel (Merck 0.40-0.65 µm; 
eluent: CHCl3/MeOH 9:1 (v/v)). After removal of the solvent, 12 is obtained as an orange 
solid in 99% yield (2.81 g, 5.75 mmol). Tm = 95-97°C - Rf = 0.74 (CHCl3/MeOH 5:1 (v/v)); 0.22 
(CHCl3/MeOH 19:1 (v/v)). - 1H NMR (400 MHz, d6-DMSO): δ [ppm] = 11.39 (br, 1H, NH), 8.58 
(s, 1H, H-imine), 8.01 (s, 1H, H-8), 6.15 (d, J = 2.1 Hz, 1H, H-1´), 5.42 (dd, J = 2.1 Hz, 6.3 
Hz, 1H, H-2´), 5.02 (dd, J = 2.8 Hz, 6.3 Hz, 1H, H-3´), 4.28 (ddd, J = 2.8 Hz, 5.7 Hz, 9.0 Hz, 
1H, H-4´), 3.49 (dd, J = 9.0 Hz, 9.9 Hz, 1H, H-5´), 3.30 (dd, J = 5.7 Hz, 9.9 Hz, 1H, H-5´), 
3.19 (s, 3H, N-CH3), 3.04 (s, 3H, N-CH3), 1.53 (s, 3H, CH3), 1.35 (s, 3H, CH3). - 13C NMR 
(101 MHz, d6-DMSO): δ [ppm] = 158.2 (C-imine), 157.7, 157.5 (C-4, C-6), 149.2 (C2), 137.9 
(C-8), 120.2 (C-5), 113.5 (C-quart), 89.4, 86.4, 84.0, 83.9 (C-1´ to C-4´), 41.1 (N-CH3), 34.9 
(N-CH3), 27.2 (CH3), 25.3 (CH3), 6.7 (C-5´) - MS-EI (70 eV) m/z = 488 (13%) +; 361 (7%) [M–
I]+; 360 (35%) [M–HI]+; 345 (1%) [M–HI, CH3]+; 206 (3%) [DAMG]+; 188 (2%) [DAMG–H2O]+; 
176 (26%) [DAMG–2CH3]+; 149 (12%) [guanine-H]+; 128 (100%) [HI]. - HR-MS: 488.06631 
calculated: 488,0669 (DAMG = 2-N´N-dimethylaminomethylene guanine). 
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5.6.11 5´-Deoxy-5´-iodoguanosine (14): 
1.20 g (2.78 mmol) of 11 (or an equivalent amount of 13) 
are resuspended in 40 ml of aqueous 50% formic acid 
and stirred for 3 days at room temperature under 
protection from light. The solvent is removed under 
reduced pressure at room temperature and the residue, 
1.07 g (2.72 mmol, 98%) of a white solid, used for the 
next step without further purification. Tm = 142-145°C 
(degradation) - Rf = 0.84 (iPrOH/NH3/H2O, 6:3:1 (v/v/v)). - 
1H NMR (400 MHz, DMSO-d6): δ [ppm] = 8.27 (s, 1H, 
NH), 7.90 (s, 1H, H-8), 6.61 (br, 2H, NH2), 5.71 (d, J = 5.6 Hz, 1H, H-1´), 4.62 (dd, J = 5.6 
Hz, 5.6 Hz, 1H, H-2´), 4.06 (dd, J = 3.4 Hz, 5.6 Hz, 1H, H-3´), 4.10 (ddd, J = 3.4 Hz, 6.5 Hz, 
1H, H-4´), 3.55 (dd, J = 6.5 Hz, 10.4 Hz, 1H, H-5´), 3.41 (dd, J = 6.5 Hz, 10.4 Hz, 1H, H-5´). - 
13C NMR (101 MHz, d6-DMSO): δ [ppm] = 157.9, 154.3, 151.8 (C-2, C-4, C-6), 136.1 (C-8), 
117.1 (C-5), 87.0, 86.4, 84.1, 83.5 (C-1´ to C-4´), 8.5 (C-5´). - FAB-MS (MeOH, mNBA): m/z 
= 394.1 (6%) [M+H]+ - EI-MS (70 eV) m/z (%) = 254 (12%) [I2]+, 149 (2%) [guanine]+, 127.9 
(100%) [HI]+, 126.9 (50%) [I]+ - HR-MS: no mass peak was obtained in electron ionization 
mode so that no high resolution mass could be determined. 
 
5.6.12 5´-Deoxy-5´-thioguanosine-monophosphorothioate (GSMP) (15): 
1.06 g (2.69 mmol) of 5´-deoxy-5´-iodoguanosine 
14 are resuspended in 60 ml of degassed water 
and a degassed solution of 3,84 g (9.7 mmol; 3.6 
eq) of trisodium thiophosphate dodecahydrate in 
water is added. The colorless reaction mixture is 
degassed three times and flooded with argon. 
After three days of stirring protected from light 
under argon, the precipitated solid is removed by 
filtration and the solvent is evaporated under 
reduced pressure at room temperature. The pale yellow residue is resuspended in 15 ml of 
ice-cooled degassed water, and 30 ml of methanol are added to precipitate the excess of 
sodium thiophosphate. The precipitate is removed by filtration and the residue washed with 
10 ml of cooled methanol/water (2:1 (v/v)). The solvent is removed from the filtrate and the 
pale yellow solid dissolved in 14 ml of water and subjected to reverse phase chromatography 
(RP-18, eluent: water). The elution of GSMP is monitored by TLC. Molybdophosphate in 
methanol (10%) stains GSMP in a weak blue that appears with a latency of several minutes 
and is easily overseen. The thiophosphate contamination is easily detected by this method. 
GSMP can be visualized on fluorescent TLC paper under UV illumination, so that a 
combination of both methods may be used to distinguish GSMP fractions with a 
thiophosphate contamination from the pure GSMP. The product fractions are pooled and 
after photometric determination of the concentration split into aliquots that can be directly 
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used for in vitro transcription. GSMP is lyophilized and stored at –20°C under argon. Yield = 
68% (0,69 g, 1.83 mmol) - Tm= 100°C (degradation) - Rf = 0.26 (iPrOH/NH3/H2O, 6:3:1 
(v/v/v)). - 1H NMR (400 MHz, D2O): δ [ppm] = 8.12 (s, 1H, H-8), 5.97 (d, J = 5.4 Hz, 1H, H-
1´), 4.89 (dd, J = 5.4 Hz, 5.4 Hz, 1H, H-2´), 4.58 (dd, J = 4.1 Hz, 5.4 Hz, 1H, H-3´), 4.44 (dt, J 
= 4.1 Hz, 6.2 Hz, 1H, H-4´), 3.27 - 3.10 (m, 2H, H-5´). 31P NMR (162 MHz, D2O) = 19.0 ppm. 
- 13C NMR (101 MHz, D2O): δ [ppm] = 161.5, 156.4, 154.2 (C-2, C-4, C-6), 140.4 (C-8), 119.0 
(C-5), 89.8, 87.2, 75.9, 74.7 (C-1‘ to C-4‘), 34.5 (C-5´). - ESI-MS (negative mode, MeOH): 
400 (2%) [M –2H + Na]-, 378 (100%) [M-H]-, - HR-MS: 378.04 calculated: 378.027. 
 
5.6.13 2´,3´-O,O-Isopropylidene- 3,5´-C- cycloguanosine (20) 
After 24 h at RT in d6-DMSO, 11 has been completely converted 
into its cyclized form 20 in an intramolecular reaction. 1H NMR (300 
MHz, d6-DMSO): δ [ppm] = 8.62 (br, 1H, NH2), 8.07 (s, 1H, H-8), 
6.52 (s, 1H, H-1´), 5.01 (d, J = 5.8 Hz, 1H, H-2´), 4.92 (t, J = 2.6 Hz, 
1H, H-4´), 4.74 (dd, J = 2.6 Hz, 14.1 Hz, 1H, H-5´), 4.55 (d, J = 5.8 
Hz, 1H, H-3´), 3.98 (dd, J = 14.1 Hz, 2.6 Hz, 1H, H-5´), 1.45 (s, 3H, 
CH3), 1.24 (s, 3H, CH3). - 13C NMR (101 MHz, d6-DMSO): δ [ppm] = 
155.5, 153.6 (C-4, C-6), 140.6 (C-2), 136.9 (C-8), 112.8 (C-5), 
113.2 (C-quart), 90.7, 85.5, 83.5, 80.7 (C-1´ to C-4´), 55.3 (C-5´), 
26.1 (CH3), 24.7 (CH3). 
 
 
5.6.14 N,N-Dimethylaminomethylene-2´,3´-O,O-isopropylidene-3,5´-C-cycloguanosine 
(21) 
After 10 days at RT in d6-DMSO, 13 has been completely 
converted into its cyclized form 21 in an intramolecular 
reaction. 1H NMR (300 MHz, d6-DMSO): δ [ppm] = 8.39 (br, 1H, 
H-imine), 8.13 (s, 1H, H-8), 6.55 (s, 1H, H-1´), 5.30 (dd, J = 
15.0 Hz, 2.7 Hz, 1H, H-5´), 4.90 (dd, J = 2.7 Hz, 2.7 Hz, 1H, H-
4´), 4.88 (d, J = 5.8 Hz, 1H, H-2´), 4.51 (d, J = 5.8 Hz, 1H, H-
3´), 3.83 (dd, J = 15.0 Hz, 2.7 Hz; 1H, H-5´), 3.31 (s, 3H, N-
CH3), 3.20 (s, 3H, N-CH3), 1.45 (s, 3H, C-CH3), 1.23 (s, 3H, C-
CH3). - 13C NMR (101 MHz, d6-DMSO): δ [ppm] = 159.8 (C-
imine), 156.1, 155.3 (C-4, C-6), 141.1 (C-2), 137.3 (C-8), 121.9 
(C-5), 112.8 (C-quart), 90.9, 85.7, 84.1, 80.7 (C-1´ to C-4´), 
54.1 (C-5´), 42.1 (N-CH3), 36.2 (N-CH3), 26.2 (C-CH3), 24.8 (C-
CH3). 
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5.7 Buffers and solutions 
5.7.1 Cell culture 
10% DMEM 
 10 %  FCS 
   1  u/ml streptomycin 
   1  u/ml tylosin 
 
antibleach 
 20  mg  p-phenylenediamine 
   2  ml   PBS+ 
   8  ml  glycerol 
 
PBS (pH 7.4) 
 140 mM NaCl 
     3 mM KCl 
   16 mM Na2HPO4 
  1.5 mM KH2PO4  
in bidistilled water 
 
PBS+ 
 1.0 mM  MgCl2 
 0.1 mM  CaCl2 
 in PBS 
 
Mowiol 
 2.4  g Mowiol 4-88  
 6  g  glycerol 
 6  ml  water  
 12  ml  Tris (0.2 M, pH 8.5)  
 
heat to 50°C to dissolve compounds; 
remove remaining particles by 
centrifugation; store at –20°C 
 
T/E 
 0.05  %  trypsin 
 0.53  mM EDTA 
 
5.7.2 Protein expression 
IPTG  100 mM in water 
 
LB-medium  20 % LB in water 
 
SOB-medium  
 2 % trypton 
 0.5 % yeast-extrakt 
 0.05 % NaCl 
 10 mM MgCl2 
 10 mM MgSO4 
 
SOC-medium  
 1x  SOB-medium 
 20 mM glucose 
 
Supermedium  
 3.0 % NaCl 
 1.5 % yeast-extract 
 3.0 % trypton 
 
Terrific broth medium 
 12  % trypton 
 24 % yeast-extract 
   4 % glycerol 
 0,17 M KH2PO4 
 0,72 M K2HPO4 
 
Trypton, yeast extract and glycerol are 
filled up to 90% of the total volume with 
water and autoclaved. The phosphate 
solution (10% of total volume) is sterilized 
separately and added when both solutions 
are cooled down. 
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5.7.3 Protein purification 
Bradford reagent  
 0.01 %  Serva Blue 
 0.8  M  ethanol (96%) 
 1.6  M phosphoric acid (85%) 
 
HEPES-stock solution 
 0.5  M  HEPES (pH 7.0) 
 
Inclusion body preparation:  
lysis buffer 
   50  mM Tris-HCl (pH 8.0) 
 300  mM NaCl 
   20  mM MgSO4 
     2  mM CaCl2 
 
add immediately prior to use  
 500  µg/ml lysozyme 
 200  µg/ml  DNase 
 
Inclusion body preparation:  
denaturing buffer 
     6  M urea 
 100  mM NaH2PO4 
   10  mM  Tris-HCl (pH 8.0) 
 
Inclusion body preparation: 
 resuspension buffer 
     6  M guanidine 
 100  mM NaH2PO4 
   10  mM Tris-HCl (pH 8.0) 
 
pGEX high pH-buffer 
 0.1  M Tris-HCl 
 5.0  M NaCl 
 adjust to pH 8.5 with HCl 
 
pGEX low pH-buffer 
 0.1  M Na-acetate 
 5.0  M NaCl 
 adjust to pH 4.5 with NaOH 
 
 
pGEX-lysis buffer 
   20 mM  HEPES (pH 7.6) 
 100 mM  KCl 
    0.2 mM  EDTA 
   20   %  glycerol 
     1   %  Triton X-100 
add immediately prior to use (per 50 ml): 
 1.0  ml DTT (50 mM) 
 
pGEX-pre-elution buffer 
 100  mM NaCl 
   25  mM HEPES (pH 7.0) 
   0,1 mM EGTA 
 
pGEX-elution buffer 
   50   mM  reduced glutathione 
   10   mM  Tris-HCl, pH 8.0 
 
Lysis buffer 
   50  mM Tris-HCl, pH 8.0 
 300  mM NaCl 
 500  µg/ml Lysozym 
 200  µg/ml DNase 
   20  mM MgCl2 
     2  mM CaCl2 
 
Lysis + buffer 
 20    mM  HEPES (pH 7.6) 
 100   mM  KCl 
    0.2 mM  EDTA 
   20  %  glycerol 
     2  %  Triton X-100 
     5  mM DTT 
 
Lysis buffer A 
pGEX lysis buffer supplemented with 
     2   %  Triton X-100 
   10   mM DTT 
 
Lysis buffer B 
pGEX lysis buffer supplemented with 
     1   %  Triton X-100 
     5   mM DTT 
 adjusted to pH 8.0 
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Lysis buffer C 
pGEX lysis buffer supplemented with 
     1   %  Triton X-100 
     5   mM DTT 
     1   M urea 
 
Lysis buffer D 
pGEX lysis buffer supplemented with 
     1   %  Triton X-100 
     5   mM DTT 
     2   M urea 
 
Ni-NTA-purification buffers (denaturing) 
 8.0  M urea 
 50  mM NaH2PO4 
pH: buffer B (lysis): pH 8.0 
 buffer C (wash): pH 6.3 
 buffer E (elution): pH 4.5 
 
Ni-NTA-purification buffers (native) 
   50 mM NaH2PO4  (pH 8.0) 
 300 mM NaCl 
 
   10 mM imidazol (lysis) 
   20 mM imidazol (wash) 
 250 mM imidazol (elution) 
 
Sodium hydrogencarbonate/EDTA 
buffer 
 2 %  sodium hydrogencarbonate 
 1  mM  EDTA, pH 8.0 
 
20x TEV buffer 
     1 M Tris-HCl, pH 8.0 
 10 mM EDTA, pH 8.0 
 
TEV storage buffer 
 100  mM  Tris-HCl pH 8.5 
 500 mM NaCl 
   50 % glycerol 
     5 mM  DTT 
   0.5  mM  EDTA 
 
5.7.4 Gel electrophoresis 
Acrylamide (AA) stock solution 
 38 % acryamide 
 2 % bisacrylamide 
 
Coomassie stain 
 0.1 % Coomassie Brilliant Blue R250 
 25 % methanol 
 10 % acetic acid 
 
Laemmli buffer (5x) 
 312.5 mM Tris-HCl (pH 6.8) 
     2.5 % SDS 
     5  % β-mercaptoethanol 
   50  % glycerol 
   0.025 % Serva Blue G 
in PBS 
 
SDS-PAGE running buffer 
   50    mM Tris-HCl (pH 8.25) 
 384    mM tricin 
     0.2 % SDS 
 
Silver stain fomaldehyde solution 
 50    % methanol  
 12    % acetic acid 
 0.5   ml/l  formaldehyde (37%) 
 
Silver stain silver solution 
     2 g/l  AgNO3  
 750 µl/l  formaldehyde (37%) 
 
Silver stain developing solution 
   60 g/l  Na2CO3 
 500 µl/l  formaldehyde (37%) 
     4 mg/l Na2S2O3 
 
Silver stain stop solution 
 50  %  methanol  
 12  %  acetic acid 
 
 
Silver stain wash solution 
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 30  %  methanol 
   3  % glycerol 
 
5.7.5 Western blotting 
Triton/BSA-solution (TBS) 
 0.1% Triton X-100 
 1.0% BSA 
 in PBS+ 
 
TBS-T 
 0.1 % Triton X-100 
 1.0 % BSA 
 in PBS+ 
add 1.0 % Tween 20 
 
Transfer buffer 
10 mM CAPS, pH 11  
10%  MeOH 
 
5.7.6 DNA/RNA techniques 
Formamide loading buffer 
 80  %  deionized formamide 
 10  mM  EDTA 
   1  mg/ml  bromophenol blue 
 
TAE (50x) 
 2 M Tris⋅acetate 
 50 mM EDTA (pH 8.0) 
 
TBE (10x, 1l) 
 108  g Tris 
 55  g boronic acid 
 40  ml  EDTA 
 
5.7.7 Synthesis 
Kaegi-Miescher stain 
   0.5  ml  anisaldehyde 
   1.0  ml  conc. sulfuric acid 
 50.0  ml  glacial acetic acid 
 
Seebach reagent 
 2.5  g  molybdophosphoric acid 
 1.0  g  cer(IV)sulfate tetrahydrate 
 6.0 g  conc. sulfuric acid 
 90.5 ml water 
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5.8 Material 
5.8.1 Apparatus 
autoclave Integra Biosciences, Fedegari, Pavia, Italy 
balances BP 610, Sartorius AG, Göttingen 
 Explorer, OHaus, Giessen 
centrifuges RC5-B Sorvall-Kühlzentrifuge, Du Pont Instruments, Bad Homburg 
 RC5-C Plus Sorvall-Kühlzentrifuge, Kendro Laboratory Products,  
 Hanau 
 Eppendorf-Tischzentrifuge 5415 6, Eppendorf, Hamburg 
 Eppendorf-Tischzentrifuge MiniSpin, Eppendorf, Hamburg 
 Eppendorf-Kühlzentrifuge 5402, Eppendorf, Hamburg 
 Eppendorf-Kühlzentrifuge 5810 R, Eppendorf, Hamburg 
 Kühlzentrifuge Sepatech Megafuge 2.0R Heraeus 
chromatography columns: Nucleosil-100, RP-18 (2mm, 25 cm, 3 µm) 
 Anion exchange: DEAE Sephadex-A25, Amersham Bioscience 
drier KL 500, Heraeus, Hanau 
evaporators IKA-Dest, IKA-Werke GmbH & Co KG, Staufen 
FAB-mass spectrometer: H1, Kratos, Manchester 
FPLC ÄKTA-FPLC, AP Biotech, Braunschweig 
 Software: Unicorn 
freeze dryer VirTis GT2, Leybold-Heraeus, Hanau 
gel chambers  Horizontalelektrophoresessystem Horizon 11-14, 20-25, Gibco-BRL, 
Bethseda Research Laboratories 
MiniSunTM DNA Cell, BioRad, Munich 
 Hoefer Mighty Small 250, 
 Hoefer Scientific Instruments, San Francisco, USA 
Blotting instrument Firma BioRad, Munich 
gel photography Camera: hama® Repro 
 Video monitor WV-BM 80, Panasonic 
 Illumination controler: CS1, Cybertech 
 Image Capture Computer, Cybertech 
 printer: Video Copy Processor, Mitsubishi 
glass tools Schott-Duran, Jenaglas, Mainz 
heating block Dri-Block, DB3, Techne, Duxford, U.K. 
homogenizer Potter S, B.Braun Melsungen AG 
incubators Heraeus-Christ, Hanau; WTB Binder, Tuttlingen 
magnetic stirrer Ika-Combimag RCT, IKA-Werke GmbH & Co KG, Staufen  
membrane pump  M72C, Vacubrand GmbH & Co, Wertheim 
microscope Wilovert S, Hund, Wetzlar 
 Fluorescence microscope Zeiss Axiovert 35 with filters (Bp 485, Ft  
 510, 515-565), Oberkochen 
microwave Microchef FM 3915, Moulinex 
NMR spectrometer DPX300 (300 MHz), DPX400 (400 MHz), Bruker, Karlsruhe 
overhead mixer Reax 2, Heidolph, Schwabach 
PCR thermoblock MJ Research PTC-200 (Peltier Thermo Cycler), Biozym, Hess.  
 Oldendorf 
pH-meter MP 220, Mettler Toledo, Greifensee, Switzerland 
peristaltic pump P1, AP Biotech, Piscataway, USA 
phosphoimager Bas Reader, Fujix Bas 1000, Fuji, Minami-Ashigara, Japan 
phosphoimaging plates Bas III, Fuji, Minami-Ashigara, Japan 
phosphoimaging decharger: Raytest-Isotopenmessgeräte 
photospectrometer SmartspecTM 3000, BioRad Laboratories, Hercules, CA, USA 
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pipettors Gilson Pipetman P20, P200, P1000 
 Abimed, Langenfeld 
 Eppendorf Reference 2,5; 10; Eppendorf Research 1000, Hamburg 
 Akkupipettierhilfe, Hirschmann, Eberstedt 
power supplies: LKB ECPS 3000/150, AP Biotech, Braunschweig 
 PS 305, Gibco BRL, Life Technologies, Freiburg 
 Power Pac 300, BioRad, Munich 
protein quantitation Multiskan Ascent, Labsystems 
rotors Typ GSA Sorvall, Du Pont, France 
 Typ GS-3 Sorvall, Newton, USA 
 SLA-3000 Superlite, Newton, USA 
 Typ SS-34 Sorval, Newton, USA 
shakers Series 25 New Brunswick Scientific CO., Inc. , Edison, USA 
 Multitron, Infors AG, Bottmingen, Switzerland 
sterilbench Biohazard, Gelaire, Mailand, Italy 
 Heraeus-Christ, Hanau 
sterilizer Memmert, Schwabach 
 Ecocell, MMM Medcenter 
thermomixer Eppendorf 5436, Hamburg 
UV-transilluminator Biometra, Göttingen 
vortex Vortex-2-Genie, Scientific Industries, Bohema, USA  
water purification Millipore-Pelicon Filtration device with polysulfone filter cassette  
 PTGC, 10000 MW, Millipore, Molsheim, France 
  
5.8.2 Consumables 
cover slips Menzel Gläser, Breda, Netherlands 
culture dishes: 6-, 24-, 96-well, Costar, Cambridge, USA 
culture tubes Costar, USA 
 Greiner, Nürtingen 
filters  Schleicher und Schüll, Dassel 
filtration columns BioRad, Munich 
membranes QIAGEN, Hilden 
 BioRad, Munich 
microscopy slides Superfrost Plus, Menzel Gläser, Breda, Netherlands 
microfuge tubes 1,5 ml, 2 ml, Eppendorf, Hamburg 
 0,5 ml ultra-thin, Biozym, Hess. Oldenburg 
 15 ml, 50 ml Falcon / Costar, GB 
parafilm ACC, Greenwich, USA 
petri dishes ∅ 90 mm, ∅ 135 mm, Falcon, GB 
pipet equipment Abimed, Langenfeld 
 Greiner, Nürtingen 
TLC-plates Silicagel 60 on aluminium, Merck, Darmstadt 
culture flasks 25er, 75er, 162er, Costar, USA 
 
5.8.3 Antibodies 
anti-rabbit-IgG-HRP (goat) Cell Signalling Technologies,  
anti-goat-IgG-AB (rabbit) Dianova, Hamburg 
anti-lamin A/C M. Osborn, Göttingen 
anti-HexA A. Hasilik, Marburg 
anti-GCS R. Pagano, San Diego, USA 
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5.8.4 Purification kits 
QIAprep (plasmid isolation)  QIAGEN, Hilden 
QIAquick (gel extraction)  QIAGEN, Hilden 
RNeasy (RNA isolation)  QIAGEN, Hilden 
NiNTA-kit (purification of His6-proteins) QIAGEN, Hilden 
 
5.8.5 Enzymes and markers 
Alkaline phosphatase (CIP) New England Biolabs, Schwalbach 
DNase RiboMAXTM Large Scale RNA Production Systems – SP6 
and T7, Promega, Madison, WI, USA 
Restriction endonucleases New England Biolabs 
Reverse transkriptase Titan Kit, Roche Diagnostics, Mannheim 
RNase Inhibitor Promega, Heidelberg 
T4-Ligase Rapid Ligation Kit, Roche Diagnostics, Mannheim 
T4-Kinase T4-Pronucleotid Kinase, Amersham Bioscience, Uppsala, 
Sweden 
T7- RNA-polymerase RiboMAXTM Large Scale RNA Production Systems – SP6 
and T7, Promega, Madison, WI, USA 
Taq-polymerase QIAGEN, Hilden  
 Expand-Long-Template, Roche Diagnostics, Mannheim 
Trypsin Paisley, Scotland, GB 
DNA marker 1kb ladder, Invitrogen Life Technologies, Karlsruhe 
Protein standard Prestained Protein Standard, Broad range, New England 
Biolabs, Schwalbach 
 
6 Oligonucleotides and Peptides 
 
synthetic siRNAs  Dharmacon Research, Lafayette, CO, USA 
Proligo, Boulder, CO, USA 
biotinylated Penetratin Qbiogene, Heidelberg 
pGEXuni5´ oligonucleotide QIAgen Operon Technologies, Hilden 
DNA-Oligonucleotides  Sigma-Aldrich, Taufkirchen (custom synthesis) 
 
6.1.1 Radioactivity 
 [32P]-ATP Amersham Bioscience, Uppsala, Sweden 
 
6.1.2 Bacterial Strains 
Escherichia coli : DH-5α, DH10 Bac, BL21, BL21 DE3, BL21 DE3 pLysS, BL21 RIL 
 
6.1.3 Cell Lines 
HeLa wt human ovary blastoma cells 
91/17-21 humane fibroblasts (normal)  
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F81/23 Nieman Pick-Type C fibroblasts  
MEB4 murine melanoma cells 
COS1,7 monkey cells 
 
6.1.4 Vectors 
pQE30 QIAGEN, Hilden 
pREP4 QIAGEN, Hilden 
pFASTBAC1 GIBCOBRL, Freiburg 
pGEX-4T2 AP Biotech, Braunschweig 
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6.1.5 Chemicals 
Molecular Biology 
 
Amersham Bioscience, Uppsala, Sweden: glutathione-sepharose, Binding Silane, Repel 
Silane, Sephadex A-25 
Fluka, Buchs, Switzerland: ampicillin 
Valeant Pharmaceuticals,Costa Mesa, CA, USA:  MEM-medium 
Invitrogen Life Technologies, Bethesda, USA: agar, agarose, DMEM, 1kb DNA length 
standard, FCS, LB Medium, Lipofectamine, MEM-Medium, OptiMEM, , 
penicillin/streptomycin, Select Agar, Select Yeast Extract, Select 
Peptone, Triton-X 100 
Janssen Chimica, Beerse, Belgium: PFA 
Macherey und Nagel, Düren: PVDF-membrane, pH-papers 
MBI Fermentas, St. Leon-Roth: DTT, IPTG, HEPES, lysozyme, X-Gal 
E. Merck, Darmstadt: amido black, bromophenol blue, disodiumhydrogen phosphate, EDTA-
sodium salt, glycerol, LiChroprep RP-18 material, N,N´-
dimethylbisacrylamide, sodium chloride, potassium acetate, potassium 
chloride, potassium dihydrogen phosphate, sodiumhydroxide, tris-
(hydroxymethyl)-aminomethane, urea 
PAA Laboratories GmbH, Pasching, Austria: FCS, HAMs Nutrient Medium F-10 
Roche, Mannheim:  ampicilin, dNTP-mix, Expand-Long Template, kanamycin, PMSF, 
rapid ligation kit, T7-polymerase, Taq-polymerase 
Roth, Karlsruhe:  acrylamide mix 29:1, 40% 
Cambrex, Baltimore, M, USA: Seakem LE agarose 
Serva, Heidelberg:  acrylamide, ammonium peroxodisulfate, glucose, PVDF-membrane, 
Coomassie R250 
Sigma-Aldrich, Taufkirchen:  APS, BSA, Coomassie blue, ethidium bromide, gentamycin, β-
mercaptoethanol, paraformaldehyde, p-phenylene diamine, poly-L-
lysine, sodium dodecyl sulfate, Triton X-100, Tween 20, TEMED  
 
Synthesis 
 
Fischer, Wiesbaden: chloroform p.a. 
Fluka, Buchs, Switzerland: absolute solvents over molecular sieve (dimethyl formamide, 
THF, pyridine), guanosine, methyltriphenoxyphosphonium iodide 
perchloric acid (70% puriss.), tosyl chloride, triethylamine (puriss.),  
KFM optichem, Lohmar: methanol p.a. 
E. Merck, Darmstadt: silica gel (40 – 65 µm), LiChroprep RP-18 material (40-65 µm) 
Riedel de Haen, Seelze: acetic acid, formic acid, formaldehyde, hydrochloric acid 
Schleicher und Schüll, Dassel: blotting papers, filter papers 
Sigma-Aldrich, Taufkichen: acetone (p.a.), trisodium thiophosphate dodecahydrate  
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Summary 
 
In recent years, RNA interference has gained a lot of importance as a tool for 
posttranscriptional silencing of genes due to its high specificity, efficiency and ease of 
application. Treatment of cells with double-stranded RNA leads to the degradation of 
homologous, endogenous mRNA and hence to the downregulation of the corresponding 
gene product. In mammalian cells, RNAi can be achieved with 21 bp short dsRNAs, so-
called short interfering RNAs (siRNAs). Numerous studies indicate the great potential of 
RNAi in the therapy of viral infections and inherited diseases. However, the application of 
RNAi is severely limited by the delivery issue, as conventional transfection methods cannot 
be applied to a number of primary and non-dividing cells or even fully-grown organisms.  
Cell-penetrating peptides (CPPs) are one means to overcome these limitations. These short 
positively charged amino acid sequences are internalized by cells, where they can be 
detected in the endosomes, lysosomes, but also in the cytosol. If attached to CPPs, large 
cargo molecules can be taken up with a high efficiency that surpasses that of most 
conventional transfection methods. 
In the work presented here, peptide-coupled siRNAs (pepsiRNAs) have been developed as a 
novel tool for transient RNAi in mammalian cells. To covalently attach the peptide with the 
siRNA, a disulfide bond was used, that is cleaved under the reducing conditions of the 
cytosol and thus releases the siRNA cargo. 
PepsiRNAs are readily taken up by many cell types that are difficult to address by 
conventional transfection methods, and siRNA-induced downregulation of the targeted genes 
is observed at concentrations between 10 and 100 nM.  
For the scale up of the pepsiRNA approach, an enzymatic method has been modified to yield 
siRNAs with a 5´-thiol modification upon their sense-strand. To this means, the synthesis 
protocol of a thiol-modified nucleotide has been optimized. For the recombinant generation of 
cell-penetrating peptides, vectors for the expression of GST-tagged AntP and Tat peptide 
have been cloned, and the standard purification protocol was improved to account for the 
strong membrane interaction of the GST-tagged CPPs. Recombinant TEV protease was 
expressed to cleave the CPPs from the fusion-tag and the cleavage activity was assessed by 
comparison with commercially obtained. Thus, alternative routes to the building blocks for 
pepsiRNAs have been provided to scale up the amount of the conjugates. 
Finally, small molecules with cell-penetrating properties have been developed as a future 
replacement of the peptide moiety. Fluorescently labeled peptoids of differing length with 
amine-functionalized side chains have been shown to enter different mammalian cells lines 
at concentrations in the lower micromolar range by an endocytosis dependent mechanism. 
Cationic molecules as small as spermine attached to fluorescein are able to enter fibroblasts 
HeLa- and COS7 cells also by an endocytosis-related mechanism. They have been shown to 
deliver bulky cargo molecules like porphyrins into the interior of the cells, where they 
exhibited a cytotoxic effect upon illumination. Thus spermine-coupled porphyrins may 
constitute a novel drug for photodynamic therapy. 
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